0001437749-20-018754.txt : 20200826 0001437749-20-018754.hdr.sgml : 20200826 20200826163654 ACCESSION NUMBER: 0001437749-20-018754 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200826 DATE AS OF CHANGE: 20200826 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 201137665 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 10-K 1 tech20200630_10k.htm FORM 10-K tech20190630_10k.htm
0000842023 BIO-TECHNE Corp false --06-30 FY 2020 398 775 980 0 0 5,000,000 5,000,000 0 0 0 0 0.01 0.01 100,000,000 100,000,000 38,453,046 38,453,046 37,934,040 37,934,040 0 0 0 0 3,239 0 0 15 0 0 0 0 5 1.28 1.28 10 3 1.4 1.4 2,522 0 0 0 0 Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made.The Company reclassified ($4,503) to interest expense and a related tax benefit tax of $1,040 during fiscal 2020. Approximately $7,035 of the $13,253 will be reclassified in the 12 months subsequent to June 30, 2020. The Company had deferred tax benefits of $4,058 and $2,921 included in the accumulated other comprehensive income loss as of June 30, 2020 and June 30, 2019, respectively. Total cash paid for the Company's operating leases during the year ended June 30, 2020 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity. Consists of holdback payments due at future dates and liabilities for contingent consideration. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5. Included in available-for-sale investments on the condensed consolidated balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) was $7.6 million and $18.8 million as of March 31, 2020 and June 30, 2019, respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $5.6 million as of March 31, 2020. The fair value of the warrant as of June 30, 2019 was not material. Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year. Finished goods inventory of $4,646 and $3,239 is included within other long-term assets in the June 30, 2020 and June 30, 2019 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date. Amounts do not total due to rounding 00008420232019-07-012020-06-30 iso4217:USD 00008420232019-12-31 xbrli:shares 00008420232020-08-21 thunderdome:item 00008420232018-07-012019-06-30 00008420232017-07-012018-06-30 iso4217:USDxbrli:shares 00008420232020-06-30 00008420232019-06-30 0000842023us-gaap:CommonStockMember2017-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2017-06-30 0000842023us-gaap:RetainedEarningsMember2017-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-06-30 00008420232017-06-30 0000842023us-gaap:RetainedEarningsMember2017-07-012018-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-07-012018-06-30 0000842023us-gaap:CommonStockMember2017-07-012018-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2017-07-012018-06-30 0000842023us-gaap:CommonStockMember2018-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2018-06-30 0000842023us-gaap:RetainedEarningsMember2018-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-30 00008420232018-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2018-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-06-30 0000842023us-gaap:RetainedEarningsMember2018-07-012019-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-07-012019-06-30 0000842023us-gaap:CommonStockMember2018-07-012019-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2018-07-012019-06-30 0000842023us-gaap:CommonStockMember2019-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2019-06-30 0000842023us-gaap:RetainedEarningsMember2019-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:CommonStockMember2019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-06-30 0000842023us-gaap:RetainedEarningsMember2019-07-012020-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012020-06-30 0000842023us-gaap:CommonStockMember2019-07-012020-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2019-07-012020-06-30 0000842023us-gaap:CommonStockMember2020-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2020-06-30 0000842023us-gaap:RetainedEarningsMember2020-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-30 utr:Y 0000842023us-gaap:EquipmentMembersrt:MinimumMember2019-07-012020-06-30 0000842023us-gaap:EquipmentMembersrt:MaximumMember2019-07-012020-06-30 0000842023tech:BuildingBuildingImprovementsAndLeaseholdImprovementsMembersrt:MinimumMember2019-07-012020-06-30 0000842023tech:BuildingBuildingImprovementsAndLeaseholdImprovementsMembersrt:MaximumMember2019-07-012020-06-30 0000842023srt:MinimumMember2019-07-012020-06-30 0000842023srt:MaximumMember2019-07-012020-06-30 0000842023us-gaap:TradeNamesMember2019-07-012020-06-30 0000842023us-gaap:TradeNamesMember2020-06-30 xbrli:pure 00008420232002-07-012020-06-30 0000842023us-gaap:AccountingStandardsUpdate201602Member2019-07-01 0000842023tech:ConsumablesMember2019-07-012020-06-30 0000842023tech:ConsumablesMember2018-07-012019-06-30 0000842023tech:ConsumablesMember2017-07-012018-06-30 0000842023tech:InstrumentsMember2019-07-012020-06-30 0000842023tech:InstrumentsMember2018-07-012019-06-30 0000842023tech:InstrumentsMember2017-07-012018-06-30 0000842023us-gaap:ServiceMember2019-07-012020-06-30 0000842023us-gaap:ServiceMember2018-07-012019-06-30 0000842023us-gaap:ServiceMember2017-07-012018-06-30 0000842023tech:ProductAndServicesMember2019-07-012020-06-30 0000842023tech:ProductAndServicesMember2018-07-012019-06-30 0000842023tech:ProductAndServicesMember2017-07-012018-06-30 0000842023us-gaap:RoyaltyMember2019-07-012020-06-30 0000842023us-gaap:RoyaltyMember2018-07-012019-06-30 0000842023us-gaap:RoyaltyMember2017-07-012018-06-30 0000842023country:US2019-07-012020-06-30 0000842023country:US2018-07-012019-06-30 0000842023country:US2017-07-012018-06-30 0000842023tech:EMEAExcludingUKMember2019-07-012020-06-30 0000842023tech:EMEAExcludingUKMember2018-07-012019-06-30 0000842023tech:EMEAExcludingUKMember2017-07-012018-06-30 0000842023country:GB2019-07-012020-06-30 0000842023country:GB2018-07-012019-06-30 0000842023country:GB2017-07-012018-06-30 0000842023tech:APACExcludingGreaterChinaMember2019-07-012020-06-30 0000842023tech:APACExcludingGreaterChinaMember2018-07-012019-06-30 0000842023tech:APACExcludingGreaterChinaMember2017-07-012018-06-30 0000842023country:CN2019-07-012020-06-30 0000842023country:CN2018-07-012019-06-30 0000842023country:CN2017-07-012018-06-30 0000842023tech:RestOfWorldMember2019-07-012020-06-30 0000842023tech:RestOfWorldMember2018-07-012019-06-30 0000842023tech:RestOfWorldMember2017-07-012018-06-30 0000842023tech:ChemoCentryxIncCCXIMember2020-06-30 0000842023tech:ChemoCentryxIncCCXIMember2019-06-30 0000842023tech:ChemoCentryxIncCCXIMember2020-06-30 0000842023tech:ChemoCentryxIncCCXIMember2019-06-30 0000842023us-gaap:OtherNoncurrentAssetsMember2020-06-30 0000842023us-gaap:OtherNoncurrentAssetsMember2019-06-30 0000842023us-gaap:LandMember2020-06-30 0000842023us-gaap:LandMember2019-06-30 0000842023us-gaap:BuildingAndBuildingImprovementsMember2020-06-30 0000842023us-gaap:BuildingAndBuildingImprovementsMember2019-06-30 0000842023us-gaap:MachineryAndEquipmentMember2020-06-30 0000842023us-gaap:MachineryAndEquipmentMember2019-06-30 0000842023us-gaap:DevelopedTechnologyRightsMembersrt:MinimumMember2019-07-012020-06-30 0000842023us-gaap:DevelopedTechnologyRightsMembersrt:MaximumMember2019-07-012020-06-30 0000842023us-gaap:DevelopedTechnologyRightsMember2020-06-30 0000842023us-gaap:DevelopedTechnologyRightsMember2019-06-30 0000842023us-gaap:TradeNamesMembersrt:MinimumMember2019-07-012020-06-30 0000842023us-gaap:TradeNamesMembersrt:MaximumMember2019-07-012020-06-30 0000842023us-gaap:TradeNamesMember2019-06-30 0000842023us-gaap:CustomerRelationshipsMembersrt:MinimumMember2019-07-012020-06-30 0000842023us-gaap:CustomerRelationshipsMembersrt:MaximumMember2019-07-012020-06-30 0000842023us-gaap:CustomerRelationshipsMember2020-06-30 0000842023us-gaap:CustomerRelationshipsMember2019-06-30 0000842023us-gaap:PatentsMember2019-07-012020-06-30 0000842023us-gaap:PatentsMember2020-06-30 0000842023us-gaap:PatentsMember2019-06-30 0000842023us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2019-07-012020-06-30 0000842023us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2018-07-012019-06-30 0000842023us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2017-07-012018-06-30 0000842023tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012020-06-30 0000842023tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2018-07-012019-06-30 0000842023tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2017-07-012018-06-30 0000842023tech:ProteinSciencesMember2018-06-30 0000842023tech:DiagnosticsAndGenomicsMember2018-06-30 0000842023tech:ProteinSciencesMember2018-07-012019-06-30 0000842023tech:DiagnosticsAndGenomicsMember2018-07-012019-06-30 0000842023tech:ProteinSciencesMember2019-06-30 0000842023tech:DiagnosticsAndGenomicsMember2019-06-30 0000842023tech:ProteinSciencesMember2019-07-012020-06-30 0000842023tech:DiagnosticsAndGenomicsMember2019-07-012020-06-30 0000842023tech:ProteinSciencesMember2020-06-30 0000842023tech:DiagnosticsAndGenomicsMember2020-06-30 0000842023tech:QTHoldingsCorporationMember2018-07-022018-07-02 0000842023tech:QTHoldingsCorporationMember2018-07-02 0000842023tech:QTHoldingsCorporationMemberus-gaap:DevelopedTechnologyRightsMember2018-07-022018-07-02 0000842023tech:ExosomeDiagnosticsIncMember2018-08-012018-08-01 0000842023tech:ExosomeDiagnosticsIncMember2018-08-01 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:TradeNamesMember2018-08-012018-08-01 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:DevelopedTechnologyRightsMember2018-08-012018-08-01 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:CustomerRelationshipsMember2018-08-012018-08-01 0000842023tech:BMoGenMember2019-06-042019-06-04 0000842023tech:BMoGenMember2019-06-04 0000842023tech:BMoGenMember2019-07-012020-06-30 0000842023tech:BMoGenMemberus-gaap:DevelopedTechnologyRightsMember2019-06-042019-06-04 0000842023tech:TrevigenIncMember2017-09-052017-09-05 0000842023tech:TrevigenIncMember2017-09-05 0000842023tech:AtlantaBiologicalsMember2018-01-022018-01-02 0000842023tech:AtlantaBiologicalsMember2018-01-02 0000842023tech:AtlantaBiologicalsMemberus-gaap:DevelopedTechnologyRightsMember2018-01-022018-01-02 0000842023tech:AtlantaBiologicalsMemberus-gaap:CustomerRelationshipsMember2018-01-022018-01-02 0000842023tech:AtlantaBiologicalsMemberus-gaap:TradeNamesMember2018-01-022018-01-02 0000842023tech:EurocellDiagnosticsSASMember2018-02-012019-02-01 0000842023tech:EurocellDiagnosticsSASMember2018-02-012018-02-01 0000842023tech:EurocellDiagnosticsSASMember2019-02-012019-02-01 0000842023tech:EurocellDiagnosticsSASMember2018-02-01 0000842023tech:EurocellDiagnosticsSASMemberus-gaap:CustomerRelationshipsMember2018-02-012018-02-01 0000842023tech:BMoGenMember2020-06-30 0000842023tech:ExosomeDiagnosticsIncMember2020-06-30 0000842023tech:QTHoldingsCorporationMember2020-06-30 0000842023tech:TrevigenIncMember2020-06-30 0000842023tech:AtlantaBiologicalsMember2020-06-30 0000842023tech:EurocellDiagnosticsSASMember2020-06-30 0000842023tech:BMoGenMemberus-gaap:DevelopedTechnologyRightsMember2020-06-30 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:DevelopedTechnologyRightsMember2020-06-30 0000842023tech:QTHoldingsCorporationMemberus-gaap:DevelopedTechnologyRightsMember2020-06-30 0000842023tech:TrevigenIncMemberus-gaap:DevelopedTechnologyRightsMember2020-06-30 0000842023tech:AtlantaBiologicalsMemberus-gaap:DevelopedTechnologyRightsMember2020-06-30 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:TradeNamesMember2020-06-30 0000842023tech:TrevigenIncMemberus-gaap:TradeNamesMember2020-06-30 0000842023tech:AtlantaBiologicalsMemberus-gaap:TradeNamesMember2020-06-30 0000842023tech:BMoGenMemberus-gaap:CustomerRelationshipsMember2020-06-30 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:CustomerRelationshipsMember2020-06-30 0000842023tech:TrevigenIncMemberus-gaap:CustomerRelationshipsMember2020-06-30 0000842023tech:AtlantaBiologicalsMemberus-gaap:CustomerRelationshipsMember2020-06-30 0000842023tech:EurocellDiagnosticsSASMemberus-gaap:CustomerRelationshipsMember2020-06-30 0000842023tech:ExosomeDiagnosticsIncMember2019-07-012020-06-30 0000842023tech:QTHoldingsCorporationMember2019-07-012020-06-30 0000842023tech:TrevigenIncMember2019-07-012020-06-30 0000842023tech:AtlantaBiologicalsMember2019-07-012020-06-30 0000842023tech:EurocellDiagnosticsSASMember2019-07-012020-06-30 0000842023us-gaap:EquitySecuritiesMember2020-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-06-30 0000842023us-gaap:CertificatesOfDepositMember2020-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2020-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2020-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Member2020-06-30 0000842023us-gaap:FairValueInputsLevel1Member2020-06-30 0000842023us-gaap:FairValueInputsLevel2Member2020-06-30 0000842023us-gaap:FairValueInputsLevel3Member2020-06-30 0000842023us-gaap:EquitySecuritiesMember2019-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2019-06-30 0000842023us-gaap:CertificatesOfDepositMember2019-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2019-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2019-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Member2019-06-30 0000842023us-gaap:FairValueInputsLevel1Member2019-06-30 0000842023us-gaap:FairValueInputsLevel2Member2019-06-30 0000842023us-gaap:FairValueInputsLevel3Member2019-06-30 0000842023tech:CCXIMember2020-06-30 0000842023tech:CCXIMember2019-06-30 0000842023us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:CashFlowHedgingMember2018-10-31 0000842023us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:CashFlowHedgingMembersrt:ScenarioForecastMember2020-10-012020-10-31 0000842023us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:CashFlowHedgingMembersrt:ScenarioForecastMember2021-10-012021-10-31 0000842023us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:CashFlowHedgingMembersrt:ScenarioForecastMember2022-10-012022-10-31 0000842023us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2019-07-012020-06-30 0000842023us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:CashFlowHedgingMember2020-06-30 00008420232019-07-01 0000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2019-06-30 0000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2018-06-30 0000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2019-07-012020-06-30 0000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2018-07-012019-06-30 0000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2020-06-30 0000842023us-gaap:RevolvingCreditFacilityMembertech:CreditAgreementMember2018-08-01 0000842023tech:CreditAgreementMembertech:TermLoanMember2018-08-01 0000842023us-gaap:RevolvingCreditFacilityMembertech:CreditAgreementMember2019-07-012020-06-30 0000842023us-gaap:RevolvingCreditFacilityMembertech:CreditAgreementMember2020-06-30 0000842023tech:CreditAgreementMembertech:TermLoanMember2018-08-012018-08-01 0000842023us-gaap:RevolvingCreditFacilityMembertech:CreditAgreementMember2018-08-012018-08-01 0000842023tech:CreditAgreementMember2020-06-30 0000842023tech:CreditAgreementMember2019-06-30 0000842023srt:MaximumMember2020-06-30 00008420232016-07-012017-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2017-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2017-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2017-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2017-07-012018-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2017-07-012018-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2017-07-012018-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2018-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201802Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201802Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedTranslationAdjustmentMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201802Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201802Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201601Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201601Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedTranslationAdjustmentMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201601Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201601Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-07-012019-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2018-07-012019-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2018-07-012019-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2019-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2019-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-07-012020-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2019-07-012020-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2019-07-012020-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2020-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2020-06-30 0000842023us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012020-06-30 0000842023srt:ScenarioForecastMember2020-07-012021-06-30 0000842023tech:EquityIncentivePlan2010Member2010-06-30 0000842023tech:EquityIncentivePlan2010Member2020-06-30 0000842023tech:EquityIncentivePlan2010Membersrt:MaximumMember2009-07-012010-06-30 0000842023tech:EquityIncentivePlan2010Member2019-06-30 0000842023tech:NonqualifiedStockOptionsPlan1998Member2019-06-30 0000842023srt:MinimumMember2018-07-012019-06-30 0000842023srt:MinimumMember2017-07-012018-06-30 0000842023srt:MaximumMember2018-07-012019-06-30 0000842023srt:MaximumMember2017-07-012018-06-30 0000842023us-gaap:RestrictedStockMember2017-06-30 0000842023us-gaap:RestrictedStockMember2017-07-012018-06-30 0000842023us-gaap:RestrictedStockMember2018-06-30 0000842023us-gaap:RestrictedStockMember2018-07-012019-06-30 0000842023us-gaap:RestrictedStockMember2019-06-30 0000842023us-gaap:RestrictedStockMember2019-07-012020-06-30 0000842023us-gaap:RestrictedStockMember2020-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2017-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2017-07-012018-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2018-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2018-07-012019-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2019-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2019-07-012020-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2020-06-30 0000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012020-06-30 0000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-07-012019-06-30 0000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2017-07-012018-06-30 0000842023us-gaap:CostOfSalesMember2019-07-012020-06-30 0000842023tech:EmployeeStockPurchasePlan2014Member2014-10-30 0000842023tech:EmployeeStockPurchasePlan2014Member2019-07-012020-06-30 0000842023tech:EmployeeStockPurchasePlan2014Member2018-07-012019-06-30 0000842023tech:EmployeeStockPurchasePlan2014Member2017-07-012018-06-30 0000842023tech:USProfitSharingAndSavingsPlanMember2019-07-012020-06-30 0000842023tech:USProfitSharingAndSavingsPlanMember2018-07-012019-06-30 0000842023tech:USProfitSharingAndSavingsPlanMember2017-07-012018-06-30 0000842023tech:GBProfitSharingAndSavingsPlanMember2018-07-012019-06-30 0000842023tech:GBProfitSharingAndSavingsPlanMember2019-07-012020-06-30 0000842023tech:GBProfitSharingAndSavingsPlanMember2017-07-012018-06-30 0000842023tech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2019-07-012020-06-30 0000842023us-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2019-07-012020-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2019-07-012020-06-30 0000842023tech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2018-07-012019-06-30 0000842023tech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2017-07-012018-06-30 0000842023us-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2018-07-012019-06-30 0000842023us-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2017-07-012018-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2018-07-012019-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2017-07-012018-06-30 0000842023us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2020-06-30 0000842023us-gaap:StateAndLocalJurisdictionMember2020-06-30 0000842023us-gaap:ForeignCountryMember2020-06-30 0000842023tech:OperatingLossCarryforwardsMember2020-06-30 0000842023tech:TaxCreditCarryforwardsMember2020-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:ProteinSciencesMember2019-07-012020-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:ProteinSciencesMember2018-07-012019-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:ProteinSciencesMember2017-07-012018-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:DiagnosticsAndGenomicsMember2019-07-012020-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:DiagnosticsAndGenomicsMember2018-07-012019-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:DiagnosticsAndGenomicsMember2017-07-012018-06-30 0000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2019-07-012020-06-30 0000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2018-07-012019-06-30 0000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2017-07-012018-06-30 0000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndGenomicsMember2019-07-012020-06-30 0000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndGenomicsMember2018-07-012019-06-30 0000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndGenomicsMember2017-07-012018-06-30 0000842023us-gaap:IntersegmentEliminationMember2019-07-012020-06-30 0000842023us-gaap:IntersegmentEliminationMember2018-07-012019-06-30 0000842023us-gaap:IntersegmentEliminationMember2017-07-012018-06-30 0000842023us-gaap:OperatingSegmentsMember2019-07-012020-06-30 0000842023us-gaap:OperatingSegmentsMember2018-07-012019-06-30 0000842023us-gaap:OperatingSegmentsMember2017-07-012018-06-30 0000842023us-gaap:CorporateNonSegmentMember2019-07-012020-06-30 0000842023us-gaap:CorporateNonSegmentMember2018-07-012019-06-30 0000842023us-gaap:CorporateNonSegmentMember2017-07-012018-06-30 0000842023tech:ConsumablesMembertech:ProteinSciencesMember2019-07-012020-06-30 0000842023tech:ConsumablesMembertech:ProteinSciencesMember2018-07-012019-06-30 0000842023tech:ConsumablesMembertech:ProteinSciencesMember2017-07-012018-06-30 0000842023tech:ConsumablesMembertech:DiagnosticsAndGenomicsMember2019-07-012020-06-30 0000842023tech:ConsumablesMembertech:DiagnosticsAndGenomicsMember2018-07-012019-06-30 0000842023tech:ConsumablesMembertech:DiagnosticsAndGenomicsMember2017-07-012018-06-30 0000842023tech:UnitedStatesAndCanadaMember2020-06-30 0000842023tech:UnitedStatesAndCanadaMember2019-06-30 0000842023srt:EuropeMember2020-06-30 0000842023srt:EuropeMember2019-06-30 0000842023srt:AsiaMember2020-06-30 0000842023srt:AsiaMember2019-06-30 00008420232019-07-012019-09-30 00008420232019-10-012019-12-31 00008420232020-01-012020-03-31 00008420232020-04-012020-06-30 00008420232018-07-012018-09-30 00008420232018-10-012018-12-31 00008420232019-01-012019-03-31 00008420232019-04-012019-06-30
 

 

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-K

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended June 30, 2020, or

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period

from                      to                     

 

Commission file number 0-17272

 

BIO-TECHNE CORPORATION

(Exact name of registrant as specified in its charter)

 

Minnesota

 

41-1427402

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

614 McKinley Place N.E.

Minneapolis, MN 55413

 

(612) 379-8854

(Address of principal executive offices) (Zip Code)

 

(Registrant's telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

TECH

The NASDAQ Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes ☒  No ☐

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes ☐  No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒  No ☐

 

 
Table of Contents

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.    ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

  Large accelerated filer

 

 ☒

  

Accelerated filer

 

☐

 

 

 

 

  Non-accelerated filer

 

 ☐

  

Smaller reporting company

 

☐

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes ☐  No ☒

 

As of December 31, 2019 the aggregate market value of the Common Stock held by non-affiliates of the Registrant was $8.4 billion based upon the closing sale price as reported on The Nasdaq Stock Market ($219.51 per share). Shares of Common Stock held by each officer and director and by each person who owns 5% or more of the outstanding Common Stock have been excluded.

 

As of August 21, 2020, 38,550,371 shares of the Company’s Common Stock ($0.01 par value) were outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the Company’s Proxy Statement for its 2020 Annual Meeting of Shareholders are incorporated by reference into Part III.

 

 

 
Table of Contents

 

 

TABLE OF CONTENTS

 

 

 

Page

PART I

 

 

 

Item 1.

Business

1

 

 

 

Item 1A.

Risk Factors

9

 

 

 

Item 1B.

Unresolved Staff Comments

17

 

 

 

Item 2.

Properties

17

 

 

 

Item 3.

Legal Proceedings

17

 

 

 

Item 4.

Mine Safety Disclosures

17

 

 

 

PART II

 

 

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

18

 

 

 

Item 6.

Selected Financial Data

20

 

 

 

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

21

 

  

  

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

33

 

 

 

Item 8.

Financial Statements and Supplementary Data

34

 

 

 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

68

 

 

 

Item 9A.

Controls and Procedures

68

 

 

 

Item 9B.

Other Information

69

 

 

 

PART III

 

 

 

Item 10.

Directors, Executive Officers

70

 

 

 

Item 11.

Executive Compensation

70

 

 

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

70

 

 

 

Item 13.

Certain Relationships and Related Transactions, and Director Independence

70

 

 

 

Item 14.

Principal Accounting Fees and Services

70

 

 

 

PART IV
 

Item 15.

Exhibits, Financial Statement Schedules

71

 

 

 

 

SIGNATURES

73

 

i.
Table of Contents

 

 

 

FORWARD-LOOKING INFORMATION AND CAUTIONARY STATEMENTS

 

Certain statements included or incorporated by reference in this Annual Report, in other documents we file with or furnish to the Securities and Exchange Commission (“SEC”), in our press releases, webcasts, conference calls, materials delivered to shareholders and other communications, are “forward-looking statements” within the meaning of the U.S. federal securities laws.  All statements other than historical factual information are forward-looking statements, including, without limitation, projections of revenue, expenses, profit, profit margins, tax rates, tax provisions, cash flows, our liquidity position or other projected financial measures; product releases and strategy, acquisition plans or activity, the competitive environment and market position, currency fluctuation and exchange rates, capital expenditures, the performance of the Company's investments, future dividend declarations, the construction and lease of certain facilities, the adequacy of owned and leased property for future operations, future regulatory approvals and the timing and conditionality thereof, outstanding claims, legal proceedings and other contingent liabilities, the impact of the current COVID-19 pandemic on our operations or financial results and other statements that address events or developments that the Company intends or believes will or may occur in the future. Terminology such as “believe,” “anticipate,” “should,” “could,” “plan,” “expect,” “estimate,” “potential,” “forecast,” and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words.

 

All such forward-looking statements are intended to enjoy the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, as amended. Although the Company believes there is a reasonable basis for the forward-looking statements, the Company's actual results could be materially different. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to the risks and uncertainties set forth in “Item 1 A. Risk Factors” in this Annual Report.   Forward-looking statements speak only as of the date they are made, and the Company does not undertake any obligation to update any forward-looking statements except as required by law.

 

 

 

 

PART I

 

ITEM 1. BUSINESS

 

OVERVIEW

 

Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

 

During our fiscal year 2020, we operated under two operating segments – our Protein Sciences segment and our Diagnostics and Genomics segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of exosomal based molecular diagnostic assays, including the ExoDx®Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.    

 

We are a Minnesota corporation with our global headquarters in Minneapolis, Minnesota. We were founded over forty years ago, in 1976, as Research and Diagnostic Systems, Inc. We became a publicly traded company in 1985 through a merger with Techne Corporation, now Bio-Techne Corporation. Our common stock is listed on the NASDAQ under the symbol “TECH.” We operate globally, with offices in many locations throughout North America, Europe and Asia. Today, our product lines extend to over 300,000 products, most of which we manufacture ourselves in multiple locations in North America, as well as England and China.

 

Our historical focus was on providing high quality proteins, antibodies and immunoassays to the life science research market and hematology controls to the diagnostics market. Over the last seven years, we have been implementing a disciplined strategy to accelerate growth in part by acquiring businesses and product portfolios that leveraged and diversified our existing product lines, filled portfolio gaps with differentiated high growth businesses, and expanded our geographic scope. From fiscal years 2013 through 2020 we have acquired sixteen companies that have expanded the product offerings and geographic footprint of both operating segments. Recognizing the importance of an integrated, global approach to meeting our mission and accomplishing our strategies, we have maintained many of the brands of the companies we have acquired, but unified under a single global brand -- Bio-Techne. 

 

 

1
Table of Contents

 

OUR PRODUCTS AND MARKETS

 

In fiscal 2020, net sales from Bio-Techne’s Protein Sciences and Diagnostics and Genomics segments represented 75% and 25% of consolidated net sales, respectively. Financial information relating to Bio-Techne’s segments is incorporated herein by reference to Note 12 to the Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.

 

Protein Sciences Segment

 

The Protein Sciences segment is comprised of divisions with complementary product offerings serving many of the same customers – the Reagent Solutions division and the Analytical Solutions division.

 

Protein Sciences Segment Products

 

The Reagent Solutions division consists of specialized proteins, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera and cell selection technologies traditionally used by researchers to further their life science experimental activities and by companies developing next generation diagnostics and therapeutics, especially companies developing cell and gene-based therapeutics. Key product brands include R&D Systems, Tocris Biosciences, and Novus Biologicals. In 2019, we acquired Quad Technologies, which has novel Quickgel™ technologies for cell separation and activation, and B-MoGen Technologies, which has a non-viral, transposon-based technology for gene editing called TcBuster, a key technology targeted for the cell and gene therapy market. We have now leveraged these and other products we have or are developing in combination with two additional companies, Wilson Wolf and Fresenius Kabi, to provide a more complete offering for the cell and gene therapy market. Our combined chemical and biological reagents portfolio provides high quality tools that customers can use in solving the complex biological pathways and glean knowledge that may lead to a more complete understanding of biological processes, and, ultimately, to the development of novel therapeutic strategies to address different pathologies.

 

The Analytical Solutions division includes manual and automated protein analysis instruments and immunoassays that are used in quantifying proteins in a variety of biological fluids. Products in this division include traditional manual plate-based immunoassays, fully automated multiplex immunoassays on various instrument platforms, and automated western blotting and isoelectric focusing analysis of complex protein samples. Key product brands include R&D Systems and ProteinSimple. A number of our products have been demonstrated to have the potential to serve as predictive biomarkers and therapeutic targets for a variety of human diseases and conditions including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. Immunoassays can also be useful in clinical diagnostics. In fact, we have received Food and Drug Administration (FDA) marketing clearance for a few of our immunoassays for use as in vitro diagnostic devices. Most recently, in collaboration with Mount Sinai Hospital and its commercial entity, Kantaro Biosciences, we relied on that expertise to rapidly develop and commercialize an immunoassay kit intended to test for antibodies to COVID-19.

 

Protein Sciences Segment Customers and Distribution Methods

 

Our customers for this segment include researchers in academia, government and industry (chiefly pharmaceutical and biotech companies), as well as diagnostic/companion diagnostic and therapeutic customers, especially customers engaged in the development of cell and gene based therapies. Our biologics line of products in the Analytical Solutions division is used primarily by production and quality control departments at biotech and pharmaceutical companies. We sell our products directly to customers who are primarily located in North America, Europe and China. We have a sales and marketing partnership agreement with Fisher Scientific that supports our market presence in North America and leverages the transactional efficiencies offered by the large Fisher organization. We also sell through third party distributors in China, Japan, certain eastern European countries and the rest of the world. Our sales are widely distributed, and no single end-user customer accounted for more than 10% of the Protein Sciences segment's net sales during fiscal 2020, 2019 or 2018.

 

2
Table of Contents

 

Protein Sciences Segment Competitors

 

With respect to the Reagent Solutions division of this segment, a number of large companies supply the worldwide market for protein-related and chemically-based research and diagnostic reagents, including BD Biosciences, Merck KGaA/EMD Chemicals, Inc., PeproTech, Inc., Abcam plc., and Thermo Fisher Scientific, Inc, as well as a number of smaller, niche competitors.  Market success is primarily dependent upon product innovation and quality, selection of products, price and reputation. We believe we are one of the leading world-wide suppliers of cytokine and growth factors in the research market. We further believe that the expansion of our product offering, the recognized quality of our products, and the ability to continue to bring novel, cutting edge products and solutions to the market will allow us to remain competitive in the growing biotechnology research, diagnostic, and therapeutics markets. Our Analytical Solutions division has a number of similar competitors. Our Simple Western platform is a complete replacement for the traditional manual Western blotting technique. As a result, we face competition from the vendors that supply instruments and reagents to traditional Western blot users. These competitors include Bio-Rad Laboratories, Merck KGaA, PerkinElmer and Thermo Fisher Scientific. All of these vendors provide elements of the traditional work flow. Similarly, our SimplePlex platform replaces the traditional manual ELISA assay and introduces an automated multiplex immunoassay feature. Competitors include those who supply instruments and reagents for ELISAs, including Meso Scale Discovery, PerkinElmer, Thermo Fisher, Luminex, Millipore, Molecular Devices, Tecan BioTek, Quanterix and Bio-Rad Laboratories. The primary competitors for our Biologics instrumentation are Agilent Technologies, Danaher and PerkinElmer, as well as Shimadzu, Thermo Fisher and Waters. We believe our competitive position is strong due to the unique aspects of our products and our product quality.

 

Protein Sciences Segment Manufacturing

 

We are not dependent on key or sole source suppliers for most of our products in the Protein Sciences segment. We develop and manufacture the majority of our proteins using recombinant DNA technology, thus significantly reducing our reliance on outside resources. Our antibodies are produced using a variety of technologies including traditional animal immunization and hybridoma technology as well as recombinant antibody techniques. Our chemical-based small molecule products are synthesized from widely available products.

 

We manufacture our Analytical Solutions division instrumentation products for this segment at various locations in the United States and Canada. We manufacture our own components where we believe it adds significant value, but we rely on suppliers for the manufacture of some of the consumables, components, subassemblies and autosamplers used with, or included in, our systems, which are manufactured to our specifications. As with other products sold in this segment, we are not dependent on any one supplier and are not required to carry significant amounts of inventory to assure ourselves of a continuous allotment of goods from suppliers. We conduct all final testing and inspection of our products. We have established a quality control program, including a set of standard manufacturing and documentation procedures. All of our Protein Sciences Segment manufacturing sites are ISO 9001 or ISO 13485 certified or are in the process of being ISO certified.

 

The majority of our Reagent Solutions division products are shipped within one day of receipt of the customers' orders, while most of our Analytical Solutions products are shipped within one to two weeks of receipt of an order.

 

There was no significant backlog of orders for our Protein Sciences segment products as of the date of this Annual Report on Form 10-K or as of a comparable date for fiscal 2019.

 

Diagnostics and Genomics Segment

 

The Diagnostics and Genomics segment also includes two divisions focused primarily in the diagnostics market – the Diagnostics Reagents division and the Genomics division.

 

Diagnostics and Genomics Segment Products

 

The Diagnostic Reagents division consists of regulated products traditionally used as calibrators and controls in the clinical setting. Also included are instrument and process control products for hematology, blood chemistry, blood gases, coagulation controls and reagents used in various diagnostic applications. Often we manufacture these reagents on a custom basis, tailored to a customer's specific diagnostic assay technology. We supply these reagents in various formats including liquid, frozen, or in lyophilized form. Most of these products are sold on an Original Equipment Manufacturer (OEM) basis to instrument manufacturers with most products being FDA-cleared.

 

The Genomics division includes products aimed at nucleic acid (RNA or DNA) analysis that can be used for diagnostic or research applications. Key product brands include Advanced Cell Diagnostics, or ACD, and Exosome Diagnostics. ACD products are aimed at RNA analysis of tissue while Exosome Diagnostics focuses on exosome-based liquid biopsy techniques that analyze genes or their transcripts. The first commercialized test from Exosome Diagnostics is a urine-based assay for early detection of high-grade prostate cancer used as an aid in deciding the need for an initial biopsy.

 

3
Table of Contents

 

Diagnostics and Genomics Segment Customers and Distribution Methods

 

The majority of Diagnostic Reagents Division's sales are through OEM agreements, but we sell some of our diagnostics reagents products directly to customers and, in Europe and Asia, also through distributors. The customers for the ACD research products include researchers in academia as well as investigators in pharmaceutical and biotech companies. We sell our products directly to those customers who are primarily located in North America, Europe and China, and through distributors elsewhere. In addition to being useful research tools, our RNA in situ hybridization assays have diagnostics applications as well, and several are currently under review by the FDA in partnership with diagnostics instrument manufacturers and pharmaceutical companies. In the United States, we offer test services to physicians using our lab-developed non-invasive urine-based assay for prostate cancer detection.  Our diagnostic laboratory is certified under and regulated by the State of Massachusetts pursuant to the Clinical Laboratory Improvement Amendments, or CLIA. Customers are physicians prescribing such tests for their patients.

 

No customers accounted for 10% or more of the reporting segment's consolidated net sales during fiscal years 2020, 2019, or 2018.

 

Diagnostics and Genomics Segment Competitors

 

In the Diagnostics Reagents division, the competitors for our hematology controls product line include Danaher, Beckman Coulter and Streck. For our other control and calibrator products sold in this division, the principal competitors are Abbott Diagnostics, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Siemens Healthcare Diagnostics Inc. and Sysmex Corporation. We compete based primarily on product performance, quality, and price in this division. SeraCare, HyTest Ltd and Thermo Fisher Scientific are additional competitors in the clinical diagnostic manufacturing and reagents markets.

 

Competitors in the Genomics division are varied, depending on the product line. While there are not any direct competitors for the RNA-based in situ hybridization products sold under the ACD brand, they are intended to be an alternative to immunohistochemistry assays and PCR-based diagnostic tests in certain circumstances. The non-invasive urine-based assay offered under our Exosome Diagnostics brand and used for prostate cancer biopsy decisions is supplemental to blood-based prostate-specific antigen (PSA) tests, and is competitive with some other companies that offer liquid biopsy-based alternatives such as 4kscore offered by Opko Health and SelectMDx offered by MDxHealth.

 

Diagnostics and Genomics Segment Manufacturing

 

The primary raw material for our hematology controls products is whole blood. We purchase human blood from commercial blood banks, and porcine and bovine blood from nearby meat processing plants. Although the cost of human blood has increased due to the requirement that it be tested for certain diseases and pathogens prior to use, the higher cost of these materials has not had a material adverse effect on our business thus far. Other controls are derived from various bodily fluids or cells from different animal species, which are then processed in-house to isolate the product of interest or from other bulk reagent suppliers that specialize in certain products. Our other reagent products are manufactured using a variety of suppliers, with no supplier representing a material portion of our business.

 

Most of the hematology controls products are shipped based on a preset, recurring schedule. However, most of our business in this segment come from large orders shipped based on our customers' needs; we are highly dependent on our customers’ demand and inventory controls. Consequently, our revenues can vary significantly from quarter to quarter and year to year.

 

Our Genomics division products and services are all synthesized from widely available products. We typically have several outside sources for all critical raw materials necessary for the manufacture of our products in this division. 

 

There was no significant backlog of orders for our Diagnostics and Genomics segment as of the date of this Annual Report on Form 10-K or as of a comparable date for fiscal 2019.

 

4
Table of Contents

 

The following discussion includes information common to both of the Company’s segments. 

 

Geographic Information

 

Following is financial information relating to geographic areas (in thousands): 

 

   

Year Ended June 30,

  
   

2020

     2019     2018  

Net sales:

                        

United States

   $ 404,407     $ 391,191     $ 346,293  

EMEA, excluding U.K.

     155,289       155,821       148,599  

U.K.

     30,411       34,975       33,704  

APAC, excluding Greater China

     60,362       52,913       48,392  

Greater China

     68,792       57,799       47,950  

Rest of world

     19,430       21,307       18,055  

Total net sales

   $ 738,691     $ 714,006     $ 642,993  

  

   

Year ended June 30,

  
   

2020

     2019  

Long-lived assets:

                

North America

   $ 162,039     $ 138,016  

Europe

     13,120       14,439  

Asia

     1,670       1,584  

Total long-lived assets

   $ 176,829     $ 154,039  

Intangible assets:

                

North America

   $ 499,875     $ 556,951  

Europe

     12,349       16,637  

Asia

     4,321       5,841  

Total intangible assets

   $ 516,545     $ 579,429  

 

Net sales are attributed to countries based on the location of the customer or distributor. Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation. See the description of risks associated with the Company's foreign subsidiaries in Item 1A of this Annual Report on Form 10-K.  

 

5
Table of Contents

 

 

 

PRODUCTS UNDER DEVELOPMENT

 

Bio-Techne is engaged in continuous research and development in all of our major product lines. We believe that our future success depends, to a large extent, on our ability to keep pace with changing technologies and market needs. In response to the global pandemic that emerged in early 2020, we diverted some of our development resources to new and existing products to meet the needs associated with COVID-19, including a major effort by the development teams in our Protein Sciences Segment to develop a diagnostic immunoassay for testing antibodies to COVID-19. However, there is no assurance that any of the products in the research and development phase can be successfully completed or, if completed, can be successfully introduced into the marketplace.

 

  

   

Year Ended June 30,

  
   

2020

     2019     2018  

Research and development expense:

                        

Protein Sciences Segment

     43,022       40,735       40,996  

Diagnostics & Genomics Segment

     22,170       21,678       14,095  

Corporate

     -       -       239  

Total research and development expense

   $ 65,192     $ 62,413     $ 55,329  
                         

Percent of net sales

     9

%

     9

%

     9

%

  

INTELLECTUAL PROPERTY

 

Our success depends in part upon our ability to protect our core technologies and intellectual property. To accomplish this, we rely on a combination of intellectual property rights, including patents, trade secrets and trademarks, as well as customary contractual protections.

 

As of June 30, 2020, we had rights to 258 granted patents and approximately 225 pending patent applications.  In particular, products in the Analytical Solutions and Genomics divisions are protected primarily through pending patent applications and issued patents. In addition, certain of our products are covered by licenses from third parties to supplement our own patent portfolio.  Patent protection, if granted, generally has a life of 20 years from the date of the patent application or patent grant. We cannot provide assurance that any of our pending patent applications will result in the grant of a patent, whether the examination process will require us to narrow our claims, and whether our claims will provide adequate coverage of our competitors' products or services.

 

In addition to pursuing patents on our products, we also preserve much of our innovation as trade secrets, particularly in the Reagent Solutions division of our Protein Sciences segment. We have taken steps to protect our intellectual property and proprietary technology, in part by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. See the description of risks associated with the Company's intellectual property in Item 1A of this Annual Report on form 10-K.

 

We can give no assurance that Bio-Techne's products do not infringe upon patents or proprietary rights owned or claimed by others. Bio-Techne has not conducted a patent infringement study for each of its products. Where we have been contacted by patent holders with certain intellectual property rights, Bio-Techne typically has entered into licensing agreements with patent holders under which it has the exclusive and/or non-exclusive right to use patented technology as well as the right to manufacture and sell certain patented products to the research and/or diagnostics markets.

 

Bio-Techne has obtained trademark registration in certain countries for certain of its brand and product names. Bio-Techne believes it has common law trademark rights to certain marks in addition to those which it has registered.

 

6
Table of Contents

 

SEASONALITY OF BUSINESS

 

Bio-Techne believes there is some seasonality as a result of vacation and academic schedules of its worldwide customer base, particularly for the Protein Sciences segment. A majority of Diagnostics Reagents division products are manufactured in large bulk lots and sold on a schedule set by the customer. Consequently, sales for that segment can be unpredictable, and not necessarily based on seasonality. As a result, we can experience material and sometimes unpredictable fluctuations in our revenue from this segment.

 

LAWS AND REGULATIONS

 

Our operations, and some of the products we offer, are subject to a number of complex laws and regulations governing the production, marketing, handling, transportation and distribution of our products and services.  The following sections describe certain significant regulations pertinent to the Company. These are not the only regulations that the Company’s business.  For a description of risks related to laws and regulations to which we are subject, refer to Item 1.A. Risk Factors.”

 

Medical Device Regulations and Other Healthcare Laws.

 

A number of our products are classified as medical devices and are subject to restrictions under domestic and foreign laws, rules, regulations, self-regulatory codes and orders, including but not limited to the U.S. Food, Drug and Cosmetic Act (the “FDCA”).  The FDCA requires these products, when sold in the United States, to be safe and effective for their intended uses and to comply with the regulations administered by the U.S. Food and Drug Administration (“FDA”).  The FDA regulates the design, development, testing, manufacture, advertising, labeling, packaging, marketing, distribution, import and export and record keeping for such products.  Many medical device products are also regulated by comparable agencies in non-U.S. countries in which they are produced or sold.

 

Any medical devices we manufacture and distribute are subject to pervasive and continuing regulation by the FDA and certain state and non-U.S. agencies.  As a medical device manufacturer, our manufacturing facilities are subject to inspection on a routine basis by the FDA.  We are required to adhere to the Current Good Manufacturing Practices (“CGMP”) requirements, as set forth in the Quality Systems Regulation (“QSR”), which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all phases of the design and manufacturing process.

 

We must also comply with post-market surveillance regulations, including medical device reporting, or MDR, requirements which require that we review and report to the FDA any incident in which our products may have caused or contributed to a death or serious injury.  We must also report any incident in which our product has malfunctioned if that malfunction would likely cause or contribute to a death or serious injury it if were to recur.

 

Labeling and promotional activities are subject to scrutiny by the FDA and, in certain circumstances, by the Federal Trade Commission.  Medical devices approved or cleared by the FDA may not be promoted for unapproved or uncleared uses, otherwise known as “off-label” promotion.  The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.

 

In the European Union (“EU”), our products are subject to the medical device laws of the various member states, which are currently based on a Directive of the European Commission.  However, the EU has adopted the EU Medical Device Regulation (the “EU MDR”) and the In Vitro Diagnostic Regulation (the “EU IVDR”), each of which impose stricter requirements for the marketing and sale of medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance.  Manufacturers of currently approved medical devices had until May 2020 to meet the requirements of the EU MDR and until May 2022 to meet the EU IVDR.  Complying with the EU MDR and EU IVDR requires modifications to our quality management systems, additional resources in certain functions and updates to technical files, among other changes.

 

One of our products under our Exosome Diagnostics brand is offered as a test under a CLIA-certified laboratory; consequently, we must comply with governmental regulations relating to all elements of our sales, marketing, billing practices and financial relationships with physicians, hospitals, and health systems.

 

Data Privacy and Security Laws

 

As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business.  For example, in the United States, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), privacy and security rules require certain of our operations to maintain controls to protect the availability and confidentiality of patient health information. Individual states also regulate data breach and security requirements and multiple governmental bodies assert authority over aspects of the protection of personal  privacy.  In particular, there is a new, broad privacy law in California, the California Consumer Privacy Act (“CCPA”), which came into effect in January 2020.  The CCPA has some of the same features as the GDPR (discussed below), and has already prompted several other states to follow with similar laws.  The EU General Data Protection Regulation that became effective in May 2018 (“GDPR”) has imposed significantly stricter requirements in how we collect, transmit, process and retain personal data, including, among other things, in certain circumstances a requirement for almost immediate notice of data breaches to supervisory authorities and prompt notice to data subjects with significant fines for non-compliance.  Several other countries such as China and Russia have passed, and other countries are considering passing, laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions.

 

Other Laws and Regulations Governing Our Sales, Marketing and Shipping Activities.

 

We are subject to the U.S. Foreign Corrupt Practices Act and various other similar anti-corruption and anti-bribery acts, which are particularly relevant to our operations in countries where the customers are government entities or are controlled by government officials.  Both we directly, and indirectly through our distributors, must comply with such laws when interacting with those entities.

 

As Bio-Techne’s businesses also include export and import activities, we are subject to pertinent laws enforced by the U.S. Departments of Commerce, State and Treasury.

 

We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by a reduction in revenue associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

 

7
Table of Contents

 

EMPLOYEE RELATIONS

 

Through its subsidiaries, Bio-Techne employed approximately 2,300 full-time and part-time employees as of June 30, 2020. None of the United States employees are unionized. Outside the United States, the Company has government-mandated collective bargaining arrangements or work councils in certain countries.   

 

  INVESTOR INFORMATION

 

We are subject to the information requirements of the Securities Exchange Act of 1934 (the Exchange Act). Therefore, we file periodic reports, proxy statements, and other information with the Securities and Exchange Commission (SEC). The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically.

 

Financial and other information about us is available on our web site (https://investors.bio-techne.com/). We make available on our web site copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Exchange Act as soon as reasonably practicable after filing such material electronically or otherwise furnishing it to the SEC.

 

EXECUTIVE OFFICERS OF THE REGISTRANT

 

Currently, the names, ages, positions and periods of service of each executive officer of the Company are as follows:

 

Name

  

Age

  

Position

  

Officer Since

 

 

 

 

 

 

 

Charles Kummeth

  

60

  

President, Chief Executive Officer and Director

  

2013

James T. Hippel

  

49

  

Chief Financial Officer

  

2014

David Eansor

  

59

  

President, Protein Sciences

  

2014

Kim Kelderman

 

53

 

President, Diagnostics and Genomics

 

2018

Brenda Furlow

  

62

  

General Counsel and Corporate Secretary

  

2014

 

Set forth below is information regarding the business experience of each executive officer. There are no family relationships among any of the officers named, nor is there any arrangement or understanding pursuant to which any person was selected as an officer.

 

Charles Kummeth has been President and Chief Executive Officer of the Company since April 1, 2013. Prior to joining the Company, he served as President of Mass Spectrometry and Chromatography at Thermo Fisher Scientific Inc. from September 2011. He was President of that company's Laboratory Consumables Division from 2009 to September 2011. Prior to Thermo Fisher, Mr. Kummeth served in various roles at 3M Corporation, most recently as the Vice President of the company's Medical Division from 2006 to 2008.

 

James T. Hippel has been Chief Financial Officer of the Company since April 1, 2014. Prior to joining the Company, Mr. Hippel served as Senior Vice President and Chief Financial Officer for Mirion Technologies, Inc., a $300 million global company that provides radiation detection and identification products. Prior to Mirion, Mr. Hippel served as Vice President, Finance at Thermo Fisher Scientific, Inc., leading finance operations for its Mass Spectrometry & Chromatography division and its Laboratory Consumables division. In addition, Mr. Hippel's experience includes nine years of progressive financial leadership at Honeywell International, within its Aerospace Segment. Mr. Hippel started his career with KPMG LLP.

 

David Eansor has been President of the Protein Sciences segment since July 1, 2018. Prior to that, he served as Senior Vice President, Biotechnology Division and as Senior Vice President, Novus Biologicals since the Company completed its acquisition of Novus on July 2, 2014. From January 2013 until the date of the acquisition, Mr. Eansor was the Senior Vice President of Corporate Development of Novus Biologicals. Prior to joining Novus Biologicals, Mr. Eansor was the President of the Bioscience Division of Thermo Fisher Scientific. Mr. Eansor was promoted to Division President in early 2010 after 5 years as President of Thermo Fisher's Life Science Research business.

    

Kim Kelderman joined Bio-Techne on April 30, 2018 as President, Diagnostics and Genomics. Prior to Bio-Techne, Mr. Kelderman was employed at Thermo Fisher Scientific where he led three different businesses of increasing scale and complexity. For the last three years, Mr. Kelderman managed the Platforms and Content of the Genetic Sciences Division, where he was responsible for the Instrumentation, Software, Consumables and Assays businesses, and brands such as Applied Biosystems and legacy Affymetrix. Before joining Thermo Fisher, Kim served as Senior Segment Leader at Becton Dickinson, managing the global Blood Tubes “Vacutainer” business.

 

Brenda Furlow joined the Company as General Counsel and Corporate Secretary on August 4, 2014. Prior to joining Bio-Techne, Ms. Furlow served as general counsel to emerging growth technology companies. Ms. Furlow was General Counsel for TomoTherapy, a global, publicly traded company that manufactured and sold radiation therapy equipment, from 2007 to 2011. From 1998 to 2007, Ms. Furlow served as General Counsel for Promega Corporation, a global life sciences company.

 

8
Table of Contents

 

ITEM 1A. RISK FACTORS

 

Statements in this Annual Report on Form 10-K and elsewhere that are forward-looking involve risks and uncertainties which may affect the Company's actual results of operations. Certain of these risks and uncertainties, which have affected and, in the future, could affect the Company's actual results are discussed below. The Company undertakes no obligation to update or revise any forward-looking statements made due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

 

The following risk factors should be read carefully in connection with evaluation of the Company's business and any forward-looking statements made in this Annual Report on Form 10-K and elsewhere. See the section entitled “forward-looking statements” set forth above. Any of the following risks or others discussed in this Annual Report on Form 10-K or the Company's other SEC filings could materially adversely affect the Company's business, operating results and financial condition.

 

Conditions in the global economy, the particular markets we serve and the financial markets brought about by material global crises may adversely affect our business and financial statements.

 

COVID-19 is having, and will continue to have, an adverse impact on our employees, operations, supply chains, and sales and distribution systems, including as a result of impacts associated with protective health measures that we, other businesses and governments are taking. Many employers in our primary locations of business have closed partially or fully and  required their employees to work from home or not work at all. While many businesses have re-opened as the pandemic eased in particular locations, a resurgence of COVID-19 cases in those geographies could continue to cause additional closures. These site closures have included our customers, which have caused and will continue to cause customers to delay or forego purchases of our products. During the pandemic, we have experienced, and will continue to experience, significant and unpredictable reductions or increases in demand for certain of our products. As the pandemic continues, we expect to experience lower than normal sales activities and customer orders in most of our businesses, and it remains uncertain what impact these declines will have on future sales and customer orders.  While there has been some improvement in sales in the summer of 2020, there is no certainty that that improvement will continue, or how long the economic recovery will take as the pandemic eases. In addition to existing travel restrictions, countries may continue to close borders, impose prolonged quarantines, and further restrict travel, which may impact our ability to support our sites and customers in the future while also significantly limiting the ability of our products from moving through the supply chain. As a result, given the rapid and evolving nature of the virus, COVID-19 will continue to negatively affect our revenue growth, and it is uncertain how materially COVID-19 will affect our global operations, which generally will become more severe over an extended period of time. Any of these impacts would have an adverse effect on our business, financial condition and results of operations, and at this point, the extent of the impact of COVID-19 remains uncertain.

 

In recent months, we have introduced new products or modified existing products to serve the research and healthcare markets as they address the global pandemic through novel diagnostic and therapeutic products. The most significant of those new product launches, we believe, is the novel two-step serology assay that was developed based on and in collaboration with Mount Sinai Hospital System and its commercial entity, Kantaro Biosciences. In the first half of calendar year 2020 we allocated significant resources to that development.  While we believe it is promising, the product only recently has been introduced commercially.  There can be no assurance that it will be widely adopted or used, especially if the pandemic eases or a vaccine is commercialized.  Alternatively, if demand is great, there is no assurance we will be able to maintain the personnel, raw materials, production facilities or other resources required to meet a significantly greater than anticipated need.         

 

 

It may be difficult for us to implement our strategies for revenue growth in light of competitive challenges.

 

We face significant competition across many of our product lines. Competitors include companies ranging from start-up companies, which may be able to more quickly respond to customers' needs, to large multinational companies, which may have greater financial, marketing, operational, and research and development resources than the Company. In addition, consolidation trends in the pharmaceutical, biotechnology and diagnostics industries have served to create fewer customer accounts and to concentrate purchasing decisions for some customers, resulting in increased pricing pressure on the Company. Moreover, customers may believe that consolidated businesses are better able to compete as sole source vendors, and therefore prefer to purchase from such businesses. The entry into the market by manufacturers in China, India and other low-cost manufacturing locations is also creating increased pricing and competitive pressures, particularly in developing markets. Failure to anticipate and respond to competitors' actions may impact the Company's future sales and earnings.

 

To address this issue, we are pursuing a number of strategies to maintain and improve our revenue growth, including:

 

 

•

strengthening our presence in selected geographic markets;
 

•

allocating research and development funding to products with higher growth prospects;
 

•

developing new applications for our technologies;
 

•

continuing key opinion leader initiatives;
 

•

finding new markets for our products;
 

•

acquiring new products and business in growing or novel markets; and
 

•

continuing the development of commercial tools and infrastructure to increase and support cross-selling opportunities of products and services to take advantage of our depth in product offerings.

 

We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.

 

Our acquisition growth strategy poses financial, management and other risks and challenges.

 

We routinely explore acquiring other businesses and assets, and have completed sixteen acquisitions and several investments in the last eight years. However, we may be unable to identify or complete promising acquisitions for many reasons, including competition among buyers, the high valuations of businesses in our industry, the need for regulatory and other approvals, and availability of capital. There can be no assurance that we will engage in any additional acquisitions or that we will be able to do so on terms that will result in any expected benefits. In addition, acquisitions financed with borrowings could make us more vulnerable to business downturns and could negatively affect our earnings due to higher leverage and interest expense.

 

9
Table of Contents

 

Our inability to complete acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect on our business. 

 

Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services. Certain acquisitions may be difficult to complete for a number of reasons, including the need for antitrust and/or other regulatory approvals. Any acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets of the acquired company. When we do identify and consummate acquisitions, we may face financial, managerial and operational challenges, including diversion of management attention, integration of different corporate cultures, increased expenses, assumption of unknown liabilities, indemnities, potential disputes with the sellers, and the need to evaluate the financial systems of and establish internal controls for acquired entities. Further, we may not be able to integrate acquired businesses successfully into our existing businesses, make such businesses profitable, or realize anticipated cost savings or synergies, if any, from these acquisitions, which could adversely affect our overall business.

 

We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets, or other investments become impaired.

 

We are required under generally accepted accounting principles to test goodwill for impairment at least annually and to review our goodwill, amortizable intangible assets, and other assets acquired through merger and acquisition activity, for impairment when events or changes in circumstance indicate the carrying value may not be recoverable. Factors that could lead to impairment of goodwill, amortizable intangible assets, and other assets acquired via acquisitions include significant adverse changes in the business climate and actual or projected operating results (affecting our company as a whole or affecting any particular segment) and declines in the financial condition of our business. We may be required in the future to record additional charges to earnings if our goodwill, amortizable intangible assets or other investments become impaired. Any such charge would adversely impact our financial results.

 

In addition, the Company's expansion strategies include collaborations and investments in joint ventures and companies developing new products related to the Company's business. These strategies carry risks that objectives will not be achieved and future earnings will be adversely affected. For example, the Company has an approximate 2% equity investment in publicly traded ChemoCentryx, Inc. (Nasdaq: CCXI) that is valued at $87.8 million as of June 30, 2020. The ownership of CCXI shares is very concentrated, the share price is highly volatile and there is limited trading of the shares. In fiscal 2017, we also invested and held a minority interest in privately-held Astute Medical, Inc. (Astute), a diagnostics company developing new diagnostics tests relating to kidney injury. In fiscal 2018, Astute was acquired by a third party and we realized a $16.2 million loss on our investment.

 

Significant developments or uncertainties stemming from the U.S. administration or resulting in potential changes resulting from the elections in the U.S. this fall, including changes in U.S. trade policies, tariffs, healthcare, taxes or other matters and the reaction of other countries thereto, could have an adverse effect on our business.

 

Changes, potential changes or uncertainties in U.S. social, political, regulatory and economic conditions or laws and policies governing foreign trade, manufacturing, and development and investment in the territories and countries where we or our customers operate, or governing the health care system, can adversely affect our business and financial statements. For example, the current U.S. administration has called for substantial changes to trade agreements and has over the last three years imposed significant increases on tariffs for goods imported into the United States, particularly from China. Other countries have responded similarly, with tariffs on goods entering their countries. The U.S. administration has also indicated an intention to ask Congress to make significant changes, replacement or elimination of the Patient Protection and Affordable Care Act, and government negotiation/regulation of drug prices paid by government programs.

 

Additionally, in a referendum vote held on June 23, 2016, the United Kingdom (UK) voted to leave the European Union (EU). This referendum has created political and economic uncertainty, particularly in the UK and the EU, and this uncertainty may last for years as the parties negotiate new trade agreements and governmental relationships . Our business could be affected during this period of uncertainty, and perhaps longer, by the impact of the UK's exit from the EU. In addition, our business could be negatively affected by new trade agreements between the UK and other countries, including the United States, and by the possible imposition of trade or other regulatory barriers in the UK. Any of these factors could adversely affect customer demand, our relationships with customers and suppliers, and our business and financial results, particularly since our European headquarters and shipping facilities are currently located in the UK. Additionally, attracting and retaining qualified employees who are citizens of EU countries to our UK facilities may be more difficult given the uncertainties resulting from the UK's withdrawal.

 

10
Table of Contents

 

Changes in governmental regulations may reduce demand for our products or increase our expenses. 

 

We compete in many markets in which we and our customers must comply with federal, state, local and international regulations, such as environmental, health and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by those regulations. Any significant change in regulations could reduce demand for our products or increase our expenses. For example, many of our instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs. Changes in the U.S. Food and Drug Administration’s regulation of the drug discovery and development process could have an adverse effect on the demand for these products.

 

We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenue associated with these customers.

 

We have agreements relating to the sale of our products to government entities in the U.S. and elsewhere and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

 

We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies. 

 

We are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the U.S. Federal Drug Administration (the FDA), the U.S. Drug Enforcement Agency (the DEA), the U.S. Department of Health and Human Services (the DHHS), and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices. Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of, the DEA, the FDA, the DHHS, foreign agencies and/or comparable state agencies as well as certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale. The manufacture, distribution and marketing of many of our products and services, including medical devices and pharma services, are subject to extensive ongoing regulation by the FDA, the DEA, and other equivalent local, state, federal and non-U.S. regulatory authorities. In addition, we are subject to inspections by these regulatory authorities. Failure by us or by our customers to comply with the requirements of these regulatory authorities, including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could expose us to contractual or product liability claims, contractual claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are the sole manufacturer of a number of products for many of our customers and a negative regulatory event could impact our customers' ability to provide products to their customers.

 

We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the importation and exportation of products, the handling, transportation and manufacture of substances that could be classified as hazardous, and our business practices in the U.S. and abroad such as anti-corruption and anti-competition laws. Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of operations. 

 

We are subject to financial, operating, legal and compliance risk associated with global operations.

 

We engage in business globally, with approximately 45% of our sales revenue in fiscal 2020 coming from outside the U.S. In addition, one of our strategies is to expand geographically, particularly in China, India and in developing countries, both through distribution and through direct operations. This subjects us to a number of risks, including international economic, political, and labor conditions; currency fluctuations; tax laws (including U.S. taxes on foreign subsidiaries); increased financial accounting and reporting burdens and complexities; unexpected changes in, or impositions of, legislative or regulatory requirements; failure of laws to protect intellectual property rights adequately; inadequate local infrastructure and difficulties in managing and staffing international operations; delays resulting from difficulty in obtaining export licenses for certain technology; tariffs, quotas and other trade barriers and restrictions; transportation delays; operating in locations with a higher incidence of corruption and fraudulent business practices; and other factors beyond our control, including terrorism, war, natural disasters, climate change and diseases.

 

The application of laws and regulations impacting global transactions is often unclear and may at times conflict. Compliance with these laws and regulations may involve significant costs or require changes in our business practices that result in reduced revenue and profitability. Non-compliance could also result in fines, damages, criminal sanctions, prohibited business conduct, and damage to our reputation. We incur additional legal compliance costs associated with our global operations and could become subject to legal penalties in foreign countries if we do not comply with local laws and regulations, which may be substantially different from those in the U.S.

 

We continue to expand our operations in countries with developing economies, where it may be common to engage in business practices that are prohibited by U.S. regulations applicable to the Company, such as the Foreign Corrupt Practices Act. Although we implement policies and procedures designed to ensure compliance with these laws, there can be no assurance that all of our employees, contractors, and agents, as well as those companies to which we outsource certain aspects of our business operations, including those based in foreign countries where practices which violate such U.S. laws may be customary, will comply with our internal policies. Any such non-compliance, even if prohibited by our internal policies, could have an adverse effect on our business and result in significant fines or penalties.

  

11
Table of Contents

 

Changes in economic conditions could negatively impact our revenues and earnings.

 

Our Protein Sciences segment products are sold primarily to research scientists at pharmaceutical and biotechnology companies and at university and government research institutions. In addition to the impacts described above relating to COVID-19, research and development spending by our customers and the availability of government research funding can fluctuate due to changes in available resources, mergers of pharmaceutical and biotechnology companies, spending priorities, general economic conditions and institutional and governmental budgetary policies. Our Genomics and Diagnostics segment products are intended primarily for the medical diagnostics market, which relies largely on government healthcare-related policies and funding. Changes in government reimbursement for certain diagnostic tests or reductions in overall healthcare spending could negatively impact us directly or our customers and, correspondingly, our sales to them. Several years ago, the U.S. and global economies experienced a period of economic downturn and have been slow to recover in some parts of the world. Such downturns, and other reductions or delays in governmental funding, could cause customers to delay or forego purchases of our products. We carry essentially no backlog of orders and changes in the level of orders received and filled daily can cause fluctuations in quarterly revenues and earnings.

 

Management could fail to maintain effective internal controls over financial reporting which could harm our operating results or cause us to fail to meet our reporting obligations. 

 

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act. A material weakness is defined as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. As we continue to grow and acquire additional business, we may fail to implement effective internal controls for our recently acquired operations that may result in a material weakness. Additionally, we may experience a breakdown in internal controls over our existing businesses that would prevent the timely identification of a material misstatement in our interim or annual financial statements. A material weakness may also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common shares.

 

Our success will be dependent on recruiting and retaining highly qualified personnel and creating a new culture that includes the employees joining through acquisition.

 

Recruiting and retaining qualified scientific, production, sales and marketing, and management personnel are critical to our success. Our anticipated growth and its expected expansion into areas and activities requiring additional expertise will require the addition of new personnel and the development of additional expertise by existing personnel. We also operate in several geographic locations where competition for talent is strong, making employee retention particularly challenging. For example, some of our fastest growing businesses are located in northern California and eastern Massachusetts, both of which generally have low unemployment and a competitive environment for finding and retaining talent. Our growth by acquisition also creates challenges in retaining employees. As we integrate past and future acquisitions and evolve our corporate culture to incorporate the new workforces, some employees may not find such integration or cultural changes appealing. The failure to attract and retain such personnel could adversely affect our business.

 

Cyber security risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, and internet applications and related tools and functions, could result in damage to our reputation, data integrity and/or subject us to costs, fines, or lawsuits under data privacy or other laws or contractual requirements.

 

The integrity and protection of our own data, and that of our customers and employees, is critical to our business. The regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve. Maintaining compliance with applicable security and privacy regulations may increase our operating costs and/or adversely impact our ability to market our products and services to customers. Although our computer and communications hardware are protected through physical and software safeguards, they are still vulnerable to fire, storm, flood, power loss, earthquakes, telecommunications failures, physical or software break-ins, software viruses, and similar events. These events could lead to the unauthorized access, disclosure and use of non-public information. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures. If our computer systems are compromised, we could be subject to fines, damages, litigation, and enforcement actions, customers could curtail or cease using its applications, and we could lose trade secrets, the occurrence of which could harm our business.

 

If we are unable to maintain reliable information technology systems and appropriate controls with respect to global data privacy and security requirements and prevent data breaches, we may suffer regulatory consequences in addition to business consequences. As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business. For example, in the United States, individual states regulate data breach and security requirements and multiple governmental bodies assert authority over aspects of the protection of personal privacy. Most notably, last year the state of California passed sweeping privacy legislation called the California Consumer Privacy Act, or CCPA that has impacted our business and could result in more material impacts as implementing regulations are issued. European laws require us to have an approved legal mechanism to transfer personal data out of Europe, and the recently-enacted EU General Data Protection Regulation, which took effect in May 2018, imposes significantly stricter requirements in how we collect and process personal data. Several countries, such as China and Russia, have passed laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions. Government enforcement actions can be costly and interrupt the regular operation of our business, and data breaches or violations of data privacy laws can result in fines, reputational damage and civil lawsuits, any of which may adversely affect our business, reputation and financial statements.

 

12
Table of Contents

 

We are dependent on maintaining our intellectual property rights.

 

Our success depends in part on our ability to protect and maintain our intellectual property, including trade secrets. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us, we may lose our technological or competitive advantage, or we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. We attempt to protect trade secrets in part through confidentiality agreements, but those agreements can be breached, and if they are, there may not be an adequate remedy. If trade secrets become publicly known, we could lose our competitive position.

  

We also attempt to protect and maintain intellectual property through the patent process. As of June 30, 2020, we owned or exclusively licensed over 515 granted patents and pending patent applications. We cannot be confident that any of our currently pending or future patent applications will result in granted patents, and we cannot predict how long it will take for such patents to be granted. It is possible that, if patents are granted to us, others will design around our patented technologies. Further, other parties may challenge any patents granted to us and courts or regulatory agencies may hold our patents to be invalid or unenforceable. We may not be successful in defending challenges made against our patents and patent applications. Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents. Our ability to establish or maintain a technological or competitive advantage over our competitors may be diminished because of these uncertainties. To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage of our competitors' products, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time consuming and expensive.

 

We may be involved in disputes to determine the scope, coverage and validity of others' proprietary rights, or to defend against third-party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business.

 

Our success depends in part on its ability to operate without infringing the proprietary rights of others, and to obtain licenses where necessary or appropriate. We have obtained and continue to negotiate licenses to produce a number of products claimed to be owned by others. Since we have not conducted a patent infringement study for each of our products, it is possible that some of our products may unintentionally infringe patents of third parties.

 

We have been and may in the future be sued by third parties alleging that we are infringing their intellectual property rights. These lawsuits are expensive, take significant time, and divert management's focus from other business concerns. If we are found to be infringing the intellectual property of others, we could be required to cease certain activities, alter our products or processes or pay licensing fees. This could cause unexpected costs and delays which may have a material adverse effect on us. If we are unable to obtain a required license on acceptable terms, or unable to design around any third party patent, we may be unable to sell some of our products and services, which could result in reduced revenue. In addition, if we do not prevail, a court may find damages or award other remedies in favor of the opposing party in any of these suits, which may adversely affect our earnings.

 

Our ExoDx Prostate(IntelliScore), or EPI test, may not receive or maintain government or private reimbursement coverage for clinical laboratory testing as planned, which may have a material adverse effect upon the revenue and profits for this product line.

 

In August 2018, we acquired Exosome Diagnostics, which sells the ExoDx Prostate or EPI test, a non-invasive urine test that predicts the aggressiveness of prostate cancer. We received public payer coverage for certain uses, but are currently seeking expanded coverage from public payors as well as coverage decisions regarding reimbursement from additional private payers. However, the process and timeline for obtaining coverage decisions is uncertain and difficult to predict. Moreover, federal and state government payers, such as Medicare and Medicaid, as well as insurers, including managed care organizations, continue to increase their efforts to control the cost, utilization and delivery of healthcare services. From time to time, Congress considers and implements changes in Medicare fee schedules affecting reimbursement rates in conjunction with budgetary legislation. Further, reimbursement reductions due to changes in policy regarding coverage of tests or other requirements for payment (such as prior authorization, diagnosis code and other claims edits, or a physician or qualified practitioner’s signature on test requisitions) may be implemented from time to time. Still further, changes in third-party payer regulations, policies, or laboratory benefit or utilization management programs, as well as actions by federal and state agencies regulating insurance, including healthcare exchanges, or changes in other laws, regulations, or policies, may have a material adverse effect on revenue and earnings associated with Exosome Diagnostics’ ExoDx Prostate test.

 

The Company could face significant monetary damages and penalties and/or exclusion from government programs if its Exosome Diagnostics’ EPI business violates federal, state, local or international laws including, but not limited to, anti-fraud and abuse laws.

  

As a healthcare provider, the Company’s Exosome Diagnostics’ ExoDx Prostate business is subject to extensive regulation at the federal, state, and local levels in the U.S. and other countries where it operates. The Company’s failure to meet governmental requirements under these regulations, including those relating to billing practices and financial relationships with physicians, hospitals, and health systems, could lead to civil and criminal penalties, exclusion from participation in Medicare and Medicaid, and possibly prohibitions or restrictions on the use of its laboratories. While the Company believes that it is in material compliance with all statutory and regulatory requirements, there is a risk that government authorities might take a contrary position. Such occurrences, regardless of their outcome, could damage the Company’s reputation and adversely affect important business relationships it has with third parties. 

 

13
Table of Contents

 

The Company’s Exosome Diagnostics ExoDx Prostate business could be harmed from the loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or interpretations of, the law or regulations of the Clinical Laboratory Improvement Act of 1967, and the Clinical Laboratory Improvement Amendments of 1988 (CLIA), or those of Medicare, Medicaid or government agencies where the Company operates its laboratory.

  

The commercial laboratory testing industry is subject to extensive U.S. regulation, and many of these statutes and regulations have not been interpreted by the courts. CLIA extends federal oversight to virtually all clinical laboratories operating in the U.S. by requiring that they be certified by the federal government or by a federally approved accreditation agency. The sanction for failure to comply with CLIA requirements may be suspension, revocation or limitation of a laboratory’s CLIA certificate, which is necessary to conduct business, as well as significant fines and/or criminal penalties. In addition, the Company’s ExoDx Prostate business is subject to regulation under state law. State laws may require that laboratories and/or laboratory personnel meet certain qualifications, specify certain quality controls or require maintenance of certain records. Applicable statutes and regulations could be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that would adversely affect the Company's ExoDx Prosate business. Potential sanctions for violation of these statutes and regulations include significant fines and the suspension or loss of various licenses, certificates and authorizations, which could have a material adverse effect on the Company’s EPI business. In addition, compliance with future legislation could impose additional requirements on the Company, which may be costly.

 

Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to the Company’s reputation and have a material adverse effect upon the Company’s business, a risk that has been elevated with the acquisition of Exosome Diagnostics, whose laboratory testing service is a healthcare provider that obtains and uses protected health information.

 

If the Company does not comply with existing or new laws and regulations related to protecting the privacy and security of personal or health information, it could be subject to monetary fines, civil penalties or criminal sanctions. In the U.S., the Health Insurance Portability and Accountability Act of 1996 (HIPAA) privacy and security regulations, including the expanded requirements under U.S. Health Information Technology for Economic and Clinical Health Act (HITECH), establish comprehensive standards with respect to the use and disclosure of protected health information (PHI) by covered entities, in addition to setting standards to protect the confidentiality, integrity and security of PHI. HIPAA restricts the Company’s ability to use or disclose PHI, without patient authorization, for purposes other than payment, treatment or healthcare operations (as defined by HIPAA), except for disclosures for various public policy purposes and other permitted purposes outlined in the privacy regulations. If the laboratory operations for the Company’s business use or disclose PHI improperly under these privacy regulations, they may incur significant fines and other penalties for wrongful use or disclosure of PHI in violation of the privacy and security regulations, including potential civil and criminal fines and penalties.

 

The Company relies heavily on internal manufacturing and related operations to produce, package and distribute its products which, if disrupted, could materially impair our business operations.

 

The Company's internal quality control, packaging and distribution operations support the majority of the Company's sales. Since certain Company products must comply with Food and Drug Administration Quality System Regulations and because in all instances, the Company creates value for its customers through the development of high-quality products, any significant decline in quality or disruption of operations for any reason could adversely affect sales and customer relationships, and therefore adversely affect the business. While the Company has taken certain steps to manage these operational risks, and while insurance coverage may reimburse, in whole or in part, for losses related to such disruptions, the Company's future sales growth and earnings may be adversely affected by perceived disruption risks or actual disruptions.

 

Our business could be adversely affected by disruptions at our sites.

 

We rely upon our manufacturing operations to produce many of the products we sell and our warehouse facilities to store products, pending sale. Any significant disruption of those operations for any reason, such as strikes or other labor unrest, power interruptions, fire, hurricanes or other events beyond our control could adversely affect our sales and customer relationships and therefore adversely affect our business. We have significant operations in California, near major earthquake faults, which make us susceptible to earthquake risk. Although most of our raw materials are available from a number of potential suppliers, our operations also depend upon our ability to obtain raw materials at reasonable prices. If we are unable to obtain the materials we need at a reasonable price, we may not be able to produce certain of our products or we may not be able to produce certain of these products at a marketable price, which could have an adverse effect on our results of operations.

 

 

14
Table of Contents

 

Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows.

 

As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. In particular, we are affected by the impact of changes to tax laws or related authoritative interpretations in the United States, including tax reform under the Tax Cuts and Jobs Act (the “Tax Act”) signed by the President of the United States on December 22, 2017, which includes broad and complex changes to the United States tax code and the states' tax response to the Tax Act. The Company anticipates changes in interpretations, assumptions and guidance regarding the Tax Act to be issued by the U.S. Treasury Department, which could have a material impact on our effective tax rate in future periods.

 

In preparing our financial statements, we record the amount of tax that is payable in each of the countries, states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash flows.

 

Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.

 

We ship a significant portion of our products to our customers through independent package delivery companies, such as FedEx in the U.S. and DHL in Europe. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.

 

As a multinational corporation, we are exposed to fluctuations in currency exchange rates, which could adversely affect our cash flows and results of operations.

 

International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in currencies other than the one in which they primarily do business (the "functional currency"). Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In fiscal 2020, currency translation had an unfavorable effect of $5.2 million on revenues due to the strengthening of the U.S. dollar relative to other currencies in which the company sells products and services.

 

15
Table of Contents

 

We have entered into and drawn on a revolving credit facility. The burden of this additional debt could adversely affect us, make us more vulnerable to adverse economic or industry conditions, and prevent us from funding our expansion strategy.

 

In connection with the acquisition of Exosome Diagnostics on August 1, 2018, we used a new credit facility governed by a Credit Agreement entered into on July 28, 2018. The Credit Agreement provides for a revolving credit facility of $600 million, which can be increased by an additional $200 million subject to certain conditions, and a term loan of $250 million. Borrowings under the Credit Agreement bear interest at a variable rate. As of August 21, 2020, the Company had drawn $337 million under the Credit Agreement.

 

The terms of the Credit Agreement and the burden of the indebtedness incurred thereunder could have negative consequences for us, such as:

 

 

•

limiting our ability to obtain additional financing to fund our working capital, capital expenditures, debt service requirements, expansion strategy, or other needs;
 

•

increasing our vulnerability to, and reducing our flexibility in planning for, adverse changes in economic, industry and competitive conditions; and
 

•

increasing our vulnerability to increases in interest rates.

  

The Credit Agreement also contains negative covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things, sell, lease or transfer any properties or assets, with certain exceptions; and enter into certain merger, consolidation or other reorganization transactions, with certain exceptions.

 

A breach of any of these covenants could result in an event of default under our credit facility. Upon the occurrence of an event of default, the lender could elect to declare all amounts outstanding under such facility to be immediately due and payable and terminate all commitments to extend further credit. In addition, the Company would be subject to additional restrictions if an event of default exists under the Credit Agreement, such as a prohibition on the payment of cash dividends.

 

Our share price will fluctuate.

 

Over the last several years, stock markets in general and our common stock in particular have experienced significant price and volume volatility. Both the market price and the daily trading volume of our common stock may continue to be subject to significant fluctuations due not only to general stock market conditions but also to a change in sentiment in the market regarding our operations and business prospects. In addition to the risk factors discussed above, the price and volume volatility of our common stock may be affected by:

 

 

•

operating results that vary from our financial guidance or the expectations of securities analysts and investors;
 

•

the financial performance of the major end markets that we target;
 

•

the operating and securities price performance of companies that investors consider to be comparable to us;
 

•

announcements of strategic developments, acquisitions and other material events by us or our competitors; and
 

•

changes in global financial markets and global economies and general market conditions, such as interest or foreign exchange rates, commodity and equity prices and the value of financial assets.

 

Dividends on our common stock could be reduced or eliminated in the future.

 

For over 10 years, our Board has consistently declared quarterly dividends of $0.25 to $0.32 cents per share. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

 

16
Table of Contents

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

There are no unresolved staff comments as of the date of this report.

  

ITEM 2. PROPERTIES

 

The Company owns the facilities that its headquarters and R&D Systems subsidiary occupy in Minneapolis, Minnesota. The Minneapolis facilities are utilized by both the Company's Protein Sciences and Diagnostics and Genomics segments.

 

The Minneapolis complex includes approximately 800,000 square feet of space in several adjoining buildings. Bio-Techne uses approximately 625,000 square feet of the complex for administrative, research, manufacturing, shipping and warehousing activities. The Company is currently leasing the remaining space in the complex as retail and office space. The Company also owns a 54,000 square foot facility in Saint Paul, Minnesota that will be utilized for additional manufacturing capabilities and activities.

 

The Company also owns a 34,000 square foot manufacturing facility in Flowery Branch, Georgia. This facility is utilized by the Company’s Protein Sciences.

 

The Company owns a 17,000 square foot facility that its Bio-Techne Europe subsidiary occupies in Abingdon, England. This facility is utilized by the Company's Protein Sciences and Diagnostics and Genomics segments.

 

The Company owns a 9,000 square foot facility that its Canada subsidiaries occupy in Toronto, Canada. This facility is utilized by the Company's Protein Sciences and Diagnostics and Genomics segments.

 

The Company leases the following material facilities, all of which are primarily utilized by the Company's Protein Sciences segment with the exception of the locations used by the Company's ProteinSimple and CyVek subsidiaries, which support both the Protein Sciences segment and the Diagnostics & Genomics segment). Certain locations are not named because they were not significant individually or in the aggregate as of the date of this report.

 

Subsidiary

  

Location

  

Type

  

Square Feet

  

  

  

  

  

  

  

  

  

Bio-Techne Europe

  

Langley, United Kingdom

  

Warehouse

  

14,300

  

Bio-Techne China

  

Shanghai and Beijing, China

  

Office/warehouse

  

9,300

  

Boston Biochem

  

Cambridge, Massachusetts

  

Office/lab

  

7,400

  

Tocris

  

Bristol, United Kingdom

  

Office/manufacturing/lab/warehouse

  

30,000

  

PrimeGene

  

Shanghai, China

  

Office/manufacturing/lab

  

20,600

  

Bionostics

  

Devens, Massachusetts

  

Office/manufacturing

  

48,000

  

Novus Biologicals

 

Centennial, Colorado

 

Office/warehouse

 

22,500

 

ProteinSimple

 

San Jose, California

 

Office/manufacturing/warehouse

 

167,000

 

CyVek

 

Wallingford, Connecticut

 

Office/manufacturing/warehouse

 

17,500

 

Cliniqa

 

San Marcos, California

 

Office/manufacturing/warehouse

 

62,200

 

Advanced Cell Diagnostics

 

Newark, California

 

Office/manufacturing/warehouse

 

46,500

 

Bio-Techne France

 

Rennes, France

 

Office/warehouse

 

11,000

 
Exosome Diagnostics   Waltham, Massachusetts   Office/manufacturing/warehouse   28,000  

 

The Company believes the owned and leased properties are adequate to meet its occupancy needs in the foreseeable future.

 

ITEM 3. LEGAL PROCEEDINGS

 

As of August 26, 2020, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

  

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

17
Table of Contents

 

PART II

 

ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED SHAREHOLDER

MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Holders of Common Stock and Dividends Paid

 

As of August 21, 2020 there were over 55,000 beneficial shareholders of the Company's common stock and over 125 shareholders of record. The Company paid annual cash dividends totaling $48.9 million, $48.4 million, and $48.0 million in fiscal 2020, 2019, and 2018, respectively. The Board of Directors periodically considers the payment of cash dividends, and there is no guarantee that the Company will pay comparable cash dividends, or any cash dividends, in the future. 

 

In connection with the acquisition of Exosome Diagnostics, Inc. on August 1, 2018, the Company entered into a new credit facility that provides for a revolving credit facility of $600 million, which can be increased by an additional $200 million subject to certain conditions, and a term loan of $250 million.  The credit facility is governed by a Credit Agreement dated August 1, 2018 and matures on August 1, 2023.  The Credit Agreement that governs the revolving line of credit contains customary events of default and would prohibit payment of dividends to Company shareholders in the event of a default thereunder.

 

Issuer Purchases of Equity Securities

 

During the years ended June 30, 2020 and June 30, 2019, the Company repurchased 279,381 shares of its common stock at an average share price of $179.37 and 95,000 shares at an average share price of $162.15, respectively. As of June 30, 2018, the maximum approximate dollar value of shares that could have been purchased under the Company's then existing stock repurchase plan was approximately $125 million, with no specified end period. During fiscal 2019, the Board rescinded the existing stock repurchase plan and implemented a new repurchase plan, which grants management the discretion to mitigate the dilutive effect of stock option exercises by authorizing repurchase of shares up to the amount of stock returned to the corporation through stock option exercises, beginning with those option exercises occurring in fiscal year 2018. As of June 30, 2020, we have authorization of approximately $58 million that may yet be used to purchase additional shares under our current stock repurchase program. 

  

18
Table of Contents

 

Stock Performance Graph

 

The following chart compares the cumulative total shareholder return on the Company's common stock with the S&P Midcap 400 Index and the S&P 400 MidCap Life Sciences Tools and Services Index.The comparison assumes $100 was invested on the last trading day before July 1, 2015 in the Company's common stock and in each of the foregoing indices and assumes reinvestment of dividends.

 

  

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*
Among Bio-Techne Corporation, the S&P Midcap 400 Index,
and S&P 400 Mid-Cap Life Sciences Tools and Services Index

 

 
 
     
  *$100 invested on 6/30/15 in stock or index, including reinvestment of dividends.
Fiscal year ending June 30.
Copyright© 2020 Standard & Poor's, a division of S&P Global. All rights reserved.		  

 

19
Table of Contents

 

ITEM 6. SELECTED FINANCIAL DATA

 (dollars in thousands, except per share data)

 

Income and Share Data:

   2020     2019(1)     2018(2)     2017(3)     2016(4)  
                                         

Net sales

   $ 738,691     $ 714,006     $ 642,993     $ 563,003     $ 499,023  

Operating income

     157,419       146,719       136,178       120,584       150,593  

Earnings before income taxes (5)

     276,477       112,015       125,952       111,961       147,481  

Net earnings

     229,296       96,072       126,150       76,086       104,476  

Diluted earnings per share

     5.82       2.47       3.31       2.03       2.80  

Average common and common equivalent shares - diluted (in thousands)

     39,401       38,892       38,055       37,500       37,326  

 

Balance Sheet Data as of June 30:

  

2020

    

2019

    

2018

    

2017

    

2016

  
                                         

       Cash, cash equivalents and short-term available-for-sale investments

   $ 270,893     $ 166,033     $ 181,754     $ 157,714     $ 95,835  

Working capital

     414,252       310,622       318,856       212,503       199,744  

Total assets

     2,027,589       1,884,410       1,593,202       1,558,219       1,129,581  

Total shareholders' equity

     1,381,192       1,165,589       1,079,061       949,627       879,280  

 

Cash Flow Data:

  

2020

    

2019

     2018     2017     2016  
                                         

       Net cash provided by operating activities

   $ 205,217     $ 181,619     $ 170,367     $ 143,721     $ 144,157  

Capital expenditures (6)

     51,744       25,411       20,934       15,179       16,898  

Cash dividends declared per share

     1.28       1.28       1.28       1.28       1.28  

 

Employee Data as of June 30:

  

2020

     2019     2018     2017     2016  
                                         

Employees

     2,300       2,255       1,943       1,789       1,560  

 

(1)

The Company acquired Quad Technologies on July 2, 2018, Exosome Diagnostics on August 1, 2018 and B-Mogen on June 4, 2019.  
   
(2) The Company acquired Trevigen on September 5, 2017, Atlanta Biologicals on January 2, 2018, and Eurocell Diagnostics on February 1, 2018.

 

(3)

The Company acquired Space on July 1, 2016, and Advanced Cell Diagnostics on August 1, 2016.

 

(4)

The Company acquired Cliniqa on July 8, 2015, and Zephyrus on March 21, 2016.

 

(5)

Earnings before income taxes included acquisition related expenses related to amortization of intangibles, costs recognized on sale of acquired inventories and professional fees associated with acquisition activity, as follows: 2020 - $61.7 million; 2019 - $64.9 million; 2018 - $74.2 million; 2017 - $73.2 million; 2016 - $37.6 million. Earnings before income taxes also include a gain on investment of $137.5 million in fiscal 2020 and a $12.4 million loss in fiscal 2019. 

 

(6)

Increase in fiscal 2020 capital expenditures due to investments in new buildings, in particular, the Company's CGMP manufacturing facility.  

 

20
Table of Contents

 

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

 

 

The following management discussion and analysis (“MD&A”) provides information that we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the effect of acquisitions and changes in foreign currency at the corporate and segment level. We also provide quantitative information about discrete tax items and other significant factors we believe are useful for understanding our results. The MD&A should be read in conjunction with the consolidated financial information and related notes included in this Form 10-K. This discussion contains various “Non-GAAP Financial Measures” and also contains various “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled “Non-GAAP Financial Measures” located at the end of this MD&A and “Forward-Looking Information and Cautionary Statements” and “Risk Factors” within Items 1 and 1A of this Form 10-K.

 

OVERVIEW

 

Bio-Techne develops, manufactures and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

 

During our fiscal year 2020, we operated with two operating segments – our Protein Sciences segment and our Diagnostics and Genomics segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Genomics and Diagnostics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx®Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.    

  

OVERALL RESULTS

 

Operational Update

 

For fiscal 2020, consolidated net sales increased 4% as compared to fiscal 2019. Organic growth was 4%, with currency translation and acquisitions having an immaterial impact on revenue. The Company experienced broad-based organic revenue growth in most major geographic regions and end-markets prior to the onset of the COVID-19 pandemic. This broad-based organic growth was partially offset by the negative impacts associated with the COVID-19 pandemic experienced by the Company in the latter half of fiscal year 2020, as further described in the COVID-19 Business Update section. 

 

For fiscal 2020, consolidated earnings increased 139% compared to fiscal 2019. The increase in earnings was primarily due to a gain of approximately $137 million on our ChemoCentryx investment and a gain of approximately $7 million on the settlement of the escrow balance associated with the Exosome acquisition. After adjusting for acquisition related costs, stock-based compensation, and certain income tax items in both years, adjusted net earnings increased 2% in fiscal 2020 as compared to fiscal 2019. Adjusted earnings growth was driven by volume leverage, which was partially offset by business impacts associated with the COVID-19 pandemic. 

 

For fiscal 2019, consolidated net sales increased 11% as compared to fiscal 2018. Organic growth for the year was 10% with currency translation having an unfavorable impact of 1% and acquisitions contributing 2%. The organic growth was broad-based with double digit organic growth in the United States, high single digit organic growth in Europe, and over 25% organic growth in China. 

 

Consolidated GAAP net earnings decreased 24% for fiscal 2019 as compared to fiscal 2018. After adjusting for acquisition related costs, stock-based compensation, and certain income tax items in both years, adjusted net earnings increased 2% in fiscal 2019 as compared to fiscal 2018. Adjusted earnings growth was driven by volume leverage, which was partially offset by negative margin acquisitions. 

 

COVID-19 Business Update

 

COVID-19 negatively impacted fiscal year 2020 sales growth due to the numerous customer site shutdowns in our academia and bio-pharma end-markets that occurred at the end of our third fiscal quarter and continued through our fourth quarter. Customer site shutdowns will continue to have a negative impact on sales while they remain in effect, but we did experience an increase in the number of customer sites that were open at the end of the fourth quarter. However, we are unable to forecast the impact of customer site closures given the uncertainty that some customer sites may close again due to increases in COVID-19 cases occurring in their region and over the duration of the COVID-19 pandemic. Once the pandemic has eased, we anticipate a positive long-term outlook for sales growth resulting from expected future funding increases within life-science research in response to the current pandemic.

 

The Company has responded to the pandemic by leveraging our deep product portfolio and scientific expertise to develop robust COVID-19 product and service offerings providing critical support for both clinical care and therapeutic development. The Company's ongoing efforts to utilize our portfolio of products and services to enable solutions for this evolving pandemic may partially offset the impact of our customer site closures.

 

Adjusted EPS was negatively impacted by COVID-19 primarily due to the sales impacts described above. We anticipate the short- and long-term impacts of COVID-19 on adjusted EPS to be similar to that of sales growth.

 

The Company remains in a strong financial position with sufficient available cash as well as access to additional funding if necessary, through our long-term debt agreement. We did not experience any material changes to our June 30, 2020 Balance Sheet resulting from COVID-19 for items such as additional reserves or asset impairments resulting from the pandemic.

 

The Company remains fully operational as we abide by local COVID-19 safety regulations across the world. To achieve this, the Company has certain employees working remotely and has adopted significant protective measures for our employees on site, including staggered shifts, social distancing and hygiene best practices recommended by the Centers for Disease Control (CDC) and local public health officials.  In addition, the Company has taken additional steps to monitor and strengthen our supply chain to maintain an uninterrupted supply of our critical products and services.

 

 

21
Table of Contents

 

RESULTS OF OPERATIONS

 

Net Sales

 

Consolidated organic net sales exclude the impact of net sales contributed by companies acquired during the fiscal year and the effect of the change from the prior year in exchange rates used to convert sales in foreign currencies (primarily the euro, British pound sterling, and Chinese yuan) into U.S. dollars.

 

Consolidated net sales growth was as follows:

  

   

Year Ended June 30,

  
   

2020

    

2019

    

2018

  
                         

Organic sales growth

     4

%

     10 %     9

%

Acquisitions sales growth

     0

%

     2

%

     3 %

Impact of foreign currency fluctuations

     0

%

     (1

)%

     2 %

Consolidated net sales growth

     4

%

     11

%

     14

%

 

Consolidated net sales by segment were as follows (in thousands): 

 

   

Year Ended June 30,

  
   

2020

    

2019

    

2018

  
                         

Protein Sciences

   $ 555,352     $ 543,159     $ 482,378  

Diagnostics and Genomics

     184,549       171,674       161,151  

Intersegment

     (1,210 )     (827

)

     (536 )

Consolidated net sales

   $ 738,691     $ 714,006     $ 642,993  

 

In fiscal 2020, Protein Sciences segment net sales increased 2% compared to fiscal 2019. Organic growth for the segment was 3% for the fiscal year, with foreign currency translation having an unfavorable impact of 1%, and acquisitions contributing an immaterial amount. 

 

Overall segment growth was driven by strong Bio-Pharma sales in North America and strong overall performance in China, which was partially offset by the disruption in research markets due to numerous customer site closures relating to the COVID-19 pandemic that occurred in the second half of fiscal 2020. 


In fiscal 2020, Diagnostics and Genomics segment net sales increased 8% compared to fiscal 2019. Organic growth was 8% with acquisitions and foreign currency having an immaterial impact on revenue.

 

Overall segment revenue growth was driven by strong performance in our ExoDx Prostate Test, RNA scope, hematology, and assay development products lines prior to the onset of the COVID-19 pandemic. The closure of academic site labs and limitation of non-essential medical procedures resulting from the COVID-19 pandemic significantly impacted sales of our RNA scope product line and our ExoDx Prostate Test, respectively, in the latter portion of the fiscal year. These negative sales impacts were partially offset through growth in supplying specialty diagnostic antibodies and other raw materials to COVID-19 testing manufacturers.

 

In fiscal 2019, Protein Sciences segment net sales increased 13% compared to fiscal 2018. Organic growth for the segment was 13% for the fiscal year, with acquisitions contributing 2% and foreign currency translation having an unfavorable impact of 2%. Growth was broad-based and especially strong in the antibodies and cell therapy consumables as well as the Simple Western and Simple Plex instrument product categories.

  

In fiscal 2019, the Diagnostics and Genomics segment net sales increased 7% compared to fiscal 2018. Organic growth for the segment was 4% with acquisitions contributing 3%. Growth in this segment was primarily driven by strong RNA scope product sales. 

  

22
Table of Contents

 

Gross Margins

 

Consolidated gross margins were 65.4%, 66.3%, and 67.2% in fiscal 2020, 2019, and 2018. Consolidated gross margins were negatively impacted as a result of purchase accounting related to inventory in fiscal 2019 and 2018 and intangible assets acquired during fiscal 2020, 2019, and 2018. Under purchase accounting, inventory is valued at fair value less expected selling and marketing costs, resulting in reduced margins in future periods as the inventory is sold. Excluding the impact of acquired inventory sold, amortization of intangibles, and stock compensation expense, adjusted gross margins were 70.3%, 71.5%, and 71.5% in fiscal 2020, 2019, and 2018 respectively. Fiscal 2020 adjusted gross margin was negatively impacted by product mix when compared to fiscal 2019 and fiscal 2018.

 

A reconciliation of the reported consolidated gross margin percentages, adjusted for acquired inventory sold and intangible amortization included in cost of sales, is as follows:

 

   

Year Ended June 30,

  
   

2020

    

2019

    

2018

  
                         

Consolidated gross margin percentage

     65.4

%

     66.3

%

     67.2

%

Identified adjustments:

                        

Costs recognized upon sale of acquired inventory

     -

%

     0.5

%

     0.4

%

Amortization of intangibles

     4.7

%

     4.7

%

     3.9

%
    Stock compensation expense - COGS     0.2 %     - %     - %

Non-GAAP adjusted gross margin percentage

     70.3

%

     71.5

%

     71.5

%

 

Fluctuations in adjusted gross margins, as a percentage of net sales, have primarily resulted from changes in foreign currency exchange rates and changes in product mix. We expect that, in the future, gross margins will continue to be impacted by the mix of our portfolio growing at different rates as well as future acquisitions.

 

Management uses adjusted operating results to monitor and evaluate performance of the Company’s two segments. Segment gross margins, as a percentage of net sales, were as follows: 

 

   

Year Ended June 30,

  
   

2020

    

2019

    

2018

  
                         

Protein Sciences

     75.0 %     76.8

%

     76.8

%

Diagnostics and Genomics

     55.6

%

     54.4

%

     55.7

%

 

The small decrease in the Protein Sciences segment’s gross margin percentage for fiscal 2020 as compared to fiscal 2019 and 2018 was primarily attributable to mix of product sales within the segment. 

 

The increase in Diagnostics and Genomics in gross margin for fiscal 2020 was primarily due to volume leverage, operational productivity, and revenue growth against a similar cost base in recent acquisitions. The decrease in the Diagnostics and Genomics gross margin percentages for fiscal 2019 as compared to fiscal 2018 were due to negative gross margins for acquisitions made in the segment, namely ExosomeDx.

 

23
Table of Contents

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses decreased $3.8 million (1%) in fiscal 2020 when compared to fiscal 2019. Selling, general, and administrative expenses decreased primarily due to a reduction in corporate expenses and a gain resulting from a settlement of amounts held in escrow from the ExosomeDx acquisition between the Company and the former shareholders. These reductions to our selling, general, and administrative expenses were partially offset by an increase in expense within the segments. 

 

Selling, general and administrative expense increased $23.7 million (10%) in fiscal 2019 when compared to fiscal 2018. The increase was primarily driven by an additional cost base from our fiscal 2019 acquisitions, additional stock-based compensation expense, and additional amortization expense associated with intangible assets recorded from our fiscal 2019 acquisitions. These increases were partially offset by a reduction in acquisition related expenses. 

 

 

Consolidated selling, general and administrative expenses were composed of the following (in thousands):

 

   

Year Ended June 30,

  
   

2020

    

2019

    

2018

  
                         

Protein Sciences

   $ 138,792     $ 135,513     $ 119,649  

Diagnostics and Genomics

     65,407       61,646       40,255  

Total segment expenses

     204,199       197,159       159,904  

Amortization of intangibles

     26,358       25,210       21,650  

Acquisition related expenses

     415       2,282       24,429  
Gain on escrow litigation     (7,159 )     -       -  

Restructuring costs

     87       -       376  

Stock-based compensation

     32,667       33,057       28,240  

Corporate selling, general and administrative expenses

     4,016       6,651       6,037  

Total selling, general and administrative expenses

   $ 260,583     $ 264,359     $ 240,636  

 

Research and Development Expenses

 

Research and development expenses increased $2.8 million (4%) and $7.1 million (13%) in fiscal 2020 and 2019, respectively, as compared to prior year periods. The increase in research and development expenses in fiscal 2020 as compared to fiscal 2019 was primarily attributable to continued investment in future growth platforms of the Company, recent acquisitions, and the development of new COVID-19 products. The increase in research and development expense in fiscal 2019 as compared to fiscal 2018 was primarily attributable to our ExosomeDx acquisition. 

 

   

Year Ended June 30,

  
   

2020

    

2019

    

2018

  
                         

Protein Sciences

   $ 43,022     $ 40,735     $ 40,996  

Diagnostics and Genomics

     22,170       21,678       14,095  

Total segment expenses

     65,192       62,413       55,091  

Unallocated corporate expenses

     -       -       238  

Total research and development expenses

   $ 65,192     $ 62,413     $ 55,329  

 

24
Table of Contents

 

Net Interest Income / (Expense)

 

Net interest income/(expense) for fiscal 2020, 2019, and 2018 was $(18.6) million, $(21.1) million, and $(9.8) million, respectively. Net interest expense in fiscal 2020 decreased when compared to fiscal 2019 due to a reduction in our average long-term debt. Net interest expense increased in fiscal 2019 when compared to fiscal 2018 due to an increase in our average long-term debt, resulting from the debt agreement the Company entered into in conjunction with our ExosomeDx acquisition. 

 

Other Non-Operating Expense, Net

 

Other non-operating expense, net, consists of foreign currency transaction gains and losses, rental income, building expenses related to rental property and the Company's gains and losses on investments as follows (in thousands):

 

   

Year Ended June 30,

  
   

2020

    

2019

    

2018

  
                         

Foreign currency gains (losses)

   $ 1,703     $ (455

)

   $ (227

)

Rental income

     1,140       1,141       1,177  

Real estate taxes, depreciation and utilities

     (1,915 )     (1,897

)

     (1,803

)

Gain (loss) on investment

     137,508       (12,370 )     397  

Miscellaneous (expense) income

     (786 )     13

 

     (9 )

Other non-operating income (expense), net

   $ 137,650     $ (13,568

)

   $ (447

)

  

During fiscal 2020, the Company recognized gains of $137.5 million related to changes in fair value associated with changes in the stock price of our ChemoCentryx, Inc. (CCXI) investment.

 

During fiscal 2019, the Company recognized losses of $16.1 million related to changes in fair value associated with changes in the stock price of our ChemoCentryx, Inc. (CCXI) investment, which were partially offset by a $3.7 million gain realized upon acquisition from our historical investment in B-MoGen.

 

During the third quarter of fiscal 2018, the Company recognized a $16.2 million impairment on the write-down of its investment in Astute Medical, Inc. (Astute) in anticipation of the amount of cash to be received upon completion of the sale of Astute to a third party. The Astute sale closed in the fourth quarter of fiscal 2018 at the anticipated amount. This loss was offset by a $16.1 million gain on the sale of a portion of the Company’s investment in ChemoCentryx, Inc. (CCXI) and a $0.5 million gain on the sale of investment property in the fourth quarter of fiscal 2018. These gains and losses are included in other income (expense) in the accompanying Consolidated Statements of Earnings and Comprehensive Income.

 

Income Taxes

 

Income taxes for fiscal 2020, 2019, and 2018 were at effective rates of 17.1%, 14.2%, and (0.2)%, respectively, of consolidated earnings before income taxes. The change in the effective tax rate was driven by discrete tax items. The Company's discrete tax benefits in fiscal 2020 primarily related to share-based compensation excess tax benefits of $17.7 million. The Company's discrete tax benefits in fiscal 2019 primarily related to share-based compensation excess tax benefits of $7.2 million, $3.2 million related to deductible acquisition payments made to employees and third parties, and $2.0 million for tax refunds relating to certain state apportionments. In fiscal 2018, the Company recognized net discrete tax benefits of $34.4 million. The primary driver in fiscal 2018 discrete tax benefits was a discrete net tax benefit of $33.0 million related to the Tax Act (as described in Note 11). Also impacting the Company’s fiscal 2018 effective tax rate was a $2.2 million tax benefit related to share-based compensation excess tax benefits offset by a net discrete tax expense of $4.2 million related to the revaluation of contingent consideration, which is not a tax deductible expense.

 

 

25
Table of Contents

 

Net Earnings

 

Non-GAAP adjusted consolidated net earnings are as follows (in thousands):

 

   

Year Ended June 30,

  
   

2020

    

2019

    

2018

  
                         

Net earnings

   $ 229,296     $ 96,072     $ 126,150  

Identified adjustments:

                        

Costs recognized upon sale of acquired inventory

     -       3,739       2,455  

Amortization of intangibles

     60,865       58,550       46,983  

Acquisition related expenses

     793       2,656       24.774  
    Gain on escrow settlement     (7,170 )     -       -  

Restructuring costs

     87       -       376  

Stock-based compensation

     34,262       33,057       28,240  

(Gain) loss on investment and other 

     (136,716

)

     12,370       (397 )

Tax impact of above adjustments

     17,324       (18,323 )     (21,625

)

Tax impact of discrete tax items and other foreign adjustments

     (19,423 )     (12,665 )     (34,360

)

Non-GAAP adjusted net earnings

   $ 179,318     $ 175,456     $ 172,596  
                         

Non-GAAP adjusted net earnings growth

     2

%

     2 %     24

%

 

Depending on the nature of discrete tax items, our reported tax rate may not be consistent on a period to period basis. The Company independently calculates a non-GAAP adjusted tax rate considering the impact of discrete items and jurisdictional mix of the identified non-GAAP adjustments. The following table summarizes the reported GAAP tax rate and the effective Non-GAAP adjusted tax rate for the periods ended June 30, 2020, 2019, and 2018.

 

   

Year Ended June 30,

  
   

2020

    

2019

    

2018

  
                         

Reported GAAP tax rate

     17.1

%

     14.2

%

     (0.2

)%

Tax rate impact of:

                        

Identified non-GAAP adjustments

     (2.5 )     (4.3

)

     (2.7

)

Discrete tax items

     7.0       11.2       27.3  

Non-GAAP adjusted tax rate

     21.6

%

     21.1

%

     24.4  

 

The difference between the reported GAAP tax rate and non-GAAP tax rate applied to the identified non-GAAP adjustments for the fiscal years ended June 30, 2020 and June 30, 2019 is primarily a result of discrete tax items. Refer to Note 11 for additional discussion relating to the change in discrete tax items between fiscal 2020 and fiscal 2019.

 

The difference between the reported GAAP tax rate and non-GAAP tax rate applied to the identified non-GAAP adjustments for the fiscal year ended June 30, 2018 is due primarily to recording the items attributable to the new tax legislation in the U.S. which resulted in a $33.0 million tax benefit. Offsetting this benefit is the impact of the revaluation of contingent consideration which is not tax deductible. For the fiscal year ended June 30, 2018, the Company recorded acquisition related expense of $20.1 million related to the change in fair value of contingent consideration. 

 

26
Table of Contents

 

LIQUIDITY AND CAPITAL RESOURCES

 

Cash, cash equivalents and available-for-sale investments at June 30, 2020 were $270.9 million compared to $166.0 million at June 30, 2019. Included in available-for-sale investments at June 30, 2020 and June 30, 2019 was the fair value of the Company's investment in CCXI of $87.8 million and $38.2 million, respectively.

 

At June 30, 2020, approximately 23% of the Company's cash and equivalent account balances of $146.6 million were located in the U.S., with the remainder located in primarily in Canada, China, the U.K. and other European countries.

  

At June 30, 2020, approximately 71% of the Company's available-for-sale investment account balances of $124.3 million were located in the U.S., with the remaining 29% in China.

 

The Company has either paid U.S. taxes on its undistributed foreign earnings or intends to indefinitely reinvest the undistributed earnings in the foreign operations or expects the earnings will be remitted in a tax neutral transaction. Management of the Company expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available funds, including funds available through our line-of-credit and cash generated from operations.

 

During fiscal 2019, the Company acquired QT Holdings Corporation (Quad), Exosome Diagnostics, Inc. (Exosome), and the outstanding shares of our B-MoGen investment for approximately $20 million plus $51 million in potential contingent consideration,  approximately $250 million plus $325 million in potential contingent consideration, and $17 million plus $38 million in potential contingent consideration, respectively. In connection with the acquisition of Exosome Diagnostics on August 1, 2018, the Company entered into a new credit facility governed by a Credit Agreement entered into on August 1, 2018 that matures on August 1, 2023. The Credit Agreement provides for a revolving credit facility of $600 million, which can be increased by an additional $200 million subject to certain conditions, and a term loan of $250 million. Borrowings under the Credit Agreement bear interest at a variable rate.

 

During fiscal 2018, the Company acquired Trevigen, Atlanta Biologicals and Eurocell Diagnostics for approximately $10.6 million, $51.3 million and $7.3 million, respectively. The acquisitions were financed through a combination of cash on hand and our revolving line of credit facility. 

   

Future acquisition strategies may or may not require additional borrowings under the line-of-credit facility or other outside sources of funding.

 

Cash Flows From Operating Activities

 

The Company generated cash from operations of $205.2 million, $181.6 million, and $170.4 million in fiscal 2020, 2019, and 2018 respectively. The increase in cash generated from operating activities in fiscal 2020 as compared to fiscal 2019 was mainly a result of higher GAAP earnings and lower accounts receivable balances in fiscal 2020, which were partially offset by the gain on investments included within earnings. The increase in cash generated from operating activities in fiscal 2019 as compared to fiscal 2018 was mainly the result of higher depreciation and amortization and adjustments to available-for-sale securities included with our GAAP earnings, partially offset by a reduction in GAAP earnings. 

 

Cash Flows From Investing Activities

 

We continue to make investments in our business, including capital expenditures. The Company did not make any acquisitions in fiscal 2020. Net cash paid for acquisitions of Quad, Exosome, and B-MoGen was $289.5 million in fiscal 2019, a substantial increase from the net cash paid of $67.9 million for the Trevigen, Atlanta Biologicals and Eurocell Diagnostics acquisitions in fiscal 2018.

 

27
Table of Contents

 

The Company's net proceeds (outflow) from the purchase, sale and maturity of available-for-sale investments in fiscal 2020, 2019, and 2018 were $76.9 million, ($21.9 million), and $27.8 million, respectively. The increase in fiscal 2020 compared to fiscal 2019 was driven by the sale of a portion of the Company’s investment in CCXI in fiscal 2020. The decrease in fiscal 2019 as compared to fiscal 2018 was driven by the sale of a portion of the Company’s investment in CCXI in fiscal 2018 and additional purchases of bonds in fiscal 2019. The Company's investment policy is to place excess cash in certificates of deposit with the objective of obtaining the highest possible return while minimizing risk and keeping the funds accessible.

 

Capital additions in fiscal year 2020, 2019, and 2018 were $51.7 million, $25.4 million, and $20.9 million. Increase in fiscal 2020 capital expenditures due to investments in new buildings, in particular, the Company's cGMP manufacturing facility. Capital additions planned for fiscal 2021 are approximately $45 million and are expected to be financed through currently available cash and cash generated from operations.

 

Cash Flows From Financing Activities

 

In fiscal 2020, 2019, and 2018, the Company paid cash dividends of $48.9 million, $48.4 million, $48.0 million, respectively. The Board of Directors periodically considers the payment of cash dividends.

 

The Company received $71.0 million, $38.0 million, $19.2 million, for the exercise of options for 56,000, 382,000, 204,000 shares of common stock in fiscal 2020, 2019 and 2018 , respectively. 

 

During fiscal 2020, the Company drew $40 million under its revolving line-of-credit facility and made repayments on its line-of-credit of $188.5 million. 

 

During fiscal 2019, the Company drew $580.0 million under its revolving line-of-credit facility to fund its acquisition of Quad, Exosome, and B-MoGen and made repayments on its line-of-credit of $413.5 million.

 

During fiscal 2018, the Company drew $55.0 million under its revolving line-of-credit facility to fund its acquisition of Atlanta Biologicals and made repayments on its line-of-credit of $59.5 million.

 

During fiscal 2020, the Company made $4.4 million ($4 million for Quad and $0.4 million for B-MoGen) in cash payments towards the Quad, Exosome, and B-MoGen contingent consideration liabilities. Of the $4.4 million in total payments, $3.4 million is classified as financing on the statement of cash flows. The remaining $1 million is recorded as operating on the statement of cash flows as it represents the consideration liability that exceeds the amount of the contingent consideration liability recognized at the acquisition date.

 

During fiscal 2019, the Company made no cash payments towards the Quad, Exosome, and B-MoGen contingent consideration liabilities.

 

During fiscal 2018, the Company made $88.5 million ($50 million for ACD, $35 million for CyVek, and $3.5 million for Zephyrus) in cash payments towards the ACD, CyVek and Zephyrus contingent consideration liabilities. Of the $88.5 million in total payments, $61.9 million is classified as financing on the statement of cash flows. The remaining $26.6 million is recorded as operating on the statement of cash flows as it represents the consideration liability that exceeds the amount of the contingent consideration liability recognized at the acquisition date.

 

In accordance with the terms of the purchase agreement, during fiscal 2019, the Company made the final payment of $1.4 million related to Eurocell. In accordance with the terms of the purchase agreement, during the first quarter of fiscal 2018, the Company made the final $2.3 million payment for the Space acquisition. These payments were included within other financing activities.

 

During fiscal 2020 and 2019, the Company repurchased $50.1 million and $15.4 million, respectively in share repurchases included as a cash outflow within Financing Activities. The Company did not repurchase any shares in fiscal 2018. 

 

28
Table of Contents

 

OFF-BALANCE SHEET ARRANGEMENTS

 

The Company is not a party to any off-balance sheet transactions, arrangements or obligations that have, or are reasonably likely to have, a current or future material effect on the Company's financial condition, changes in the financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

CONTRACTUAL OBLIGATIONS

 

The following table summarizes the Company's contractual obligations and commercial commitments as of June 30, 2020 (in thousands):

 

           

Payments Due by Period

  
   

Total

    

Less than
1 Year

    

1-2
Years

    

3-4
Years

    

After
5 Years

  

Long-term debt

   $ 356,743       12,500       25,000       319,243       -  

Lease obligations

   $ 93,021     $ 12,590     $ 23,409     $ 19,706     $ 37,316  

Total contractual obligations

   $ 449,764     $ 20,090     $ 48,409     $ 338,949     $ 37,316  

 

The interest rate on the Company's long-term debt is calculated as the sum of LIBOR plus an applicable margin. The applicable margin is determined for the total leverage ratio of the Company and updated on a quarterly basis. The Company also has a derivative instrument related to our debt, which converts the variable interest rate payment of the debt to fixed interest payments as disclosed Note 5. Additionally, there is an annualized fee for any unused portion of the credit facility which is currently 15 basis points as further described in Note 6. 

 

CRITICAL ACCOUNTING POLICIES

 

Management's discussion and analysis of the Company's financial condition and results of operations are based upon the Company's Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

The Company has identified the policies outlined below as critical to its business operations and an understanding of results of operations. The listing is not intended to be a comprehensive list of all accounting policies; investors should also refer to Note 1 to the Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.

 

Business Combinations

 

We allocate the purchase price of acquired businesses to the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition. The calculations used to determine the fair value of the long-lived assets acquired, primarily intangible assets, can be complex and require significant judgment. We weigh many factors when completing these estimates including, but not limited to, the nature of the acquired company’s business; its competitive position, strengths, and challenges; its historical financial position and performance; estimated customer retention rates; discount rates; and future plans for the combined entity. We may also engage independent valuation specialists, when necessary, to assist in the fair value calculations for significant acquired long-lived assets.

 

The fair value of acquired technology is generally the primary asset identified and therefore estimated using the multi-period excess earnings method. The multi-period excess earnings method model estimates revenues and cash flows derived from the primary asset and then deducts portions of the cash flow that can be attributed to supporting assets, such as Trade Names, that contributed to the generation of the cash flows. The resulting cash flow, which is attributable solely to the primary asset acquired, is then discounted at a rate of return commensurate with the risk of the asset to calculate a present value. The Trade Name is generally calculated using the relief from royalty method, which calculates the cost savings associated with owning rather than licensing the technology. Assumed royalty rates are applied to the projected revenues for the remaining useful life of the technology to estimate the royalty savings. In circumstances that Customer Relationship assets are identified that are not the primary asset, they are valued using the distributor model income approach, which isolates revenues and cash flow associated with the sales and distribution function of the entity and attributable to customer-related assets, which are then discounted at a rate of return commensurate with the risk of the asset to calculate a present value.  

 

29
Table of Contents

 

We estimate the fair value of liabilities for contingent consideration by discounting to present value the probability weighted contingent payments expected to be made. For potential payments related to financial performance based milestones, projected revenue and/or EBITDA amounts, volatility and discount rates assumptions are included in the estimated amounts. For potential payments related to product development milestones, the fair value is based on the probability of achievement of such milestones. The excess of the purchase price over the estimated fair value of the net assets acquired is recorded as goodwill. Goodwill is not amortized, but is subject to impairment testing on at least an annual basis.

 

We are also required to estimate the useful lives of the acquired intangible assets, which determines the amount of acquisition-related amortization expense we will record in future periods. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization.

 

While we use our best estimates and assumptions, our fair value estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Any adjustments required after the measurement period are recorded in the consolidated statements of earnings.

 

The judgments required in determining the estimated fair values and expected useful lives assigned to each class of assets and liabilities acquired can significantly affect net income. For example, different classes of assets will have useful lives that differ. Consequently, to the extent a longer-lived asset is ascribed greater value than a shorter-lived asset, net income in a given period may be higher. Additionally, assigning a lower value to amortizable intangibles would result in a higher amount assigned to goodwill. As goodwill is not amortized, this would benefit net income in a given period, although goodwill is subject to annual impairment analysis.

 

Impairment of Goodwill

 

Goodwill

 

Goodwill was $728.3 million as of June 30, 2020, which represented 35.9% of total assets. Goodwill is tested for impairment on an annual basis in the fourth quarter of each year, or more frequently if events occur or circumstances change that could indicate a possible impairment.

 

To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business.

 

There has been no impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC 350 guidance for goodwill and other intangibles on July 1, 2002.

  

30
Table of Contents

 

2020 Goodwill Impairment Analyses

 

In completing our 2020 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU 2017-04, a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit's financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value-weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

 

Because our 2020 quantitative analyses included all of our reporting units, the summation of our reporting units' fair values, as indicated by our discounted cash flow calculations, were compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit's results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

The quantitative assessment completed as of April 1, 2020 indicated that all of the reporting units had a substantial amount of headroom. Accordingly, the Company determined there was no indication of impairment of goodwill in our annual goodwill impairment analysis. Further, no triggering events were identified in the year ended June 30, 2020 that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.

 

2019 Goodwill Impairment Analyses

 

At the beginning of the quarter ended March 31, 2019, the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative impairment assessments performed utilized a consistent process with our fiscal 2020 quantitative goodwill impairment assessment described above. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment. This impairment assessment performed was sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit's results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

In conducting our annual goodwill impairment test as of April 1, 2019, we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Based on its annual analysis, the Company determined there was no indication of impairment of goodwill. 

 

2018 Goodwill Impairment Analyses

 

In completing our 2018 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. The quantitative impairment assessments performed utilized a consistent process with our fiscal 2020 quantitative goodwill impairment assessment described above. The quantitative assessment completed during the fourth quarter of fiscal 2018 indicated that all of the reporting units had a substantial amount of headroom. This impairment assessment performed was sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit's results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

  

NEW ACCOUNTING PRONOUNCEMENTS

 

Information regarding the accounting policies adopted during fiscal 2020 and those not yet adopted can be found under caption “Note 1: Description of Business and Summary of Significant Accounting Policies” of the Notes to the Consolidated Financial Statements appear in Item 8 of this report. 

 

31
Table of Contents

 

SUBSEQUENT EVENTS

 

None

 

NON-GAAP FINANCIAL MEASURES

 

This Annual Report on Form 10-K, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:

 

● Organic growth

●

Adjusted gross margin

●

Adjusted net earnings

●

Adjusted net earnings growth

●

Adjusted effective tax rate

 

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

 

Our non-GAAP financial measure of organic growth represents revenue growth excluding revenue from acquisitions within the preceeding 12 months as well as the impact of foreign currency. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period.

 

Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, and adjusted net earnings, in total and on a per share basis, exclude the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including non-recurring costs and gains. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory and acquisition-related expenses inclusive of the changes in fair value contingent consideration, and other non-recurring items including gains or losses on legal settlements and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Additionally, these amounts can vary significantly from period to period based on current activity.

 

The Company’s non-GAAP adjusted operating margin and adjusted net earnings, in total and on a per share basis, also excludes stock-based compensation expense, which is inclusive of the employer portion of payroll taxes on those stock awards, restructuring, impairments of equity method investments, gain and losses from investments, and certain adjustments to income tax expense. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjective assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. Impairments of equity investments are excluded as they are not part of our day-to-day operating decisions. Additionally, gains and losses from other investments that are either isolated or cannot be expected to occur again with any predictability are excluded.   Costs related to restructuring activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.

 

The Company periodically reassesses the components of our non-GAAP adjustments for changes in how we evaluate our performance, changes in how we make financial and operational decisions, and considers the use of these measures by our competitors and peers to ensure the adjustments are still relevant and meaningful.

 

Readers are encouraged to review the reconciliations of the adjusted financial measures used in management's discussion and analysis of the financial condition of the Company to their most directly comparable GAAP financial measures provided within the Company's consolidated financial statements.

 

32
Table of Contents

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES

ABOUT MARKET RISK

  

The Company operates internationally, and thus is subject to potentially adverse movements in foreign currency exchange rates. Approximately 44 % of the Company's consolidated net sales in fiscal 2020 were made in foreign currencies, including  20% in euro, 6% in British pound sterling, 9% in Chinese yuan and the remaining 9% in other currencies. The Company is exposed to market risk primarily from foreign exchange rate fluctuations of the euro, British pound sterling, Chinese yuan and Canadian dollar as compared to the U.S. dollar as the financial position and operating results of the Company's foreign operations are translated into U.S. dollars for consolidation.

 

Month-end exchange rates between the euro, British pound sterling, Chinese yuan, Canadian dollar and the U.S. dollar, which have not been weighted for actual sales volume in the applicable months in the periods, were as follows:

 

   

Year Ended June 30,

          
   

2020

    

2019

    

2018

  

Euro:

                        

High

   $ 1.12     $ 1.17     $ 1.24  

Low

     1.09       1.12       1.16  

Average

     1.11       1.14       1.20  

British pound sterling:

                        

High

   $ 1.32     $ 1.32     $ 1.42  

Low

     1.22       1.27       1.29  

Average

     1.26       1.29       1.35  

Chinese yuan:

                        

High

   $ 0.15     $ 0.15     $ 0.16  

Low

     0.14       0.14       0.15  

Average

     0.14       0.15       0.15  

Canadian dollar:

                        

High

   $ 0.77     $ 0.77     $ 0.81  

Low

     0.71       0.74       0.76  

Average

     0.74       0.76       0.79  

 

The Company's exposure to foreign exchange rate fluctuations also arises from trade receivables and intercompany payables denominated in one currency in the financial statements, but receivable or payable in another currency.

 

The Company does not enter into foreign currency forward contracts to reduce its exposure to foreign currency rate changes on forecasted intercompany sales transactions or on intercompany foreign currency denominated balance sheet positions. Foreign currency transaction gains and losses are included in "Other non-operating expense, net" in the Consolidated Statement of Earnings and Comprehensive Income. The effect of translating net assets of foreign subsidiaries into U.S. dollars are recorded on the Consolidated Balance Sheet as part of "Accumulated other comprehensive income (loss)."

 

The effects of a hypothetical simultaneous 10% appreciation in the U.S. dollar from June 30, 2020 levels against the euro, British pound sterling, Chinese yuan and Canadian dollar are as follows (in thousands):

 

Decrease in translation of 2020 earnings into U.S. dollars

   $ 4,340  

Decrease in translation of net assets of foreign subsidiaries

     44,766  

Additional transaction losses

    
1,001
 
33
Table of Contents

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

 

CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME

Bio-Techne Corporation and Subsidiaries
(in thousands, except per share data)

 

  

Year Ended June 30,

 
  

2020

  2019  2018 
             

Net sales

 $738,691  $714,006  $642,993 

Cost of sales

  255,497   240,515   210,850 

Gross margin

  483,194   473,491   432,143 
             

Operating expenses:

            

Selling, general and administrative

  260,583   264,359   240,636 

Research and development

  65,192   62,413   55,329 

Total operating expenses

  325,775   326,772   295,965 

Operating income

  157,419   146,719   136,178 
             

Other income (expense):

            

Interest expense

  (19,197)  (21,705

)

  (10,188

)

Interest income

  605   569   409 

Other non-operating income (expense), net

  137,650

 

  (13,568

)

  (447

)

Total other income (expense), net

  119,058

 

  (34,704

)

  (10,226

)

Earnings before income taxes

  276,477   112,015   125,952 

Income taxes (benefit)

  47,181

 

  15,943

 

  (198)

Net earnings

  229,296   96,072   126,150 

Other comprehensive income (loss):

            

Foreign currency translation adjustments

  (9,963)  (4,487

)

  (1,572

)

Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8.  (3,715)  (9,537)  - 

Unrealized gains (losses) on available-for-sale investments, net of tax of $398 in FY18

  -   -   5,693 

Other comprehensive income (loss)

  (13,678)  (14,024)  4,121 

Comprehensive income

 $215,618   82,048  $130,271 
             

Earnings per share:

            

Basic

 $6.00  $2.54  $3.36 

Diluted

 $5.82  $2.47  $3.31 
             

Weighted average common shares outstanding:

            

Basic

  38,201   37,781   37,476 

Diluted

  39,401   38,892   38,055 

 

See Notes to Consolidated Financial Statements.

 

34
Table of Contents

 

 

CONSOLIDATED BALANCE SHEETS

Bio-Techne Corporation and Subsidiaries
(in thousands, except share and per share data)

 

  

June 30,

 
  

2020

  2019 

ASSETS

        

Current assets:

        

Cash and cash equivalents

 $146,625  $100,886 

Short-term available-for-sale investments

  124,268   65,147 

Accounts receivable, less allowance for doubtful accounts of $775 and $980, respectively

  122,534   137,466 

Inventories

  103,152   91,050 

Other current assets

  24,341   18,058 

Total current assets

  520,920   412,607 
         

Property and equipment, net

  176,829   154,039 
Right of use asset  71,465   - 

Goodwill

  728,308   732,667 

Intangible assets, net

  516,545   579,429 

Other assets

  13,522   5,668 

Total assets

 $2,027,589  $1,884,410 

LIABILITIES AND SHAREHOLDERS' EQUITY

        

Current liabilities:

        

Trade accounts payable

 $23,090  $16,210 

Salaries, wages and related accruals

  31,087   28,638 

Accrued expenses

  9,093   26,389 

Contract liabilities

  13,049   9,084 

Income taxes payable

  2,376   5,764 
Operating lease liabilities - current  9,535   - 

Contingent consideration payable

  5,938   3,400 
Current portion of long-term debt obligations  12,500   12,500 

Total current liabilities

  106,668   101,985 
         

Deferred income taxes

  101,090   89,754 

Long-term debt obligations

  344,243   492,660 

Long-term contingent consideration payable

  199   9,200 
Operating lease liabilities  67,248   - 

Other long-term liabilities

  26,949   25,222 
         

Shareholders' equity:

        

Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding

  -   - 

Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 38,453,046 and 37,934,040 shares, respectively

  385   379 

Additional paid-in capital

  420,536   316,797 

Retained earnings

  

 

1,057,470

   931,934 

Accumulated other comprehensive loss

  (97,199

)

  (83,521

)

Total shareholders' equity

  1,381,192   1,165,589 

Total liabilities and shareholders’ equity

 $2,027,589  $1,884,410 

 

See Notes to Consolidated Financial Statements.

 

35
Table of Contents

 

 

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Bio-Techne Corporation and Subsidiaries
(in thousands) 

 

   

Common Stock

    

Additional
Paid-in

    

Retained

    

Accumulated
Other
Comprehensive

          
   

Shares

    

Amount

    

Capital

    

Earnings

    

Income(Loss)

    

Total

  
                                                 

Balances at June 30, 2017

     37,356     $ 374     $ 199,161     $ 799,027     $ (48,935

)

   $ 949,627  

Net earnings

                             126,150               126,150  

Other comprehensive income (loss)

                                     4,121       4,121  

Common stock issued for exercise of options

     204       2       17,661                       17,663

 

Common stock issued for restricted stock awards

     34       -       -       (273

)

             (273 )

Cash dividends

             -               (47,973

)

             (47,973

)

Stock-based compensation expense

                     27,959                       27,959

 

Common stock issued to employee stock purchase plan

     14       -       1,506                       1,506  

Employee stock purchase plan expense

                     281                       281  

Balances at June 30, 2018

     37,608     $ 376     $ 246,568     $ 876,931     $ (44,814

)

   $ 1,079,061  
Cumulative effect adjustments due to adoption of new accounting standards and other                             25,276       (24,682 )     594  

Net earnings

                             96,072               96,072  

Other comprehensive income (loss)

                                     (14,024 )     (14,024 )
    Share repurchases     (95 )     (1 )             (15,404 )             (15,405 )

Common stock issued for exercise of options

    

382

       4       36,272                       36,276  

Common stock issued for restricted stock awards

     29       -               (2,575 )             (2,575 )

Cash dividends

                             (48,366 )             (48,364 )

Stock-based compensation expense

                     31,775                       31,775  

Common stock issued to employee stock purchase plan

     10       -       1,676                      

1,676

  

    Employee stock purchase plan expense

                     505                       505  

Balances at June 30, 2019

     37,934     $ 379     $ 316,797     $ 931,934     $ (83,521 )   $ 1,165,589  
Cumulative effect adjustments due to adoption of new accounting standards and other                         (879 )           (879 )
Net earnings                            

229,296

               229,296  
Other comprehensive income (loss)                                     (13,678 )     (13,678 )
Share repurchases     (279 )     (3 )           (50,109 )           (50,112 )
Surrender and retirement of stock to exercise option     (2 )     -       (400 )                 (400 )
Common stock issued for exercise of options     730       7       69,461       (1,642 )             67,826  
Common stock issued for restricted stock awards     56       1       (1 )     (2,229 )             (2,228 )
Cash dividends                             (48,902 )             (48,902 )
Stock-based compensation expense                     31,932                       31,932  
Common stock issued to employee stock purchase plan     14       -       2,312                       2,312  
Employee stock purchase plan expense                     435                       435  
Balances at June 30, 2020     38,453     $ 385     $ 420,536     $ 1,057,470     $ (97,199 )   $ 1,381,192  

 

See Notes to Consolidated Financial Statements.

 

36
Table of Contents

 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

Bio-Techne Corporation and Subsidiaries
(in thousands)

 

   

Year Ended June 30,

  
   

2020

     2019     2018  

Cash flows from operating activities:

                        

Net earnings

   $ 229,296     $ 96,072     $ 126,150  

Adjustments to reconcile net earnings to net cash provided by operating activities:

                        

Depreciation and amortization

     82,737       78,171       64,463  

Costs recognized on sale of acquired inventory

     -       3,739       2,455  

Deferred income taxes

     13,130       (13,582

)

     (46,716

)

Stock-based compensation expense

     32,367       32,280       28,240  

Fair value adjustment to contingent consideration payable

     (905 )     (2,000 )     20,100  

Contingent consideration payments

     (958 )     -

 

     (26,600

)

(Gain) Loss on investment, net

     -       (3,702

)

     (397 )
Fair value adjustment on available for sale investments     (137,527 )     16,067       -  
              Leases, net     225       -       -  
Gain on escrow settlement     (7,170 )     -       -  

Other operating activity

     (732 )     2,325       776  

Change in operating assets and liabilities, net of acquisitions:

                        

Trade accounts and other receivables

     6,556       (15,000

)

     (2,700

)

Inventories

     (14,861

)

     (13,647

)

     (13,327

)

Prepaid expenses

     (2,605 )     (698 )     2,782

 

Trade accounts payable and accrued expenses

     10,343       6,101       5,026  

Salaries, wages and related accruals

     2,552

 

     5,013

 

     (89 )

Income taxes payable

     (7,231 )     (9,520 )     10,204  

Net cash provided by operating activities

     205,217       181,619       170,367  
                         

Cash flows from investing activities:

                        

Proceeds from sale and maturities of available-for-sale investments

     147,120       21,579       36,390  

Purchase of available-for-sale investments

     (70,187 )     (43,475

)

     (8,571

)

Additions to property and equipment

     (51,744

)

     (25,411

)

     (20,934

)

Acquisitions, net of cash acquired

     -

 

     (289,492

)

     (67,851

)

Investment in unconsolidated entity

     1,906       -       21,574

 

Other investing activities

     -       -       680  

Net cash provided by (used in) investing activities

     27,095

 

     (336,799

)

     (38,712

)
                         

Cash flows from financing activities:

                        

Cash dividends

     (48,902

)

     (48,364

)

     (47,973

)

Proceeds from stock option exercises

     70,983       37,950       19,170  
       Re-purchases of common stock     (50,112 )     (15,405 )     -  

Borrowings under line-of-credit agreement

     40,000       580,000       55,000  

Payments on line-of-credit

     (188,500 )     (413,500

)

     (59,500

)

Contingent consideration payments

     (3,400

)

     -

 

     (61,900

)

Other financing activities

     (3,872

)

     (6,297

)

     (3,985

)

Net cash provided by (used in) financing activities

     (183,802

)

     134,384

 

     (99,188 )
                         

Effect of exchange rate changes on cash and cash equivalents

     (2,771

)

     (308

)

     (2,089 )

Net change in cash and cash equivalents

     45,739       (21,104 )     30,378  

Cash and cash equivalents at beginning of year

     100,886       121,990       91,612  

Cash and cash equivalents at end of year

   $ 146,625     $ 100,886     $ 121,990  

 

 See Notes to Consolidated Financial Statements.

 

37
Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Bio-Techne Corporation and Subsidiaries

 

Years ended June 30, 2020, 2019 and 2018

 

 

Note 1. Description of Business and Summary of Significant Accounting Policies:

 

Description of business: Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (the Company), develop, manufacture and sell life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

 

Use of estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.

 

Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.

 

Translation of foreign financial statements: Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.

 

Revenue recognition: The Company adopted ASC 606 - Revenue from Contracts with Customers on July 1, 2018 using the modified retrospective transition approach. ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to the Recently Adopted Accounting Pronouncements section of Note 1 for additional information regarding our adoption of ASC 606 and Note 2 for additional information regarding our revenue recognition policy under ASC 606.

 

Research and development: Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.

 

Advertising costs: Advertising expenses were $4.2 million, $4.1 million, and $3.8 million for fiscal 2020, 2019, and 2018 respectively. The Company expenses advertising expenses as incurred.

  

Income taxes: The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense.

 

See Note 11 for additional information regarding income taxes.

 

38
Table of Contents
 

Comprehensive income: Comprehensive income includes charges and credits to shareholders' equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity.

 

Cash and cash equivalents: Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of three months or less.

 

Available-for-sale investments: Available-for-sale investments consist of debt instruments with original maturities of generally three months to six months and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value.  Unrealized gains and losses on available-for-sale securities are included within other income (expense) beginning in fiscal 2019 as the Company adopted ASU  2018-02 on July 1, 2018, as further described in the Recently Adopted Accounting Pronouncements section of Note 1. Unrealized gains or losses on available-for-sale securities were recorded within comprehensive income in fiscal year 2018.

 

Trade accounts receivable: Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer.

 

Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration.

 

For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Company’s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with ASC 330 - Inventory.

 

Property and equipment: Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of 5 to 40 years.

 

Contingent Consideration: Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income

 

Intangibles assets: Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life. In the current year, the Company identified one item as described in the Impairment of long-lived assets and amortizable intangibles section below. 

 

39
Table of Contents
 

Impairment of long-lived assets and amortizable intangibles: We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.

 

The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During fiscal year 2020, the Company accelerated the amortization of a certain trade name based on the Company's planned integration of the products under that acquired trade name into a legacy brand. The accelerated amortization resulted in $1.3 million in additional amortization expense in fiscal 2020 and an estimated $0.6 million in fiscal 2021. No other triggering events were identified and no impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years 2018, 2019, and 2020.

 

Impairment of goodwill: We evaluate the carrying value of goodwill during the fourth quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.

 

To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business.

 

2020 Goodwill Impairment Analyses

 

In completing our 2020 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU 2017- 04, a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit’s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value- weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

 

The result of our quantitative assessment, where we compared the discounted cash flows of each reporting unit to its carrying value, indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2020. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2020, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. 

 

2019 Goodwill Impairment Analyses

 

At the beginning of the quarter ended March 31, 2019, the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment.

 

Because our quantitative analysis performed as of January 1, 2019 included all of our reporting units, except for Exosome a recent acquisition that was a separate reporting unit that was not impacted by the business process realignment, the summation of the calculated reporting units’ fair values combined with the fair value of the Exosome acquisition, was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.

 

The quantitative assessments completed as of January 1, 2019 indicated that all tested reporting units had a substantial amount of headroom. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

In conducting our annual goodwill impairment test on April 1, we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than not that the fair value of a reporting unit is less than its carrying amount.

 

Based on its annual analysis, the Company determined there was no indication of impairment of goodwill. Further, no triggering events or items beyond the realignment discussed above were identified in the year ended June 30, 2019 that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.

 

40
Table of Contents
 

2018 Goodwill Impairment Analyses

 

In completing our 2018 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units, with a process consistent to that described in our 2020 Goodwill Impairment Analyses section above. The quantitative assessment completed indicated that all of the reporting units had a substantial amount of headroom. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

There has been no impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC 350 guidance for goodwill and other intangibles on July 1, 2002.

 

Investments in unconsolidated entities: The Company periodically invests in the equity of start-up and early development stage companies. The accounting treatment of each investment (cost method or equity method) is dependent upon a number of factors, including, but not limited to, the Company's share in the equity of the investee and the Company's ability to exercise significant influence over the operating and financial policies of the investee.

 

Other Significant Accounting Policies

 

The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:

 

Policy

 

Note

 

Fair value measurements

  5 

Earnings per share

  9 

Share-based compensation

  10 

Operating segments

  12 

 

 

41
Table of Contents
 

Recently Adopted Accounting Pronouncements

 

In  February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. The FASB has issued narrow codification improvements to Leases (Topic 842) through ASU No. 2018-10 and ASU 2019-01. Additionally, the FASB issued ASU 2018-11, allowing an entity to elect a transition method where they do not recast prior periods presented in the financial statements in the period of adoption. The Company has elected the transition method allowed for under ASU 2018-11 when adopting Leases (Topic 842). The Company adopted the standard effective  July 1, 2019 and correspondingly recorded incremental operating lease liabilities of $80.6 million, a right-of-use lease asset of $79.5 million, retained earnings of $0.8 million and a deferred tax adjustment of $0.3 million. Additionally, the Company reclassified $4.0 million of deferred rent recorded within accrued expenses under ASC 840 - Leases into operating lease liabilities upon adoption of Topic 842. In adopting ASC 842, the Company elected the package of available practical expedients and to use hindsight in determining the lease term for all existing leases. Further, as part of our adoption of ASC 842, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Refer to Note 7 for additional information on leases.

 

Pronouncements Issued but Not Yet Adopted

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The amendment in this update replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade and loan receivables and available-for-sale debt securities. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. This ASU is effective for annual periods and interim periods for those annual periods beginning after December 15, 2019, which for us is July 1, 2020. Entities may early adopt beginning after December 15, 2018. We have completed our evaluation of the impact of the adoption of ASU 2016-13, noting the impact of adoption is not expected to have a material impact on our consolidated financial statements.

 

In August 2018, the FASB issued ASU No. 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is not affected by the new standard.  This ASU is effective for annual periods and interim periods for those annual periods beginning after December 15, 2019, which for us is July 1, 2020 and may be adopted retrospectively or prospectively to eligible costs incurred on or after the date the guidance is first applied. We do not expect this standard to have a material impact on our consolidated financial statements and we will adopt the standard prospectively on July 1, 2020.

 

In  March 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides expedients and exceptions to existing guidance on contract modifications and hedge accounting that is optional to facilitate the market transition from a reference rate, including LIBOR which is being phased out in 2021, to a new reference rate. The provisions of the ASU would impact contract modifications and other changes that occur while LIBOR is phased out. The Company is in the process of evaluating the optional relief guidance provided within this ASU and is also reviewing its debt and derivative instrument that utilizes LIBOR as the reference rate. The Company will continue to evaluate and monitor developments and our assessment of ASU 2020-04 during the LIBOR transition period.

.

 

42
Table of Contents
 
 

Note 2. Revenue Recognition:

 

Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. The vast majority of service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects. Revenue for these contracts are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. The remaining service revenues were not material to the period and consist of laboratory services recognized at point in time. Given the Company does not have significant historical experience collecting payments from Medicare or insurance providers, the Company considered the variable consideration for such services to be constrained as it would not be probable that a significant amount of revenue would not need to be reversed in future periods for the services provided. Accordingly, the Company does not record revenue upon completion of the performance obligation, but rather upon cash receipt, which is subsequent to the performance obligation being satisfied. Royalty revenues are based on net sales of the Company’s licensed products by a third party. We recognize royalty revenues in the period the sales occur using third party evidence to estimate the amount to be recorded. The Company has also elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date. 

 

The Company has elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance.  The Company's unfulfilled performance obligations for contracts with an original length greater than one year were not material as of June 30, 2020 and June 30, 2019.

 

Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts’ inception.

 

Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.

 

Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense costs of obtaining contracts less than one year that would otherwise be capitalized and amortized over the contract period. Contract assets as of June 30, 2020 are not material.

 

Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of June 30, 2020 and June 30, 2019 were approximately $14.2 million and $10.4 million, respectively. Contract liabilities as of June 30, 2019 subsequently recognized as revenue during the year ended June 30, 2020 were approximately $7.6 million. Contract liabilities in excess of one year are included in Other long-term liabilities on the balance sheet. 

 

Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material.

 

Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We have elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized.

 

43
Table of Contents
 

The following tables present our disaggregated revenue for the periods presented.

 

Revenue by type is as follows:

 

  

Year ended June 30,

     
  

2020

  

2019

  2018 

Consumables

 $602,642  $588,979  $534,738 

Instruments

  71,462   67,538   61,784 

Services

  47,459   38,050   34,137 

Total product and services revenue, net

  721,563  $694,567   630,659 

Royalty revenues

  17,128   19,439   12,334 

Total revenues, net

 $738,691  $714,006  $642,993 

 

Revenue by geography is as follows:

 

  

Year Ended June 30,

 
  

2020

  

2019

  

2018

 

Net sales:

            

United States

 $404,407  $391,191  $346,293 

EMEA, excluding U.K.

  155,289   155,821   148,599 

U.K.

  30,411   34,975   33,704 

APAC, excluding Greater China

  60,362   52,913   48,392 

Greater China

  68,792   57,799   47,950 

Rest of world

  19,430   21,307   18,055 

Total external sales

 $738,691  $714,006  $642,993

 

44
Table of Contents
 
 

Note 3. Supplemental Balance Sheet and Cash Flow Information:

 

Available-For-Sale Investments:

 

The fair value of the Company's available-for-sale investments as of June 30, 2020 and June 30, 2019 were $87.8 million and $38.2 million, respectively. The increase was due to year-over-year increase in the stock price of CCXI, which was $9.30 per share at June 30, 2019 compared to $57.54 per share at June 30, 2020. The amortized cost basis of the Company's investment in CCXI was $6.6 million and $18.8 million as of June 30, 2020 and 2019 respectively.

 

Inventories:

 

Inventories consist of (in thousands):

 

  

June 30,

 
  

2020

  

2019

 
         

Raw materials

 $51,530  $40,913 

Finished goods(1)

  56,268   53,376 

Inventories, net

 $107,798  $94,289 

 

(1) Finished goods inventory of $4,646 and $3,239 is included within other long-term assets in the June 30, 2020 and June 30, 2019 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.  

 

Property and Equipment:

 

Property and equipment consist of (in thousands):

 

  

June 30,

 
  

2020

  

2019

 

Cost:

        

Land

 $8,516  $7,065 

Buildings and improvements

  184,430   175,019 

Machinery, equipment and other

  153,704   124,233 

Property and equipment

  346,650   306,317 

Accumulated depreciation and amortization

  (169,821

)

  (152,278

)

Property and equipment, net

 $176,829  $154,039 

 

45
Table of Contents
 

Intangibles assets were comprised of the following (in thousands):

 

       

June 30,

 
  

Useful Life

(years)

  

2020

  

2019

 
              

Developed technology

 9-15  $434,653  $435,679 

Trade names

 2-20   146,713   147,296 

Customer relationships

 7-16   211,750   214,320 

Patents

  10    2,475   2,133 

Intangible assets

       795,591   799,428 

Accumulated amortization

       (279,046

)

  (219,999

)

Intangibles assets, net

      $516,545  $579,429 

 

Changes to the carrying amount of net intangible assets consist of (in thousands):

 

  

June 30,

 
  

2020

  

2019

 
         

Beginning balance

 $579,429  $446,332 

Acquisitions (Note 4)

  -   191,956 

Other additions

  311   633 

Amortization expense

  (61,095)  (58,715

)

Currency translation

  (2,100)  (777

)

Ending balance

 $516,545  $579,429 

 

Amortization expense related to technologies included in cost of sales was $34.5 million, $33.3 million, and $25.3 million in fiscal 2020, 2019, and 2018, respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was $26.6  million, $25.4 million, and $21.6 million, in fiscal 2020, 2019, and 2018 respectively.

 

The estimated future amortization expense for intangible assets as of June 30, 2020 is as follows (in thousands):

 

2021

 $59,766 

2020

  57,564 

2023

  55,696 

2024

  53,198 

2025

  50,024 

Thereafter

  240,297 

Total

 $516,545 

 

46
Table of Contents
 

Changes in goodwill by segment and in total consist of (in thousands):

 

  

Protein

Sciences

  

Diagnostics &

Genomics

  

Total

 

June 30, 2018

 $347,918  $249,972  $597,890 

Acquisitions (Note 4)

  30,939   105,362   136,301 

Currency translation

  (1,450)  (74)  (1,524

)

June 30, 2019

 $377,407  $355,260  $732,667 
Acquisitions (Note 4)  (326)  -   (326)
Currency Translation  (4,000)  (31)  (4,031)
June 30, 2020 $373,081  $355,229  $728,310 

 

Other Assets:

 

Other assets consist of (in thousands):

 

  

June 30,

 
  

2020

  

2019

 
         

Long-term deposits

 $6,234  $487 

Other

  7,288   5,181 

Other long-term assets

 $13,522  $5,668 

 

As of June 30, 2020, the Company had $13.5 million of other assets compared to $5.7 million as of June 30, 2019.  The increase in other long-term assets in fiscal 2020 is primarily attributable to deposits made on our GMP manufacturing facility. 

 

Supplemental Cash Flow Information:

 

Supplemental cash flow information was as follows (in thousands):

 

  

Year Ended June 30,

 
  

2020

  

2019

  

2018

 

Income taxes paid

 $41,992  $36,814  $35,076 

Interest paid

  18,615   21,497   9,844 

Non-cash activities:

            

Acquisition-related liabilities (1)

  (2,105)  12,600   1,396 

 

 

(1) Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.

 

47
Table of Contents
    
 

Note 4. Acquisitions:

 

We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.

 

2019 Acquisitions

 

Quad Technologies

 

On July 2, 2018, the Company acquired QT Holdings Corporation (Quad) for approximately $20.5 million, net of cash acquired, plus contingent consideration of up to $51.0 million, subject to certain product development milestones and revenue thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences operating segment in the first quarter of fiscal year 2019. Purchase accounting was finalized during fiscal 2019.

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible assets acquired in fiscal 2019 is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for our calculation of acquired net operating losses (NOLs).

 

Exosome Diagnostics

 

On August 1, 2018, the Company acquired Exosome Diagnostics, Inc. (ExosomeDx) for approximately $251.6 million, net of cash acquired, plus contingent consideration of up to $325.0 million, subject to certain EBITA thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’ product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the first quarter of fiscal year 2019. Purchase accounting was finalized during fiscal 2019. 

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using either a relief-from-royalty or a multiperiod excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2019 are 15 years for developed technology and trade names, and 14 years for customer relationships. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the preliminary calculation of acquired NOLs.

 

Note: As part of the ExosomeDx acquisition, a certain amount of the cash payment was held in escrow. As part of the finalization of the outstanding amounts held in escrow, the Company recognized a gain of $7.2 million related to returned proceeds and a relief of any future contingent payments as described in Note 5. The gain was recorded within selling, general, and administrative costs in the Consolidated Statement of Comprehensive Income. 

 

48
Table of Contents
 

B-MoGen Biotechnologies

 

On June 4, 2019, the Company acquired the remaining interest in B-MoGen Biotechnologies Inc. (B-MoGen) for approximately $17.5 million, net of cash acquired, plus contingent consideration of up to $38.0 million, subject to certain product development milestones and revenue thresholds. The Company previously held an investment of $1.4 million in B-MoGen and recognized a gain of approximately $3.7 million on the transaction within other non-operating income fiscal year 2019 in the consolidated statements of earnings and comprehensive income, which represented the adjustment of our historical investment to its fair value. 

 

The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences segment in the fourth quarter of fiscal year 2019. Purchase accounting remained opened as disclosed in our prior year 10-K/A for working capital adjustments and our income tax assessment of acquired net operating losses (NOLs) with the completion of the stub period tax returns. Our purchase accounting was finalized in fiscal 2020 with an immaterial adjustment of $0.3 million to deferred tax amounts and goodwill. 

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible asset acquired in fiscal 2019 is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the preliminary calculation of acquired NOLs.

 

49
Table of Contents
 

2018 Acquisitions

 

Trevigen

 

On September 5, 2017 the Company acquired the stock of Trevigen Inc. for approximately $10.6 million, net of cash received. The Company has had a long-standing business relationship with Trevigen as a distributor of its product line. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences segment in the first quarter of fiscal 2018.  

 

Atlanta Biologicals

 

On January 2, 2018 the Company acquired the stock of Atlanta Biologicals, Inc. and its affiliated company, Scientific Ventures, Inc., for approximately $51.3 million, net of cash acquired. The transaction was financed through available cash on hand and an additional draw from the Company’s line-of-credit. Atlanta Biologicals fetal bovine serum (FBS) product line strengthens and complements our current tissue culture reagents offering and furthers our efforts to provide more complete solutions to our research customers. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences segment in the third quarter of fiscal 2018. Purchase accounting was finalized during fiscal 2018.

 

Tangible assets acquired in the acquisition, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2018 are 13 years for developed technology, 12 years for customer relationships, and 15 years for trade names. The deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not deductible for income tax purposes.

 

Eurocell Diagnostics

 

On February 1, 2018, the Company acquired Eurocell Diagnostics SAS, a company based in Rennes, France, for approximately $7.3 million, net of cash acquired. The Company paid $6.0 million on the acquisition date and the remaining $1.3 million was paid on February 1, 2019. The Company has had a long-standing business relationship with Eurocell as a distributor of its product line. Eurocell sells directly to the laboratory markets in the French region as well as servicing the EMEA markets via a network of distributors. The transaction was financed through cash on hand.  The primary asset in this acquisition is the customer relationships; however, the acquisition resulted in some goodwill as we expect strategic benefits of revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Company’s Diagnostics and Genomics segment in the third quarter of fiscal 2018. Purchase accounting was finalized during fiscal 2018. 

 

Tangible assets acquired, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to customer relationships was based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. Amortization expense related customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships acquired in fiscal 2018 is 7 years. The deferred income tax liability represents the net amount of the estimated future impact of intangible asset amortization, which is not deductible for income tax purposes.

 

50
Table of Contents
 
  B-MoGen Biotechnologies  Exosome Diagnostics  Quad Technologies  

Trevigen

  Atlanta Biologicals  Eurocell Diagnostics 

Current assets, net of cash

 $504  $2,611  $36  $1,662  $15,722  $512 

Equipment and other long-term assets

  269   2,212   228   53   4,901   188 

Intangible assets:

 
Developed technology  14,000   105,000   12,256   5,100   23,000   - 
Trade name  -   58,000   -   160   2,300   - 

Customer relationships

  400   2,300   -   260   3,600   6,272 

Goodwill

  16,131   105,362   14,481   5,991   10,195   2,910 

Total assets acquired

  31,304   275,485   27,001   13,226   59,718   9,882 
                         

Liabilities

  211   3,716   296   387   90   483 

Deferred income taxes, net

  3,051   16,346   943   2,195   8,354   2,070 

Net assets acquired

 $28,042  $255,423  $25,762  $10,644  $51,274  $7,329 
                         

Cash paid, net of cash acquired

  17,448   251,623   20,462  $10,644  $51,274  $5,933 

Consideration payable

  5,500   -   -   -   -   1,396 
Contingent consideration payable  5,094   3,800   5,300   -   -   - 
Net assets acquired $28,042  $255,423  $25,762  $10,644  $51,274  $7,329 

 

 

Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of good sold in the Consolidated Statements of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statements of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not deductible for income tax purposes, and the future tax benefit of net operating loss and tax credit carryforwards which will be deductible by the Company in future periods. 

 

51
Table of Contents
 
 

Note 5. Fair Value Measurements:

 

The Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt.

 

Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.

 

The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.

 

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):

 

  

Total carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30, 2020

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $87,842  $79,846  $7,996  $- 

Certificates of deposit (2)

  36,426   36,426   -   - 

Total Assets

 $124,268  $116,272  $7,996  $- 
                 

Liabilities

                

Contingent consideration

 $6,137  $-  $-  $6,137 
    Derivative instruments - cash flow hedges  17,331   -   17,331   - 
    Total Liabilities $23,468  $-  $17,331  $6,137 

 

  

Total carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30, 2019

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $38,219  $38,219  $-  $- 

Certificates of deposit (2)

  26,928   26,928   -   - 

Total Assets

 $65,147  $65,147  $-  $- 
                 
Liabilities                
Contingent consideration  12,600         12,600 
Derivative instruments - cash flow hedges  12,458      12,458    
Total Liabilities $25,058  $-  $12,458  $12,600 

 

 

(1) Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at June 30, 2020 and June 30, 2019 was $6.6 million and $18.8 million respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $8.0 million as of June 30, 2020. The fair value of the warrant as of  June 30, 2019 was not material. 

 (2) Included in available-for-sale investments on the balance sheet.  The certificate of deposits have contractual maturity dates within one year.

 

52
Table of Contents
 

Fair value measurements of available for sale securities

 

Available for sale securities excluding warrants are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 assets. The Company's warrant to purchase additional shares at a specified future price was valued using a Black-Scholes model with observable inputs in active markets and therefore was classified as a Level 2 asset. 

 

Fair value measurements of derivative instruments

 

In October 2018, the Company entered into forward starting swaps designated as cash flow hedges on outstanding debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt described in Note 6 to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company will exchange, at specified intervals, the difference between floating and fixed interest amounts based on an initial $380 million of notional principal amount, with the notional amount decreasing by $100 million in  October, 2020, $80 million in October 2021, and $200 million in October 2022. The change in the fair value of the designated hedged instrument is reported as a component of other comprehensive income and reclassified into interest expense over the corresponding term of the cash flow hedge. The Company reclassified $3.5 million, net of taxes, out of other comprehensive income into interest expense during the fiscal year ended June 30, 2020. In June 2020, the Company de-designated $80 million of the notional amount set to expire in  October 2020. The change in fair value of the dedesignated notional hedged amount was not material as of June 30, 2020. The net loss associated with the dedesignated portion of the derivative instrument was not reclassified into earnings based on the amount of probable variable interest payments to occur within a two month time period of the forecasted hedged transaction. The liability related to the derivative instrument was recorded within Other long-term liabilities on the Consolidated Balance Sheet. The instrument was valued using observable market inputs in active markets and therefore classified as a Level 2 liability.

 

Fair value measurements of contingent consideration

 

In connection with the ExosomeDx, Quad, and B-Mogen acquisitions the Company is required to make contingent consideration payments of up to $325.0 million, $51.0 million, and $38.0 million respectively. The contingent consideration agreement with ExosomeDx was based on achieving certain EBITA thresholds, the contingent agreement with Quad is based on meeting certain product development milestones and revenue thresholds, and the contingent agreement with B-Mogen is based on meeting certain product development milestones and revenue thresholds. The preliminary fair value of the liabilities for the contingent payments recognized upon the acquisition as part of the purchase accounting opening balance sheet totaled $14.6 million ($3.8 million for ExosomeDx, $5.3 million for Quad, and $5.5 million for B-Mogen) as discussed in Note 4.  The preliminary fair value of the development milestone payments was estimated by discounting the probability-weighted contingent payments expected to be made to present value. Assumptions used in these calculations were probability of success, duration of the earn-out, and discount rate.   The preliminary fair value for the EBITA and revenue milestone payments was determined using a Monte Carlo simulation-based model discounted to present value.  Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate and various probability factors.

 

During the fourth quarter of fiscal 2020, the Company's obligation for potential contingent consideration payments related to the ExosomeDx acqusition were relieved as part of the Company's escrow settlement with the former shareholders of ExosomeDx. As the result of this settlement, the Company reversed an accrual for the fair value of the contingent liability at the date of settlement. The ultimate settlement of contingent consideration liabilities for the Quad and B-Mogen acquisitions could deviate from current estimates based on the actual results of the financial measures described above. This liability is considered to be a Level 3 financial liability that is re-measured each reporting period. The change in fair value of contingent consideration for these acquisitions is included in general and administrative expense.

 

The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

 

  

June 30,

 
  

2020

  

2019

 
         

Fair value at the beginning of period

 $12,600  $- 

Purchase price contingent consideration (Note 4)

  -   14,600 

Payments

  (4,358

)

  -

 

Gain on escrow settlement  (1,200)   

Change in fair value of contingent consideration

  (905)  (2,000)

Contingent consideration payable

 $6,137  $12,600 

 

Fair value measurements of other financial instruments – The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.

 

Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items.

 

Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility  and long-term debt approximates fair value because our interest rate is variable and reflects current market rates. 

 

53
Table of Contents
 
 

Note 6. Debt and Other Financing Arrangements: 

 

On August 1, 2018, the Company entered into a new uncollateralized revolving line-of-credit and term loan governed by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $600.0 million, which can be increased by an additional $200.0 million subject to certain conditions, and a term loan of $250.0 million. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the Eurodollar Loans term for which the interest rate is calculated as the sum of LIBOR plus an applicable margin. The applicable margin is determined for the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 15 basis points. The Company has recorded $12.5 million of our outstanding borrowings under the Credit Agreement as a current liability in our Consolidated Balance sheet, which represents our required quarterly debt payments to be made in fiscal year 2021.

 

The Credit Agreement matures on August 1, 2023 and contains customary restrictive and financial covenants and customary events of default. At the closing on August 1, 2018 the company borrowed $250.0 million under the term loan and $330.0 million under the revolving credit facility. As of June 30, 2020 and 2019, the outstanding balance under the Credit Agreement was $357 million and $505.2 million respectively. 

  

 

 

Note 7. Leases: 

 

As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU No. 2016-02 and related standards (collectively ASC 842, Leases), which replaced previous lease accounting guidance, on July 1, 2019. 


The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company’s incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During fiscal year 2020, the Company recognized $3.4 million in variable lease expense in the Consolidated Statements of Earnings and Comprehensive Income.  During fiscal year 2020, the Company also recognized $13.0 million relating to fixed lease expense in the Consolidated Statements of Earnings and Comprehensive Income. 

 

The following table summarizes the balance sheet classification of the Company’s operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands):

 

 

Balance Sheet Classification

 

As of:

June 30,

2020

 

Operating leases:

     

Operating lease right of use assets

Right of Use Asset

 $71,465 
      

Current operating lease liabilities

Operating lease liabilities current

 $9,535 

Noncurrent operating lease liabilities

Operating lease liabilities

  67,248 
Total operating lease liabilities  $76,783 
 

 

    
Weighted average remaining lease term (in years):   8.72 
 

 

    
Weighted average discount rate:   4.40%

 

The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended  June 30, 2020 (in thousands):

 

  

For the year ended June 30, 2020

 

Cash amounts paid on operating lease liabilities(1)

 $12,763 
     

Right of use assets obtained in exchange for lease liabilities

  1,758 

 

(1) Total cash paid for the Company's operating leases during the year ended June 30, 2020 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.  

 

54
Table of Contents
 

The following table summarizes payments by date for the Company’s operating leases, which is then reconciled to our total lease obligation (in thousands):

 

  

June 30, 2020

Operating

Leases

 

2021

 $12,590 

2022

  12,113 

2023

  11,296 

2024

  10,317 

2025

  9,388 

Thereafter

  37,316 

Total

 $93,020 
Less: Amounts representing interest  16,237 
Total lease obligations  76,783 

 

Certain leases include one or more options to renew, with terms that extend the lease term up to five years. The Company includes option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is not reasonably certain to exercise such options.

 

Disclosures related to periods prior to adoption of new lease standard:

 

At June 30, 2019, aggregate net minimum rental commitments under non-cancelable leases having an initial or remaining term of more than one year are payable as follows (in thousands):

 

  

Operating

Leases

 

2020

 $13,707 

2021

  13,469 

2022

  13,154 

2023

  12,716 

2024

  11,392 

Thereafter

  51,895 

Total

 $116,333 

 

Total rent expense was approximately $12.9 million, $10.8 million, and $9.8 million for the years ended June 30, 2019, 2018, and 2017, respectively.  

 

55
Table of Contents
 
 

Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (loss): 

 

Supplemental Equity

 

The Company has declared cash dividends per share of $1.28 in each of the full fiscal years ended   June 30, 2020, June 30, 2019, and June 30, 2018. During the years ended June 30, 2020 and June 30, 2019, the Company repurchased 279,381 shares at an average share price of $179.37 and 95,000 shares at an average share price of $162.15, respectively. The Company's accounting policy is to record the portion of share repurchases in excess of the par value entirely in retained earnings. During fiscal year 2020, the Company recorded ($0.4) million within the Consolidated Statements of Shareholders' Equity for the surrender and retirement of stock to exercise option due to net settlement stock options exercises. 

 

Accumulated Other Comprehensive Income (loss) 

 

Changes in accumulated other comprehensive income (loss), net of tax, at June 30 consists of (in thousands):

 

   

Unrealized

Gains (Losses)

on Available-

for-Sale

Investments

  

Foreign

Currency

Translation

Adjustments

  

Unrealized Gains (Losses) on Derivatives Instruments

  

Total

 
 

Balance June 30, 2017

 $18,989  $(67,924

)

 $-  $(48,935

)

 

Other comprehensive income (loss) before reclassifications

  18,108   (1,572

)

  -   16,536 
 

Amounts reclassified from accumulated other comprehensive loss to income

  (12,415

)

  -   -   (12,415

)

 

Balance June 30, 2018

 $24,682  $(69,496

)

 $-  $(44,814

)

 Cumulative effect adjustment for adoption for ASU 2018-02  2,371   -   -   2,371 
 Cumulative effect adjustment for adoption for ASU 2016-01  (27,053)  -   -   (27,053)
 

Other comprehensive income (loss) before reclassifications 

  -   (4,487)  (9,537)  (14,024)
 

Balance June 30, 2019

 $-  $(73,983

)

 $(9,537) $(83,521

)

 Other comprehensive income (loss) before reclassifications  -   (9,963)  (7,179)  (17,142)
 Reclassification from loss on derivatives to interest expense, net of taxes(1)  -   -   3,464   3,464 
 Balance June 30, 2020 $-  $(83,946) $(13,253) $(97,199)

 

(1) Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made.The Company reclassified ($4,503) to interest expense and a related tax benefit tax of $1,040 during fiscal 2020. Approximately $7,035 of the $13,253 will be reclassified in the 12 months subsequent to June 30, 2020. The Company had deferred tax benefits of $4,058 and $2,921 included in the accumulated other comprehensive income loss as of June 30, 2020 and June 30, 2019, respectively.

 

56
Table of Contents
 
 

Note 9. Earnings Per Share:

 

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

 

  

Year Ended June 30,

 
  

2020

  2019  2018 

Earnings per share – basic:

            

Net income

 $229,296  $96,072  $126,150 

Income allocated to participating securities

  (224

)

  (105

)

  (108

)

Income available to common shareholders

 $229,072  $95,967  $126,042 

Weighted-average shares outstanding – basic

  38,201   37,781   37,476 

Earnings per share – basic

 $6.00  $2.54  $3.36 
             

Earnings per share – diluted:

            

Net income

 $229,296  $96,072  $126,150 

Income allocated to participating securities

  (224

)

  (105

)

  (108

)

Income available to common shareholders

 $229,072  $95,967  $126,042 

Weighted-average shares outstanding – basic

  38,201   37,781   37,476 

Dilutive effect of stock options and restricted stock units

  1,200   1,111   579 

Weighted-average common shares outstanding – diluted

  39,401   38,892   38,055 

Earnings per share – diluted

 $5.82  $2.47  $3.31 

 

Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period.

 

The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.9 million, 1.3 million, and 0.9 million for the fiscal years ended June 30, 2020, 2019 and 2018, respectively.

 

57
Table of Contents
 
 

Note 10. Share-based Compensation and Other Benefit Plans:

 

The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. 

 

Equity incentive plan: The Company's Second Amended and Restated 2010 Equity Incentive Plan (the Second A&R 2010 Plan) provides for the granting of incentive and nonqualified stock options, restricted stock, restricted stock units, performance shares, performance units and stock appreciation rights. There are 7.5 million shares of common stock authorized for grant under the Second A&R 2010 Plan. At June 30, 2020, there were 1.9 million shares of common stock available for grant under the Second A&R 2010 Plan. The maximum term of incentive options granted under the Second A&R 2010 Plan is ten years. The Second A&R 2010 Plan amended and restated the Company's Amended and Restate 2010 Equity Incentive Plan (the A&R 2010 Plan). The A&R 2010 Plan replaced the Company's 1998 Nonqualified Stock Option Plan (the 1998 Plan). The Second A&R 2010 Plan and the 1998 Plan (collectively, the Plans) are administered by the Board of Directors and its Executive Compensation Committee, which determine the persons who are to receive awards under the Plans, the number of shares subject to each award and the term and exercise price of each award. The number of shares of common stock subject to outstanding awards as of  June 30, 2020 under the Second A&R 2010 Plan were 3.6 million. For June 30, 2019 under the Second A&R 2010 Plan and the 1998 Plan were 3.6 million and 20,000, respectively.  On April 26, 2018 the Executive Compensation Committee of the Board of Directors approved a modification to the Plans.   The modification implements a new retirement policy that permits retirees to continue vesting in certain time-based stock options granted during employment, resulting in accelerated stock compensation expense for those employees meeting the definition of retirement eligible.  This modification resulted in an additional $8.3 million of expense during fiscal year 2018 and affected all employees who participate in the plan.

  

The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:

 

  

Year Ended June 30,

 
  

2020

  

2019

  

2018

 
                

Dividend yield

  0.67%    0.74%    1.1%  

Expected volatility

 22%-24%  20%-23%  21%-24% 
Risk-free interest rates 1.3%-1.9%  2.5%-3.0%  1.7%-2.8% 

Expected lives (years)

  4.0    4.1    4.7  

 

The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted.

 

Stock option activity under the Plans for the three years ended June 30, 2020, consists of the following (shares in thousands): 

 

  

Number of

Shares (in

thousands)

  

Weighted
Average
Exercise
Price

  

Aggregate
Intrinsic
Value

(millions)

  

Weighted

Average

Contractual

Life (years)

 
                 

Outstanding at June 30, 2017

  2,821  $98.42         

Granted

  1,087   120.67         

Forfeited

  (252

)

  86.62         

Exercised

  (204

)

  111.51         

Outstanding at June 30, 2018

  3,452  $105.17         

Granted

  917   173.89         

Forfeited

  (330

)

  129.93         

Exercised

  (383

)

  95.29         

Outstanding at June 30, 2019

  3,656  $121.16         

Granted

  752   190.80         

Forfeited

  (56

)

  95.97         

Exercised

  (743

)

  157.45         

Outstanding at June 30, 2020

  3,609  $140.28  $446.7   4.3 
                 

Exercisable at June 30, 2018:

  1,151   90.75         

Exercisable at June 30, 2019:

  1,467   98.70         

Exercisable at June 30, 2020:

  1,564   112.60  $236.8   3.3 

  

The weighted average fair value of options granted during fiscal 2020, 2019, and 2018 was $37.01, $34.66, and $22.07 respectively. The total intrinsic value of options exercised during fiscal 2020, 2019, and 2018 were $99.3 million, $159.0 million, and $10.6 million, respectively. The total fair value of options vested during fiscal 2020, 2019, and 2018 were $71.1 million, $31.7 million, and $8.8 million, respectively.

 

58
Table of Contents
 

Restricted common stock activity under the Plans for the three years ended June 30, 2020, consists of the following (units in thousands):

 

  

Number of

Shares (in

thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Unvested at June 30, 2017

  32  $105.80     

Granted

  20   125.05     

Vested

  (17

)

  104.66     

Forfeited

  -   -     

Unvested at June 30, 2018

  35  $117.39     

Granted

  15   177.93     

Vested

  (20

)

  116.76     

Forfeited

  -   -     

Unvested at June 30, 2019

  30  $147.94     

Granted

  15   193.48     

Vested

  (18

)

  142.12     

Forfeited

  -   -     

Unvested at June 30, 2020

  28  $177.20   6.14 

 

The total fair value of restricted shares that vested was $2.5 million for fiscal 2020, $2.3 million for fiscal 2019, and $1.7 million for fiscal 2018.

 

Restricted stock unit activity under the Plans for the three years ended June 30, 2020, consists of the following (units in thousands):

 

  

Number of

Units

(in thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Outstanding at June 30, 2017

  111  $106.39     

Granted

  71   129.99     

Vested

  (16

)

  95.46     

Forfeited

  (18

)

  115.01     

Outstanding at June 30, 2018

  148  $117.95     

Granted

  56   170.96     

Vested

  (28

)

  110.86     

Forfeited

  (36

)

  143.72     

Outstanding at June 30, 2019

  139  $134.17     

Granted

  31   192.08     

Vested

  (51

)

  111.07     

Forfeited

  (3

)

  155.6     

Outstanding at June 30, 2020

  116  $159.25   5.20 

 

The total fair value of restricted stock units that vested was $5.7 million for fiscal 2020, $3.1 million for fiscal 2019, and $1.6 million for fiscal 2018. The restricted stock units vest over a three-year period.

 

Stock-based compensation cost of $32.4 million, $32.3 million, and $28.2 million was included in selling, general and administrative expense in fiscal 2020, 2019 and 2018, respectively. Additionally, Stock-based compensation costs of $1.6 million was included in cost of goods sold in 2020. As of June 30, 2020, there was $25.3 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal 2021 through 2023 using a 3% forfeiture rate. The weighted average period over which the compensation cost is expected to be recognized is 1.9 years.

 

Employee stock purchase plan: In fiscal year 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. The Company recorded expense of $0.4 million, $0.5 million, and $0.3 million for the ESPP in fiscal 2020, 2019, and 2018, respectively.

 

Profit sharing and savings plans: The Company has profit sharing and savings plans for its U.S. employees, which conform to IRS provisions for 401(k) plans. The Company makes matching contributions to the Plan. The Company has recorded an expense for contributions to the plans of $3.2 million, $2.8 million, and $2.5 million for the years ended June 30, 2020, 2019, and 2018, respectively. The Company operates defined contribution pension plans for its U.K. employees. The Company has recorded an expense for contributions to the plans of $1.4 million for each of the years ended June 30, 2020, 2019, and 2018.

 

Performance incentive programs: In fiscal 2020, under certain employment agreements and a Management Incentive Plan available to executive officers and certain management personnel, the Company recorded cash bonuses of $10.5 million, granted options for 751,499 shares of common stock, issued 15,398 restricted common shares and 30,858 restricted stock units. In fiscal 2019 and fiscal 2018, the Company recorded cash bonuses of $9.3 million and $7.2 million, granted options for 618,898 and 553,750 shares of common stock, and issued 11,279 and 14,194 restricted common stock shares and 25,903 and 35,174 restricted stock, respectively.

  

59
Table of Contents
 
 

Note 11. Income Taxes:

 

Income before income taxes was comprised of the following (in thousands):

 

  

Year Ended June 30,

 
  

2020

  

2019

  2018 

Domestic

 $245,365  $64,081  $81,557 

Foreign

  31,112   47,934   44,395 

Income before income taxes

 $276,477  $112,015  $125,952 

 

The provision for income taxes consisted of the following (in thousands):

 

  

Year Ended June 30,

 
  

2020

  

2019

  2018 

Taxes on income consist of:

            

Currently tax provision:

            

Federal

 $18,976  $16,090  $28,416 

State

  6,018   544   5,315 

Foreign

  8,580   13,329   11,983 

Total current tax provision

  33,574   29,963   45,714 

Deferred tax provision:

            

Federal

  14,074   (6,903

)

  (40,378

)

State

  2,055

 

  (3,977

)

  (1,381

)

Foreign

  (2,522)   (3,142

)

  (4,154

)

Total deferred tax provision

  13,607   (14,021

)

  (45,912

)

Total income tax provision

 $47,181  $15,943

 

 $(198)

 

The Company's effective income tax rate for fiscal 2020 was 17.1% for fiscal 2020 vs 14.2% in the prior year. The change in the effective tax rate for fiscal 2020 and 2019 were driven by the changes in the net discrete tax benefits $19.4 million and $12.7 million, respectively. 

 

The Company’s effective income tax rate for fiscal 2019 was 14.2% vs (0.2%) in the prior year. The change in the effective tax rate for fiscal 2019 and 2018 was driven by changes in net discrete tax benefits of $12.7 million and $34.4 million for fiscal year 2019 and 2018, respectively.

 

The Company's discrete tax benefits in fiscal 2020 primarily related to share-based compensation excess tax benefits of $17.7 million.
 
The Company's discrete tax benefits in fiscal 2019 primarily related to share-based compensation excess tax benefits of $7.2 million,  $3.2 million related to fiscal 2019 acquisitions, and $2.0 million for tax refunds relating to certain state apportionments. The prior fiscal year was benefited from acquisition payments made to employees and third parties, which were deductible for tax purposes. 
 

In fiscal 2018, the Company recognized net discrete tax benefits of $34.4 million. The primary driver in fiscal 2018 discrete tax benefits was a discrete net tax benefit of $33.0 million related to the Tax Act (as described further below). This net tax benefit consisted of $36.5 million due to the re-measurement of the Company’s deferred tax accounts to reflect the U.S. federal corporate tax rate reduction impact to our net deferred tax balances offset by expense for the federal transition tax of $3.3 million. Also impacting the Company’s fiscal 2018 effective tax rate was a $2.2 million tax benefit related to stock option exercises offset by a net discrete tax expense of $4.2 million related to the revaluation of contingent consideration, which is not a tax deductible expense.

 

On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted, which reduced the U.S. federal corporate tax rate from 35% to 21%, required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and created new taxes on certain foreign sourced earnings. The Tax Act added many new provisions including changes the deduction for executive compensation, a tax on global intangible low taxed income (“GILTI”), the base erosion anti abuse tax (“BEAT”) and a deduction for foreign derived intangible income (“FDII”).

 

The Company continues to monitor newly enacted regulations, clarifications, and changes in guidance  the “Tax Act”, which was enacted on  December 22, 2017. The Company recognizes changes in legislation in the period enacted, which may have a material impact on our effective tax rate in future periods.

 

60
Table of Contents
 

The following is a reconciliation of the federal tax calculated at the statutory rate of to the actual income taxes provided:

 

  

Year Ended June 30,

 
  

2020

  2019  2018 
             

Income tax expense at federal statutory rate

  

21.0

%

  21.0

%

  28.1

%

State income taxes, net of federal benefit

  2.3

%

  0.8

%

  2.5

%

Qualified production activity deduction

  -

%

  -

%

  (2.4

)%

Research and development tax credit

  (0.7

)%

  (1.6

)%

  (1.4

)%

Contingent consideration adjustment

  (0.2)%  (0.4

)%

  3.3

%

Foreign tax rate differences

  (0.2)%  0.2

%

  (3.5

)%

Option exercises

  (5.7)%  (5.8

)%

  (1.8

)%

Domestic tax legislation changes  -   1.7

%

  (26.2

)%

State apportionment changes  -   (2.3)%  - 
Executive compensation limitations  1.6%  0.4%  - 

Other, net

  (1.0

)%

  0.2

%

  1.2

%

Effective tax rate

  17.1

%

  14.2

%

  (0.2

)%

  

Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands):

 

  

June 30

 
  

2020

  2019 
         

Inventory

 $7,769  $7,743 

Net operating loss carryovers

  25,707   33,294 

Tax credit carryovers

  9,568   9,640 

Excess tax basis in equity investments

  2,423   3,433 

Deferred compensation

  10,755   10,333 
Derivative - cash flow hedge  4,058   2,921 
Lease liability  16,256   - 

Other

  4,340   5,207 

Valuation allowance

  (7,523

)

  (6,974

)

Deferred tax assets

  73,353   65,597 
         

Net unrealized gain on available-for-sale investments

  (19,102)  (4,542

)

Intangible asset amortization

  (128,279)  (141,998

)

Depreciation

  (10,764)  (8,371

)

Right of use asset  (15,118)  - 

Other

  (1,180)  (440

)

Deferred tax liabilities

  (174,443

)

  (155,351

)

Net deferred tax liabilities

 $(101,090) $(89,754

)

 

61
Table of Contents
 

A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. The valuation allowance as of June 30, 2020 was $7.5 million compared to $7.0 million in the prior year. 

 

As of June 30, 2020, the $7.5 million valuation allowance relates to certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired Quad, Exosome, ACD, Novus, ProteinSimple and CyVek as well as immaterial amounts generated after the acquisitions. The Company believes it is more likely than not that these tax carryovers will not be realized.

 

As of June 30, 2020, the Company has federal operating loss carryforwards of approximately $64.2 million and state operating loss carryforwards of $130.6 million from its acquisitions of Quad, Exosome, ACD, ProteinSimple and CyVek, which are not limited under IRC Section 382. As of June 30, 2020, the Company has foreign net operating loss carryforwards of $13.7 million. The net operating loss carryforwards expire between fiscal 2021 and 2036. The Company has a deferred tax asset of $20.2 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of June 30, 2020, the Company has federal and state tax credit carryforwards of $5.0 million and $5.7 million, respectively. The federal tax credit carryforwards expire between 2028 and 2038. The majority of the state credit carryforwards have no expiry date. The Company has a deferred tax asset of $7.5 million, net of the valuation allowance discussed above, related to the tax credit carryovers.

 

The Company has not recognized a deferred tax liability for unremitted foreign earnings of approximately $186 million from its foreign operations because its subsidiaries have invested or will invest the undistributed earnings indefinitely. The transition tax included as part of the Tax Act resulted in the previously untaxed foreign earnings being included in the federal and state fiscal 2018 taxable income.  The one-time transition tax was based on certain foreign earnings for which earnings have been previously indefinitely reinvested as well as the amount of earnings held in cash and other specified assets.   No additional income taxes have been provided for cumulative unremitted foreign earnings as at this time our intention with respect to unremitted foreign earnings is to continue to indefinitely reinvest outside the U.S. those earnings needed for working capital or additional foreign investment. If there are policy changes, we would record applicable taxes at that time.

 

We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation.  In addition, we anticipate that further guidance from the IRS and US Treasury related to the Tax Act could impact the amount of any related taxes.  Therefore, it is not practical to estimate the amount of the deferred income tax liabilities related to investments in these foreign subsidiaries.

 

The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):

 

  

Year Ended June 30,

 
  

2020

  2019  2018 

Beginning balance

 $5,032  $1,947  $1,747 

Additions due to acquisitions

  -   900   - 

Additions for tax positions of current year

  306   2,185   35 

Closure of tax years

  (1,041)  -   -

 

Tax reform

  -   -   165 

Ending balances

 $4,297  $5,032  $1,947 

 

The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelve months. The Company files income tax returns in the U.S. federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company's federal returns are subject to tax assessment for 2017 and subsequent years. State and foreign income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.

 

62
Table of Contents
 
 

Note 12. Segment Information:

 

The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics.

 

The Company's Protein Sciences segment is comprised of the Reagent Solutions division and Analytical Solution division. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields. No customer in the Protein Sciences segment accounted for more than 10% of the segment’s net sales for the years ended June 30, 2020, 2019, and 2018.

  

The Company's Diagnostics and Genomics is comprised of the Diagnostics Reagents division and the Genomics division. The Diagnostics Reagents division develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits. The Genomics division consists of Genomics and Exosome products and sells a portfolio of clinical molecular diagnostic oncology assays, as well as tissue-based in-situ hybridization assays for research in clinical use. No customer in the Diagnostics and Genomics segment accounted for more than 10% of the segment’s net sales for the fiscal years ended June 30, 2020, 2019, and 2018. 

 

There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term.

 

Following is financial information relating to the operating segments (in thousands):

 

  

Year Ended June 30,

 
  

2020

  2019  2018 

Net sales:

            

Protein Sciences

 $555,352  $543,159  $482,378 

Diagnostics and Genomics

  184,549   171,674   161,151 

Intersegment

  (1,210

)

  (827

)

  (536

)

Consolidated net sales

 $738,691  $714,006  $642,993 
             

Operating Income:

            

Protein Sciences

 $234,929  $240,919  $209,880 

Diagnostics and Genomics

  14,965   10,079   35,496 

Segment operating income

  249,894   250,998   245,376 

Costs recognized upon sale of acquired inventory

  -

 

  (3,739

)

  (2,455

)

Amortization of acquired intangible assets

  (60,865

)

  (58,550

)

  (46,983

)

Gain on escrow settlement  7,169   -   - 

Acquisition related expenses

  (416

)

  (2,282

)

  (24,429

)

Restructuring costs

  (87

)

  -

 

  (376)

Stock-based compensation

  

(34,262

)

  (33,057

)

  (28,240

)

Corporate general, selling and administrative expenses

  (4,015

)

  (6,651

)

  (6,715

)

Consolidated operating income

 $157,419  $146,719  $136,178 

 

63
Table of Contents
 

The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by operating segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each operating segment’s operating results, it is not discretely identifiable.

 

The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note 2. The Company has disclosed dis-aggregated product and service revenue by consumables, instruments, and services in Note 2. The Company considers total instrument and total service revenue to represent similar groups of products in the fiscal years presented. The Company considered our consumables sold in the Protein Sciences and Diagnostics and Genomics segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands) :

 

  

Year Ended June 30,

 
  

2020

  2019  

2018

 
Consumables revenue - Protein Sciences $

431,052

  $430,655  $384,350 

Consumables revenue - Diagnostics and Genomics

  171,590   158,324   150,388 

Total consumable revenue

 $602,642  $588,979  $534,738 

 

The following is financial information relating to geographic areas (in thousands):

 

  

Year ended June 30,

 

Long-lived assets:

 

2020

  2019 

United States and Canada

 $162,039  $138,016 

Europe

  13,120   14,439 

Asia

  1,670   1,584 

Total long-lived assets

 $176,829  $154,039 

Intangible assets:

        

United States and Canada

 $499,875  $556,951 

Europe

  12,349   16,637 

Asia

  4,321   5,841 

Total intangible assets

 $516,545  $579,429 

 

Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

 

64
Table of Contents
 
 

Note 13. Quarterly Financial Data (unaudited):

 

(in thousands, except per share data)

                    

2020

 

First

Quarter

  

Second

Quarter

  

Third

Quarter

  

Fourth

Quarter

  

Year

 

Net sales

 $183,243  $184,934  $194,680  $175,834  $738,691 

Cost of sales

 $64,829  $63,531  $64,617  $62,520  $255,497 

Net earnings1

 $14,398  $119,623  $36,432  $58,847  $229,296 
                     
(1) - Amounts do not total due to rounding                    
                     

Earnings per common share:

                    

Basic

 $0.38  $3.13  $0.95  $1.54  $6.00 

Diluted

 $0.37  $3.02  $0.92  $1.48  $5.82 
                     

Weighted average common shares outstanding:

                    

Basic

  38,032   38,167   38,303   38,304   38,201 

Diluted

  39,253   39,550   39,435   39,700   39,401 

 

(in thousands, except per share data)

                    

2019

 

First

Quarter

  

Second

Quarter

  

Third

Quarter

  

Fourth

Quarter

  

Year

 

Net sales

 $162,970  $174,510  $184,861  $191,664  $714,006 

Cost of sales

 $55,367  $61,492  $60,251  $63,405  $240,515 

Net earnings

 $17,403  $17,556  $44,654  $16,459  $96,072 
                     

Earnings per common share:

                    

Basic

 $0.46  $0.46  $1.18  $0.43  $2.54 

Diluted

 $0.45  $0.45  $1.15  $0.42  $2.47 
                     

Weighted average common shares outstanding:

                    

Basic

  37,697   37,766   37,772   37,881   37,781 

Diluted

  38,813   38,748   38,861   39,135   38,892 

 

 
 

Note 14. Subsequent Events:

 

None

 

65
Table of Contents
 

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors

Bio-Techne Corporation:

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Bio-Techne Corporation and subsidiaries (the Company) as of June 30, 2020 and 2019, the related consolidated statements of earnings and comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended June 30, 2020, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the three-year period ended June 30, 2020, in conformity with U.S. generally accepted accounting principles.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of June 30, 2020, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated August 26, 2020 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

 

Change in Accounting Principle

 

As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for revenue as of July 1, 2018, due to the adoption of Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606), and related amendments.

 

As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for Leases as of July 1, 2019, due to the adoption of Accounting Standards Update 2016-02, Leases (Topic 842) and related amendments. 

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

    

  Goodwill impairment analysis for the Exosome reporting unit

 

As discussed in Note 1 to the consolidated financial statements, the goodwill balance as of June 30, 2020 was $728.3 million, of which $105.4 million related to the Exosome reporting unit. The Company performs goodwill impairment testing on an annual basis and whenever events or changes in circumstances indicate that the carrying value of a reporting unit likely exceeds its fair value. This involves estimating the fair value of the reporting units using discounted cash flow models.

 

We identified the evaluation of the goodwill impairment analysis for the Exosome reporting unit as a critical audit matter. There was a high degree of subjectivity in applying and evaluating certain key assumptions used in the discounted cash flow model to estimate the fair value of the Exosome reporting unit. Specifically, the revenue growth rates and the discount rate were challenging to test as they represented subjective determinations of future market and economic conditions. Changes to those assumptions could have had a significant effect on the Company’s assessment of the fair value of the goodwill.

 

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the critical audit matter. This included controls related to the Company’s determination of the estimated fair value of the Exosome reporting unit, including controls related to the:

 

 

●

development of revenue growth rates
 

●

selection of the discount rate

 

We performed sensitivity analyses over the revenue growth rate and discount rate assumptions to assess their impact on the Company’s determination that the fair value of the Exosome reporting unit exceeded its carrying value. We evaluated the reasonableness of the Company’s forecasted revenue growth rates for the Exosome reporting unit by comparing the growth assumptions to industry benchmarks and other industry related third-party data. We also compared the Company’s historical revenue forecasts to actual results to assess the Company’s ability to accurately forecast. In addition, we involved valuation professionals with specialized skills and knowledge, who assisted in:

 

 

●

evaluating the discount rate used in the valuation, by comparing it against a discount rate range that was independently developed using publicly available market data for comparable entities, and
 

●

testing the estimate of the Exosome reporting unit’s fair value using the reporting unit’s cash flow forecast and discount rate, and comparing the result to the Company’s fair value estimate.

 

We have served as the Company’s auditor since 2002.

 

/s/ KPMG LLP

 

Minneapolis, Minnesota
August 26, 2020

 

66
Table of Contents

 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and Board of Directors
Bio-Techne Corporation:

 

Opinion on Internal Control Over Financial Reporting

 

We have audited Bio-Techne Corporation and subsidiaries’ (the Company) internal control over financial reporting as of June 30, 2020, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of June 30, 2020, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of June 30, 2020 and 2019, the related consolidated statements of earnings and comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended June 30, 2020, and the related notes (collectively, the consolidated financial statements), and our report dated August 26, 2020 expressed an unqualified opinion on those consolidated financial statements.

 

Basis for Opinion

 

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

 

Definition and Limitations of Internal Control Over Financial Reporting

 

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

/s/ KPMG LLP

 

Minneapolis, Minnesota
August 26, 2020

  

67
Table of Contents

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

  

ITEM 9A. CONTROLS AND PROCEDURES

   

 

(a)

 Evaluation of Disclosure Controls and Procedures

 

As required by Rule 13a-15(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this report, the effectiveness of our disclosure controls and procedures as defined in Exchange Act Rule 13a-15(e). The evaluation was based upon reports and certifications provided by a number of executives.  Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2020, our disclosure controls and procedures were effective.

 

(b)

Management's Annual Report on Internal Control Over Financial Reporting

 

The Company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting also includes those policies and procedures that:

 

(i)

Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

 

 

(ii)

 

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

 

 

(iii)

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

 

Under the supervision of the Audit Committee of the Board of Directors and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our assessment and those criteria, our Chief Executive Officer and Chief Financial Officer concluded that our internal control over financial reporting was effective as of June 30, 2020.

 

The attestation report on our internal control over financial reporting issued by KPMG LLP appears in Item 8 of this report.

 

68
Table of Contents

 

(c)

Changes in Internal Control Over Financial Reporting

 

As previously announced, we acquired Quad on July 2, 2018, Exosome on August 1, 2018, and B-Mogen on June 4, 2019 and we have implemented our internal control structure over these and incorporated its operations into our assessment of internal control over financial reporting as of June 30, 2020.  

There were no other changes in the Company's internal control over financial reporting during fiscal year 2020 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

 

 

ITEM 9B. OTHER INFORMATION

 

None.

 

69
Table of Contents

 

PART III

 

  

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Other than "Executive Officers of the Registrant" which is set forth at the end of Item 1 in Part I of this report, the information required by Item 10 is incorporated herein by reference to the sections entitled "Election of Directors," "Principle Shareholders" and "Additional Corporate Governance Matters" in the Company's Proxy Statement for its 2020 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year for which this report is filed.

 

 

ITEM 11. EXECUTIVE COMPENSATION

 

The information required by Item 11 is incorporated herein by reference to the sections entitled "Election of Directors" and "Executive Compensation" in the Company's Proxy Statement for its 2020 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year for which this report is filed.

 

  

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL

OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS

 

The information required by Item 12 is incorporated by reference to the sections entitled "Principal Shareholders" and "Management Shareholdings" in the Company's Proxy Statement for its 2020 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year for which this report is filed.

 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The information required by Item 13 is incorporated by reference to the sections entitled "Election of Directors" and "Additional Corporate Governance Matters" in the Company's Proxy Statement for its 2020 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year for which this report is filed.

  

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 

The information required by Item 14 is incorporated herein by reference to the section entitled "Audit Matters" in the Company's Proxy Statement for its 2020 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year for which this report is filed.

 

70
Table of Contents

 

PART IV

 

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

A. (1) List of Financial Statements.

 

     The following Consolidated Financial Statements are filed as part of this Annual Report on Form 10-K:

 

     Consolidated Statements of Earnings and Comprehensive Income for the Years Ended June 30, 2020, 2019, and 2018

 

     Consolidated Balance Sheets as of June 30, 2020 and 2019

 

     Consolidated Statements of Shareholders' Equity for the Years Ended June 30, 2020, 2019, and 2018

 

     Consolidated Statements of Cash Flows for the Years Ended June 30, 2020, 2019, and 2018

 

     Notes to Consolidated Financial Statements for the Years Ended June 30, 2020, 2019, and 2018

 

     Reports of Independent Registered Public Accounting Firm          

 

 

A. (2) Financial Statement Schedules.

 

     All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the Consolidated Financial Statements or Notes thereto.

 

A. (3) Exhibits.

 

EXHIBIT INDEX

for Form 10-K for the 2020 Fiscal Year

 

 

Exhibit

Number  

Description

3.1

Amended and Restated Articles of Incorporation of the Company--incorporated by reference to Exhibit 3.1 of the Company's Form 10-Q dated February 9, 2015*

 

 

3.2

Third Amended and Restated Bylaws of the Company--incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K dated February 1, 2018*
   
4.1 Description of Capital Stock -- attached as Exhibit 4.1 hereto

 

 

10.1**

Management Incentive Plan--incorporated by reference to Exhibit 10.13 of the Company's Form 10-K for the year ended June 30, 2013*

 

 

10.2**

Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated October 26, 2017*

 

 

10.3**

Form of Time Vesting Restricted Stock Award Agreement.
   
10.4** Form of Performance Vesting Restricted Stock Award Agreement.

 

 

10.5**

Form of Time Vesting Restricted Stock Unit Award Agreement.
   
10.6** Form of Performance Vesting Restricted Stock Unit Award Agreement.

 

 

10.7**

Form of the Time Vesting Performance Unit Award Agreement.

   
10.8** Form of Performance Vesting Performance Unit Award Agreement. 

 

 

10.9**

Form of Time Vesting Incentive Stock Option Agreement. .
   
10.10** Form of Performance Vesting Incentive Stock Option Agreement. 

 

 

10.11**

Form of Employee Non-Qualified Stock Option Agreement.

 

 

10.12**

Form of Director Non-Qualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.2 of the Company's Form 8-K dated October 26, 2017*

 

 

10.13**

Employment Agreement by and between the Company and Charles Kummeth--incorporated by reference to Exhibit 10.11 of the Company's Form 10-K dated September 7, 2017*

 

71
Table of Contents

 

Exhibit

Number 

Description

10.14**

Form of Employment Agreement by and between the Company and Executive Officers of the Company other than the CEO--incorporated by reference to Exhibit 10.12 of the Company's Form 10-K dated September 7, 2017*
   
10.15** Form of Amendment No. 1 to Executive Employment Agreement – incorporated by reference to Exhibit 10.15 of the Company’s Form 10-Q dated May 11, 2020. 

 

 

10.16

Credit Agreement by and among the Company, the Guarantors party thereto, the Lenders party thereto, and BMO Harris Bank N.A., as Administrative Agent, dated August 1, 2018--incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated August 2, 2018*

 

 

10.17**

Form of Indemnification Agreement entered into with each director and executive officer of the Company--incorporated by reference to Exhibit 10.1 of the Company's Form 10-Q dated February 8, 2018*

 

 

10.18

Agreement and Plan of Merger by and among the Company, Aero Merger Sub Inc., Advanced Cell Diagnostics, Inc. and Fortis Advisors, LLC as the Securityholders’ Representative, dated July 6, 2016--incorporated by reference to Exhibit 2.1 of the Company's Form 8-K dated July 7, 2016*

 

 
10.20 Development, Supply and Commercialization Agreement by and between the Company and Kantaro Biosciences, LLC dated May 18, 2020 (portions of which have been redacted as noted, subject to confidential treatment) – incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated May 19, 2020*
   

21

Subsidiaries of the Company

 

 

23

Consent of KPMG LLP, Independent Registered Public Accounting Firm

 

 

31.1

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

31.2

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

32.1

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

32.2

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

101

The following financial statements from the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2020, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) the Consolidated Statements of Earnings and Comprehensive Income, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Shareholders' Equity, (iv) the Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements.
   
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

-------------

*     Incorporated by reference; SEC File No. 000-17272

**   Management contract or compensatory plan or arrangement

 

 

 

 

Exhibits for Form 10-K have not been included in this report. Exhibits have been filed with the Securities and Exchange Commission. Upon request to the Investor Relations Department, Bio-Techne Corporation will furnish, without charge, any such exhibits as well as copies of periodic reports filed with the Securities and Exchange Commission.

 

 

ITEM 16. FORM 10-K SUMMARY

 None.

 

72
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BIO-TECHNE CORPORATION

 

 

 

 

 

 

 

 

 

Date: August 26, 2020

 

/s/ Charles Kummeth

 

 

 

     By: Charles Kummeth

 

 

 

     Its: President and CEO

 

                                          

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Date    

Signature and Title

 

 

August 26, 2020 

/s/ Robert V. Baumgartner

 

Robert V. Baumgartner

 

Chairman of the Board and Director

 

 
August 26, 2020 /s/ Julie Bushman
  Julie Bushman, Director
   

August 26, 2020 

/s/ Rupert Vessey

 

Dr. Rupert Vessey, Director

 

 

August 26, 2020

/s/ Joseph Keegan, Ph.D.

 

Dr. Joseph Keegan, Director

 

 

August 26, 2020 

/s/ John L. Higgins

 

John L. Higgins, Director

 

 

August 26, 2020

/s/ Roeland Nusse, Ph.D.

 

Dr. Roeland Nusse, Director

 

 

August 26, 2020

/s/ Alpna Seth, Ph.D.

 

Dr. Alpna Seth, Director

 

 

August 26, 2020

/s/ Randolph C. Steer, Ph.D., M.D.

 

Dr. Randolph C. Steer, Director

 

 

August 26, 2020

/s/ Harold J. Wiens

 

Harold J. Wiens, Director

 

 

August 26, 2020

/s/ Charles Kummeth

 

Charles Kummeth, Director and Chief Executive Officer (principal executive officer)

 

 

August 26, 2020 

/s/ James Hippel

 

James Hippel, Chief Financial Officer

 

(principal financial officer and principal accounting officer)

 

 

73
EX-4.1 2 ex_201045.htm EXHIBIT 4.1 ex_201045.htm

Exhibit 4.1

 

DESCRIPTION OF COMMON STOCK

 

The following summary of the common stock, par value $0.01 per share (the “Common Stock”), of Bio-Techne Corporation (the “Company,” “we,” or “our”) is based on and qualified by our Amended and Restated Articles of Incorporation (the “Articles”) and our Third Amended and Restated Bylaws (the “Bylaws”). For a complete description of the terms and provisions of our Common Stock, refer to the full text of the Articles of Incorporation and Bylaws, both of which are exhibits to our Annual Report on Form 10-K to which this description is also an exhibit, and the Minnesota Business Corporation Act (“MBCA”), which is available at https://www.revisor.mn.gov/statutes/cite/302A.

 

Authorized Shares

 

The Company is authorized to issue up to 105,000,000 shares, which consists of 5,000,000 undesignated shares and 100,000,000 shares of Common Stock. As of June 30, 2020, the Company had 38,453,046 shares of Common Stock issued and outstanding.

 

The Common Stock is the only outstanding class of stock of the Company. The Board of Directors of the Company (the “Board”) is authorized to establish one or more classes or series of shares from the undesignated shares and to fix the relative rights and preferences of each such class or series, but the Board has not designated any class or series of shares from the undesignated shares.

 

Dividend Rights

 

Subject to the rights of holders of any preferred stock outstanding, holders of Common Stock are entitled to receive dividends when, as, and if declared by the Board out of net earnings or net assets of the Company that are legally available for the declaration of dividends.

 

Voting Rights

 

All voting rights are vested in the holders of shares of Common Stock. Each holder of Common Stock is entitled to one vote per share, and voting rights are noncumulative. Subject to the rights of the holders of any preferred stock outstanding and except as specifically required otherwise under the MBCA all matters submitted to Company shareholders are decided by a majority vote of the shares entitled to vote and represented at the meeting at which there is a quorum, except for election of directors, which is decided by a majority of votes cast in uncontested elections and by a plurality vote in contested elections.

 

Liquidation and Dissolution Rights

 

Pursuant to applicable law, in the event of the Company’s dissolution, the holders of Common Stock will be entitled to share pro rata in any of the Company’s assets available for distribution after making adequate provision for the discharge of debts, obligations, and liabilities of the Company and after the holders of any series of outstanding preferred stock have received any liquidation preferences.

 

Other Shareholder and Board Rights

 

Holders of shares of Common Stock are not entitled to preemptive rights. The Board may issue rights to subscribe for, purchase, exchange securities for, or convert securities into, shares of the Company or any class or series, and to fix the terms, provisions and conditions of such rights, including the exchange or conversion basis or the price at which such shares may be purchased or subscribed for. The Board may effectuate share dividends or splits by issuance of shares of one class or series to holders of that class or series or to holders of another class or series.

 

 
 

 

Nominations Procedures

 

Shareholders can nominate candidates for election to the Board. However, a shareholder must follow the advance notice procedures provided in Section 2.10 of the Bylaws. In general, for an annual meeting, a shareholder must submit a written notice of such nomination to the Company’s corporate secretary at least 60 days but not more than 90 days prior to the anniversary of the prior year’s annual meeting. The written notice must contain the consent of the nominee(s) to serve as director and provide certain information about the proposed nominee(s) and the shareholder proposing the nomination, as required by Section 2.10 of the Bylaws.

 

Proposal Procedures

 

Shareholders may propose that business (other than nominations to the Board) be considered at a meeting of shareholders only if a shareholder follows the advance notice procedures provided in Section 2.10 of the Bylaws. In general, for an annual meeting, a shareholder must submit a written notice of the proposed business to the Company’s corporate secretary at least 60 days but not more than 90 days prior to the anniversary of the prior year’s annual meeting. The written notice must provide certain information about the proposed business and the shareholder proposing the business, as required by Section 2.10 of the Bylaws..

 

Limitations on Change of Control

 

Certain provisions of the Articles, the Bylaws, and the MBCA may discourage, delay, or prevent a merger, acquisition, or other change of control, including through a change to the members of the Company’s management. These provisions include:

 

 

●

Advance notice requirements for shareholder proposals and nominations (Section 2.10 of the Bylaws);

 

 

●

The ability of the Board to amend the Bylaws (Section 9.1 of the Bylaws);

 

 

●

The ability of the Board to issue purchase rights and additional Common Stock and to designate the terms of and issue new series of preferred stock without shareholder approval (Article 3 of the Articles);

 

 

●

Limitations, pursuant to Section 302A.671 of the MBCA, with respect to the voting of shares acquired in a “control share acquisition”;

 

 

●

The prohibition, pursuant to Section 302A.673 of the MBCA, of business combination transactions involving an “interested shareholder” and the Company for a period of four years after such individual or entity becomes an interest shareholder, unless a proscribed approval is obtained; and

 

 

●

The limitation, pursuant to Section 302A.675 of the MBCA, on purchasing additional shares of Common Stock by a party who has made a takeover offer for the Company unless holders of Common Stock are able to sell shares on substantially equivalent terms to the prior takeover offer, unless a proscribed approval is obtained.

 

 
 

 

Amendment of Articles of Incorporation and Bylaws

 

The holders of a majority of the outstanding shares of Common Stock have the power to amend the Articles of Incorporation. The Board may amend, adopt, or repeal the Bylaws, subject to the limitations see forth in our Bylaws and the MBCA. The holders of a majority of the outstanding shares of Common Stock also have the power to alter or amend, make or adopt, or repeal the Bylaws. 

 

Transfer Agent and Registrar

 

American Stock Transfer & Trust Company is the transfer agent and registrar for the Company’s Common Stock.

 

Listing of Common Stock

 

The Company’s Common Stock is listed on NASDAQ under the symbol “TECH.”

 

 
 EX-10.3 3 ex_200241.htm EXHIBIT 10.3 ex_200241.htm

Exhibit 10.3

 

RESTRICTED STOCK AWARD AGREEMENT
(TIME VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a restricted stock award to Participant for shares of Company Common Stock pursuant to the Bio-Techne Second Corporation Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a restricted stock award to Participant;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Restricted Stock Award. The Company hereby grants to the Participant on the date set forth above a restricted stock award (the “Award”) for [●] ([●]) shares of Company Common Stock (the “Shares”) on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. The Company shall cause to be issued such Shares in the Participant’s name, and shall hold such Shares until such time as the risks of forfeiture set forth in this Agreement have lapsed. The Company may also place transfer restrictions on such Shares describing the risks of forfeiture and other transfer restrictions set forth in this Agreement providing for the cancellation of such Shares if they are forfeited as provided in Section 2 below. Subject to the foregoing restrictions on transfer and the terms and conditions of the Plan, the Participant shall have all the rights of a stockholder with respect to the Shares during the period in which the Shares are subject to risk of forfeiture, including without limitation, the right to vote such shares and receive all dividends attributable to such shares.

 

2.     Lapse of Risks of Forfeiture for Restricted Stock; Termination of Relationship.

 

(a)     General. The Shares subject to this Award shall remain subject to forfeiture until the following dates (the “Vesting Dates”), provided that Participant remains employed by the Company or has terminated employment through Retirement as of the applicable Vesting Date as set forth in Section 2(b) of this Agreement.

 

 
 

 

 
Date Shares Vesting
   
[●] [●]
[●] [●]
[●] [●]
[●] [●]

 

     If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.               

 

Subject to such other terms and conditions set forth in this Agreement, the Participant shall not be entitled to the removal of transfer restrictions on the Shares until the Administrator determines the number of Shares, if any, which have vested and for which risks of forfeiture have lapsed.

 

(b)     Termination of Relationship. Except as otherwise provided in this Agreement or agreed to in writing by Participant and Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to any Vesting Date, for any reason other than the Participant’s Retirement, the Participant shall forfeit all Shares subject to this Award which, as of the termination date, have not yet vested and for which the risks of forfeiture have not lapsed. If the Participant’s employment with the Company or any Affiliate terminates because of Retirement, if this Award was granted at least six months prior to the date of Participant’s Retirement, then this Award shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company. If, however, this Award was not granted at least six months prior to the date of Participant’s Retirement, then to the extent this Award was not exercisable on the date of Participant’s Retirement, all rights of Participant under this Award shall be forfeited.

 

Solely for purposes of this Section 2(b), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Further, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, (i) a material breach or Participant's willful and substantial non-performance of Participant's assigned duties and responsibilities (other than as a result of incapacity due to physical or mental illness), (ii) a conviction of or no contest plea with respect to bribery, extortion, embezzlement, fraud, grand larceny, or any felony or similar conviction under local law involving abuse or misuse of Participant's position to seek or obtain an illegal or personal gain at the expense of the Company, the Employer or any Subsidiary, or similar crimes, or conspiracy to commit any such crimes or attempt to commit any such crimes, or (iii) Participant's violation of any policy of the Company, the Employer or any Subsidiary to which Participant may be subject or Participant's willful engagement in any misconduct in the performance of Participant's duties that materially injures the Company, the Employer or any Subsidiary.

 

- 2 -
 

 

3.     [TO BE USED IN AGREEMENTS WITH EXECUTIVE OFFICERS: Holding Requirement. Notwithstanding anything in the Plan or this Agreement to the contrary, Participant shall be required to hold 50% of the Net Shares received through this Award until Participant satisfies the stock ownership guidelines established by the Company. Once Participant satisfies such stock ownership guidelines, Participant shall be required to hold 50% of the Net Shares until the earlier of one year after the Vesting Date relating to such Net Shares or the Participant’s termination of service. “Net Shares” are those Shares received pursuant to this Award upon a Vesting Date, net of any shares withheld for withholding taxes.

 

**OR**

 

Intentionally omitted.]

 

4.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to continuance of employment or any other relationship with the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares as will be sufficient to satisfy the requirements of this Agreement.

 

(c)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Award are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the issuance of any shares of Company Common Stock subject to this Award. Subject to such rules as the Administrator may adopt, the Administrator may, in its sole discretion, permit Participant to satisfy such withholding tax obligations, in whole or in part, (i) by delivering shares of Company Common Stock, or (ii) by electing to have the Company withhold shares of Company Common Stock otherwise issuable to Participant upon the grant of this Award. In either case, such shares shall have a Fair Market Value, as of the date the amount of tax to be withheld is determined under applicable tax law, equal to such tax withholding, including payroll taxes, which are applicable to the supplemental income attributable to this Award. The Participant’s election to deliver shares or to have shares withheld for this purpose shall be made on or before the date that the amount of such tax withholding is determined under applicable tax law. Such election shall be approved by the Administrator and otherwise comply with such rules as the Administrator may adopt to assure compliance with Rule 16b-3, or any successor provision, as then in effect, of the General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

 

- 3 -
 

 

(d)     Nontransferability. For so long as the shares of Company Common Stock underlying this Award remain subject to risks of forfeiture, such shares shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(e)     Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. The Plan governs this Agreement and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(f)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Common Stock in compliance with the Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of the Company Common Stock underlying this Award, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering, Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of the Company Common Stock underlying this Award without the prior written consent of the underwriter(s) or its representative(s).

 

(g)     Stock Legend. The Administrator may require that the certificates or book entries for any shares of Company Common Stock issued to Participant pursuant to this Award bear an appropriate legend and stop transfer order to reflect the restrictions of Section 4(e) and Section 4(f) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 4(e) and Section 4(f).

 

(h)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or successors of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(i)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

- 4 -
 

 

(j)     Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(k)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(l)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 4(l), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 4(l) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 4(l), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4(l).

 

- 5 -
 

 

(m)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota. 

 

 

 

[Signature page follows.]

 

- 6 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written.

 

 

 

BIO-TECHNE CORPORATION

 

 

  

 

 

 

  

 

 

By 

 

 

 

 Its

 

 

 

PARTICIPANT

 

 

 

By: ___________________________________

       Printed Name: [●]

 

 
 EX-10.4 4 ex_200242.htm EXHIBIT 10.4 ex_200242.htm

Exhibit 10.4

 

RESTRICTED STOCK AWARD AGREEMENT
(PERFORMANCE VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a restricted stock award to Participant for shares of Company Common Stock pursuant to the Bio-Techne Second Corporation Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a restricted stock award to Participant;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Restricted Stock Award. The Company hereby grants to the Participant on the date set forth above a restricted stock award (the “Award”) for [●] ([●]) shares of Company Common Stock (the “Shares”) on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. The Company shall cause to be issued such Shares in the Participant’s name, and shall hold such Shares until such time as the risks of forfeiture set forth in this Agreement have lapsed. The Company may also place transfer restrictions on such Shares describing the risks of forfeiture and other transfer restrictions set forth in this Agreement providing for the cancellation of such Shares if they are forfeited as provided in Section 2 below. Subject to the foregoing restrictions on transfer and the terms and conditions of the Plan, the Participant shall have all the rights of a stockholder with respect to the Shares during the period in which the Shares are subject to risk of forfeiture, including without limitation, the right to vote such shares and receive all dividends attributable to such shares.

 

2.     Lapse of Risks of Forfeiture for Restricted Stock; Termination of Relationship.

 

(a)     General. The risks of forfeiture for the Shares subject to this Award shall lapse, if at all, on the Vesting Date[s] (as hereinafter defined), subject to the Company’s achievement of the performance objectives during the performance period[s], as both are set forth in Exhibit A to this Agreement, provided that Participant remains employed by the Company on the Vesting Date[s] as set forth in Section 2(b) of this Agreement. Performance for the period[s] shall be evaluated and determined by and in the sole discretion of the Administrator, and performance between the threshold and maximum levels specified on Exhibit A shall result in vesting in accordance with the scale determined by the Administrator and set forth on Exhibit A. The “Vesting Date[s]” for the Award shall be the later of [●] or the date on which the Administrator evaluates and certifies achievement of the performance criteria for the performance period[s], as set forth on Exhibit A. In the event the risks of forfeiture do not lapse with respect to all or any portion of the Award on the Vesting Date[s] pursuant to the performance objectives set forth on Exhibit A, the unvested portion of the Award shall terminate on such date and all Shares subject to such portion Award shall be forfeited.

 

 
 

 

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan. 

 

Further, in the event of Participant’s Retirement, a pro rata portion of the Shares subject to this Award shall become vested on the Vesting Date immediately following the date of Participant’s Retirement, with such portion determined by multiplying the Shares subject to this Award by a fraction, the numerator of which is the number of whole months that Participant was employed during the performance period and the denominator of which is the total number of months in the performance period. For purposes of this Agreement, “Retirement” means termination of employment for any reason other than for cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Further, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, (i) a material breach or Participant's willful and substantial non-performance of Participant's assigned duties and responsibilities (other than as a result of incapacity due to physical or mental illness), (ii) a conviction of or no contest plea with respect to bribery, extortion, embezzlement, fraud, grand larceny, or any felony or similar conviction under local law involving abuse or misuse of Participant's position to seek or obtain an illegal or personal gain at the expense of the Company, the Employer or any Subsidiary, or similar crimes, or conspiracy to commit any such crimes or attempt to commit any such crimes, or (iii) Participant's violation of any policy of the Company, the Employer or any Subsidiary to which Participant may be subject or Participant's willful engagement in any misconduct in the performance of Participant's duties that materially injures the Company, the Employer or any Subsidiary.

 

Subject to such other terms and conditions set forth in this Agreement, the Participant shall not be entitled to the removal of transfer restrictions on the Shares until the Administrator determines the number of Shares, if any, which have vested and for which risks of forfeiture have lapsed.]

 

(b)     Termination of Relationship. Unless otherwise provided in this Agreement or agreed to in writing by Participant and Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to any Vesting Date, for any reason other than the Participant’s Retirement, the Participant shall forfeit all Shares subject to this Award which, as of the termination date, have not yet vested and for which the risks of forfeiture have not lapsed.

 

- 2 -
 

 

3.     [TO BE USED IN AGREEMENTS WITH EXECUTIVE OFFICERS: Holding Requirement. Notwithstanding anything in the Plan or this Agreement to the contrary, Participant shall be required to hold 50% of the Net Shares received through this Award until Participant satisfies the stock ownership guidelines established by the Company. Once Participant satisfies such stock ownership guidelines, Participant shall be required to hold 50% of the Net Shares until the earlier of one year after the Vesting Date relating to such Net Shares or the Participant’s termination of service. “Net Shares” are those Shares received pursuant to this Award upon a Vesting Date, net of any shares withheld for withholding taxes.

 

**OR**

 

Intentionally omitted.]

 

4.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to continuance of employment or any other relationship with the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares as will be sufficient to satisfy the requirements of this Agreement.

 

(c)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Award are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the issuance of any shares of Company Common Stock subject to this Award. Subject to such rules as the Administrator may adopt, the Administrator may, in its sole discretion, permit Participant to satisfy such withholding tax obligations, in whole or in part, (i) by delivering shares of Company Common Stock, or (ii) by electing to have the Company withhold shares of Company Common Stock otherwise issuable to Participant upon the grant of this Award. In either case, such shares shall have a Fair Market Value, as of the date the amount of tax to be withheld is determined under applicable tax law, equal to such tax withholding, including payroll taxes, which are applicable to the supplemental income attributable to this Award. The Participant’s election to deliver shares or to have shares withheld for this purpose shall be made on or before the date that the amount of such tax withholding is determined under applicable tax law. Such election shall be approved by the Administrator and otherwise comply with such rules as the Administrator may adopt to assure compliance with Rule 16b-3, or any successor provision, as then in effect, of the General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

 

- 3 -
 

 

(d)     Nontransferability. For so long as the shares of Company Common Stock underlying this Award remain subject to risks of forfeiture, such shares shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(e)     Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. The Plan governs this Agreement and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(f)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Common Stock in compliance with the Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of the Company Common Stock underlying this Award, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering, Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of the Company Common Stock underlying this Award without the prior written consent of the underwriter(s) or its representative(s).

 

(g)     Stock Legend. The Administrator may require that the certificates or book entries for any shares of Company Common Stock issued to Participant pursuant to this Award bear an appropriate legend and stop transfer order to reflect the restrictions of Section 4(e) and Section 4(f) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 4(e) and Section 4(f).

 

(h)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or successors of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(i)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

- 4 -
 

 

(j)     Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(k)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(l)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 4(l), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 4(l) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 4(l), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4(l).

 

- 5 -
 

 

(m)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota. 

 

 

 

[Signature page follows.]

 

- 6 -
 

 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written. 

 

 

BIO-TECHNE CORPORATION

 

 

  

 

 

 

  

 

 

By 

 

 

 

 Its

 

 

 

PARTICIPANT

 

 

 

By: ___________________________________ 

       Printed Name: [●]

 

 
 EX-10.5 5 ex_200243.htm EXHIBIT 10.5 ex_200243.htm

Exhibit 10.5

 

GLOBAL RESTRICTED STOCK UNIT AGREEMENT

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a restricted stock unit award to Participant for shares of the Company's Common Stock pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a restricted stock unit award to Participant.

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows;

 

1.     Grant of Restricted Stock Unit Award. The Company hereby grants to Participant on the date set forth above (the “Date of Grant”) a restricted stock unit award for [●] ([●]) restricted stock units (the “Award”) on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. Each restricted stock unit shall entitle the Participant to receive one share of Company Common Stock (a “Share,” or the “Shares”). For purposes of this Agreement, to the extent Participant is not employed by the Company, the “Employer” means the Subsidiary that employs Participant.

 

2.     Vesting of Restricted Stock Units; Termination of Relationship.

 

(a)     General. The Award shall vest on the following dates (the “Vesting Dates”), provided that Participant remains employed by the Company or a Subsidiary on the applicable Vesting Date as set forth in Section 2(b) of this Agreement:

     

Date   Shares Vesting
     

[●]

  

[●]
[●]   [●]
[●]   [●]
[●]   [●]

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by Participant and the Company or the Employer, or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.

 

 
 

 

Subject to such other terms and conditions set forth in this Agreement, Participant shall not be entitled to the issuance of Shares for any portion of the restricted stock units subject to this Award until the Administrator determines the number of restricted stock units, if any, which have vested.

 

(b)     Termination of Relationship. Except as otherwise provided in this Agreement (including in Section 2(c)) or agreed to in writing by Participant and the Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to any Vesting Date, for any reason, including the Participant’s voluntary resignation, the unvested portion of the Award shall terminate and the Participant shall forfeit all Shares subject to this Award which, as of the Termination Date, have not yet vested.

 

(c)     Retirement. If Participant’s employment with the Company or any Subsidiary terminates because of Retirement, this Award was granted at least six months prior to the date of Participant’s Retirement, and this Award is scheduled to vest pro rata during a period of at least three years and six months following the Date of Grant, then this Award shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company on the applicable Vesting Dates. If, however, this Award was not granted at least six months prior to the date of Participant’s Retirement or is scheduled to vest in less than three years and six months following the Date of Grant, then this award will terminate upon Participant’s Retirement with no further vesting under Section 2(a).

 

Solely for purposes of this Section 2(c), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. For purposes of this Agreement, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, the following: (i) habitual neglect of, or the willful or material failure to perform the duties of employment hereunder, as determined in good faith by the Company; (ii) embezzlement or any act of fraud; (iii) commission of acts that can be charged as a felony during employment; (iv) dishonesty in dealing between Participant and the Company or between Participant and other employees of the Company; (v) use or misuse of any controlled substance, illegal or narcotic drug without a prescription; or use of alcohol in a manner, regardless of time or place, which either adversely affects Participant’s job performance or otherwise could reflect negatively on the public image of the Company; (vi) habitual absenteeism; or (vii) willfully acting in a manner materially adverse to the best interests of the Company.

 

(d)     EU Age Discrimination Rules. If Participant is a local national of and employed in a country that is a member of the European Union, the grant of this Award and the terms and conditions governing this Award are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

 

2
 

 

(e)     Termination Date. For purposes of this Agreement, if Participant is employed in the United States, "Termination Date" means the effective date of termination of Participant's employment. If Participant is employed outside of the United States, “Termination Date” means the earliest of (i) the date on which notice of termination is provided to Participant, (ii) the last day of Participant's active service with the Employer or (iii) the last day on which Participant is an employee of the Employer, as determined in each case, without including any required advanced notice period and irrespective of the status of the termination under local labor or employment laws

 

3.     Issuance of Shares.

 

(a)     General. As soon as practicable after each Vesting Date, Participant shall be recorded on the stock transfer books of the Company as the owner of the vested number of Shares set forth in Section 2(a) of this Agreement, less any Shares withheld for payment of taxes as provided in Section 5 below, and the Company shall deliver to Participant one or more duly issued stock certificates or cause book entries to be made evidencing such ownership. All requisite original issue or transfer documentary stamp taxes shall be paid by the Company. Until the issuance of such Shares, Participant shall not be entitled to vote the Shares represented by such restricted stock units, shall not be entitled to receive dividends or distributions attributable to such Shares, and shall not have any other rights as a shareholder with respect to such Shares. No adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property), distributions or other rights for which the record date is prior to the date such Shares are issued, except as provided in Section 15 of the Plan.

 

(b)     Repatriation and Compliance Obligations. As a condition of the grant of this Award, Participant agrees to repatriate all payments attributable to this Award in accordance with local foreign exchange rules and regulations in Participant's country of residence (and country of employment, if different). In addition, Participant agrees to take any and all actions, and consents to any and all actions taken by the Employer, the Company and its Subsidiaries as may be required to allow the Employer, the Company and its Subsidiaries to comply with local laws, rules and regulations in Participant's country of residence (and country of employment, if different). Finally, Participant agrees to take any and all actions that may be required to comply with Participant's personal legal and tax obligations under local laws, rules and regulations in Participant's country of residence (and country of employment, if different).

 

4.    [TO BE USED IN AGREEMENTS WITH EXECUTIVE OFFICERS: Holding Requirement. Notwithstanding anything in the Plan or this Agreement to the contrary, Participant shall be required to hold 50% of the Net Shares received through this Award until Participant satisfies the stock ownership guidelines established by the Company. Once Participant satisfies such stock ownership guidelines, Participant shall be required to hold 50% of the Net Shares until the earlier of one year after the Vesting Date relating to such Net Shares or the Participant’s termination of service. “Net Shares” are those shares received pursuant to this Award upon a Vesting Date, net of any shares withheld for withholding taxes.

 

**OR**

 

Intentionally omitted.]

 

3
 

 

5.    Tax Obligations. Regardless of any action the Company or the Employer takes with respect to any or all federal, state, local or foreign income tax, social insurance, payroll tax, payment on account or other tax related-items (“Tax Related-Items”), Participant acknowledges that the ultimate liability for all Tax Related-Items associated with this Award is and remains Participant’s responsibility and may exceed the amount actually withheld by the Company, and the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Tax Related-Items in connection with any aspect of this Award, including, but not limited to, the grant of the Award, the vesting of the Award, the subsequent sale of Shares acquired pursuant to the Award and the receipt of any dividends; and (ii) do not commit to structure the terms of the grant or any aspect of this Award to reduce or eliminate Participant’s liability for Tax Related-Items. Further, if Participant is subject to tax in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related-Items in more than one jurisdiction.

 

Prior to the delivery of Shares upon the vesting of this Award, if Participant's country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company or the Employer: (i) shall withhold a sufficient number of whole Shares otherwise issuable upon the vesting of the Award that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld (in which case, the cash equivalent of such withheld Shares shall be used to settle the withholding obligation); (ii) shall withhold an amount from Participant's regular salary and/or wages, or from any other amounts payable to Participant; or (iii) require Participant to make a payment to the Company or the Employer equal to the amount of Tax-Related Items required to be withheld. Depending on the applicable method, the Company or the Employer, as applicable, may withhold or account for Tax-Related Items by considering applicable statutory withholding rates, but such withholding shall not exceed an amount of withholding based on the maximum statutory rates in Participant's applicable tax jurisdictions.

 

In the event the withholding requirements are not satisfied through the withholding of Shares or through Participant's regular salary and/or wages or other amounts payable to Participant, no Shares will be issued to Participant unless and until satisfactory arrangements (as determined by the Committee) have been made by Participant with respect to the payment of any Tax-Related Items which the Company determines, in its sole discretion, must be withheld or collected with respect to this Award. If Participant is subject to taxation in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer may be required to withhold or account for Tax-Related Items in more than one jurisdiction. By accepting the this Award, Participant expressly consents to the withholding of Shares and/or the withholding of amounts from Participant's regular salary and/or wages, or other amounts payable to Participant, as provided for hereunder. All other Tax-Related Items related to this Award and any Shares acquired pursuant to the vesting of this Award are Participant's sole responsibility.

 

4
 

 

6.     Clawback/Recoupment Policy. Notwithstanding any other provision of this Agreement to the contrary, Participant acknowledges and agrees that all Shares acquired pursuant to the Plan shall be and remain subject to any incentive compensation clawback or recoupment policy of the Company currently in effect or as may be adopted by the Company and, in each case, as may be amended from time to time. No such policy adoption or amendment shall require Participant's prior consent. For purposes of the foregoing, Participant expressly and explicitly authorizes the Company to issue instructions, on Participant's behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold Participant's Shares, and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company.

 

7.     Nature of Grant. In accepting the grant of this Award, Participant acknowledges, understands and agrees that:

 

(a)     the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan;

 

(b)     the grant of this Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of an Award, or benefits in lieu of an Award, even if Awards have been granted in the past;

 

(c)     all decisions with respect to future grants of Awards or other grants, if any, will be at the sole discretion of the Company;

 

(d)     Participant is voluntarily participating in the Plan;

 

(e)     this Award and the Shares subject to this Award, and the income from and value of same, are not intended to replace any pension rights or compensation;

 

(f)     this Award and the Shares subject to this Award, and the income from and value of same, are not part of normal or expected compensation for purposes of, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments;

 

(g)     unless otherwise agreed with the Company in writing, this Award and the Shares subject to this Award, and the income from and value of same, are not granted as consideration for, or in connection with, the service Participant may provide as a director of a Subsidiary;

 

(h)     the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;

 

5
 

 

(i)     no claim or entitlement to compensation or damages shall arise from forfeiture of this Award resulting from the termination of Participant's employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant's employment agreement, if any); and

 

(j)     neither the Company nor the Employer shall be liable for any foreign exchange rate fluctuation between Participant's local currency and the United States Dollar that may affect the value of this Award or of any amounts due to Participant pursuant to the settlement of this Award or the subsequent sale of any Shares acquired upon settlement.

 

8.    Data Privacy. The Company is located at 614 McKinley Place N.E., Minneapolis, Minnesota, U.S.A. and grants Awards under the Plan to employees of the Company and its Subsidiaries, at its sole discretion. In conjunction with the Company's grant of Awards under the Plan and its ongoing administration of such Awards, the Company is providing the following information about its data collection, processing and transfer practices. In accepting the grant of this Award, Participant expressly and explicitly consents to the personal data activities as described herein.

 

(a)     Data Collection, Processing and Usage. The Company and the Employer will collect, process and use certain personal information about Participant, specifically, Participant's name, home address, email address and telephone number, date of birth, social security or insurance number, passport number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant's favor (“Personal Data”), for the exclusive purpose of implementing, administering and managing the Plan. Participant's Personal Data also may be disclosed to certain securities or other regulatory authorities where the Company’s securities are listed or traded or regulatory filings are made. The Company's legal basis for the collection, processing and use of Participant's Personal Data is Participant's consent.

 

(b)     Stock Plan Administration Service Providers. The Company and the Employer transfer Participant's Personal Data to Morgan Stanley a broker firm/third party service provider based in the United States of America and engaged by the Company to assist with the implementation, administration and management of awards granted under the Plan (the “Stock Plan Administrator”). In the future, the Company may select a different Stock Plan Administrator and share Participant's Personal Data with another company that serves in a similar manner. The Stock Plan Administrator will open an account for Participant to receive and trade Shares acquired under the Plan. Participant will be asked to agree to separate terms and data processing practices with the Stock Plan Administrator, which is a condition of Participant's ability to participate in the Plan.

 

(c)     International Personal Data Transfers. The Company and the Stock Plan Administrator are based in the United States of America. You should note that Participant's country of residence may have enacted data privacy laws that are different from the United States of America. The Company's legal basis for the transfer of Participant's Personal Data to the United States of America is Participant's consent.

 

6
 

 

(d)     Voluntariness and Consequences of Consent, Denial or Withdrawal. Participant's participation in the Plan and Participant's grant of consent hereunder is purely voluntary. Participant may deny or withdraw his or her consent at any time. If Participant does not consent, or if Participant later withdraws his or her consent, Participant may be unable to participate in the Plan. This would not affect Participant's existing employment or salary; instead, Participant merely may forfeit the opportunities associated with participation in the Plan.

 

(e)     Personal Data Retention. Participant understands that Participant's Personal Data will be held only as long as is necessary to implement, administer and manage this Award and Participant's participation in the Plan. When the Company no longer needs Participant's Personal Data, the Company will remove it from its systems. If the Company retains Participant's Personal Data longer, it would be to satisfy the Company's legal or regulatory obligations and the Company's legal basis would be for compliance with applicable laws, rules and regulations.

 

(f)     Personal Data Subject Rights. Participant understands that Participant may have the right under applicable law to (i) access or copy Participant's Personal Data that the Company possesses, (ii) rectify incorrect Personal Data concerning Participant, (iii) delete Participant's Personal Data, (iv) restrict processing of Participant's Personal Data, or (vi) lodge complaints with the competent supervisory authorities in Participant's country of residence. To receive clarification regarding these rights or to exercise these rights, Participant understands that Participant can contact his or her Employer's human resources representative.

 

9.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to the continuance of employment or any other relationship with the Employer, the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant, the Employer and the Company or any Subsidiary.

 

(b)     Securities Law Compliance. The issuance of Shares upon vesting of this Award shall be effective only at such time as counsel to the Company shall have determined that the issuance and delivery of Shares upon vesting will not violate any state or federal securities or other laws. Notwithstanding any other provision of the Plan or this Agreement, unless there is an exemption from any registration, qualification or other legal requirement applicable to the Shares the Company shall not be required to deliver any Shares issuable upon settlement of this Award prior to the completion of any registration or qualification of the Shares under any local, state, federal or foreign securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or of any other governmental regulatory body, or prior to obtaining any approval or other clearance from any local, state, federal or foreign governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. Participant understands that the Company is under no obligation to register or qualify the shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the Shares. Further, Participant agrees that the Company shall have unilateral authority to amend the Agreement without his or her consent to the extent necessary to comply with securities or other laws applicable to issuance of Shares.

 

7
 

 

(c)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of this Agreement.

 

(d)     Nontransferability. The Award For so long as the Shares underlying this Award remain unvested, such Shares shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(e)     Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. All defined terms of the Plan shall have the same meaning when used in this Agreement. The Plan governs this Award and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(f)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Shares in compliance with the U.S. Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of this Award or the Shares underlying this Award, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering, Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of this Award or any of the Shares underlying this Award without the prior written consent of the underwriter(s) or its representative(s).

 

(g)     Stock Legend. The Administrator may require that the certificates or book entries for any Shares issued to Participant (or Participant's permitted successors or assigns) pursuant to this Award bear an appropriate legend and stop transfer order to reflect the restrictions of Section 5 and Sections 9(e) through 9(f) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 5 or Sections 9(e) through 9(f).

 

(h)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or assigns of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

8
 

 

(i)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, United States of America, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota, United States of America.

 

(j)     Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(k)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(l)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 5(m), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless Participant and the Company otherwise agree in writing, any determination required under this Section 9(l) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 9(l), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 9(l).

 

9
 

 

(m)     Governing Law.  The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota, United States of America.

 

(n)     Language. Participant acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is proficient in the English language, so as to enable Participant to understand the provisions of this Agreement and the Plan. If Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

 

(o)     Electronic Delivery and Participation. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

 

(p)     Severability. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

 

(q)     Addendum. Notwithstanding any provisions of this Agreement to the contrary, this Award shall be subject to any special terms and conditions for Participant's country of residence (and country of employment, if different), as are forth in the applicable Addendum to this Agreement. Further, if Participant transfers residence and/or employment to another country reflected in an Addendum to this Agreement, the special terms and conditions for such country will apply to Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of this Award and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate Participant's transfer). Any applicable Addendum shall constitute part of this Agreement.

 

(r)     Imposition of Other Requirements. The Company reserves the right to impose other requirements on this Award, any payment made pursuant to this Award, and Participant's participation in the Plan, to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of this Award and the Plan. Such requirements may include (but are not limited to) requiring Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

 

10
 

 

(s)     Waiver. Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach, whether or like or different nature.

 

(t)     Private Offering. The grant of this Award is not intended to be a public offering of securities in Participant’s country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filing with the local securities authorities with respect to the grant of this Award (unless otherwise required under local law). No employee of the Company is permitted to advise Participant on whether Participant should acquire Shares under the Plan or provide Participant with any legal, tax or financial advice with respect to the grant of this Award. Investment in Shares involves a degree of risk. Before deciding to acquire Shares pursuant to this Award, Participant should carefully consider all risk factors and tax considerations relevant to the acquisition of Shares under the Plan or the disposition of them. Further, Participant should carefully review all of the materials related to this Award and the Plan, and Participant should consult with Participant’s personal legal, tax and financial advisors for professional advice in relation to Participant’s personal circumstances.

 

(u)     Exchange Control, Foreign Asset/Account and/or Tax Reporting. Participant acknowledges that there may be certain exchange control, foreign asset/account and/or tax reporting requirements which may affect Participant’s ability to acquire or hold Shares or cash received from participating in the Plan (including the proceeds from the sale of Shares and the receipt of any dividends paid on Shares) in a brokerage or bank account outside Participant’s country. Participant may be required to report such accounts, assets or related transactions to the tax or other authorities in Participant’s country. Participant also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to Participant’s country within a certain time after receipt. Participant acknowledges that it is Participant’s responsibility to comply with such regulations and that Participant should speak to his or her personal advisor on this matter.

 

(v)     Insider Trading/Market Abuse. Participant may be subject to insider trading restrictions and/or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions, including the United States, Participant’s country and the designated broker’s country, which may affect Participant’s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., this Award) or rights linked to the value of Shares under the Plan during such times that Participant is considered to have “inside information” regarding the Company (as defined by the laws or regulations in Participant’s country).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. Participant acknowledges that it is Participant’s responsibility to comply with any applicable restrictions and that Participant should speak to his or her personal advisor on this matter.

 

(w)     Consent and Agreement With Respect to Plan. Participant (a) acknowledges that a copy of the Plan and the U.S. prospectus for the Plan has been available to Participant; (b) represents that he or she has read and is familiar with the terms and provisions thereof, has had an opportunity to obtain the advice of counsel of his or her choice prior to executing this Agreement and fully understands all provisions of this Agreement and the Plan; (c) accepts this Award subject to all of the terms and provisions thereof; and (d) agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Agreement.

 

 

[Signature page follows.]

 

11
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written.

 

  BIO-TECHNE CORPORATION
       
       
       
  By     
    Its  

 

 

PARTICIPANT

 

 

 

By: ___________________________________

       Printed Name: [●]

 

 

 

[Signature Page to Global Restricted Stock Unit Agreement]

 

 
 

 

BIO-TECHNE CORPORATION

 

ADDENDUM TO
GLOBAL RESTRICTED STOCK UNIT AGREEMENT

 

BIO-TECHNE CORPORATION
SECOND AMENDED AND RESTATED
2010 EQUITY INCENTIVE PLAN

 

In addition to the terms of the Plan and the Agreement, the Award is subject to the following additional terms and conditions as set forth in this addendum (the “Addendum”). All defined terms as contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 9(q) of the Agreement, to the extent Participant transfers residence and/or employment to another country, the additional terms and conditions as set forth in the Addendum for such country (if any) shall also apply to the Award to the extent the Company determines, in its sole discretion, that the application of such addendum is necessary or advisable in order to comply with local laws, rules and regulations, or to facilitate the operation and administration of the Award and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate Participant’s transfer).

 

European Union (“EU”) / European Economic Area (“EEA”) / Switzerland / United Kingdom

 

1.    Data Privacy. If Participant resides and/or works in the EU/EEA, Switzerland or the United Kingdom, Section 8 of the Agreement shall be replaced with the following:

 

The Company is located at 614 McKinley Place N.E., Minneapolis, Minnesota, U.S.A. and grants Awards under the Plan to employees of the Company and its Subsidiaries, at its sole discretion. In conjunction with the Company's grant of the Award under the Plan and its ongoing administration of such award, the Company is providing the following information about its data collection, processing and transfer practices, which Participant should carefully review.

 

(a)     Data Collection, Processing and Usage. The Company and the Employer will collect, process and use certain personal information about Participant, specifically, Participant's name, home address, email address and telephone number, date of birth, social security or insurance number, passport number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant's favor (“Personal Data”), for the exclusive purpose of implementing, administering and managing the Plan. Participant's Personal Data also may be disclosed to certain securities or other regulatory authorities where the Company’s securities are listed or traded or regulatory filings are made. The Company's legal basis for such disclosure of Participant's Personal Data is to satisfy its contractual obligations under the terms of the Agreement and this Addendum, and to comply with applicable laws, rules and regulations.

 

1
 

 

(b)     Stock Plan Administrator. The Company and the Employer transfer Participant's Personal Data to Morgan Stanley a broker firm/third party service provider based in the United States of America and engaged by the Company to assist with the implementation, administration and management of Awards granted under the Plan (the “Stock Plan Administrator”). In the future, the Company may select a different Stock Plan Administrator and share Participant's Personal Data with another company that serves in a similar manner. The Stock Plan Administrator will open an account for Participant to receive and trade Shares acquired under the Plan. Participant will be asked to agree to separate terms and data processing practices with the Stock Plan Administrator, which is a condition of Participant's ability to participate in the Plan.

 

(c)     International Personal Data Transfers. The Company and the Stock Plan Administrator are based in the United States of America. Participant should note that Participant's country of residence may have enacted data privacy laws that are different from the United States of America. The Company's legal basis for the transfer of Participant's Personal Data to the United States of America is to satisfy its contractual obligations under the terms and conditions of this Agreement.

 

(d)     Data Retention. Participant understand that Participant's Personal Data will be held only as long as is necessary to implement, administer and manage the Award and Participant's participation in the Plan. When the Company no longer needs Participant's Personal Data, the Company will remove it from its systems. If the Company retains Participant's Personal Data longer, it would be to satisfy the Company's legal or regulatory obligations and the Company's legal basis would be for compliance with applicable laws, rules and regulations.

 

(e)     Data Subject Rights. Participant understands that Participant may have the right under applicable law to (i) access or copy Participant's Personal Data that the Company possesses, (ii) rectify incorrect Personal Data concerning Participant, (iii) delete Participant's Personal Data, (iv) restrict processing of Participant's Personal Data, or (v) lodge complaints with the competent supervisory authorities in Participant's country of residence. To receive clarification regarding these rights or to exercise these rights, Participant understand that Participant can contact his or her Employer's human resources representative.

 

Austria

 

No country-specific provisions.

 

Belgium

 

No country-specific provisions.

 

Canada

 

1.    Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, the Award shall be settled only in Shares (and may not be settled in cash).

 

2.   Consent to Receive Information in English. To the extent Participant is resident in Quebec, the parties acknowledge that it is their express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be written in English.

 

2
 

 

Les parties reconnaissent avoir exigé la rédaction en anglais du présent Contrat, ainsi que de tous documents exécutés, avis donnés ou procédures judiciaires intentées, en vertu du, ou liés directement ou indirectement, au présent Contrat.

 

3.    Data Privacy. The following provision supplements Section 8 of the Agreement:

 

Participant hereby authorizes the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of Participant’s awards under the Plan. Participant further authorizes the Company, its Subsidiaries, and the stock plan administrator to disclose and discuss Participant’s participation in the Plan with their respective advisors. Participant further authorizes the Company and its Subsidiaries to record such information and to keep such information in his or her employee file.

 

China

 

1.    Award Conditioned on Satisfaction of Regulatory Obligations. If Participant is a national of the People’s Republic of China (“PRC”), the grant of the Award is conditioned upon the Company securing all necessary approvals from the PRC State Administration of Foreign Exchange to permit the operation of the Plan and the participation of PRC nationals employed by the Employer, as determined by the Company in its sole discretion.

 

2.    Immediate Sale of Shares. If Participant is a PRC national, he/she may be required to immediately sell all Shares acquired upon vesting of the Award (in which case, this Addendum shall give the Company the authority to issue sales instructions on Participant's behalf). Participant agrees to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Stock Plan Administrator) to effectuate the sale of the Shares (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. Participant acknowledges that neither the Company nor the Stock Plan Administrator is under any obligation to arrange for such sale of Shares at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the Shares are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to Participant in accordance with applicable exchange control laws and regulations.

 

3
 

 

3.    Exchange Control Restrictions. Participant understands and agrees that, if Participant is subject to exchange control laws in China, Participant will be required to repatriate immediately to China the proceeds from the sale of any Shares acquired under the Plan. Participant further understands that such repatriation of sale proceeds must be effected through a special bank account established by the Company with a financial institution in China and Participant hereby consents and agrees that proceeds from the sale of Shares acquired under the Plan may be transferred to such account by the Company on Participant's behalf prior to being delivered to Participant and that no interest shall be paid with respect to funds held in such account. Sale proceeds may be paid to Participant in U.S. dollars or local currency at the Company’s discretion. If the sale proceeds are paid to Participant in U.S. dollars, Participant understands that Participant must establish and maintain a U.S. dollar bank account in China so that the proceeds may be deposited into such account. If the sale proceeds are paid to Participant in local currency, Participant acknowledges that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the sale proceeds to local currency due to exchange control restrictions. Participant agrees to bear any currency fluctuation risk between the time the shares of Common Stock are sold and the net proceeds are converted into local currency and distributed to Participant. Participant further agrees to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

 

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses Participant may incur or suffer resulting from the enforcement of the terms of this section or otherwise from the Company’s operation and enforcement of the terms of the Plan, the Agreement and this Addendum, and the Award in accordance with Chinese law including, without limitation, any applicable rules, regulations, requirements and approvals issued by the State Administration of Foreign Exchange.

 

Czech Republic

 

No country-specific provisions.

 

Denmark

 

1.     Danish Stock Option Act. Notwithstanding anything in the Agreement or the Plan to the contrary, the treatment of the Award upon Participant’s termination of employment with the Company or any Subsidiary, as applicable, shall be governed by the Danish Stock Option Act, as in effect at the time of Participant’s termination (as determined by the Committee in its discretion in consultation with legal counsel). By accepting the Award, Participant acknowledges that he or she has received a Danish translation of an Employer Statement, which is being provided to comply with the Danish Stock Option Act.

 

Finland

 

No country-specific provisions.

 

4
 

 

France

 

1.     Award Not Tax-Qualified. The Award is not intended to qualify for special tax and social security treatment pursuant to Sections L. 225-197-1 to L. 225-197-6 of the French Commercial Code, as amended.

 

2.     Consent to Receive Information in English. By accepting the Award, Participant confirms having read and understood the Plan, the Agreement and this Addendum, including all terms and conditions included therein, which were provided in the English language. Participant accepts the terms of those documents accordingly.

 

Consentement afin de Recevoir des Informations en Anglais

 

En acceptant les Attributions, le Participant confirme avoir lu et compris le Plan, le Contrat et la présente Annexe, en ce compris tous les termes et conditions y relatifs, qui ont été fournis en langue anglaise. Le Participant accepte les dispositions de ces documents en connaissance de cause.

 

Germany

 

No country-specific provisions.

 

Hong Kong

 

1.     Restriction on Sale of Shares. Shares received pursuant to the Award is accepted as a personal investment. To facilitate compliance with securities laws in Hong Kong, Participant agrees not to sell the Shares issued in settlement of the Award within six (6) months of the Date of Grant.

 

2.     Award Is Not Wages. The Award and the Shares underlying the Award do not form part of Participant's wages for purposes of calculating any statutory or contractual payments under applicable law in Hong Kong.

 

3.    Securities Law Notice. WARNING: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. Participant is advised to exercise caution in relation to the offer. If Participant is in any doubt about any of the contents of this document, Participant should obtain independent professional advice. Neither the grant of the Award nor the issuance of Shares upon vesting of the Award constitutes a public offering of securities under Hong Kong law and is available only to employees of the Company and its Subsidiaries. The Agreement, including this Addendum, the Plan and other incidental communication materials distributed in connection with the Award (i) have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each eligible employee of the Company or its Subsidiaries and may not be distributed to any other person.

 

4.     Nature of Plan. The Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance.

 

Hungary

 

No country-specific provisions.

 

5
 

 

India

 

1.    Repatriation Requirements. Participant expressly agrees to repatriate all amounts acquired under the Plan in accordance with local foreign exchange rules and regulations. Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from Participant’s failure to comply with applicable laws, rules and regulations.

 

Italy

 

1.    Plan Document Acknowledgement. In accepting the Award, Participant acknowledges that he or she has received a copy of the Plan and the Agreement and has reviewed the Plan and the Agreement (including this Addendum), in their entirety and fully understands and accepts all provisions of the Plan and the Agreement (including this Addendum). Participant further acknowledges that he or she has read and specifically and expressly approves the following provisions of the Agreement: Section 5: Tax Obligations; Section 7: Nature of Grant; Section 9(m): Governing Law; Section 9(q): Addendum; Section 9(r): Imposition of Other Requirements; and the Data Privacy provisions for the European Union reflected above.

 

Japan

 

No country-specific provisions.

 

Korea

 

No country-specific provisions.

 

Luxembourg

 

No country-specific provisions.

 

Netherlands

 

1.     Waiver of Termination Rights. As a condition to the grant of the Award, Participant hereby waives any and all rights to compensation or damages as a result of the termination of Participant's employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) Participant ceasing to have rights under or ceasing to be entitled to any Award under the Plan as a result of such termination.

 

Poland

 

No country-specific provisions.

 

6
 

 

Singapore

 

1.     Securities Law Notice. The grant of the Award is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”) and is not made to Participant with a view to the underlying Shares being subsequently offered for sale to any other party. The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore. Participant should note that the Award are subject to section 257 of the SFA and Participant should not make (i) any subsequent sale of the Shares in Singapore or (ii) any offer of such subsequent sale of the Shares subject to the Award in Singapore, unless such sale or offer is made after six (6) months from the Date of Grant or pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA. The Shares are currently traded on the NASDAQ Stock Market LLC, which is located outside of Singapore, under the ticker symbol “TECH” and Shares acquired under the Plan may be sold through this exchange.

 

Spain

 

1.     Nature of Award. The following provision supplements Section 7 of the Agreement:

 

In accepting the grant of the Award, Participant acknowledges that he or she consents to participation in the Plan and has received a copy of the Plan.

 

Participant understands that the Company, in its sole discretion, has unilaterally and gratuitously decided to grant Awards under the Plan to individuals who may be employees of the Company or its Subsidiaries throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any Award will not economically or otherwise bind the Company or any of its Subsidiaries on an ongoing basis. Consequently, Participant understands that the Award is granted on the assumption and condition that the Award and any Shares acquired upon vesting of the Award shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.

 

Further, Participant understands and agrees that, unless otherwise expressly provided for by the Company or set forth in the Agreement, the Award will be cancelled without entitlement to any Shares if Participant terminates employment by reason of, including, but not limited to: resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause (i.e., subject to a “despido improcedente”), material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, or under Article 10.3 of Royal Decree 1382/1985. The Committee, in its sole discretion, shall determine the date when Participant’s employment has terminated for purposes of the Award.

 

Participant understands that the grant of this Award would not be granted but for the assumptions and conditions referred to above; thus, Participant acknowledges and freely accepts that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of, or right to, the Award shall be null and void.

 

7
 

 

Sweden

 

1.     Tax Obligations. The following provision supplements Section 5 of the Agreement:

 

Without limiting the Company's and the Employer's authority to satisfy their withholding obligations for Tax-Related Items as set forth in Section 4 of the Agreement, in accepting the grant of the Award, Participant authorizes the Company and/or the Employer to withhold Shares or to sell Shares otherwise deliverable to Participant upon exercise to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

 

Switzerland

 

1.     Securities Law Notice. Neither the Agreement, the Addendum nor any other materials relating to the Award (i) constitutes a prospectus according to article 35 et seq. of the Swiss Federal Act on Financial Services ("FinSA"), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company, or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (FINMA).

 

Taiwan

 

No country-specific provisions.

 

United Kingdom

 

1.     Tax Obligations. The following provision supplements Section 5 of the Agreement:

 

Without limitation to Section 5 of the Agreement, Participant hereby agrees that Participant is liable for all Tax Related-Items and hereby covenants to pay all such Tax Related-Items, as and when requested by the Company, or if different, the Employer, or by Her Majesty’s Revenue & Customs (“HMRC”) (or any other tax authority or any other relevant authority). Participant also hereby agrees to indemnify and keep indemnified the Company and, if different, the Employer, against any Tax Related-Items that they are required to pay or withhold, or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on Participant’s behalf.

 

Notwithstanding the foregoing, if Participant is a director or executive officer of the Company (within the meaning of Section 13(k) of the Exchange Act), Participant may not be able to indemnify the Company or the Employer for the amount of any income tax not collected from or paid by Participant, as it may be considered a loan. In this case, the amount of any uncollected amounts may constitute a benefit to Participant on which additional income tax and National Insurance Contributions may be payable. Participant will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying the Company or the Employer for the value of any National Insurance Contributions due on this additional benefit, which the Company or the Employer may recover by any of the means referred to in Section 5 of the Agreement.

 

2.     Exclusion of Claim. Participant acknowledges and agrees that Participant will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from Participant ceasing to have rights under or to be entitled to the Award, whether or not as a result of termination of employment (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of the Award, Participant shall be deemed to have waived irrevocably such entitlement.

 

8
 EX-10.6 6 ex_200244.htm EXHIBIT 10.6 ex_200244.htm

Exhibit 10.6

 

RESTRICTED STOCK UNIT AGREEMENT
(Performance Vesting)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a restricted stock unit award to Participant for shares of Company Common Stock pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a restricted stock unit award to Participant;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.    Grant of Restricted Stock Unit Award. The Company hereby grants to Participant on the date set forth above a restricted stock unit award for [●] ([●]) restricted stock units (the “Award”) on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. Each restricted stock unit shall entitle the Participant to receive one share of Company Common Stock.

 

2.     Vesting of Restricted Stock Units; Termination of Relationship.

 

(a)     Vesting. Vesting of the Award shall occur, if at all, on the Vesting Date[s] (as hereinafter defined), subject to the Company’s achievement of the performance objectives during the performance period[s], as both are set forth in Exhibit A to this Agreement, provided that Participant remains employed by the Company on the Vesting Date[s] as set forth in Section 2(b) of this Agreement. Performance for the period[s] shall be evaluated and determined by and in the sole discretion of the Administrator, and performance between the threshold and maximum levels specified on Exhibit A shall result in vesting in accordance with the scale determined by the Administrator and set forth on Exhibit A. The “Vesting Date[s]” for the Award shall be the later of [●] or the date on which the Administrator evaluates and certifies achievement of the performance criteria for the performance period[s], as set forth on Exhibit A. In the event all or any portion of the Award does not vest on the Vesting Date[s] pursuant to the performance objectives set forth on Exhibit A, the unvested portion of the Award shall terminate on such date and all restricted stock units subject to such portion Award shall be forfeited.

 

 
 

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan. Further, in the event of Participant’s Retirement a pro rata portion of this Award shall become vested on the Vesting Date immediately following the date of Participant’s Retirement, with such portion determined by multiplying the Award by a fraction, the numerator of which is the number of whole months that Participant was employed during the performance period and the denominator of which is the total number of months in the performance period.

 

For purposes of this Agreement, “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Further, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, (i) a material breach or Participant's willful and substantial non-performance of Participant's assigned duties and responsibilities (other than as a result of incapacity due to physical or mental illness), (ii) a conviction of or no contest plea with respect to bribery, extortion, embezzlement, fraud, grand larceny, or any felony or similar conviction under local law involving abuse or misuse of Participant's position to seek or obtain an illegal or personal gain at the expense of the Company, the Employer or any Subsidiary, or similar crimes, or conspiracy to commit any such crimes or attempt to commit any such crimes, or (iii) Participant's violation of any policy of the Company, the Employer or any Subsidiary to which Participant may be subject or Participant's willful engagement in any misconduct in the performance of Participant's duties that materially injures the Company, the Employer or any Subsidiary.

 

Subject to such other terms and conditions set forth in this Agreement, the Participant shall not be entitled to the issuance of shares of stock for any portion of the restricted stock units subject to this Award until the Administrator determines the number of restricted stock units, if any, which have vested.

 

(b)     Termination of Relationship. Unless otherwise provided in this Agreement or agreed to in writing by Participant and Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to any Vesting Date, for any reason, including the Participant’s voluntary resignation, the Participant shall forfeit all shares subject to this Award which, as of the termination date, have not yet vested.

 

3.    Issuance of Shares. As soon as practicable after each Vesting Date, Participant shall be recorded on the stock transfer books of the Company as the owner of shares representing the respective number of shares of Company Common Stock set forth in Section 2(a) of this Agreement, less any shares withheld for payment of taxes as provided in Section 5(d) below, and the Company shall deliver to Participant one or more duly issued stock certificates or cause book entries to be made evidencing such ownership. All requisite original issue or transfer documentary stamp taxes shall be paid by the Company. Until the issuance of such shares, Participant shall not be entitled to vote the shares of Company Common Stock represented by such restricted stock units, shall not be entitled to receive dividends or distributions attributable to such shares of Company Common Stock, and shall not have any other rights as a shareholder with respect to such shares. No adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property), distributions or other rights for which the record date is prior to the date such shares are issued, except as provided in Section 15 of the Plan.

 

2
 

 

4.    [TO BE USED IN AGREEMENTS WITH EXECUTIVE OFFICERS: Holding Requirement. Notwithstanding anything in the Plan or this Agreement to the contrary, Participant shall be required to hold 50% of the Net Shares received through this Award until Participant satisfies the stock ownership guidelines established by the Company. Once Participant satisfies such stock ownership guidelines, Participant shall be required to hold 50% of the Net Shares until the earlier of one year after the Vesting Date relating to such Net Shares or the Participant’s termination of service. “Net Shares” are those shares received pursuant to this Award upon a Vesting Date, net of any shares withheld for withholding taxes.

 

**OR**

 

Intentionally omitted.]

 

5.    General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to continuance of employment or any other relationship with the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Securities Law Compliance. The issuance of shares upon vesting of this Award shall be effective only at such time as counsel to the Company shall have determined that such issuance will not violate any state or federal securities or other laws. Participant may be required by the Company, as a condition of the issuance of shares, to agree in writing that such shares will be held until such time that the shares are registered or otherwise freely tradeable under applicable state and federal securities laws, for Participant’s own account without a view to any further distribution thereof, and that the certificate(s) for such shares will bear an appropriate legend to that effect and that such shares will not be transferred or disposed of except in compliance with applicable state and federal securities laws.

 

(c)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares as will be sufficient to satisfy the requirements of this Agreement.

 

3
 

 

(d)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Award are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the issuance of any shares of Company Common Stock subject to this Award. Subject to such rules as the Administrator may adopt, the Administrator may, in its sole discretion, permit Participant to satisfy such withholding tax obligations, in whole or in part, (i) by delivering shares of Company Common Stock, or (ii) by electing to have the Company withhold shares of Company Common Stock otherwise issuable to Participant upon vesting of this Award. In either case, such shares shall have a Fair Market Value, as of the date the amount of tax to be withheld is determined under applicable tax law, equal to such tax withholding, including payroll taxes, applicable to the supplemental income attributable to this Option. The Participant’s election to deliver shares or to have shares withheld for this purpose shall be made on or before the date that the amount of such tax withholding is determined under applicable tax law. Such election shall be approved by the Administrator and otherwise comply with such rules as the Administrator may adopt to assure compliance with Rule 16b-3, or any successor provision, as then in effect, of the General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

 

(e)     Nontransferability. For so long as the shares of Company Common Stock underlying this Award remain unvested, such shares shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(f)     Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. The Plan governs this Agreement and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(g)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Common Stock in compliance with the Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of the Company Common Stock underlying this Award, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering, Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of the Company Common Stock underlying this Award without the prior written consent of the underwriter(s) or its representative(s).

 

(h)     Stock Legend. The Administrator may require that the certificates or book entries for any shares of Company Common Stock issued to Participant pursuant to this Award bear an appropriate legend and stop transfer order to reflect the restrictions of Section 5(b) and Sections 5(f) through 5(g) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 5(b) or Sections 5(f) through 5(g).

 

(i)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or successors of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

4
 

 

(j)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

(k)     Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(l)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(m)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 5(m), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 5(m) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 5(m), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 5(m).

 

(n)     Governing Law.  The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota.

 

[Signature page follows.]

 

5
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written. 

 

  BIO-TECHNE CORPORATION
       
       
       
  By     
    Its  

 

 

PARTICIPANT

 

 

 

By: ___________________________________ 

       Printed Name: [●]

 

 

 

 

 

62400201

 

 

 

[Signature Page to Restricted Stock Unit Agreement]

 

 
 EX-10.7 7 ex_200245.htm EXHIBIT 10.7 ex_200245.htm

Exhibit 10.7

 

PERFORMANCE UNIT AGREEMENT
(TIME VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a performance unit award to Participant pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a performance unit to Participant;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Performance Unit Award; Term. The Company hereby grants to Participant on the date set forth above a performance unit (the “Award”) for [●] dollars ($[●]), on the terms and conditions set forth herein.

 

2.     Vesting of Performance Unit.

 

(a)     General. The Award shall vest on the following dates (the “Vesting Dates”), provided that Participant remains employed by the Company or has terminated employment by Retirement as of the applicable Vesting Date as set forth in Section 2(b) of this Agreement:

 

Date   Performance Unit Vesting
     
[●]   [●]
[●]   [●]
[●]   [●]
[●]   [●]

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.   

  

 
 

 

Subject to such other terms and conditions set forth in this Agreement, the Participant shall not be entitled to payment for any portion of the performance units subject to this Award until the Administrator determines the portion of the Award, if any, that has vested.]

 

(b)     Termination of Relationship. Except as otherwise provided in this Agreement or agreed to in writing by Participant and Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to the Vesting Date, for any reason other than Retirement, this Award shall terminate and the unvested portion of this Award shall be forfeited by Participant. If the Participant’s employment with the Company or any Affiliate terminates because of Retirement, if this Award was granted at least six months prior to the date of Participant’s Retirement, then this Award shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company. If, however, this Award was not granted at least six months prior to the date of Participant’s Retirement, then to the extent this Award was not exercisable on the date of Participant’s Retirement, all rights of Participant under this Award shall be forfeited.

 

Solely for purposes of this Section 2(b), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Further, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, (i) a material breach or Participant's willful and substantial non-performance of Participant's assigned duties and responsibilities (other than as a result of incapacity due to physical or mental illness), (ii) a conviction of or no contest plea with respect to bribery, extortion, embezzlement, fraud, grand larceny, or any felony or similar conviction under local law involving abuse or misuse of Participant's position to seek or obtain an illegal or personal gain at the expense of the Company, the Employer or any Subsidiary, or similar crimes, or conspiracy to commit any such crimes or attempt to commit any such crimes, or (iii) Participant's violation of any policy of the Company, the Employer or any Subsidiary to which Participant may be subject or Participant's willful engagement in any misconduct in the performance of Participant's duties that materially injures the Company, the Employer or any Subsidiary.

 

3.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to continuance of employment or any other relationship by the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Award are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the payment of the Award to the Participant by the Company.

 

- 2 -
 

 

(c)     Nontransferability. The Award shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(d)     Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. The Plan governs this Agreement and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(e)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or successors of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(f)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

(g)     Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(h)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

- 3 -
 

 

(i)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 3(i), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 3(i) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 3(i), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 3(i). 

 

(j)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota.

 

 

[Signature page follows.]

 

- 4 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written. 

 

  BIO-TECHNE CORPORATION
       
       
       
  By     
    Its  

 

 

PARTICIPANT

 

 

 

By: ___________________________________ 

       Printed Name: [●]

 

 

 

 

62399827

 

 
 EX-10.8 8 ex_200246.htm EXHIBIT 10.8 ex_200246.htm

Exhibit 10.8

 

PERFORMANCE UNIT AGREEMENT

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a performance unit award to Participant pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a performance unit to Participant;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Performance Unit Award; Term. The Company hereby grants to Participant on the date set forth above a performance unit (the “Award”) for [●] dollars ($[●]), on the terms and conditions set forth herein.

 

2.     Vesting of Performance Unit.

 

(a)     General. Vesting of the Award shall occur, if at all, on the Vesting Date[s] (as hereinafter defined), subject to the Company’s achievement of the performance objectives during the performance period[s], as both are set forth in Exhibit A to this Agreement, provided that Participant remains employed by the Company on the Vesting Date[s] as set forth in Section 2(b) of this Agreement. Performance for the period[s] shall be evaluated and determined by and in the sole discretion of the Administrator, and performance between the threshold and maximum levels specified on Exhibit A shall result in vesting in accordance with the scale determined by the Administrator and set forth on Exhibit A. The “Vesting Date[s]” for the Award shall be the later of [●] or the date on which the Administrator evaluates and certifies achievement of the performance criteria for the performance period[s], as set forth on Exhibit A. In the event all or any portion of the Award does not vest on the Vesting Date[s] pursuant to the performance objectives set forth on Exhibit A, the unvested portion of the Award shall terminate and be forfeited on such date.

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.

 

 
 

 

Further, in the event of Participant’s Retirement prior to the Vesting Date, if this Award was granted at least six months prior to the date of Participant’s Retirement, then a pro rata portion of the Award shall become vested on the Vesting Date immediately following the date of Participant’s Retirement, with such portion determined by multiplying the Award by a fraction, the numerator of which is the number of whole months that Participant was employed during the performance period and the denominator of which is the total number of months in the performance period. For purposes of this Agreement, “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. For purposes of this Agreement, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, (i) a material breach or Participant's willful and substantial non-performance of Participant's assigned duties and responsibilities (other than as a result of incapacity due to physical or mental illness), (ii) a conviction of or no contest plea with respect to bribery, extortion, embezzlement, fraud, grand larceny, or any felony or similar conviction under local law involving abuse or misuse of Participant's position to seek or obtain an illegal or personal gain at the expense of the Company, the Employer or any Subsidiary, or similar crimes, or conspiracy to commit any such crimes or attempt to commit any such crimes, or (iii) Participant's violation of any policy of the Company, the Employer or any Subsidiary to which Participant may be subject or Participant's willful engagement in any misconduct in the performance of Participant's duties that materially injures the Company, the Employer or any Subsidiary.

 

Subject to such other terms and conditions set forth in this Agreement, the Participant shall not be entitled to payment for any portion of the performance units subject to this Award until the Administrator determines the portion of the Award, if any, that has vested.]

 

(b)     Termination of Relationship. Unless otherwise provided in this Agreement or agreed to in writing by Participant and Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to the Vesting Date, for any reason other than Retirement, this Award shall terminate and the unvested portion of this Award shall be forfeited by Participant.

 

3.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to continuance of employment or any other relationship by the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Award are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the payment of the Award to the Participant by the Company.

 

- 2 -
 

 

(c)     Nontransferability. The Award shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(d)     Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. The Plan governs this Agreement and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(e)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or successors of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(f)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

(g)     Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(h)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

- 3 -
 

 

(i)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 3(i), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 3(i) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 3(i), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 3(i). 

 

(j)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota.

 

 

[Signature page follows.]

 

- 4 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written. 

 

  BIO-TECHNE CORPORATION
     
     
     
     By  
    Its  

 

 

 

PARTICIPANT

 

 

 

By: ___________________________________ 

       Printed Name: [●]

 

 

 

 

62399827

 

 
 EX-10.9 9 ex_200247.htm EXHIBIT 10.9 ex_200247.htm

Exhibit 10.9

 

INCENTIVE STOCK OPTION AGREEMENT
(TIME VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant an incentive stock option to Participant to purchase shares of the Company's Common Stock pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of an incentive stock option to Participant and has determined that, as of the effective date of this Agreement, the fair market value of the Company's Common Stock is $[●] per share;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Option. The Company hereby grants to Participant on the date set forth above (the “Date of Grant”), the right and option (the “Option”) to purchase all or portions of an aggregate of [●] ([●]) shares of Common Stock at a per share price of $[●] on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. This Option is intended to be an incentive stock option within the meaning of Section 422, or any successor provision, of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder, to the extent permitted under Code Section 422(d). If the number of shares vesting for Participant in any single year exceeds the limit established by Section 422 of the Internal Revenue Code for incentive stock option treatment, the Option shall be deemed an incentive stock option to the extent of the number of shares within the limit and a nonqualified stock option the extent of the number of shares that exceed the limit.

 

2.     Duration and Exercisability.

 

(a)     General. The term during which this Option may be exercised shall terminate on [●], except as otherwise provided in Sections 2(b) through 2(e) below. This Option shall become exercisable on the following dates (the “Vesting Dates”), provided that Participant remains employed by the Company on the applicable Vesting Date as set forth in Sections 2(b) through 2(e) of this Agreement:

 

Date 

Shares Vesting 
   

[●]

[●]

[●]

[●]

[●]

[●]

[●]

[●]

 

 
 

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Option may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.

 

Once the Option becomes exercisable with respect to any of the shares specified in Section 1, Participant may continue to exercise this Option with respect to such vested shares under the terms and conditions of this Agreement until the termination of the Option as provided herein. If Participant does not purchase upon an exercise of this Option the full number of shares which Participant is then entitled to purchase, Participant may purchase upon any subsequent exercise prior to this Option's termination such previously unpurchased shares in addition to those Participant is otherwise entitled to purchase.

 

(b)     Termination of Employment (other than Disability, Death, or Retirement). Unless otherwise agreed to in writing by Participant and the Company, if Participant ceases to be an employee of the Company or any Subsidiary during the term of this Option for any reason other than disability, death, or Retirement (as defined in Section 2(e) of this Agreement) this Option shall completely terminate on the earlier of: (i) the close of business on the three-month anniversary date of such termination of employment; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such termination of employment, but had not previously been exercised. To the extent this Option was not exercisable upon such termination of employment, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(b), all rights of Participant under this Option shall be forfeited.

 

(c)     Disability. If Participant's employment terminates because of disability (as defined in Code Section 22(e), or any successor provision), this Option shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of such termination of employment; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such termination of employment, but had not previously been exercised. To the extent this Option was not exercisable upon such termination of employment, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(c), all rights of Participant under this Option shall be forfeited.

 

- 2 -
 

 

(d)     Death. In the event of Participant's death, this Option shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of Participant's death; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following Participant's death, this Option may be exercised by the person or persons to whom Participant's rights under this Option shall have passed by Participant's will or by the laws of descent and distribution only to the extent the Option was exercisable on the Vesting Date immediately preceding the date of Participant's death, but had not previously been exercised. To the extent this Option was not exercisable on the date of Participant’s death, all rights of Participant under this Option shall be forfeited. If such person or persons fail to exercise this Option within the time specified in this Section 2(d), all rights under this Option shall be forfeited.

 

(e)     Retirement. If Participant’s employment with the Company or any Affiliate terminates because of Retirement, this Option shall terminate on the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment because of Retirement, if this Option was granted at least six months prior to the date of Participant’s Retirement and is scheduled to vest pro rata during a period of at least three years and six months following the Date of Grant, then this Option shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company. If, however, this Option was not granted at least six months prior to the date of Participant’s Retirement or is scheduled to vest in less than three years and six months following the Date of Grant, then to the extent this Option was not exercisable on the date of Participant’s Retirement, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(e), all rights of Participant under this Option shall be forfeited.

 

Solely for purposes of this Section 2(e), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Notwithstanding anything in this Option Agreement to the contrary, if, pursuant to this Section 2(e), this Option is exercised after the expiration of the exercise periods that apply for purposes of Code Section 422, or any successor provision, this Option shall be thereafter treated as a nonqualified stock option. For purposes of this Option, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, the following: (i) habitual neglect of, or the willful or material failure to perform the duties of employment hereunder, as determined in good faith by the Company; (ii) embezzlement or any act of fraud; (iii) commission of acts that can be charged as a felony during employment; (iv) dishonesty in dealing between Participant and Company or between Participant and other employees of the Company; (v) use or misuse of any controlled substance, illegal or narcotic drug without a prescription; or use of alcohol in a manner, regardless of time or place, which either adversely affects Participant’s job performance or otherwise could reflect negatively on the public image of the Company; (vi) habitual absenteeism; or (vii) willfully acting in a manner materially adverse to the best interests of the Company.

 

3.     Manner of Exercise.

 

(a)     General. The Option may be exercised only by Participant (or other proper party in the event of death or incapacity), subject to the conditions of the Plan and subject to such other administrative rules as the Administrator may deem advisable, by delivering within the option period written notice of exercise to the Company at its principal office. The notice shall state the number of shares as to which the Option is being exercised and shall be accompanied by payment in full of the option price for all shares designated in the notice. The exercise of the Option shall be deemed effective upon receipt of such notice by the Company and upon payment that complies with the terms of the Plan and this Agreement. The Option may be exercised with respect to any number or all of the shares as to which it can then be exercised and, if partially exercised, may be so exercised as to the unexercised shares any number of times during the option period as provided herein.

 

- 3 -
 

 

(b)     Form of Payment. Subject to approval by the Administrator, payment of the option price by Participant may be (i) in cash, or with a personal check or certified check, (ii) by the transfer from Participant to the Company of previously acquired shares of Common Stock, (iii) through the withholding of shares of Stock from the number of shares otherwise issuable upon the exercise of the Option (e.g., a net share settlement), (iv) through broker-assisted cashless exercise if such exercise complies with applicable securities laws and any insider trading policy of the Company, (v) such other form of payment as may be authorized by the Administrator, or (vi) by a combination thereof. In the event Participant elects to pay the exercise price in whole or in part with previously acquired shares of Common Stock or through a net share settlement, the Fair Market Value of the shares of Stock delivered or withheld shall equal the total exercise price for the shares being purchased in such manner. For purposes of this Agreement, “previously acquired shares of Common Stock” shall include shares of Common Stock that are already owned by Participant at the time of exercise.

 

(c)     Issuance of Shares. As soon as practicable after the effective exercise of all or any part of the Option, Participant shall be recorded on the stock transfer books of the Company as the owner of the shares purchased, less any shares withheld for payment of taxes as provided in Section 4(d) below, and the Company shall deliver to Participant one or more duly issued stock certificates or cause book entries to be made evidencing such ownership. All requisite original issue or transfer documentary stamp taxes shall be paid by the Company. Until the issuance of such shares, Participant shall not be entitled to vote the shares of Company Common Stock represented by the Option, shall not be entitled to receive dividends or distributions attributable to such shares of Company Common Stock, and shall not have any other rights as a shareholder with respect to such shares. No adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property), distributions or other rights for which the record date is prior to the date such shares are issued, except as provided in Section 15 of the Plan.

 

4.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to the continuance of employment or any other relationship with the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Securities Law Compliance. The exercise of all or any parts of this Option shall be effective only at such time as counsel to the Company shall have determined that the issuance and delivery of Common Stock pursuant to such exercise will not violate any state or federal securities or other laws. Participant may be required by the Company, as a condition of the effectiveness of any exercise of this Option, to agree in writing that all Common Stock to be acquired pursuant to such exercise will be held until such time that the shares are registered or otherwise freely tradeable under applicable state and federal securities laws, for Participant’s own account without a view to any further distribution thereof, and that the certificate(s) for such shares will bear an appropriate legend to that effect and that such shares will not be transferred or disposed of except in compliance with applicable state and federal securities laws.

 

- 4 -
 

 

(c)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares as will be sufficient to satisfy the requirements of this Agreement.

 

(d)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Option are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the date the Company’s withholding obligation arises. Subject to such rules as the Administrator may adopt, the Administrator may, in its sole discretion, permit Participant to satisfy such withholding tax obligations, in whole or in part, (i) by delivering shares of Company Common Stock, or (ii) by electing to have the Company withhold shares of Company Common Stock otherwise issuable to Participant upon exercise of the Option. In either case, such shares shall have a Fair Market Value, as of the date the amount of tax to be withheld is determined under applicable tax law, equal to such tax withholding, including payroll taxes, applicable to the supplemental income attributable to this Option. The Participant’s election to deliver shares or to have shares withheld for this purpose shall be made on or before the date that the amount of such tax withholding is determined under applicable tax law. Such election shall be approved by the Administrator and otherwise comply with such rules as the Administrator may adopt to assure compliance with Rule 16b-3 or any successor provision, as then in effect, of the General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

 

(e)     Nontransferability. During the lifetime of Participant, the accrued Option shall be exercisable only by Participant or by the Participant's guardian or other legal representative. The Option shall not be assignable or transferable by Participant, in whole or in part, other than by will or by the laws of descent and distribution.

 

(f)     Second Amended and Restated 2010 Equity Incentive Plan. The Option evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. All defined terms of the Plan shall have the same meaning when used in this Agreement. The Plan governs this Option and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

- 5 -
 

 

(g)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Common Stock in compliance with the Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of this Option or the Company Common Stock underlying this Option, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of this Option or any of the underlying shares of Company Common Stock without the prior written consent of the underwriter(s) or its representative(s).

 

(h)     Stock Legend. The Administrator may require that the certificates or book entries for any shares of Company Common Stock purchased by Participant (or, in the case of death, Participant's successors) bear an appropriate legend and stop transfer order to reflect the restrictions of Section 4(b) and Sections 4(f) through 4(g) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 4(b) or Sections 4(f) through 4(g).

 

(i)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor(s) of Participant permitted by Section 2 or Section 4(e) above. This Option is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(j)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

(k)     Delay in Payment for Specified Employee. In the event this Option is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

- 6 -
 

 

(l)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(m)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 4(m), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 4(m) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 4(m), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4(m).

 

(n)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota.

 

[Signature page follows.]

 

- 7 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written.

 

 

BIO-TECHNE CORPORATION
     
     
     
 

   By

  
   

Its

  

 

 

PARTICIPANT

 

 

 

By: ___________________________________ 

       Printed Name: [●]

 

 

[Signature Page to Incentive Stock Option Agreement]

 

 
 EX-10.10 10 ex_200248.htm EXHIBIT 10.10 ex_200248.htm

Exhibit 10.10

 

INCENTIVE STOCK OPTION AGREEMENT
(PERFORMANCE VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant an incentive stock option to Participant to purchase shares of the Company's Common Stock pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of an incentive stock option to Participant and has determined that, as of the effective date of this Agreement, the fair market value of the Company's Common Stock is $[●] per share;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Option. The Company hereby grants to Participant on the date set forth above (the “Date of Grant”), the right and option (the “Option”) to purchase all or portions of an aggregate of [●] ([●]) shares of Common Stock at a per share price of $[●] on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. This Option is intended to be an incentive stock option within the meaning of Section 422, or any successor provision, of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder, to the extent permitted under Code Section 422(d). If the number of shares vesting for Participant in any single year exceeds the limit established by Section 422 of the Internal Revenue Code for incentive stock option treatment, the Option shall be deemed an incentive stock option to the extent of the number of shares within the limit and a nonqualified stock option the extent of the number of shares that exceed the limit.

 

2.     Duration and Exercisability.

 

(a)     General. The term during which this Option may be exercised shall terminate on [●], except as otherwise provided in Sections 2(b) through 2(e) below. This Option shall vest and become exercisable, if at all, on the Vesting Date[s] (as hereinafter defined), subject to the Company’s achievement of the performance objectives during the performance period[s], as both are set forth in Exhibit A to this Agreement, provided that Participant remains employed by the Company on the applicable Vesting Date as set forth in Sections 2(b) through 2(e) of this Agreement. Performance for the period[s] shall be evaluated and determined by and in the sole discretion of the Administrator, and performance between the threshold and maximum levels specified on Exhibit A shall result in vesting in accordance with the scale determined by the Administrator and set forth on Exhibit A. The “Vesting Date[s]” for the Option shall be the later of [●] or the date on which the Administrator evaluates and certifies achievement of the performance criteria for the performance period[s], as set forth on Exhibit A. In the event that any portion of this Option does not vest and become exercisable, Participant’s right and option to purchase the number of shares relating to such unvested portion shall immediately terminate and be forfeited.

 

 
 

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Option may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.

 

Once the Option becomes exercisable with respect to any of the shares specified in Section 1, Participant may continue to exercise this Option with respect to such vested shares under the terms and conditions of this Agreement until the termination of the Option as provided herein. If Participant does not purchase upon an exercise of this Option the full number of shares which Participant is then entitled to purchase, Participant may purchase upon any subsequent exercise prior to this Option's termination such previously unpurchased shares in addition to those Participant is otherwise entitled to purchase.]

 

(b)     Termination of Employment (other than Disability, Death or Retirement). Unless otherwise agreed to in writing by Participant and the Company, if Participant ceases to be an employee of the Company or any Subsidiary during the term of this Option for any reason other than disability, death or Retirement (as defined in Section 2(e) of this Agreement), this Option shall completely terminate on the earlier of: (i) the close of business on the three-month anniversary date of such termination of employment; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such termination of employment, but had not previously been exercised. To the extent this Option was not exercisable upon such termination of employment, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(b), all rights of Participant under this Option shall be forfeited.

 

(c)     Disability. If Participant's employment terminates because of disability (as defined in Code Section 22(e), or any successor provision), this Option shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of such termination of employment; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such termination of employment, but had not previously been exercised. To the extent this Option was not exercisable upon such termination of employment, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(c), all rights of Participant under this Option shall be forfeited.

 

- 2 -
 

 

(d)     Death. In the event of Participant's death, this Option shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of Participant's death; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following Participant's death, this Option may be exercised by the person or persons to whom Participant's rights under this Option shall have passed by Participant's will or by the laws of descent and distribution only to the extent the Option was exercisable on the Vesting Date immediately preceding the date of Participant's death, but had not previously been exercised. To the extent this Option was not exercisable on the date of Participant’s death, all rights of Participant under this Option shall be forfeited. If such person or persons fail to exercise this Option within the time specified in this Section 2(d), all rights under this Option shall be forfeited.

 

(e)     Retirement. If Participant’s employment with the Company or any Affiliate terminates because of Retirement, this Option shall terminate on the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment because of Retirement, if this Option was granted at least six months prior to the date of Participant’s Retirement and is scheduled to vest pro rata during a period of at least three years and six months following the Date of Grant, then this Option shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company. If, however, this Option was not granted at least six months prior to the date of Participant’s Retirement or is scheduled to vest in less than three years and six months following the Date of Grant, then to the extent this Option was not exercisable on the date of Participant’s Retirement, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(e), all rights of Participant under this Option shall be forfeited.

 

Solely for purposes of this Section 2(e), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Notwithstanding anything in this Option Agreement to the contrary, if, pursuant to this Section 2(e), this Option is exercised after the expiration of the exercise periods that apply for purposes of Code Section 422, or any successor provision, this Option shall be thereafter treated as a nonqualified stock option. For purposes of this Option, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, the following: (i) habitual neglect of, or the willful or material failure to perform the duties of employment hereunder, as determined in good faith by the Company; (ii) embezzlement or any act of fraud; (iii) commission of acts that can be charged as a felony during employment; (iv) dishonesty in dealing between Participant and Company or between Participant and other employees of the Company; (v) use or misuse of any controlled substance, illegal or narcotic drug without a prescription; or use of alcohol in a manner, regardless of time or place, which either adversely affects Participant’s job performance or otherwise could reflect negatively on the public image of the Company; (vi) habitual absenteeism; or (vii) willfully acting in a manner materially adverse to the best interests of the Company.

 

- 3 -
 

 

3.     Manner of Exercise.

 

(a)     General. The Option may be exercised only by Participant (or other proper party in the event of death or incapacity), subject to the conditions of the Plan and subject to such other administrative rules as the Administrator may deem advisable, by delivering within the option period written notice of exercise to the Company at its principal office. The notice shall state the number of shares as to which the Option is being exercised and shall be accompanied by payment in full of the option price for all shares designated in the notice. The exercise of the Option shall be deemed effective upon receipt of such notice by the Company and upon payment that complies with the terms of the Plan and this Agreement. The Option may be exercised with respect to any number or all of the shares as to which it can then be exercised and, if partially exercised, may be so exercised as to the unexercised shares any number of times during the option period as provided herein.

 

(b)     Form of Payment. Subject to approval by the Administrator, payment of the option price by Participant may be (i) in cash, or with a personal check or certified check, (ii) by the transfer from Participant to the Company of previously acquired shares of Common Stock, (iii) through the withholding of shares of Stock from the number of shares otherwise issuable upon the exercise of the Option (e.g., a net share settlement), (iv) through broker-assisted cashless exercise if such exercise complies with applicable securities laws and any insider trading policy of the Company, (v) such other form of payment as may be authorized by the Administrator, or (vi) by a combination thereof. In the event Participant elects to pay the exercise price in whole or in part with previously acquired shares of Common Stock or through a net share settlement, the Fair Market Value of the shares of Stock delivered or withheld shall equal the total exercise price for the shares being purchased in such manner. For purposes of this Agreement, “previously acquired shares of Common Stock” shall include shares of Common Stock that are already owned by Participant at the time of exercise.

 

(c)     Issuance of Shares. As soon as practicable after the effective exercise of all or any part of the Option, Participant shall be recorded on the stock transfer books of the Company as the owner of the shares purchased, less any shares withheld for payment of taxes as provided in Section 4(d) below, and the Company shall deliver to Participant one or more duly issued stock certificates or cause book entries to be made evidencing such ownership. All requisite original issue or transfer documentary stamp taxes shall be paid by the Company. Until the issuance of such shares, Participant shall not be entitled to vote the shares of Company Common Stock represented by the Option, shall not be entitled to receive dividends or distributions attributable to such shares of Company Common Stock, and shall not have any other rights as a shareholder with respect to such shares. No adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property), distributions or other rights for which the record date is prior to the date such shares are issued, except as provided in Section 15 of the Plan.

 

4.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to the continuance of employment or any other relationship with the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

- 4 -
 

 

(b)     Securities Law Compliance. The exercise of all or any parts of this Option shall be effective only at such time as counsel to the Company shall have determined that the issuance and delivery of Common Stock pursuant to such exercise will not violate any state or federal securities or other laws. Participant may be required by the Company, as a condition of the effectiveness of any exercise of this Option, to agree in writing that all Common Stock to be acquired pursuant to such exercise will be held until such time that the shares are registered or otherwise freely tradeable under applicable state and federal securities laws, for Participant’s own account without a view to any further distribution thereof, and that the certificate(s) for such shares will bear an appropriate legend to that effect and that such shares will not be transferred or disposed of except in compliance with applicable state and federal securities laws.

 

(c)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares as will be sufficient to satisfy the requirements of this Agreement.

 

(d)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Option are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the date the Company’s withholding obligation arises. Subject to such rules as the Administrator may adopt, the Administrator may, in its sole discretion, permit Participant to satisfy such withholding tax obligations, in whole or in part, (i) by delivering shares of Company Common Stock, or (ii) by electing to have the Company withhold shares of Company Common Stock otherwise issuable to Participant upon exercise of the Option. In either case, such shares shall have a Fair Market Value, as of the date the amount of tax to be withheld is determined under applicable tax law, equal to such tax withholding, including payroll taxes, applicable to the supplemental income attributable to this Option. The Participant’s election to deliver shares or to have shares withheld for this purpose shall be made on or before the date that the amount of such tax withholding is determined under applicable tax law. Such election shall be approved by the Administrator and otherwise comply with such rules as the Administrator may adopt to assure compliance with Rule 16b-3 or any successor provision, as then in effect, of the General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

 

(e)     Nontransferability. During the lifetime of Participant, the accrued Option shall be exercisable only by Participant or by the Participant's guardian or other legal representative. The Option shall not be assignable or transferable by Participant, in whole or in part, other than by will or by the laws of descent and distribution.

 

(f)     Second Amended and Restated 2010 Equity Incentive Plan. The Option evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. All defined terms of the Plan shall have the same meaning when used in this Agreement. The Plan governs this Option and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

- 5 -
 

 

(g)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Common Stock in compliance with the Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of this Option or the Company Common Stock underlying this Option, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of this Option or any of the underlying shares of Company Common Stock without the prior written consent of the underwriter(s) or its representative(s).

 

(h)     Stock Legend. The Administrator may require that the certificates or book entries for any shares of Company Common Stock purchased by Participant (or, in the case of death, Participant's successors) bear an appropriate legend and stop transfer order to reflect the restrictions of Section 4(b) and Sections 4(f) through 4(g) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 4(b) or Sections 4(f) through 4(g).

 

(i)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor(s) of Participant permitted by Section 2 or Section 4(e) above. This Option is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(j)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

- 6 -
 

 

(k)     Delay in Payment for Specified Employee. In the event this Option is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(l)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(m)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 4(m), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 4(m) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 4(m), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4(m).

 

(n)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota.

 

[Signature page follows.]

 

- 7 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written.

 

 

 

BIO-TECHNE CORPORATION
     
     
     
 

   By

  
   

Its

  

 

 

PARTICIPANT

 

 

 

By: ___________________________________ 

       Printed Name: [●]

 

 

 

 

70246401 v2

 

 

[Signature Page to Incentive Stock Option Agreement]

 

 
 EX-10.11 11 ex_200249.htm EXHIBIT 10.11 ex_200249.htm

Exhibit 10.11

 

GLOBAL EMPLOYEE NONQUALIFIED STOCK OPTION AGREEMENT

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S E T H:

 

WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a nonqualified stock option to Participant to purchase shares of the Company's Common Stock pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a nonqualified stock option to Participant and has determined that, as of the effective date of this Agreement, the fair market value of the Company's Common Stock is $[●] per share.

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows;

 

1.     Grant of Option. The Company hereby grants to Participant on the date set forth above (the “Date of Grant”), the right and option (the “Option”) to purchase all or portions of an aggregate of [●] ([●]) shares of Common Stock (the “Shares”) at a per Share price of $[●] on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. This Option is a nonqualified stock option and will not be treated as an incentive stock option, as defined under Section 422, or any successor provision, of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder. For purposes of this Agreement, to the extent Participant is not employed by the Company, the “Employer” means the Subsidiary that employs Participant.

 

2.     Duration and Exercisability.

 

(a)     General. The term during which this Option may be exercised shall terminate on [●], except as otherwise provided in Sections 2(b) through 2(e) below. This Option shall become exercisable on the following dates (the “Vesting Dates”), provided that Participant remains employed by the Company or a Subsidiary on the applicable Vesting Date as set forth in Sections 2(b) through 2(e) of this Agreement:

 

Date  Shares Vesting
   
[●] [●]
[●] [●]
[●] [●]
[●] [●]

  

 
 

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by Participant and the Company or the Employer, or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Option may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.

 

Once the Option becomes vested and exercisable with respect to any of the Shares specified in Section 1, Participant may continue to exercise the vested portion of this Option under the terms and conditions of this Agreement until the termination of the Option as provided herein. If Participant does not purchase upon an exercise of this Option the full number of Shares which Participant is then entitled to purchase, Participant may purchase upon any subsequent exercise prior to this Option's termination such previously unpurchased Shares in addition to those Participant is otherwise entitled to purchase.

 

(b)     Termination of Employment (other than Disability, Death, or Retirement). Unless otherwise agreed to in writing by Participant and the Company, if Participant ceases to be an employee of the Company or any Subsidiary during the term of this Option for any reason other than disability, death, or Retirement (as defined in Section 2(e) of this Agreement), this Option, whether vested or unvested, shall completely terminate on the earlier of: (i) the close of business on the three-month anniversary date of the Termination Date; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the Termination Date, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such Termination Date, but had not previously been exercised. To the extent this Option was not exercisable upon such Termination Date, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(b), all rights of Participant under this Option shall be forfeited.

 

(c)     Disability. If Participant's employment terminates due to disability (as defined in Code Section 22(e), or any successor provision, if Participant is employed in the United States), this Option, whether vested or unvested, shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of such termination of employment due to disability; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment due to disability, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such termination of employment due to disability, but had not previously been exercised. To the extent this Option was not exercisable upon such termination of employment due to disability, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(c), all rights of Participant under this Option shall be forfeited. For purposes of this Agreement, if Participant is employed outside of the United States, “disability” shall have the same meaning as defined under any long term disability plan maintained by the Employer or, in the absence of such arrangement, as determined by the Committee in its sole discretion.

 

- 2 -
 

 

(d)     Death. In the event of Participant's death, this Option, whether vested or unvested, shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of Participant's death; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following Participant's death, this Option may be exercised by the person or persons to whom Participant's rights under this Option shall have passed by Participant's will or by the laws of descent and distribution only to the extent the Option was exercisable on the Vesting Date immediately preceding the date of Participant's death, but had not previously been exercised. To the extent this Option was not exercisable on the date of Participant’s death, all rights of Participant under this Option shall be forfeited. If such person or persons fail to exercise this Option within the time specified in this Section 2(d), all rights under this Option shall be forfeited.

 

(e)     Retirement. If Participant’s employment with the Company or any Subsidiary terminates because of Retirement, this Option, whether vested or unvested, shall terminate on the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment because of Retirement, if this Option was granted at least six months prior to the date of Participant’s Retirement and is scheduled to vest pro rata during a period of at least three years and six months following the Date of Grant, then this Option shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company or a Subsidiary. If, however, this Option was not granted at least six months prior to the date of Participant’s Retirement or is scheduled to vest in less than three years and six months following the Date of Grant, then to the extent this Option was not exercisable on the date of Participant’s Retirement, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(e), all rights of Participant under this Option shall be forfeited. Solely for purposes of this Section 2(e), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Subsidiary; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. For purposes of this Option, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, the following: (i) habitual neglect of, or the willful or material failure to perform the duties of employment hereunder, as determined in good faith by the Company; (ii) embezzlement or any act of fraud; (iii) commission of acts that can be charged as a felony during employment; (iv) dishonesty in dealing between Participant and Company or between Participant and other employees of the Company; (v) use or misuse of any controlled substance, illegal or narcotic drug without a prescription; or use of alcohol in a manner, regardless of time or place, which either adversely affects Participant’s job performance or otherwise could reflect negatively on the public image of the Company; (vi) habitual absenteeism; or (vii) willfully acting in a manner materially adverse to the best interests of the Company.

 

(f)     EU Age Discrimination Rules. If Participant is a local national of and employed in a country that is a member of the European Union, the grant of this Option and the terms and conditions governing this Option are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

 

- 3 -
 

 

(g)     Termination Date. For purposes of this Agreement, if Participant is employed in, the United States, "Termination Date" means the effective date of termination of Participant's employment. If Participant is employed outside of the United States, "Termination Date" means the earliest of (i) the date on which notice of termination is provided to Participant, (ii) the last day of Participant's active service with the Employer or (iii) the last day on which Participant is an employee of the Employer, as determined in each case without including any required advanced notice period and irrespective of the status of the termination under local labor or employment laws.

 

3.     Manner of Exercise.

 

(a)     General. The Option may be exercised only by Participant (or other proper party in the event of death or incapacity), subject to the conditions of the Plan and subject to such other administrative rules as the Administrator may deem advisable, by delivering within the option period written notice of exercise to the Company at its principal office. The notice shall state the number of Shares as to which this Option is being exercised and shall be accompanied by payment in full of the option price for all Shares designated in the notice. The exercise of the Option shall be deemed effective upon receipt of such notice by the Company and upon payment that complies with the terms of the Plan and this Agreement. The Option may be exercised with respect to any number or all of the Shares as to which it can then be exercised and, if partially exercised, may be so exercised as to the unexercised shares any number of times during the option period as provided herein.

 

(b)     Form of Payment. Subject to approval by the Administrator, payment of this Option price by Participant may be (i) in cash, or with a personal check or certified check, (ii) by the transfer from Participant to the Company of previously acquired Shares, (iii) through the withholding of Shares from the number of Shares otherwise issuable upon the exercise of this Option (e.g., a net share settlement), (iv) through broker-assisted cashless exercise if such exercise complies with applicable securities laws and any insider trading policy of the Company, (v) such other form of payment as may be authorized by the Administrator, or (vi) by a combination thereof. In the event Participant elects to pay the exercise price in whole or in part with previously acquired Shares or through a net share settlement, the Fair Market Value of the Shares delivered or withheld shall equal the total exercise price for the Shares being purchased in such manner. For purposes of this Agreement, "previously acquired Shares" shall include Shares that are already owned by Participant at the time of exercise.

 

(c)     Issuance of Shares. As soon as practicable after the effective exercise of all or any part of the Option, Participant shall be recorded on the stock transfer books of the Company as the owner of the Shares purchased, less any Shares withheld for payment of taxes as provided in Section 4(d) below, and the Company shall deliver to Participant one or more duly issued stock certificates or cause book entries to be made evidencing such ownership. All requisite original issue or transfer documentary stamp taxes shall be paid by the Company. Until the issuance of such Shares, Participant shall not be entitled to vote the Shares represented by the Option, shall not be entitled to receive dividends or distributions attributable to such Shares, and shall not have any other rights as a shareholder with respect to such Shares. No adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property), distributions or other rights for which the record date is prior to the date such Shares are issued, except as provided in Section 15 of the Plan.

 

- 4 -
 

 

(d)     Repatriation and Compliance Obligations. As a condition of the grant of this Option, Participant agrees to repatriate all payments attributable to this Option in accordance with local foreign exchange rules and regulations in Participant's country of residence (and country of employment, if different). In addition, Participant agrees to take any and all actions, and consents to any and all actions taken by the Employer, the Company and its Subsidiaries as may be required to allow the Employer, the Company and its Subsidiaries to comply with local laws, rules and regulations in Participant's country of residence (and country of employment, if different). Finally, Participant agrees to take any and all actions that may be required to comply with Participant's personal legal and tax obligations under local laws, rules and regulations in Participant's country of residence (and country of employment, if different).

 

4.     Tax Obligations. Regardless of any action the Company or the Employer takes with respect to any or all federal, state, local or foreign income tax, social insurance, payroll tax, payment on account or other tax related-items (“Tax Related-Items”), Participant acknowledges that the ultimate liability for all Tax Related-Items associated with this Option is and remains Participant’s responsibility and may exceed the amount actually withheld by the Company, and the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Tax Related-Items in connection with any aspect of this Option, including, but not limited to, the grant, vesting or exercise of this Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends; and (ii) do not commit to structure the terms of the grant or any aspect of this Option to reduce or eliminate Participant’s liability for Tax Related-Items. Further, if Participant is subject to tax in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related-Items in more than one jurisdiction.

 

Prior to the delivery of Shares upon the exercise of this Option, if Participant's country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company or the Employer: (i) shall withhold a sufficient number of whole Shares otherwise issuable upon the exercise of this Option that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld (in which case, the cash equivalent of such withheld Shares shall be used to settle the withholding obligation); (ii) shall withhold an amount from Participant's regular salary and/or wages, or from any other amounts payable to Participant; or (iii) require Participant to make a payment to the Company or the Employer equal to the amount of Tax-Related Items required to be withheld. Depending on the applicable method, the Company or the Employer, as applicable, may withhold or account for Tax-Related Items by considering applicable statutory withholding rates, but such withholding shall not exceed an amount of withholding based on the maximum statutory rates in Participant's applicable tax jurisdictions.

 

In the event the withholding requirements are not satisfied through the withholding of Shares or through Participant's regular salary and/or wages or other amounts payable to Participant, no Shares will be issued to Participant unless and until satisfactory arrangements (as determined by the Committee) have been made by Participant with respect to the payment of any Tax-Related Items which the Company determines, in its sole discretion, must be withheld or collected with respect to this Option. If Participant is subject to taxation in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer may be required to withhold or account for Tax-Related Items in more than one jurisdiction. By accepting the grant of this Option, Participant expressly consents to the withholding of Shares and/or the withholding of amounts from Participant's regular salary and/or wages, or other amounts payable to Participant, as provided for hereunder. All other Tax-Related Items related to this Option and any Shares acquired pursuant to the exercise of this Option are Participant's sole responsibility.

 

- 5 -
 

 

5.     Nature of Grant. In accepting the grant of this Option, Participant acknowledges, understands and agrees that:

 

(a)     the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan;

 

(b)     the grant of this Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past;

 

(c)     all decisions with respect to future options or other grants, if any, will be at the sole discretion of the Company;

 

(d)     Participant is voluntarily participating in the Plan;

 

(e)     this Option and the Shares subject to this Option, and the income from and value of same, are not intended to replace any pension rights or compensation;

 

(f)     this Option and the Shares subject to this Option, and the income from and value of same, are not part of normal or expected compensation for purposes of, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments;

 

(g)     unless otherwise agreed with the Company in writing, this Option and the Shares subject to this Option, and the income from and value of same, are not granted as consideration for, or in connection with, the service Participant may provide as a director of a Subsidiary;

 

(h)     the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;

 

(i)     if the underlying Shares do not increase in value, this Option will have no value;

 

(j)     if Participant exercises this Option and acquires Shares, the value of such Shares may increase or decrease in value, even below the exercise price;

 

- 6 -
 

 

(k)     no claim or entitlement to compensation or damages shall arise from forfeiture of this Option resulting from the termination of Participant's employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant's employment agreement, if any); and

 

(l)     neither the Company nor the Employer shall be liable for any foreign exchange rate fluctuation between Participant's local currency and the United States Dollar that may affect the value of this Option or of any amounts due to Participant pursuant to the exercise of this Option or the subsequent sale of any Shares acquired upon exercise.

 

6.     Data Privacy. The Company is located at 614 McKinley Place N.E., Minneapolis, Minnesota, U.S.A. and grants Options to acquire Shares under the Plan to employees of the Company and its Subsidiaries, at its sole discretion. In conjunction with the Company's grant of the Option under the Plan and its ongoing administration of such awards, the Company is providing the following information about its data collection, processing and transfer practices. In accepting the grant of the Option, Participant expressly and explicitly consents to the personal data activities as described herein.

 

(a)     Data Collection, Processing and Usage. The Company and the Employer will collect, process and use certain personal information about Participant, specifically, Participant's name, home address, email address and telephone number, date of birth, social security or insurance number, passport number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Options or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant's favor (“Personal Data”), for the exclusive purpose of implementing, administering and managing the Plan. Participant's Personal Data also may be disclosed to certain securities or other regulatory authorities where the Company’s securities are listed or traded or regulatory filings are made. The Company's legal basis for the collection, processing and use of Participant's Personal Data is Participant's consent.

 

(b)     Stock Plan Administration Service Providers. The Company and the Employer transfer Participant's Personal Data to Morgan Stanley a broker firm/third party service provider based in the United States of America and engaged by the Company to assist with the implementation, administration and management of awards granted under the Plan (the “Stock Plan Administrator”). In the future, the Company may select a different Stock Plan Administrator and share Participant's Personal Data with another company that serves in a similar manner. The Stock Plan Administrator will open an account for Participant to receive and trade Shares acquired under the Plan. Participant will be asked to agree to separate terms and data processing practices with the Stock Plan Administrator, which is a condition of Participant's ability to participate in the Plan.

 

(c)     International Personal Data Transfers. The Company and the Stock Plan Administrator are based in the United States of America. You should note that Participant's country of residence may have enacted data privacy laws that are different from the United States of America. The Company's legal basis for the transfer of Participant's Personal Data to the United States of America is Participant's consent.

 

- 7 -
 

 

(d)     Voluntariness and Consequences of Consent, Denial or Withdrawal. Participant's participation in the Plan and Participant's grant of consent hereunder is purely voluntary. Participant may deny or withdraw his or her consent at any time. If Participant does not consent, or if Participant later withdraws his or her consent, Participant may be unable to participate in the Plan. This would not affect Participant's existing employment or salary; instead, Participant merely may forfeit the opportunities associated with participation in the Plan.

 

(e)     Personal Data Retention. Participant understands that Participant's Personal Data will be held only as long as is necessary to implement, administer and manage the Option and Participant's participation in the Plan. When the Company no longer needs Participant's Personal Data, the Company will remove it from its systems. If the Company retains Participant's Personal Data longer, it would be to satisfy the Company's legal or regulatory obligations and the Company's legal basis would be for compliance with applicable laws, rules and regulations.

 

(f)     Personal Data Subject Rights. Participant understands that Participant may have the right under applicable law to (i) access or copy Participant's Personal Data that the Company possesses, (ii) rectify incorrect Personal Data concerning Participant, (iii) delete Participant's Personal Data, (iv) restrict processing of Participant's Personal Data, or (vi) lodge complaints with the competent supervisory authorities in Participant's country of residence. To receive clarification regarding these rights or to exercise these rights, Participant understands that Participant can contact his or her Employer's human resources representative.

 

7.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to the continuance of employment or any other relationship with the Employer, the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant, the Employer and the Company or any Subsidiary.

 

(b)     Securities Law Compliance. The exercise of all or any parts of this Option shall be effective only at such time as counsel to the Company shall have determined that the issuance and delivery of Shares pursuant to such exercise will not violate any state or federal securities or other laws. Notwithstanding any other provision of the Plan or this Agreement, unless there is an exemption from any registration, qualification or other legal requirement applicable to the Shares the Company shall not be required to deliver any Shares issuable upon exercise of this Option prior to the completion of any registration or qualification of the Shares under any local, state, federal or foreign securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or of any other governmental regulatory body, or prior to obtaining any approval or other clearance from any local, state, federal or foreign governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. Participant understands that the Company is under no obligation to register or qualify the shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the Shares. Further, Participant agrees that the Company shall have unilateral authority to amend the Agreement without his or her consent to the extent necessary to comply with securities or other laws applicable to issuance of Shares.

 

- 8 -
 

 

(c)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of this Agreement.

 

(d)     Transferability. Participant may transfer any or all of this Option to any member of Participant's "immediate family" as such term is defined in Rule 16a-1(e) promulgated under the U.S. Securities Exchange Act of 1934, or any successor provision, or to one or more trusts whose beneficiaries are members of such Participant's "immediate family" or partnerships in which such family members are the only partners; provided, however, that Participant cannot receive any consideration for the transfer and such transferred Option shall continue to be subject to the same terms and conditions as were applicable to such Option immediately prior to its transfer. Further, the transferee shall be subject to all restrictions that generally apply to shareholders of the Company, including but not limited to restrictions on the pledge, encumbrance, sale, assignment, transfer, gift, or disposition of any stock acquired through the exercise of the Option.

 

(e)     Second Amended and Restated 2010 Equity Incentive Plan. The Option evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. All defined terms of the Plan shall have the same meaning when used in this Agreement. The Plan governs this Option and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(f)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Shares in compliance with the U.S. Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of this Option or the Shares underlying this Option, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of this Option or any of the underlying Shares without the prior written consent of the underwriter(s) or its representative(s).

 

(g)     Stock Legend. The Administrator may require that the certificates or book entries for any Shares purchased by Participant (or Participant’s permitted successors or assigns) bear an appropriate legend and stop transfer order to reflect the restrictions of Section 6(b) and Section 6(g) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 6(b) or Section 6(f).

 

(h)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or assigns of Participant permitted by Section 2 or Section 6(e) above. This Option is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

- 9 -
 

 

(i)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, United States of America, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota, United States of America.

 

(j)     Delay in Payment for Specified Employee. In the event this Option is subject to Code Section 409A and the Administrator determines that Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(k)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(l)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 6(l), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless Participant and the Company otherwise agree in writing, any determination required under this Section 6(l) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 6(l), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 6(l).

 

- 10 -
 

 

(m)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota, United States of America.

 

(n)     Language. Participant acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is proficient in the English language, so as to enable Participant to understand the provisions of this Agreement and the Plan. If Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

 

(o)     Electronic Delivery and Participation. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

 

(p)     Severability. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

 

(q)     Addendum. Notwithstanding any provisions of this Agreement to the contrary, this Option shall be subject to any special terms and conditions for Participant's country of residence (and country of employment, if different), as are forth in the applicable Addendum to this Agreement. Further, if Participant transfers residence and/or employment to another country reflected in an Addendum to this Agreement, the special terms and conditions for such country will apply to Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of this Option and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate Participant's transfer). Any applicable Addendum shall constitute part of this Agreement.

 

(r)     Imposition of Other Requirements. The Company reserves the right to impose other requirements on this Option, any payment made pursuant to this Option, and Participant's participation in the Plan, to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of this Option and the Plan. Such requirements may include (but are not limited to) requiring Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

 

- 11 -
 

 

(s)     Waiver. Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach, whether or like or different nature.

 

(t)     Private Offering. The grant of this Options is not intended to be a public offering of securities in Participant’s country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filing with the local securities authorities with respect to the grant of this Options (unless otherwise required under local law). No employee of the Company is permitted to advise Participant on whether Participant should purchase Shares under the Plan or provide Participant with any legal, tax or financial advice with respect to the grant of this Options. Investment in Shares involves a degree of risk. Before deciding to purchase Shares pursuant to this Options, Participant should carefully consider all risk factors and tax considerations relevant to the acquisition of Shares under the Plan or the disposition of them. Further, Participant should carefully review all of the materials related to this Options and the Plan, and Participant should consult with Participant’s personal legal, tax and financial advisors for professional advice in relation to Participant’s personal circumstances.

 

(u)     Exchange Control, Foreign Asset/Account and/or Tax Reporting. Participant acknowledges that there may be certain exchange control, foreign asset/account and/or tax reporting requirements which may affect Participant’s ability to acquire or hold Shares or cash received from participating in the Plan (including the proceeds from the sale of Shares and the receipt of any dividends paid on Shares) in a brokerage or bank account outside Participant’s country. Participant may be required to report such accounts, assets or related transactions to the tax or other authorities in Participant’s country. Participant also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to Participant’s country within a certain time after receipt. Participant acknowledges that it is Participant’s responsibility to comply with such regulations and that Participant should speak to his or her personal advisor on this matter.

 

(v)     Insider Trading/Market Abuse. Participant may be subject to insider trading restrictions and/or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions, including the United States, Participant’s country and the designated broker’s country, which may affect Participant’s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., this Option) or rights linked to the value of Shares under the Plan during such times that Participant is considered to have “inside information” regarding the Company (as defined by the laws or regulations in Participant’s country).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. Participant acknowledges that it is Participant’s responsibility to comply with any applicable restrictions and that Participant should speak to his or her personal advisor on this matter.

 

- 12 -
 

 

(w)     Consent and Agreement With Respect to Plan. Participant (a) acknowledges that a copy of the Plan and the U.S. prospectus for the Plan has been available to Participant; (b) represents that he or she has read and is familiar with the terms and provisions thereof, has had an opportunity to obtain the advice of counsel of his or her choice prior to executing this Agreement and fully understands all provisions of this Agreement and the Plan; (c) accepts this Option subject to all of the terms and provisions thereof; and (d) agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Agreement.

 

[Signature page follows.]

 

- 13 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written.

 

 

BIO-TECHNE CORPORATION
     
     
     
 

   By

  
   

Its

  

  

 

PARTICIPANT

 

 

 

By: ___________________________________

       Printed Name: [●]

 

 

 

 

[Signature Page to Employee Nonqualified Stock Option Agreement]

 

 
 

 

BIO-TECHNE CORPORATION

 

ADDENDUM TO
GLOBAL EMPLOYEE NONQUALIFIED STOCK OPTION AGREEMENT

 

BIO-TECHNE CORPORATION
SECOND AMENDED AND RESTATED
2010 EQUITY INCENTIVE PLAN

 

In addition to the terms of the Plan and the Agreement, the Option is subject to the following additional terms and conditions as set forth in this addendum (the “Addendum”). All defined terms as contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 7(q) of the Agreement, to the extent Participant transfers residence and/or employment to another country, the additional terms and conditions as set forth in the Addendum for such country (if any) shall also apply to the Option to the extent the Company determines, in its sole discretion, that the application of such addendum is necessary or advisable in order to comply with local laws, rules and regulations, or to facilitate the operation and administration of the Option and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer).

 

European Union (“EU”) / European Economic Area (“EEA”) / Switzerland / United Kingdom

 

1.     Data Privacy. If Participant resides and/or works in the EU/EEA, Switzerland or the United Kingdom, Section 6 of the Agreement shall be replaced with the following:

 

Data Privacy. The Company is located at 614 McKinley Place N.E., Minneapolis, Minnesota, U.S.A. and grants Options to acquire Shares under the Plan to employees of the Company and its Subsidiaries, at its sole discretion. In conjunction with the Company's grant of the Option under the Plan and its ongoing administration of such award, the Company is providing the following information about its data collection, processing and transfer practices, which Participant should carefully review.

 

(a)     Data Collection, Processing and Usage. The Company and the Employer will collect, process and use certain personal information about Participant, specifically, Participant's name, home address, email address and telephone number, date of birth, social security or insurance number, passport number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Options or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant's favor (“Personal Data”), for the exclusive purpose of implementing, administering and managing the Plan. Participant's Personal Data also may be disclosed to certain securities or other regulatory authorities where the Company’s securities are listed or traded or regulatory filings are made. The Company's legal basis for such disclosure of Participant's Personal Data is to satisfy its contractual obligations under the terms of the Agreement and this Addendum, and to comply with applicable laws, rules and regulations.

 

- 2 -
 

 

(b)     Stock Plan Administrator. The Company and the Employer transfer Participant's Personal Data to Morgan Stanley a broker firm/third party service provider based in the United States of America and engaged by the Company to assist with the implementation, administration and management of awards granted under the Plan (the “Stock Plan Administrator”). In the future, the Company may select a different Stock Plan Administrator and share Participant's Personal Data with another company that serves in a similar manner. The Stock Plan Administrator will open an account for Participant to receive and trade Shares acquired under the Plan. Participant will be asked to agree to separate terms and data processing practices with the Stock Plan Administrator, which is a condition of Participant's ability to participate in the Plan.

 

(c)     International Personal Data Transfers. The Company and the Stock Plan Administrator are based in the United States of America. Participant should note that Participant's country of residence may have enacted data privacy laws that are different from the United States of America. The Company's legal basis for the transfer of Participant's Personal Data to the United States of America is to satisfy its contractual obligations under the terms and conditions of this Agreement.

 

(d)     Data Retention. Participant understand that Participant's Personal Data will be held only as long as is necessary to implement, administer and manage the Option and Participant's participation in the Plan. When the Company no longer needs Participant's Personal Data, the Company will remove it from its systems. If the Company retains Participant's Personal Data longer, it would be to satisfy the Company's legal or regulatory obligations and the Company's legal basis would be for compliance with applicable laws, rules and regulations.

 

(e)     Data Subject Rights. Participant understands that Participant may have the right under applicable law to (i) access or copy Participant's Personal Data that the Company possesses, (ii) rectify incorrect Personal Data concerning Participant, (iii) delete Participant's Personal Data, (iv) restrict processing of Participant's Personal Data, or (vi) lodge complaints with the competent supervisory authorities in Participant's country of residence. To receive clarification regarding these rights or to exercise these rights, Participant understand that Participant can contact his or her Employer's human resources representative.

 

Austria

 

No country-specific provisions.

 

- 3 -
 

 

Belgium

 

1.     Acceptance of Option. In order for the Option to be subject to taxation at the time of grant, Participant must affirmatively accept the Option in writing within 60 days of the Date of Grant specified above by signing below and returning this original executed Addendum to:

 

VP of Human Resources, Minneapolis Minnesota

 

Participant hereby accepts the Option granted by the Company on the Date of Grant. Participant acknowledges that Participant has been advised to discuss the acceptance of the Option and the applicable tax treatment with a financial and/or tax advisor, and that Participant’s decision to accept the Option is made in full knowledge.

 

Participant Signature:  _______________________________
   
Participant Printed Name:  _______________________________
   
Date of Acceptance:  _______________________________

 

If Participant fails to affirmatively accept the Option in writing within 60 days of the Date of Grant, the Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date Participant exercises the Option (or such other treatment as may apply under Belgian tax law at the time of exercise).

 

2.     Undertaking for Qualifying Option. If Participant is accepting the Option in writing within 60 days of the Date of Grant and wishes to have the Option subject to a lower valuation for Belgium tax purposes pursuant to article 43, §6 of the Belgian law of 26 March 1999, Participant may agree and undertake to (a) not exercise the Option before December 31 of the third (3rd) calendar year following the calendar year in which the Date of Grant falls, and (b) not transfer the Option under any circumstances (except upon rights Participant’s heir might have in the Option upon Participant’s death). If Participant wishes to make this undertaking, Participant must sign below and return this executed Addendum to the address listed above.

 

Participant Signature: _______________________________
   
Participant Printed Name: _______________________________

 

3.     Payment of Option Price Limited to Cash Payment. Notwithstanding anything to the contrary in the Agreement or the Plan, Participant shall be permitted to pay the Option price only by means of a cash payment.

 

- 4 -
 

 

Canada

 

1.     No Exercise by Using Previously Owned Shares. Notwithstanding anything in the Agreement or the Plan to the contrary, if Participant is a resident in Canada, Participant shall be unable to use previously-owned Shares to pay the exercise price of the Option.

 

2.     Consent to Receive Information in English. To the extent Participant is resident in Quebec, the parties acknowledge that it is their express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be written in English.

 

Les parties reconnaissent avoir exigé la rédaction en anglais du présent Contrat, ainsi que de tous documents exécutés, avis donnés ou procédures judiciaires intentées, en vertu du, ou liés directement ou indirectement, au présent Contrat.

 

3.     Data Privacy. The following provision supplements Section 6 of the Agreement:

 

Participant hereby authorizes the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of Participant’s awards under the Plan. Participant further authorizes the Company, its Subsidiaries, and the stock plan administrator to disclose and discuss Participant’s participation in the Plan with their respective advisors. Participant further authorizes the Company and its Subsidiaries to record such information and to keep such information in his or her employee file.

 

China

 

1.     Option Conditioned on Satisfaction of Regulatory Obligations. If Participant is a national of the People’s Republic of China (“PRC”), the grant of the Option is conditioned upon the Company securing all necessary approvals from the PRC State Administration of Foreign Exchange to permit the operation of the Plan and the participation of PRC nationals employed by the Employer, as determined by the Company in its sole discretion.

 

2.     Mandatory Full Cashless Exercise. Notwithstanding anything in the Agreement or the Plan to the contrary, the Option may be exercised only by using the Broker-Assisted Cashless Exercise method as provided in Section 3(b)(iv) of the Agreement.

 

- 5 -
 

 

3.     Exchange Control Restrictions. Participant understands and agrees that, if Participant is subject to exchange control laws in China, Participant will be required to repatriate immediately to China the proceeds from the sale of any Shares acquired under the Plan. Participant further understands that such repatriation of sale proceeds must be effected through a special bank account established by the Company with a financial institution in China and Participant hereby consents and agrees that proceeds from the sale of Shares acquired under the Plan may be transferred to such account by the Company on Participant's behalf prior to being delivered to Participant and that no interest shall be paid with respect to funds held in such account. Sale proceeds may be paid to Participant in U.S. dollars or local currency at the Company’s discretion. If the sale proceeds are paid to Participant in U.S. dollars, Participant understands that Participant must establish and maintain a U.S. dollar bank account in China so that the proceeds may be deposited into such account. If the sale proceeds are paid to Participant in local currency, Participant acknowledges that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the sale proceeds to local currency due to exchange control restrictions. Participant agrees to bear any currency fluctuation risk between the time the shares of Common Stock are sold and the net proceeds are converted into local currency and distributed to Participant. Participant further agrees to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

 

4.     Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses Participant may incur or suffer resulting from the enforcement of the terms of this section or otherwise from the Company’s operation and enforcement of the terms of the Plan, the Agreement and this Addendum, and the Option in accordance with Chinese law including, without limitation, any applicable rules, regulations, requirements and approvals issued by the State Administration of Foreign Exchange.

 

Czech Republic

 

No country-specific provisions.

 

Denmark

 

1.     Danish Stock Option Act. Notwithstanding anything in the Agreement or the Plan to the contrary, the treatment of the Option upon Participant’s termination of employment with the Company or any Subsidiary, as applicable, shall be governed by the Danish Stock Option Act, as in effect at the time of Participant’s termination (as determined by the Committee in its discretion in consultation with legal counsel). By accepting the Option, Participant acknowledges that he or she has received a Danish translation of an Employer Statement, which is being provided to comply with the Danish Stock Option Act.

 

Finland

 

No country-specific provisions.

 

France

 

1.     Option Not Tax-Qualified. The Option is not intended to qualify for specific tax or social security treatment in France.

 

2.     Consent to Receive Information in English. By accepting the Option, Participant confirms having read and understood the Plan, the Agreement and this Addendum, including all terms and conditions included therein, which were provided in the English language. Participant accepts the terms of those documents accordingly.

 

Consentement afin de Recevoir des Informations en Anglais

 

En acceptant les Options d’Achat d’Actions, le Participant confirme avoir lu et compris le Plan, le Contrat et la présente Annexe, en ce compris tous les termes et conditions y relatifs, qui ont été fournis en langue anglaise. Le Participant accepte les dispositions de ces documents en connaissance de cause.

 

- 6 -
 

 

Germany

 

No country-specific provisions.

 

Hong Kong

 

1.     Sale Restriction. Shares received at exercise are accepted as a personal investment. If, for any reason, the Option vests and becomes exercisable and the Option is exercised and Shares are issued to Participant (or Participant’s heirs) within six (6) months of the Date of Grant, Participant (or Participant’s heirs) agrees that he or she will not dispose of any such Shares prior to the six (6)-month anniversary of the Date of Grant.

 

2.     Securities Law Notice. WARNING: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. Participant is advised to exercise caution in relation to the offer. If Participant is in any doubt about any of the contents of this document, Participant should obtain independent professional advice. Neither the offer of Options nor the issuance of Shares upon exercise of the Options constitutes a public offering of securities under Hong Kong law and is available only to employees of the Company and its Subsidiaries. The Agreement, including this Addendum, the Plan and other incidental communication materials distributed in connection with the Options (i) have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each eligible employee of the Company or its Subsidiaries and may not be distributed to any other person.

 

3.     Nature of Plan. The Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance.

 

Hungary

 

No country-specific provisions.

 

India

 

1.     Mandatory Full Cashless Exercise. Notwithstanding anything in the Agreement or the Plan to the contrary, the Option may be exercised only by using the Broker-Assisted Cashless Exercise method as provided in Section 3(b)(iv) of the Agreement.

 

- 7 -
 

 

Italy

 

1.     Mandatory Full Cashless Exercise. Notwithstanding anything in the Agreement or the Plan to the contrary, the Option may be exercised only by using the Broker-Assisted Cashless Exercise method as provided in Section 3(b)(iv) of the Agreement.

 

2.     Plan Document Acknowledgement. In accepting the Option, Participant acknowledges that he or she has received a copy of the Plan and the Agreement and has reviewed the Plan and the Agreement (including this Addendum), in their entirety and fully understands and accepts all provisions of the Plan and the Agreement (including this Addendum). Participant further acknowledges that he or she has read and specifically and expressly approves the following provisions of the Agreement: Section 4: Tax Obligations; Section 6: Nature of Grant; Section 8(m): Governing Law; Section 8(q): Addendum; Section 8(r): Imposition of Other Requirements; and the Data Privacy provisions for the European Union reflected above..

 

Japan

 

No country-specific provisions.

 

Korea

 

No country-specific provisions.

 

Luxembourg

 

No country-specific provisions.

 

Netherlands

 

1.     Waiver of Termination Rights. As a condition to the grant of the Option, Participant hereby waive any and all rights to compensation or damages as a result of the termination of Participant's employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) Participant ceasing to have rights under or ceasing to be entitled to any Option under the Plan as a result of such termination.

 

Poland

 

No country-specific provisions.

 

Singapore

 

1.     Securities Law Notice. The grant of the Option is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”) and is not made to Participant with a view to the underlying Shares being subsequently offered for sale to any other party. The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore. Participant should note that the Options are subject to section 257 of the SFA and Participant should not make (i) any subsequent sale of the Shares in Singapore or (ii) any offer of such subsequent sale of the Shares subject to the Option in Singapore, unless such sale or offer is made after six (6) months from the Date of Grant or pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA. The Shares are currently traded on the NASDAQ Stock Market LLC, which is located outside of Singapore, under the ticker symbol “TECH” and Shares acquired under the Plan may be sold through this exchange.

 

- 8 -
 

 

Spain

 

1.     Nature of Option. The following provision supplements Section 6 of the Agreement:

 

In accepting the grant of the Option, Participant acknowledges that he or she consents to participation in the Plan and has received a copy of the Plan.

 

Participant understands that the Company, in its sole discretion, has unilaterally and gratuitously decided to grant Options under the Plan to individuals who may be employees of the Company or its Subsidiaries throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any Options will not economically or otherwise bind the Company or any of its Subsidiaries on an ongoing basis. Consequently, Participant understands that the Option is granted on the assumption and condition that the Option and the Shares issued upon exercise of the Option shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be considered a mandatory benefit, or salary for any purposes (including severance compensation) or any other right whatsoever.

 

Further, Participant understands and agrees that, unless otherwise expressly provided for by the Company or set forth in the Agreement, the Option will be cancelled without entitlement to any Shares if Participant’s employment is terminated for any reason, including, but not limited to: resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (i.e., subject to a “despido improcedente”), material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, or under Article 10.3 of Royal Decree 1382/1985. The Committee, in its sole discretion, shall determine the date when Participant’s employment has terminated for purposes of the Option.

 

Participant understands that this Option grant would not be made to Participant but for the assumptions and conditions referred to above; thus, Participant acknowledges and freely accepts that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of, or right to, the Option shall be null and void.

 

Sweden

 

1. Tax Obligations. The following provision supplements Section 4 of the Agreement:

 

Without limiting the Company's and the Employer's authority to satisfy their withholding obligations for Tax-Related Items as set forth in Section 4 of the Agreement, in accepting the grant of Option, Participant authorizes the Company and/or the Employer to withhold Shares or to sell Shares otherwise deliverable to Participant upon exercise to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

 

- 9 -
 

 

Switzerland

 

1.     Securities Law Notice. Neither the Agreement, the Addendum nor any other materials relating to the Option (i) constitutes a prospectus according to article 35 et seq. of the Swiss Federal Act on Financial Services ("FinSA"), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company, or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (FINMA).

 

Taiwan

 

No country-specific provisions.

 

United Kingdom

 

1.     Tax Obligations. The following provision supplements Section 4 of the Agreement:

 

Without limitation to Section 4 of the Agreement, Participant hereby agrees that Participant is liable for all Tax Related-Items and hereby covenants to pay all such Tax Related-Items, as and when requested by the Company, or if different, the Employer, or by Her Majesty’s Revenue & Customs (“HMRC”) (or any other tax authority or any other relevant authority). Participant also hereby agrees to indemnify and keep indemnified the Company and, if different, the Employer, against any Tax Related-Items that they are required to pay or withhold, or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on Participant’s behalf.

 

Notwithstanding the foregoing, if Participant is a director or executive officer of the Company (within the meaning of Section 13(k) of the Exchange Act), Participant may not be able to indemnify the Company or the Employer for the amount of any income tax not collected from or paid by Participant, as it may be considered a loan. In this case, the amount of any uncollected amounts may constitute a benefit to Participant on which additional income tax and National Insurance Contributions may be payable. Participant will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying the Company or the Employer for the value of any National Insurance Contributions due on this additional benefit, which the Company or the Employer may recover by any of the means referred to in Section 6(d) of the Agreement.

 

2.     Exclusion of Claim. Participant acknowledges and agrees that Participant will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from the Participant ceasing to have rights under or to be entitled to the Option, whether or not as a result of termination of employment (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Option. Upon the grant of the Option, Participant shall be deemed to have waived irrevocably such entitlement.

 

 

 

*********************

 

- 10 -
 EX-21 12 ex_187163.htm EXHIBIT 21 ex_156245.htm

Exhibit 21

 

Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2020. Certain subsidiaries are not named because they were not significant individually or in the aggregate as of such date. Bio-Techne Corporation is not a subsidiary of any other entity. 

 

 

 

 

 

Name

State/Country of Incorporation

Research and Diagnostic Systems Inc. (R&D Systems)

Minnesota

Bionostics, Inc

Massachusetts

Bio-Techne China Co. Ltd

China

Shanghai PrimeGene Bio-Tech Co., Ltd.

China

ProteinSimple

Delaware

ProteinSimple Ltd.

Canada

Novus Biologicals, LLC

Delaware

Bio-Techne Ltd.

United Kingdom

Tocris Cookson Limited

United Kingdom

Cliniqa Corporation

California

Advanced Cell Diagnostics, Inc.

California

QT Holdings Corporation

Delaware

Exosome Diagnostics, Inc. 

Delaware

B-MoGen Biotechnologies Inc.

Minnesota

 

 

 
 EX-23 13 ex_187164.htm EXHIBIT 23 ex_156246.htm

Exhibit 23

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors
Bio-Techne Corporation:

 

We consent to the incorporation by reference in the registration statements (Nos. 333-37263, 333-88885, 333-49962, 333-170576, 333-199847, 333-207710, and 333-221143) on Form S-8 of Bio-Techne Corporation of our reports dated August 26, 2020, with respect to the consolidated balance sheets of Bio-Techne Corporation as of June 30, 2020 and 2019, the related consolidated statements of earnings and comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended June 30, 2020, and the related notes (collectively, “the consolidated financial statements”), and the effectiveness of internal control over financial reporting as of June 30, 2020 which reports appear in the June 30, 2020 annual report on Form 10-K of Bio-Techne Corporation.

 

Our report refers to changes in the methods of accounting for revenue and leases.

 

/s/ KPMG LLP

 

Minneapolis, Minnesota

August 26, 2020

 

 

 

 

 
 EX-31.1 14 ex_187165.htm EXHIBIT 31.1 ex_156098.htm

Exhibit 31.1

 

CERTIFICATION

 

I, Charles Kummeth, certify that:

 

 

1.

I have reviewed this annual report on Form 10-K of Bio-Techne Corporation;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

 

4.

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: August 26, 2020

 

 

 

/s/ Charles Kummeth

  
 

Charles Kummeth

Chief Executive Officer

  

 

 

 
 EX-31.2 15 ex_187166.htm EXHIBIT 31.2 ex_156099.htm

Exhibit 31.2

 

 

CERTIFICATION

 

I, James T. Hippel, certify that:

 

 

1.

I have reviewed this annual report on Form 10-K of Bio-Techne Corporation;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

 

4.

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: August 26, 2020

 

 

  /s/ James T. Hippel  

 

James T. Hippel

Chief Financial Officer

  

 

 

 
 EX-32.1 16 ex_187167.htm EXHIBIT 32.1 ex_156100.htm

Exhibit 32.1

 

 

BIO-TECHNE CORPORATION

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report of Bio-Techne Corporation (the “Company”) on Form 10-K for the year ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles Kummeth, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

  /s/ Charles Kummeth  
 

Charles Kummeth

Chief Executive Officer

August 26, 2020

  

 

 

 

 
 EX-32.2 17 ex_187168.htm EXHIBIT 32.2 ex_156101.htm

Exhibit 32.2

 

 

BIO-TECHNE CORPORATION

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report of Bio-Techne Corporation (the “Company”) on Form 10-K for the year ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James T. Hippel, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

       

 

 

 

 

/s/ James T. Hippel

  
 

James T. Hippel

Chief Financial Officer

August 26, 2020

  

 

 
 EX-101.SCH 18 tech-20200630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Statements of Earnings and Comprehensive Income link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Statements of Earnings and Comprehensive Income (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Revenue Recognition link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Acquisitions link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Debt and Other Financing Arrangements link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Leases link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Earnings Per Share link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Segment Information link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - Quarterly Financial Data (Unaudited) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 14 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Revenue Recognition (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Acquisitions (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 7 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 9 - Earnings Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 11 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 12 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 13 - Quarterly Financial Data (Unaudited) (Tables) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 2 - Revenue Recognition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 4 - Acquisitions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 5 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 6 - Debt and Other Financing Arrangements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 7 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 7 - Leases - Balance Sheet Classification (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 7 - Leases - Cash Paid (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 7 - Leases - Aggregate Net Minimum Rental Commitments (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 9 - Earnings Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 11 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) link:calculationLink link:definitionLink link:presentationLink 069 - Disclosure - Note 12 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 070 - Disclosure - Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) link:calculationLink link:definitionLink link:presentationLink 071 - Disclosure - Note 13 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 19 tech-20200630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 20 tech-20200630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 21 tech-20200630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Intangible assets Dividend yield us-gaap_DerivativeNotionalAmount Derivative, Notional Amount Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Revenue Recognition Hedging Relationship [Domain] Note 3 - Supplemental Balance Sheet and Cash Flow Information us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets Current assets, net of cash Risk-free interest rates Note 4 - Acquisitions Cash Flow Hedging [Member] Note 5 - Fair Value Measurements Note 7 - Leases Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) Note 9 - Earnings Per Share Note 10 - Share-based Compensation and Other Benefit Plans Hedging Relationship [Axis] Income Tax Disclosure [Text Block] Note 11 - Income Taxes Note 12 - Segment Information Unrealized gains (losses) on available-for-sale investments, net of tax of $398 in FY18 Note 13 - Quarterly Financial Data (Unaudited) Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) Contingent consideration payable Expected volatility us-gaap_LiabilitiesCurrent Total current liabilities Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) Expected lives (years) (Year) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms Balance, weighted average contractual life (Year) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1 Net assets acquired us-gaap_FinitelivedIntangibleAssetsAcquired1 Acquisitions (Note 4) Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) Note 7 - Leases - Balance Sheet Classification (Details) us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred Consideration payable Note 7 - Leases - Cash Paid (Details) Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details) Note 7 - Leases - Aggregate Net Minimum Rental Commitments (Details) Share-based Payment Arrangement, Option, Activity [Table Text Block] Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Granted, weighted average exercise price (in dollars per share) Foreign currency translation adjustments Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Vested, weighted average exercise price (in dollars per share) Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Forfeited, weighted average exercise price (in dollars per share) Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Balance, weighted average exercise price (in dollars per share) Balance, weighted average exercise price (in dollars per share) Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited, shares (in shares) Forfeited, shares (in shares) Forfeited, shares (in shares) Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details) Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Balance, shares (in shares) Balance, shares (in shares) Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent Other comprehensive income (loss) before reclassifications Note 13 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Amounts reclassified from accumulated other comprehensive loss to income Notes To Financial Statements us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Granted, shares (in shares) Proceeds from sale and maturities of available-for-sale investments Notes To Financial Statements [Abstract] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested, shares (in shares) us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount Current portion of long-term debt obligations us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Exercisable, weighted average exercise price (in dollars per share) Equity Securities [Member] Exercisable, weighted average contractual life (Year) Exercisable, aggregate intrinsic value us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount Business Acquisition, Goodwill, Expected Tax Deductible Amount us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Exercisable, shares (in shares) us-gaap_LinesOfCreditCurrent Line of Credit, Current Outstanding, weighted average contractual life (Year) Outstanding, aggregate intrinsic value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Forfeited, weighted average exercise price (in dollars per share) Contract liabilities Schedule of Goodwill [Table Text Block] Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Accrued expenses Salaries, wages and related accruals Income taxes payable Lessee, Operating Leases [Text Block] Trade accounts payable Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) Outstanding, shares (in shares) Outstanding, shares (in shares) Retirement Plan Type [Axis] Retirement Plan Type [Domain] Credit Facility [Axis] Credit Facility [Domain] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] us-gaap_PolicyTextBlockAbstract Accounting Policies Trade Names [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost Share-based Payment Arrangement, Accelerated Cost us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Additions to property and equipment Dilutive effect of stock options and restricted stock units (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Income taxes paid Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] Weighted average common shares outstanding: Developed Technology Rights [Member] us-gaap_Assets Total assets Patents [Member] Plan Name [Axis] Plan Name [Domain] us-gaap_OperatingLeaseExpense Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Income available to common shareholders Customer Relationships [Member] us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Income available to common shareholders us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic Income allocated to participating securities Income allocated to participating securities Finite-Lived Intangible Assets by Major Class [Axis] Trevigen Inc. [Member] Information pertaining to Trevigen Inc. Share-based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Costs recognized on sale of acquired inventory Costs recognized upon sale of acquired inventory The noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting. Award Type [Domain] Business Description and Accounting Policies [Text Block] Award Type [Axis] Net earnings1 Net earnings Net earnings Net income us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated amortization us-gaap_FiniteLivedIntangibleAssetsNet Total Total intangible assets Intangible assets, net Intangibles assets, net Beginning balance Ending balance Restricted Stock Units (RSUs) [Member] us-gaap_FiniteLivedIntangibleAssetsGross Intangible assets Restricted Stock [Member] us-gaap_GoodwillForeignCurrencyTranslationGainLoss Currency translation us-gaap_GoodwillPurchaseAccountingAdjustments Goodwill, Purchase Accounting Adjustments us-gaap_GoodwillAcquiredDuringPeriod Acquisitions (Note 4) Business Combination Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization Property and equipment, net Property and equipment, net Goodwill Goodwill Balance Balance Property and equipment, cost Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] us-gaap_DerivativeFairValueOfDerivativeLiability Derivative instruments - cash flow hedges us-gaap_Investments Investments, Total Embedded Derivative Financial Instruments [Member] Derivative Instrument [Axis] Other operating activity Derivative Contract [Domain] Cash flows from investing activities: Earnings per share: Earnings Per Share [Text Block] Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding Represents the value of undesignated capital stock as of the balance sheet date. Surrender and retirement of stock to exercise option Surrender and Retirement of Stock to Exercise Options, Value Represents the value of stocks surrendered and retired to exercise options. Income taxes payable us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Trade accounts payable and accrued expenses tech_LineOfCreditFacilityAdditionalBorrowingCapacity Line of Credit Facility, Additional Borrowing Capacity The element representing the additional borrowing capacity under a line of credit. Surrender and retirement of stock to exercise option (in shares) Represents the shares of stock surrendered and retired to exercise options during the period. Intersegment Eliminations [Member] Salaries, wages and related accruals us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Income taxes (benefit) Total income tax provision Contingent Consideration, Policy [Policy Text Block] Disclosure of accounting policy for contingent consideration. CCXI [Member] Related to the CCXI investment. CHINA B-MoGen [Member] Represents information pertaining to B-MoGen Biotechnologies. Building, Building Improvements and Leasehold Improvements [Member] Information pertaining to building, building improvements and leasehold improvements. Unrealized gains (losses) on available-for-sale investments, tax us-gaap_OperatingExpenses Total operating expenses tech_BusinessCombinationStepAcquisitionEquityInterestInAcquireeBeforeRemeasurementToFairValue Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value Represents the amount of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages, before remeasurement to fair value. us-gaap_DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost tech_StockRepurchasedDuringPeriodAverageSharePrice Stock Repurchased During Period, Average Share Price (in dollars per share) Total cost of shares repurchased divided by the total number of shares repurchased. GB Profit Sharing and Savings Plan [Member] Represents the GB Profit Sharing and Savings Plan US Profit Sharing and Savings Plan [Member] Represents the US Profit Sharing and Savings Plan. tech_EffectiveIncomeTaxRateReconciliationGILTIAndFDIIPercent State apportionment changes Percentage of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Global Intangible Low-Taxed Income (GILTI) and Foreign-Derived Intangible Income (FDII). Cash and cash equivalents Royalty [Member] UNITED KINGDOM ChemoCentryx, Inc (CCXI) [Member] Represents ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer primarily focused on orphan and rare diseases. us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense Stock-based compensation us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Change in fair value of contingent consideration Amendment Flag tech_IncomeTaxExpenseBenefitDiscreteTaxItemsStateApportionments Income Tax Expense (Benefit) Discrete Tax Items State Apportionments Represents income tax expense (benefit) for discrete tax items relating to certain state appointments. us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Common stock, shares outstanding (in shares) Balances (in shares) Balances (in shares) Fair value adjustment on available for sale investments The amount of fair value adjustment made on available for sale securities during the period. Current Fiscal Year End Date us-gaap_VariableLeaseCost Variable Lease, Cost Weighted average discount rate: Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] United States and Canada [Member] Geographical location of the United States and Canada. Document Period End Date Right of use assets obtained in exchange for lease liabilities Rest of World [Member] Rest of the geographical locations in the world. us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expenses Weighted average remaining lease term (in years): (Year) Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Entity Small Business Entity Shell Company us-gaap_DividendsCommonStockCash Cash dividends Document Information [Line Items] Document Information [Table] Service [Member] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Fair value at the beginning of period Contingent consideration payable Entity Public Float us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Payments Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] us-gaap_RestructuringCharges Restructuring costs Entity Voluntary Filers us-gaap_BusinessCombinationAcquisitionRelatedCosts Acquisition related expenses Entity Well-known Seasoned Issuer Purchase price contingent consideration (Note 4) Equity Incentive Plan 2010 [Member] Information pertaining to the 2010 Equity Incentive Plan. us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use Nonqualified Stock Options Plan 1998 [Member] Information pertaining to the 1998 Nonqualified Stock Options Plan. us-gaap_GoodwillImpairmentLoss Goodwill, Impairment Loss Employee Stock Purchase Plan 2014 [Member] Information pertaining to the 2014 Employee Stock Purchase Plan. Performance Incentive Programs [Member] Information pertaining to the Performance Incentive Programs. Stock-based compensation expense Quarterly Financial Information [Text Block] us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Trade accounts and other receivables Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Liability Class [Axis] Employee stock purchase plan expense Fair Value by Liability Class [Domain] Entity [Domain] Legal Entity [Axis] Customer Concentration Risk [Member] Entity Address, Address Line One Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets, Total Amortization expense Gain on escrow settlement Gain (Loss) on Escrow Settlement Gain on escrow settlement The amount of gain (loss) during the period on escrow settlement. tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill Total assets acquired Amount of assets acquired, including goodwill, at the acquisition date. Entity Address, City or Town Leases, net The amount of noncash portion of lease expense during the period. Entity Address, Postal Zip Code Entity Address, State or Province Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares (in shares) Share repurchases (in shares) Entity Common Stock, Shares Outstanding Revenue, Segment Benchmark [Member] us-gaap_StockRepurchasedDuringPeriodValue Share repurchases us-gaap_AdvertisingExpense Advertising Expense tech_DerivativeNotionalAmountDedesignated Derivative Notional Amount, Dedesignated The amount of dedesignated derivative notional amount. tech_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainOnEscrowSettelement Gain on escrow settlement Amount of gain on escrow settlement of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Undesignated capital stock, shares authorized (in shares) Represents the shares authorized for undesignated capital stock. Undesignated capital stock, no par (in dollars per share) Represents the no par value for undesignated capital stock. Undesignated capital stock, shares outstanding (in shares) Represents the shares outstanding for undesignated capital stock. Undesignated capital stock, shares issued (in shares) Represents the shares issued for undesignated capital stock. tech_DerivativeNotionalAmountDecreaseInPeriod Derivative Notional Amount, Decrease in Period The amount of decrease during the period in the notional amount of the derivative. Investments [Domain] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Investment Type [Axis] Common stock issued to employee stock purchase plan (in shares) Local Phone Number Common stock issued for exercise of options (in shares) Exercised, shares (in shares) us-gaap_TableTextBlock Notes Tables Common stock issued to employee stock purchase plan Common stock issued for restricted stock awards (in shares) us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Operating Loss Carryforwards [Member] Information for deferred tax assets related to operating loss carryforwards. Common stock issued for exercise of options Tax Credit Carryforwards [Member] Information for deferred assets related to tax credit carryforwards. Common stock issued for restricted stock awards us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage us-gaap_GainOnSaleOfInvestments (Gain) Loss on investment, net Selling, general and administrative Corporate general, selling and administrative expenses Granted, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) Raw materials us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and shareholders’ equity UNITED STATES Retained earnings Retained Earnings (Accumulated Deficit), Ending Balance Accumulated other comprehensive loss Research and development Debt Disclosure [Text Block] us-gaap_InterestExpense Interest Expense, Total Interest expense Change in operating assets and liabilities, net of acquisitions: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Operating lease liabilities Noncurrent operating lease liabilities Schedule of Inventory, Current [Table Text Block] Total lease obligations us-gaap_OperatingLeaseLiability Operating Lease, Liability, Total Total operating lease liabilities Deferred income taxes us-gaap_DeferredIncomeTaxesAndTaxCredits Operating lease liabilities - current Current operating lease liabilities Thereafter us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive Subsequent Events [Text Block] Long-term deposits Right of use asset Operating Lease, Right-of-Use Asset 2020 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo 2023 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total 2024 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour Less: Amounts representing interest us-gaap_DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit), Total Total deferred tax provision 2025 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive 2023 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2024 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2025 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive 2021 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths Thereafter us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive 2021 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths us-gaap_OfficersCompensation Salary and Wage, Officer, Excluding Cost of Good and Service Sold 2022 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Contingent Consideration [Member] Liabilities that are contingent on agreed-upon conditions that arise from business combinations. Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Asset, Expected Amortization, Year One us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities Excess Tax Benefit from Share-based Compensation, Operating Activities Foreign Currency Transactions and Translations Policy [Policy Text Block] Other assets Other Assets, Noncurrent, Total Other long-term assets Lessee, Operating Lease, Liability, Maturity [Table Text Block] Stock-based compensation expense us-gaap_ShareBasedCompensation us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss Currency translation Operating expenses: Comprehensive Income, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Total Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) Research and Development Expense, Policy [Policy Text Block] Acquisitions (Note 4) tech_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustements Amount of increase (decrease) from new acquisitions and adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Depreciation and amortization us-gaap_LiabilitiesFairValueDisclosure Total Liabilities tech_DeferredTaxAssetsLeaseLiabilities Lease liability Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from lease liabilities. us-gaap_AssetsCurrent Total current assets Investments, Fair Value Disclosure us-gaap_InvestmentsFairValueDisclosure Investments, Fair Value Disclosure, Total Contingent consideration payments Advertising Cost [Policy Text Block] Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 38,453,046 and 37,934,040 shares, respectively Fair value adjustment to contingent consideration payable Adjustments to reconcile net earnings to net cash provided by operating activities: Common stock, shares authorized (in shares) Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Common stock, shares issued (in shares) Certificates of Deposit [Member] Common stock, par value (in dollars per share) us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Asia [Member] Deferred Tax Asset [Domain] us-gaap_DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance, Total Valuation allowance Statistical Measurement [Domain] Cash amounts paid on operating lease liabilities(1) Maximum [Member] Minimum [Member] Valuation Allowance by Deferred Tax Asset [Axis] Product and Service [Axis] Other current assets us-gaap_DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance, Total Deferred tax assets Product and Service [Domain] Statistical Measurement [Axis] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] us-gaap_NumberOfReportingUnits Number of Reporting Units Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Interest paid Other us-gaap_NoncurrentAssets Total long-lived assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Geographical [Axis] Property, Plant and Equipment [Table Text Block] Geographical [Domain] us-gaap_DeferredIncomeTaxLiabilities Deferred tax liabilities Europe [Member] Inventories Excess tax basis in equity investments Net sales us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Fair Value, Inputs, Level 3 [Member] Lessee, Operating Lease, Disclosure [Table Text Block] Fair Value Hierarchy and NAV [Domain] Derivative - cash flow hedge us-gaap_DeferredTaxAssetsInventory Inventory Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Cumulative Effect, Period of Adoption [Domain] Lessee, Operating Lease, Asset and Liabilities [Table Text Block] The tabular disclosure for asset and liabilities of operating leases of the lessee. Cumulative Effect, Period of Adoption [Axis] us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Cumulative Effect, Period of Adoption, Adjustment [Member] Lessee, Operating Lease, Cash Flow Information [Table Text Block] The tabular disclosure of cash flow information of operating leases of the lessee. Cash flows from operating activities: Schedule of Segment Reporting Information, by Segment [Table Text Block] Revenue [Policy Text Block] Statement [Line Items] Accounts receivable, allowance for doubtful accounts Accounts receivable, less allowance for doubtful accounts of $775 and $980, respectively us-gaap_NumberOfReportableSegments Number of Reportable Segments Deferred compensation Term Loan [Member] Represents information about term loan. AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Building and Building Improvements [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] AOCI Attributable to Parent [Member] Additional paid-in capital tech_UnrecognizedTaxBenefitsDecreaseResultingFromClosureOfTaxYears Closure of tax years Amount of decrease in unrecognized tax benefits resulting from closure of tax years. Land [Member] Acquisition-related liabilities (1) Non-cash change in the liability related to acquisition. Property, Plant and Equipment, Policy [Policy Text Block] Other non-operating income (expense), net Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total other income (expense), net Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] Tax reform Amount of increase in unrecognized tax benefits resulting from tax reform. Tax credit carryovers Net operating loss carryovers Exosome Diagnostics, Inc [Member] Represents information about Exosome Diagnostics, Inc. us-gaap_OtherAssetsMiscellaneousNoncurrent Other QT Holdings Corporation [Member] Represents information about QT Holdings Corporation. tech_IncomeTaxExpenseBenefitFederalTranslationTax Income Tax Expense (Benefit), Federal Translation Tax Represents the income tax expense (benefit) related to federal translation tax. Current assets: Interest income Schedule of Other Assets, Noncurrent [Table Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Inventory, Policy [Policy Text Block] tech_IncomeTaxExpenseBenefitStockOptionsExercises Income Tax Expense (Benefit), Stock Options Exercises Represents the income tax expense (benefit) related to stock options exercises. tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate Represents the forfeiture rate used under share-based compensation arrangement by share-based payment award. Effect of exchange rate changes on cash and cash equivalents us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities Accounting Standards Update 2016-01 [Member] Executive Officer [Member] Operating income Operating income us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities tech_InvestmentInUnconsolidatedEntity Investment in unconsolidated entity Represents the amount of investment in unconsolidated entity. Other income (expense): Other us-gaap_DeferredTaxLiabilitiesOther us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by (used in) investing activities us-gaap_DeferredTaxLiabilities Net deferred tax liabilities us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets Intangible asset amortization us-gaap_GrossProfit Gross margin Cost of sales Cost of sales Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent tech_EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment Contingent consideration adjustment Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to contingent consideration adjustments. Consolidation Items [Domain] Shareholders' equity: us-gaap_ContractWithCustomerLiability Contract with Customer, Liability, Total Right of use asset us-gaap_DeferredTaxLiabilitiesLeasingArrangements Consolidation Items [Axis] Accounting Standards Update 2016-02 [Member] Other financing activities us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome Net unrealized gain on available-for-sale investments Marketable Securities, Policy [Policy Text Block] Equity Method Investments [Policy Text Block] us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Contingent consideration payments Accounting Standards Update [Domain] us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Depreciation Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] Accounting Standards Update [Axis] tech_InventoryNetCurrentAndNonCurrent Inventories, net Amount of inventory, net of reserves, including both current and non-current portions. Finished goods(1) Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. Includes both current and non-current amounts. tech_IncomeTaxExpenseBenefitDiscreteTaxItemsAcquisitions Income Tax Expense (Benefit), Discrete Tax Items, Acquisitions Represents income tax expense (benefit) for discrete tax items relating to acquisitions. tech_InventoryFinishedGoodsNetOfReservesNonCurrent Inventory, Finished Goods, Net of Reserves, Non-current Non-current amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. us-gaap_PaymentsOfDividendsCommonStock Cash dividends us-gaap_UndistributedEarningsOfForeignSubsidiaries Undistributed Earnings of Foreign Subsidiaries us-gaap_PaymentsForRepurchaseOfCommonStock Re-purchases of common stock Scenario [Domain] us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability Forecast [Member] Retained Earnings [Member] Proceeds from stock option exercises Revenues, net Net sales Title of Individual [Domain] State Title of Individual [Axis] us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit State Scenario [Axis] us-gaap_CurrentForeignTaxExpenseBenefit Foreign us-gaap_DeferredRentCredit New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification us-gaap_DeferredForeignIncomeTaxExpenseBenefit Foreign Additional Paid-in Capital [Member] Federal Common Stock [Member] us-gaap_DeferredFederalIncomeTaxExpenseBenefit Federal Equity Components [Axis] Accounting Standards Update 2018-02 [Member] Equity Component [Domain] us-gaap_LongTermDebt Long-term Debt, Total us-gaap_CurrentIncomeTaxExpenseBenefit Total current tax provision Other Noncurrent Assets [Member] Atlanta Biologicals [Member] Represents information pertaining Atlanta Biologicals. Other Noncurrent Liabilities [Member] Foreign us-gaap_ReclassificationFromAociCurrentPeriodTax Reclassification from AOCI, Current Period, Tax, Total tech_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfContingentConsideration Effective Income Tax Rate Reconciliation, Nondeductible Expense, Revaluation of Contingent Consideration Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expense related to the revaluation of contingent consideration. us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before income taxes Domestic Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Comprehensive Income (Loss) Note [Text Block] Other comprehensive income (loss): Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] tech_IncomeTaxExpenseBenefitDiscreteTaxItems Income Tax Expense (Benefit), Discrete Tax Items Represents the income tax expense (benefit) related to discrete tax items. State and Local Jurisdiction [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Internal Revenue Service (IRS) [Member] Income Tax Authority [Axis] Income Tax Authority [Domain] Disaggregation of Revenue [Table Text Block] Domestic Tax Authority [Member] Foreign Tax Authority [Member] Equipment [Member] Revenue from Contract with Customer [Text Block] Document Annual Report Accounts Receivable [Policy Text Block] Machinery and Equipment [Member] Cash and Cash Equivalents, Policy [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Balance Ending balances Accounting Policies [Abstract] Document Transition Report Selling, General and Administrative Expenses [Member] Entity Interactive Data Current us-gaap_CommonStockDividendsPerShareDeclared Common Stock, Dividends, Per Share, Declared (in dollars per share) Additions due to acquisitions Security Exchange Name tech_FixedLeaseCost Fixed Lease, Cost Represents the amount of fixed lease cost. Additions for tax positions of current year Title of 12(b) Security Long-term debt obligations us-gaap_ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt, Total Cost of Sales [Member] Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] Represents information pertaining to trade names, customer relationships, non-compete agreements and patents. Borrowings under line-of-credit agreement Proceeds from Long-term Lines of Credit tech_FinitelivedIntangibleAssetsOtherAdditions Other additions Amount of other additions lacking physical substance with a definite life. Income Statement Location [Axis] Income Statement Location [Domain] tech_AmortizationOfAcquiredIntangibleAssets Amortization of acquired intangible assets Represents the amount of amortization of acquired intangible assets. tech_EffectiveIncomeTaxRateReconciliationOptionExercises Option exercises Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to option exercises. Segments [Axis] Segments [Domain] us-gaap_PaymentsToAcquireAvailableForSaleSecurities Purchase of available-for-sale investments us-gaap_TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount us-gaap_SharePrice Share Price (in dollars per share) us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) us-gaap_RepaymentsOfLinesOfCredit Payments on line-of-credit Diluted (in shares) Diluted (in shares) Eurocell Diagnostics, SAS [Member] Represents information pertaining Eurocell Diagnostics, SAS us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards, Total Asset Class [Axis] tech_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. Asset Class [Domain] Statement [Table] Statement of Financial Position [Abstract] Diluted (in dollars per share) Diluted (in dollars per share) us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter Thereafter Basic (in shares) Basic (in shares) us-gaap_OperatingLeasesFutureMinimumPaymentsDue Total us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments Other, net EMEA, excluding U.K. [Member] Regions of Europe, Middle East and Africa, excluding the United Kingdom. us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent, Total Effective tax rate APAC, excluding Greater China [Member] Represents the APAC, excluding Greater China. Instruments [Member] Represents the information pertaining to instruments which typically consist of longer-lived assets. us-gaap_AvailableForSaleSecurities Available-for-sale Securities, Total Business Acquisition [Axis] us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears 2023 Consumables [Member] Represents the information pertaining to consumables products. Basic (in dollars per share) Basic (in dollars per share) us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Domestic tax legislation changes Business Acquisition, Acquiree [Domain] us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears 2024 Product and Services [Member] Represents the product and services provided by the company. us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears 2021 Statement of Cash Flows [Abstract] Diagnostics and Genomics [Member] Consist of the ACD operating segment and the Diagnostics operating segment. us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears 2022 Protein Sciences [Member] Consist of the remaining portion of the Biotechnology segment and the Protein Platforms operating segment. Short-term available-for-sale investments us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent 2020 Other comprehensive income (loss) us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other comprehensive income (loss) us-gaap_BusinessCombinationContingentConsiderationLiability Contingent consideration Credit Agreement [Member] Represents the information pertaining to credit agreement. Quarterly Financial Information [Table Text Block] Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities Qualified production activity deduction Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_AvailableForSaleEquitySecuritiesAmortizedCostBasis Available-for-sale Equity Securities, Amortized Cost Basis, Total us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Executive compensation limitations Schedule of Intangible Assets and Goodwill [Table Text Block] us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Long-term contingent consideration payable Contingent consideration payable us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes State income taxes, net of federal benefit tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal Liabilities Amount of liabilities excluding deferred income taxes assumed at the acquisition date. us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Foreign tax rate differences tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets Equipment and other long-term assets Amount of equipment and other long-term assets acquired at the acquisition date. us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Research and development tax credit us-gaap_PaymentsForProceedsFromOtherInvestingActivities Other investing activities Cash flows from financing activities: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Other long-term liabilities us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Income tax expense at federal statutory rate us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized Business Combination, Liabilities Arising from Contingencies, Amount Recognized Corporate, Non-Segment [Member] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Net assets acquired us-gaap_StockholdersEquity Stockholders' Equity Attributable to Parent, Ending Balance Total shareholders' equity Balance Balance us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Payments to Acquire Businesses, Net of Cash Acquired, Total Acquisitions, net of cash acquired Class of Stock [Axis] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Deferred income taxes, net Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8. Operating Segments [Member] EX-101.PRE 22 tech-20200630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 23 graph02.jpg begin 644 graph02.jpg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

#?[=/!%>VKG_ !BT>ZB>6V\=5U1TF2.4*T4D M@5XI(Y-$@TE'=75O;WEC DGC6-T]U'!_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO M>_=>Z][]U[HF7RX^;W7OQ%J.JMLY7KSN+O'MOO#-;EPW4G1/Q_VWMG=/:V^4 MV1M^7=6^LWCJ/>N\^O=H8[;VS-OQBHKZO(9FC0&6*&$2U$T43I5NA)?7-C#! M)(]O8R7EPR@%;>UCEBA,\N=1!FFBB1(UDED=J)&P5B%0M@MB-PN;F*&U:[BM M8RY(\6ZG662*WCHK=[1P32$OIC1(V:1U %0C[*_FI?&_J7KGJ#LO?.UN^<+C M>XNE^TN]L=M:MZDRV/[+V9L_J.+:5+N?';]ZURU;CMZ8K==7NW?>(V_04-)1 MUYJLO71C6E)>K"^^@FM-UW':+>,W=Q;P6DBM!1XYFO[F&ULH(V;1IFN#*\H6 M<0K%#:W1N'A>'PV9VV"YW&QL]P%L\,4NY2V3"6BM$\%K?W<\K@%@\$46WRUD MMS,9&FMO 659U8!KC/YS/QM_T9][;SWSU1\G.I.Q_CWO+IGK[>?QC[&ZZVC3 M_(;,;R^1TE!!\?\ !;+P.U.R-V=?;AJ>W:G(I'C'_O+##3.LG\0>B$4A6[VL M[P[(^V1_77%_NMQML<4!!D6]LXEN+J&3Q#&B_3VS"Y>4.83#W)(Y[>F8I(FF MN_JY1;;=%LXW47,H802;>9)(1<1%5:1JW$36_@^&+@3%$:(:U).K\2OECUQ\ MQ^K*SM#KO#[XVC+MW?>]NJ^PNN.S\)C]N]E=7=H]]^Z]UPD021 MR1DD"1&0D?4!U*DC_$7]I;ZU6^LKRR9BJS1.A(X@.I6H^RO5D8HZ..((/[.M M)[8/\HK^8+\:Q+MCXT_&+!;/[7Z9F^>L-5\Q<;WEU?3I\T^K?D+A.P:?X^]1 M5^TYMZ8K>>*EZ\W-OG'97(Q;JH<5B,^)XDRWNWP7&]1D:U(MMM@O)82W^.D3+9) T8T]'.];I:_UV MW7F^.Q^NNGYI&^VK*1$]O#';SSS;42]"&O[LI;,J%K,Z_JIIHV0$79?-+X ; MIRW4G\L?KWXW]48'<-?\5OF)\#\UV!FJ2KV+MC-X;X\_&Z'<%'E=[PF+:)3S#-.PX+-N&SW MMG:UC6K,SR20VX8*WAH%UE(D)4'[1MYV[V@YKY1ED,N^R[%96T(8EFDG3==L MN[G]0]JEUMYIY&=E61UXM(R E(^0G\N3NK>_\PZ#M[IOX.;"ZC[#R/S)Z-^0 M&2_F@;5^0XKLU7]$[$P6W\7V5U/NWJS=>\JGLW'[MWOMW OMD[=V_A%V)5T5 M0E;45,51YE8EY"F&R[AM,UT/H]KM'WDWENH$B;DE]'=?3QJPU.Q-S/#=3&[, M8M'@(L]8$0Z,N_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO> M_=>Z][]U[KWOW7NJM?YQ?P\[ ^;WPAW-U%U9BL5N;L#;O9O3/F!QM50TE=*\4%-631/+)'$'D5"42UYFY$YB MFVTWMCM6[+//;!E5I[>2">UF1?$*QL0EP7\.1ECE"&-B _2Q0+O8^<=A&Y&R MGW3:9K:*Y"LW@3ZHYH)&"=^GQ845F0%T5BZJQ4*:X/AK_+[^4^V.YM@56>^. ML7Q5^',OSKW#\O-M?%*'LSJS>>/^.&(Z\^,4W6^R=K-1; WGN/:44_;/?NYZ MG>(QVUI]78O]PV_9M\6WG(;].3=;ZUAM M;$:@'<66SR;HA=P(4^J^GA=T1*A[=5N;X[ZUCMT4%KN<^P07,;D,SC;?JMPO M=R0J2I>XW"TV>WJY^HEC5II(A1RH^]E_RW>S>S?D;_-DP>#V9@.J.B/E_P#R M[>G/C'TQO?$U6SJ/;L&_L;C>^Z#=5*-C[;R3[FP6/VY5[\Q]1/+/BZ6GJUJ' M^V>9UD"@NZLKNX]MN>MA1E&]S'I)&MGNEM9\_>VW,4T;R[=9[3?0WK(:2>+=[D\SD%J%YGAD:82#4OB8=M M=1T&/\G+X(?);XR]YUN^MZ_&O'?#'J_$?#/J7X^]E]=XKMO8G9]'\I/E!L'< MK>\L+ J*[5$(;@7D99:PZKJ66#4MN\B/]*)Y&$LA'4?0[3U%A$L1"N%ME@GE7Q(T\ 7 MH/T@0-CKV$NA#U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6N%_-U_ MEP=E?(/Y:=??)[:7Q,POS?VG6?#SM[XJ9SI_(]G=?=9Y#K'L3/[II-\]/?(& MAJ^S-P[4P.1QVSLY+61U;T%9-G\;+]M5X^DGFC&@C@LKV!O<*TL)#:[KO-OM M[66XAV!VV[L7N%:1E2LP#Q7"O'+;QR2 Q2PL%CF:HB.XV4NVXWES= MPZF[YA':)M-JTC+ID-K52Z@'HG&P/@C\V,!_(XZG^ LW5M?@>V^PN]7V+\A= MNXSLCJZ.KV?\7^ROF'N?>W<>?3=5)O>7;&7CR71&4FCDH<575F5DCR)@CIFJ M%>):2-MNX\P^QB;DP;EW:MNV([CJ4L@FV?98F6U=-):9)-VM;>VBQN+QE+%18^@HZ>(+'!2 MT=) D<:* JHH X'LON[JXOKJYO;N4R74TC.[')9V)9F)]222>B:QLK;;;*TV M^SB"6D$2QHHX*B*%4?D !TY^T_2KKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][] MU[KWOW7NO>_=>Z][]U[KWOW7NM/&?^5+\U.D/E3V#O;X_?&7%5F_L=_,([B^ M<>R_G=C.Y^M,-D-Y_'OL7:FX]P9GX15VQLWO+#]@T>7WGO[*KC*B"KQ\&RV5 MQE)%[#^3O7G^R:C==:^4V!A M=P5-7M#Y ]3]O?(.MCWSN?,X;%/139C"Y?,5$$>1(R,\0\*5$[1*PUO[G9X/ M=WV^WC84\'DG:>8[ Z@"-&U;;;W%K9EDH))!!"R!(PC2+XCZ4%7Z!3INV[^V MONC;[S9Q)SEONQ;W(($IX:[GO+FYGAB>IC0/,_AF0NL;+&FN32JGHL'SS_EQ M?.'NC^8)O[NKK[IJFWAD=S]D?"GR\#\D M?C7EMQ8W*?(C==9E:W-56VL@VW]UST)KZ=:2JP[4^KV2^WLB['O6WW>Y.T!A MYCO+V\D),D=YMMQ8QV:VMI$M?I;XPJ]O+ M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HF?\ ,0^->>^8GP;^ M5'Q@VKF*#;^ZN[>E=[[$VOF,L\\>(HMRY7%2G /EY::&HJ8<3)EHH4J7CC>1 M(&8JK$ $@YDL;J^V^W-E'XEW;7UG=*FLQ^(;2ZAN?"$@^ R"(HK_ (68,2 . MCSEV]M;'=4DOG9;*6&>"1E74R)C[6V53GX?4OP[^+F\M[?!.G^1/1^/[RZEWW0[GW[\2\OO;NGL/Y4U%)LK?6 M@@2F,J2?8[M:)OLV[/* MIV]9MHEVZVL5T:HT>2\O#N.F$O:0FP#^*L\X5@%)MNX)R\-KBO&&]Q&_MP;@)-_CO@Q(R)7JV+-H_MK-'Y-]Z^7[VV5QNIV1+*!F*I+%96F[PS1AT#_3I$UU; MHM0I ?5"KA&TCJ]W#]3VCO+2Y=;_ &O>]VNKJ15#21+<6^TQVTOZA59G9K25 M54,Q'A 2:$9"2.?RKOY;ORCZ@^9FS/D!W9L/M;I;K#XW_$#U]M1T^*J-\4T>_Y-PQ6-_"AMZQ@ ME=FSV'>EG7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=4.?S?/@3O'Y*=Y?";Y)8+XOXGYP;*^.L/R V+VS\36S<+C<)NC$9'M;<6T>M\P^PMW[6HZNIQV4R5-Y87$].)*BGCC8J@MY+?=N; M)/I58;OR]]##/4 V%Y!=I=6UU_OP(5,T9D@5YX7,_F;_$/J*O[# MS?3E#\EODK\.TOC[\5]HUG<'7S46Z.T.S^ZM^=A=A[2R6^=[[XVZ(-I] M-[4Q'7N'J\CDY\=+FZ3 3+0/4L8S[$O,^YWC;3S0VQW33\S[I>[+:33NJJCV M^T[4D[W'<-VF^G)\5WBA:6-%DUDGVNRV>YWW9!=V#V'*UG/S#N$< M D++"=RNXS8[2F@24DM[2PCC%QI>W@&X/'&[+$ZJ NQ?@=\[.Q?A[NO/=G_$ M'L;;GSYPOS-^(GSO[7WCW%\@_C%N&?YG=@]+;ZIE74.D-1,JZR@2.WVOE'D#E*"]6YDVG;I8Y9D5U1YKJ_O=PD$8D57*1& M\$(9U4N8RP4*1U>^N)]XYOYJYFEM3!;W0L+>"-BI?P-NVVTL%ED*%EUSO!), M%!.B-XT;N5NK/_:'IWKWOW7NO__0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7__T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]+?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__U-_CW[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW0?]L=I;$Z.ZL[+[K[2SO]U^LNG^O]Y=I=B[E_AF8S?]W=B=?[_P!E8^2W^RN?.;_G)K_9?^Y/]ET_YQF^ M27_,]O\ 1UN/_1%_S,3X^_Z/_P#F8'\/_P"+[_N'_P"5W_)O)[]U[HG_ &)_ M/W^ O7]+U_N[J'^??\O^\=P8CY ?&'^^'5O:7PQZ7Q&Q-T=$U_R.ZKQGR9_C MN0V=_*ZL__ .@H[^11 M_P!YS?\ LLWS#_\ N???NO="!U/_ ,*//Y,?>/:?6G2G5OS)_O1V;W!V!LWJ MWKK;7^R\_*O"?WBWWV!N/&[3VC@OXSN+HW$;?Q'\7W!EZ>G^ZKJNEHZ?R:YI M8XU9Q[KW1:OYU&^NQJ+YR?RV.J<#D?YB6F^X=_ M9+9N&ZGJ]I9>MEH^W^F,%FL5LZIR%1-+][E/)!3SRB%&,C*R'8U%US3SK#<1 M7,L-MRY:S1!&_2AF;^9/?VT/@E\P=O9+M/Y M.8??/1O\ROXD=<[ ZH^5'8/8V$^;/2G0';?:'1>-P>&[W[*Z]WI@\YOBEWT, MEFZ[$U4&YMQ8W)XAQ2Y"KR$7W-(HPV14W7V6/O>(4N8(;?DU+^S2=JR%_" M1)[NUE5F=+9[E9(HS%,DT,DSBTT,>FU MEC473F2-YFTB,("X/3D?DY\*_P"8)N'N;X*]:_*W?V([HV-0TN:[3PGQX[ [ M3Z-[OZYH=L;HV_\ =-2]E[9HMOY' QS9>KI**K6@R!-92U+Q>N%Y/;0VV3=K M&;>K.21]LL+X1221N53QC]3$(I!@NI:& JD@WB/;9=MM[B*)+W= M-O6:&.9%=S!/!#<"5 =01Q#/$P<'4GB"A#TI4#_+IS[_ !8^('SL_F,]T?)3 MYU?(:L^)_<'S[Z_H.NNYOF+W-VKU_FNN>B.QLYA=CXH;)['W/GMJQ;U:@V_3 M4D><:#[J.2:1[V=U9NZWF7:O;/V\WF&UMI=XY@V3;GD,H55%Y=WS6\;I(03; MQZO#$N@T\+74'%%5KL\>[>YG.?+DE_);[1L^].B,I8Z;:/:[>YE\501X^D33 M2(K4JZQ9&@'J1MO_ (4//M':/=:^%_R+WUMSXF8/Y.]9T?PS[BJMQ[7P MNZ\_V+M+JN;XX=U5];G-^U>$W?M?=?8V"DEW!3BF@R=#)5R0XJG>G".=OL]Q M=37.R;-)XV\1\R;5M,=TRE;&Z&[SS017D(#-(J6S6\AG@,DC,C0.LJ>-I0NL M;R&:/9]ZW**2VV6YVS=+V:WP][9#:[%=P>&6NA)'NK<3")Q'$L4T$D3+(!K( MN?S-.Z?YG75'\M#YD;I[?GZAZ^WEMF'XZ9SI'O/X>=A]J=59:NJ]V]Z;"Q^[ M>O,QB<[G=P;UVI483&UL>-FS])F7I<_2U=03CJ)/\G="BPCFOVML;4,^Y-SQ MMMH\4I M;ZV>1.Z0*&,4,TA>*:TE6XH@#>)*#3I?L[I?[9S9>SA8MIDY*WF[ MUA=<]C<)MMT\>@U03RQ!5N(IXQ;E)%55H_>KAW?_ #5?F1\:-J_S-=K]F]?? M&_,]Q_##XM]*?*GJ;+;-I>S:KKS.;<[@S6Y=O#8/9&+S6[\=N7.Y_:F0VG.' MS&,KE]+_ #7>^OC[OSYD;9^876G3=;C>@_@!MK^85L-^A,AO&CJ) M-H9FNW'MNNZ8WID=_P!?7T^MG=WCV_8^ M=WMV$F^[+S)9;35R(K:X?W6-ET3AWDJOZBE:^&N]B67=]Q]L_'= M8-FYAV>]O2U"\MM^[?I6NM5"%D5X;H21*H4JRF)F<4E+Q_+@_FWUORR^1W^R MS;]["^&/:N[=U?&ZB^3&U=R?"[LZIW]@>OXJ?Y5--K>Q7?U(CGM&]JR2Q,\ITRP2AU$OAJ4G='*\IWKVW@0;PEP!;.:W-E+!'!,L=P0%603Q2 M2E76*+PY+:6(AZ"3K#NF?MOYZ?S-/E]\4LK\D?DA\9^B?A9T_P#'/*;=V]\: M]\Q].;Q[4[-[WHMS;PJNQ]S]@46*R.Z,SM#9=#MRGQE%AH9H:2$C1-+S*W:_6>U^K>B\=_>/ M)[D['V-U/O.*K[)[$Q='GL3A&IL5F-NC+U8GK911!7C*^*X;F3>Y;6SM+>TB MV_EV'<;UUU&.X)N+>R7Z.*I\$7<\IDJSS1VR L!*&2,%\MO;;!M%[N=W<7-Q M#<\PKMUC S+XT32PW-TR74^@!A:06DQ),,9.4N2["[B/,&\; EXCNK"&*Y?<-PM(T=0=3Q7"6T* !U M:VD6:9WF22*%!HZ2_F,?);Y/_,3?O6O3FW?CSMWXS[ ^+?Q!^6&1W7VC3[_H MNR*K:?R.VEO#[;VREVNWD63F#95OF!'BM R;D;6>)$309F,/;"H9:SJ7:3PV6 M/HINQ?YN/RN[/[8S?QUI-R?#C=.=[F^'WR6[RZ7[:^/^S_D?F^L.H-Z=.X?$ M24&W8$F'(ON;=QRW, M.Z;)L]M?&;P_IS-!<2^%.D-O(7F@FC4UMKIFFMY'.K0?#>("FT$%OS=R+;R1 MQ2[;NG,,^V^"7$K1O##--%)--'2,K(80L]KHCFC4LHD)H_0!?$[YI?)_8'67 M\C'L/Y)]JUG8^,[4^-?S=[O['R&S\YW1AT::O\ OI)LCEL=4T:U,B2XRCQLI=F&/-]Q8Z2O8ADV;V^@NO#3^R, MZ[GMT,7@)+XG@%K::..68LUP91,QG%O*\!#.PVVX\P\M[*T=THN=S]RX+"-V M&ETBGCWKQ5DDC*:HQ"2:WBG6P_H3^97\NK,WV_U?C>V\ON+(5FT^T8MY[4VW4I M75>$Q^ 7"ULD<1BJXPTQU=;%<;1S!S#R-N\Z-S98;-=7WB1 _2O)8_3_ %EI MH:L@,0G+17.O3/X3+X,6I2:R[I#=[#_6_:(V'+Z;Q!8M',?UV2YN9[6"[5D& MA=4L<6NU*LT:2%Q<.5* $N@_YM_S4WBWPT[/[3ZQ^,J=#?*+YZ=U? ^KQFPX M>SZ#MC&9S:&]>W,#L/M:AJL]NW-;2Q^$2#J^6BRV%EBKJFKF/W]/6TJ2C'Q) M.7K2/1;'<=27^__=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z] M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7 MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][ M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0/_(7I3:OR4Z" M[P^.F^LAN#$[)[^Z?[+Z4WCE-IU6.H=U8W:O:FR\UL7<.0VU79C%9W$4>X*/ M$9V:2BEJJ&LIHZE4:6"9 T;>Z]T4#/\ \O[?V_9]D4G;O\QGYO\ ;^R=E]P= M'=UR=;;LVK_+TVYM7=FZOCUW+L3OCKO'[ERW5/P)ZX[$BV_%V)UQBIZV+%9W M%U-531/!YU21[^Z]U8_[]U[KWOW7NJ\/F3_+HV?\Q>U^@^\7^1GRD^-?:WQQ MQ':&"Z^WI\9-V=6;7RLN*[>IMLT6\:3/'LWI[MFGJXYJ3:M/'#]NE)H6277K M)0HGM(7L=RW7<[6ZD26]L8[2901H>&*?ZE01IU5\;2Q.JG8M *&JJXN5N]GM M-FN;2)X+?<1>QN0WB).MO-;54ZM-/!GE4@J3W<>@6@_DO_&BHZM[9V#N_M/Y M,=E[V[Y[CZ&[N[E^1/8O86SMQ]\]A[G^-VZ-N;HZIPN6SG^C6DV+C-EX-]LQ M47\-QFWJ",44\XB:*9Q.IO87YVNYY+GVZUBABV/=Y=SAC4-HFO9XFAFFN26, MDAD1@#I>/3X:!-" J2F^M&W.UYIMMQNYISNNRMM3.Q&JWLF=I!%:@*(XRKLS M:F1R[$M+XC4(5O8G\H7XM=D]@]A[GRFXN\\)UEW3VAB.[>]_B]M;LP8CXV]V M]MX.KVY7T6^M_P"RC@:K MV*65S-%5);FT2)K<02MD4,!$#21JD[0JL1ET54VDHB1HD<:+''&JHB(H5$10 M%5%4 !5518 < >Z,2Y9F)+'B?,UZ8CCCAC2*) L2@ "@ H . P!T2/JG M^7[\?NK?C[WU\8IJ?=79'47R2[%[_P"Q^T<'V/E,575&1J_DEN++;D["VYCZ MS:N!VB:';,%5F9H<:NEZ^EA":ZJ:5?+[2W5I%> MF4W+A=E]5T%0U5A-O;'Q&T,1L;#TF=P%0L+TNZ,C3Y/> --%Y+!/&P'A0&.2CE+>**.5@IG24@'I)M@39KJPE MVQ!%M]K;RP16HJ;<0SQ+#-$ZL3),CQ*4 GEE\)7D6#PE:G0>9W^3-\>MZ]2] M[]8=F=V_+'M;,_(7%]2[8WIW%V)VCM//=IXG8O1^^:'?_6^PMFE.M:+K? ;> MQ&6H%BJ)CMR;*Y.!BU;65%2$J$407\EO>\O;A##&MW8/W^+F5WI0F9=9\-E*H,:HW\USNK^7)\=-_=P]F=P[^CWEO.;M_X=8CX.[] MZ^SF7PW^CS,]+XG<.=W&:C[+&[>1J=PSPSUL>76F$(3PTT,J^4TNU M%[:\Z6DM0N^;I:;A,RLR/#(XD1&5P 5:FW-)M;^W\ MEG*5DY;M+NWMB0K>)'>FT,WU (*R&EG&H"B-=+RAU?4NA_\ BY\(]N_%S,9# M-T7R!^5O=]2VT<3UYMBB^07=%1O?;VP=@8"JDJL+MC:VU,#@MG;7JJG'AEA_ MCV8H\MNJHIXUBJ,I,FH,82[E>=E'BRR#4 < 1PCO.I+:. M%)#I>57=58(8]OMH#81VBM#MUI&R06Z,1%$K+&I&299:")='CR2^#J=8?#1B MO22^27\N3J#Y$]K0]\XSLSY#_&SO.?8T'5VY^VOBUVH_5F[.P.LJ;*/EZ;8V M_P"&KP>Z-M[GQF/JJBH^PK)<>,QB152M05E+(5=2:&SBA&\0!W.V;@R-=6Q8 MB">2.,Q)*R@ATE$9\,RPO&[QA8Y&9!IZ.&NS(-L::WB>ZL?$^FE9:R0"4AG5 M6K1HBZK+X,JR0^(-?AU+51==_*5^)-#TST!U!U9!V7T%7?%K.[JW9T+W/T]O MJ3&=X;#WAO\ H.S%%E)V5YH&,<>@S MN[R[N-UAW>"QEBET959)!,JN\8*LJ^"QBT^'11DVW_ "HOC'M. MB^/,6#RW;<.8^/GRJS_S0_O?D=YXW<.\NZ/D!NS;&Z-J;IW=WCN'<>V7Q"PHFO;7]Y6.^6FX7$DUQN.X;?>3SMI\9Y-L>-K M5!I41)"JQ1Q>$D2J(EI'X;$L2393^4[N3Y$_.W^:-OSOO-]\=6_'3Y0X_P"* MNU=NMT]W3MG;.%^1/7FRNH:G;?:^P.PMK4$FZMPXG;T>>6.BFJ)*/;^9GIII MHZ*N-)/.'+.7+:VL>4_I-SC$UV.<+_<#:2_J6\D/A;>;&=P,5\>*=C$LB&3P MHQ=1/&L2]'&_;E>ST3F*.UY32S^IC 2>"Z?<=REN(T+#NK:S6Y$C1R M)&7)MWCG$A%E>T_Y?7Q^V=VM\A.T\7#NR1/DGT!U+\9]\==5&5Q4?7>'ZJZ: MV_O':VU\7LZBQV!Q^Z<36UF"WM54];-49:L5UCA,"4Y5B]MT4[WR_P WV,-FO.1[W:D6!^7 MK 6EFJBJB(7/U2EPVHLZR *""JZ!1E+5;HO'3O\ )W^/_3N^.B-\0=S_ "E[ M#E^./2W:GQRZMVUV;V-LS/[3P_1/:N(QF#JNM9,;B^L\!5?P_:.,PU+%BLG! M409^5((UR=?D5CC5%&ZW$N^)SO\ O=OJ+CF+:DL;^5L23K',LRSU72(Y]08' MPU6!A+(Y@,K"16H8HK23EMMOC%M%M&\G&:&5*.7+PR^,9&$A>1' M2-89(H0\3S^HOY0/QQZB'Q)I(.Q._NP,!\+,7WSM;I?:O9N[-A;CP"=??(#9 M5!U[N#K7=,5%UEALAF=E[1VKCUI\'%%4TM8A>1Z^IKVW6Y@NO&?05 N6:WCC+J%B$0*K"KT<4BA%K:Q65A(]O;1X) M\302-3T#TL3,I]%?7JKN,US=/<;Q=V'T,EY*=5TUG^B3!K "4=K>)I9?#^HF M*@332)116[M;>Z MXXA!M7UPO6MHNRW:[#3.)V7+=KSR,D(<6T;D/'"KC5UB MVG_*;^.FSNNOC7UEC-Z=U3X'XM?,;=OS=Z_JZ_<>Q9O=DE>;UC>2[?>\FWT*J9MCYZ][]U[KWOW7NO>_=>Z][]U[KWOW M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z] M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7 MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][ M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_];?X]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__7W^/?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=)_=F[-J["VKN7?6^MR[?V7LG9>W\SNS>.\=V9G';F.W9F-G;:S.X8M_-B,7N#=F( MV%G:K&44\R5-?386OE@1THZAH_=>Z]F?YFO\MO;F.VGF-P_S!OA!@L1OW;]3 MNS8N4S/ROZ&Q>.WIM6CW5N78M7N7:==7;^@IMQ[?I=[;+S&'DK:-IJ9,KB:R MD9Q44L\:>Z]T%_2G\U'XM=V?-?NGX/X/LKJFG[,ZWRE;MW8E'!W3UCFMV=M[ MKV)1Y9N]=JXCK/%;@GWUMK<'3>3Q$\551Y*DAJLC24==7TL;T-!45"^Z]T.& MW?YA/P%W?L3L7M+:?SA^(&Z.LNG_ .Z/^EKL7;OR6Z7S>Q.KO](&8GV[L/\ MTB[NQN]:G;^R?[[;@II*'$?Q.HI?XE61M#3^212H]U[I04OS=^%]=CNE,Q0_ M+OXP5F(^2FX,KM/XZ92E[]ZIJ,=W]NK!;JQ^Q[_ (T=;;+ROQRZ:H_D-7]C M4V3^5OS)FWU#\9>IZS8>&Q63Q.S]Q1["R>U:RNWOV++E'&+BK-P8.C2GH*J5 MII&01%#9W!O.8;K9WNK>WC@VX72B4E7O&^H2%K:V8E45XXR9I7;Q"B%"L,E2 M.E\ULMML WD6MQI?YF_>^_P#^6;\W?FK'M;JG M==7\=-F]R;D^/7K=];L?M+;^Q8=^+7X" MHB;<-0,@<7+/15_CD4I3G M6K+=P(P#QK(A;Q$*LZOD6VM>:N=8>7Y;C7L[B F6'#1R2P-+-9LS!T>>R<+% M/(H"&0LACBDC=%!CXG_S3?F#G/DS\&.D/D-G_@)WKA?G7UCNK?>.C^&![0V[ MVA\ M56D=KG8[*2Y%VA#6LHCO8K/P6&FL%M9M;18Y$Q)];N$E[:V:.3 MJ7PI+R*UB("AJ2N-8+*R"/F5)-KY&DYCVYE;=TFO&\.2I1[?;[,;C=! NEO& M^CBNF0ZBNI$JC4*L%^UOYQGR)WE_-%^:/Q/Q77W35-\5_CU\>_D-O/K/L8;? MWMENT=X]L_&_!]1G?]/F*P=DXC:%?LS%[O[$JL>:*FQU#62O1:?OXR&5[)WDCW&[MK:\8D#3+\OAAA_F)N_:_Q^Z1RF8P75G6==@A(_9G8&T7[-W7G= MK[-KMTWHJ3"XO-[MW%42)(E,M8L4E0#[W"MFY9OO"26UMY942%W:7PW8E88TCA4R3/"@U]%/*R?O=.5Y=R< [INES:P11T2>=+2 MZ6&X>)79D ACDB+/(ZJTC!(U:1TA+/\ ';^R9<9V#V+1Q[?V/A*ROIXHJ>ISU=F\ MC/Y(]VL+=IOW9MVW;?MRL+.*I62Y:QNIHJ('- R0K"T\DK M10B2515"ZH#)]T?S3^H>GMC[1[+H>@_F+VYU_GNEA\B-U;NZQZ!R,&&ZBZ=C MCFFR6Z.T)^T<]UE)CS;GN]ANT\=O M:6,L,S^K/DYWIN M"G^+W67S)@J.D>K<+NS%5WQ[[-JL[%!O>&HR^^-M55$=IT&#^\R='6PTE9-% M5018R/(U;24T;FX0MM$O.2;P?I8>7]T%CN$CU,=M(8%G$C&,.6B*L5'AAYB8 MY7$/@Q/*&-LE@WFWY.GVRX263?[.6>QC!I),8I!$8=+:=$K,:!G*P(2J2SQR M21(]A'7O>_4W:72&U/D?LO>N(R/2N\^N\?VM@M_5,CXO#/L+(X1=Q1;@KGR2 M4LN+IJ;$L9:A:E8GIM#+(%96 WS- _*$V[P[^5@-CJ,IJ&4!174I6H=66C(5 MKK!!6M1TWL4XYDCL'VF*222Y?0B%2LGB:S&8V4Y5UD!1E/!@1Y=42=/?SS-W M;YV9_-P[[W7T=0;?Z+^"6Q^M.R/CCA:M,OMOLKNO8O8FP-S[JVENO>]?D,SF ML9A<;VI-C<;78.*'%4-5C\1DHS51SSFRLFUW5.1]CW*6T6/GF_YKDV86DA*1 MVTLC;7':Q7."PN(FW&M[I;2I4PJJO&S,80):7?N#;\NVMV).5/ZO_O'ZN.DA MN!!-N$5W):T*JUN#82QVQ8'QM'U D,,T:J];J_F[_(KXN[4^6N"^775W1>XN MZNE/B1TM\N>IZ3H[,[RVKL;?.,[\WWE>J=M]5[GCWUDMX9K&9S97945#05V< MIJ@TN6I*K[J&AHC^P#&XL!+2@B"23I4&UW"7/]6]YW.,P7X7_ "V^0._OD5\C?A]\L-N=.47=?16PND.Y,9O#H==W MX[K_ 'CUMWK3[MAQ]"VVM]9KY=LN U*.Z6MM=PW,8&8X[B*X/Z#EWA>)E,LH(;I"+NZ MCN^7$N$C$&[[.=PA KKA"73V\MO*:Z96C_299T$:R:V_2CT@&SCV5]&G7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U__]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TG M]V;3VKOW:NY=B[ZVUM_>FR=Z;?S.T]X[.W9AL=N/:N[-J[CQU3A]P[:W+M[, M4U9B,[M_.XBLFI:VBJH9::JII7BE1D9E/NO=% IOY97\MNCVKF=BTG\OGX04 MNR=Q[@VUNS<.SJ;XH=#0;5SNZMEX[=F'V=N7,[>BV"N(RFX-IXC?N=I<96SP MO4T%-FJ^*!T2LJ%D]U[I ]W_ ,K;X/;]Z@R^SMB?!WX XK?NV.JMX; ^/^;[ M#^&W2.^-D]05V;R&\MWX,4.SQM&@>/9.-[0WSDMQ5F%Q]100UV1R-=,62HK) MYV]U[HH4?\GO9E)4]0U^W?C/_+DV9NO8&[<%-OCMJDZ%J=T=K=T=;Y_;V8ZP M^1>QNY=T9C%T&8[B/R)Z3WQN?"Y^;<]=DHJW)9@9.MBK)X C^Z]T?NF_EE?R MVZ/:N9V+2?R^?A!2[)W'N#;6[-P[.IOBAT-!M7.[JV7CMV8?9VYA^(GQ@H\1\ M:]P97=GQTQ=+T%U33X[H'=6=W5C]]9S_>@,_MW;N%WCMOM?XH?+/:V3 MR?Q^[QH=Q1X^3;^?R&[MH;:W9O;9&[MD5E'+]O)'C,OCZNGJW2:DU(C^T20N M+^_-Y:P7>TW-LD826H>UE274;B"@*R&2,F*6*4 %57PY(BSL5IEA;;X(X9Y[ M7=(;KQ1+%0K-$8V1K:=258)JTR1R1L"D@)=)5HHK(VY_)1[AVI\9\?M#$;R^ M-D'8=#_,(B^?TOQEQ.SMX[:^ M0]'AHL#C?CG1[2IXLKN;$]>8]Z6#.0Y(XF MJ6/4[F;EO&C91/X+67U!BM% M(E*P^(ID!DJI?*IW,^X#7I6Q??#MHK:+J*KM[V[N)]1A^H.X>"RWS P^(IC% M"$(<+>K_ .2+\R-A[:^?U#%W%\:ML[0^:WQ:^0'4NQ?BKLFJ[_;HGXG]@=JO MD%KS_0$^KD>VC#@IX8C:5@QED=FO ^$GP9Z ^& M?4?6^W.N_C_\=NK^TL;U;L3:7:N^.E.J=E;)J]^[KP6V<-C=S9G*;FP>T=K[ MBW3%F,YCWJ?N,DBU-02LDJ+(2 +N9-WM]QWK?YMF22WY>N+Z::&WH(TCC:1F MB7PD8Q*40A:+55X*:= #EC:+S;=AY?MM\E2YY@MK.**:XJTC/(J!9&$LBB1@ MS:C5@&:I+"I/1.OYD_\ +*WU\[N[MD;LHMR; PW6N*^%?S8^-VXX,_D]QTV[ MX=]?(O#; I^MMS8"@QFUSVJLA--7TU5 5B-/!4$L$!20[E9_U\ MOMKN5BWN\L-H&WR9I#?;5N_[S228T)6.JH%9!*Q;4#&%R1U#>V?C>WR7EN9= MNV_?;JYO4_W[97>UW&W3119S*PG;#E$"YUU&DDT^(W\E7Y+_ !_/469WOVAT MYO3>]#\!/FWT7WKNRGW)ONJR&]OE!\N.X,;VC+OG&2UG6F,.2Z_I%IGIJROJ MEHLFACB$6.D4G0<MQ=)=G?&[_23%_+(VYBKIY8C"Z[ MGR\BYLN_>&QM2\?+O-%Q!=*S!1<07$%E)8NA4%XS'2+6"B-XWB-"S1@),&SX M_P#\JWYO_#[9_P ,M_?'OL?XS9CY)=(_!W,?!WN'"=G97L\=/9; 5_94/96V M^T^NMS8/K^KW--N+8N::H=L17[?H*7/1S+!-540B68WWG=)K[<>=%VV4V^V[ M[9;,KRE \]I=[18RVBS0Q,?"N(Y!/(OARR1A=*2G42\/35C86<%ELL=^C7%S MM/,&]WMN*Z%N;7>+H3/;W#+1H)-$-LYDB6;0XEC2J%9.I7S _E3?-WY2C,8K MLKO?H/Y*8O?/PA@^/^8E[VH>R]C;.ZI^1B'BR.WEQ-++35%5IDIY SOVWVFX+SQ!M=D(%O+NUGL9GD:2XMX[:) M(VL]3*RVZW$@>X>[@!D225D,$R+'H.]BW&XVZ3D>YW"7QVL)+KZR#0JP70N) MEDBEDT%&N/I8E^F^EE"Q7$>IO%MGDD)*CU5T/\WNLOY@>\OCMT-GOC+#W%L' M^2#\*NB>Q)>SZKLO)];#*XS>'9VQJK?&Q]S[[_7W3:]@W9T"&D,XAW2U(CS^P,U#@Z MS&Y?YMG;PWC1UFVNOH<"F_>ZMK;5Z,Z@VQ4Y_K//8ZGI-HQ8'(1TG M]WY:F.MB-4T4L9<+N^CY2>QA6 H)65WA5X);*X@=JN'-Q=S6Q3<"5 M=#%%;WC!S"U^DL^:>5MRA64[#9\O-MLL8*I+IE?<$DMX2%*"SBM[M9;<- M247;3&35$(P%ONK^41\BOE%M3Y;9WY==H]&;=[K[L^)/2WQ'ZGK.CL/O'=.Q M=BXOH/?>6[6VWVIN=]]8S9^:RF=WKV7+0U]=@Z: 4N)I*7[6&NK3:H]K[B_% MM--OFQP!.8YNED.UVZ6W] M6]FW.0S\L[;RSN6S54".>=-WB2"]N&6K)$ZQ10+%$LCJ6C9RZ:]*GE^%_P 2 MOD!L'Y$_(SY@_*_Y=SN"U* M([VMM:0VT9&9([>*W/Z[A'F>5F,40 7I"+2ZDN^7'N7C-OM.S_N^$BNN8-=2 M7$MQ**:8C)^BJP(76+0WZTNH$6;^ROHTZ][]U[KWOW7NO>_=>Z][]U[KWOW7 MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][ M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][] MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO M_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M?__2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3-N/<> V?M[/; MMW5F<;MS:^UL-E-Q[DW#FJR#'8?!8#"4,^3S&9RV0JGBI:#&XO'4LD\\TC+' M%$C,Q !/OW7NBB8/YQ;%KLWU_%NKJ7Y!=6=?]O;@VWM3J3NCLSKJCP/6V^-R M[S@FFV;A*^&AW+F.Q>HJO=\R146*;L#;^T8_=>ZK?\ F]\_,O\ %KLSX^?'WJSI.E[W^0_R93L6OZVVENON+:OQ\ZVI M\)U9CL/D-UUVZ.V-UX7=0I,G(VX*.#'8O&X;*Y"NED9A$D4;R!BQ>YW/>;_: M+&W#M9V"7EP2X#"%[A;=1!'0M/*7+$I6-$5=4DJ!@>E-S';6&S0;U?W#)!/? MK90A4+:IV@EN/U&JJ0QB.%JNQJS$)&DC]O23W?\ S+\EU=\#NZ/F=W/\1/D# MU#N7H;<6:V;OWH7>N,AH,PV2'V]N+P0#DP[==1R#?+BVAB\<_2_2R7,[6^G< P=K3PY$-:J^M&A M>/6LR'JFVVUS=WO,ME=0E9-KMI[AC!_C*W4<-G]8/H670+F21/TA%V.DZO%* M$9&Z2?7O\U>FWO\ "KYL_*YNF,3-G?A%C^SUW5MC8GS MZNDZ?^1F+V'CJ3=.W9$RJ8BNR+;9AGQ>6IZF"2C=H;/3F>44&D\?DAU!57*UC_67F^+E0SK$9(K:595I* M!%=P&XA#K5-%PL>DS0:CX>M"LDBN"4'\>_YK?>FZNZ?B!U+\L/@W1_&S&_/' M9V?W3\:.PNO?E!MSY&X+,5>V^NZ?M*OV[V#A1U5T_N?8E?/L^I26">.ER=*\ MY\3R1FY C_<93?N<>4Y[G1S+LMI+E3MNAJ*3875VW9I8MU=J;ZDH*VOQ6S< U/C MLS44BO28^HKBZ M+&;4J,O24V^,QLZM.^NP*_+[F?'X'&C%XFGRTU%*\]5CTY JYKM8.4^8/Y# MW.%8X-XYDN7@L[=W)35"D3W#S3A*QQ1_40('6%RTLR*51:R!E[*_G-8-,)LS M7:5DI+>K+)$T$("F: M*."-;BX8O&T<,B%$D\2SM9"$&NP>"&Y$\XU+"/ MJ+F.VA(602S:JZ(U:0&X^4?STVOT)_+KW[_,/V)LN;M[9VV^B,'WUM+94^Y! ML.HWGM[<(-RY0W@;!+8 MBXW<;S;[:45Z RSW:6FI6*G4 SZE!"ZP *K6HUR9+::K#>;6PN!>:*+%'N,ME!;UAU'6[2W;QZ?%3NMY!49T%D M6X2-R5SES7+8R)>;3=7,"VW$S/;VM[?U\6@\-'L+)KK5X:7ZD?HI"ZJH4I-*3(L)FJ3RW^QV,40K=\NQ[NQ9E00PM<7<#EF/Z8AC M%JS&>22)M6M6@1%CEF:?B1_,RZL^9ORH^2GQZZ@P@R6TOCUUET-OYNSZC)[B MPV;SN5[J7>\E7LC<_3^\-A;2WAU?N#94.T8I)H,I,];4)7HSTM,H4RF=IMES M-R]NN_W&F-;??9-N15994E6*TMKAIUF1BF))WMFC75HD@<-)KU1HGN[NWAO> M7;.!S)]?MDMVQ96C:+P[D0+&4<:F$L;)<))V@QR(55E8.97R*^>V\MB?(VC^ M'_Q>^,^?^6'R-H^JZ;O#L' CL[:/2O7'576.3S]5MG;5?O/LG==!N!VW3O;, M8VLBP^(Q^*K9IEI9):F2DI[3$ELY+KL=[9S MN#)=E[5GRRY+ ]9[*ZTV]O+<7=V)R-!A*G(8O*[3HLI1Y+&1M41D*D@1=>&Q MA?8ULK[ZD;A8BZB58Y!-'$ /%^I@*F2U,!($QF"I&&C&PY\3CMGU6;VUOK$G$3THPN6I MJ#)U.3"4$$$M=+%3OZXAEMKQ-O="UX^V'<(UC_5\:S$D$1G@,6M;A=5Q%VPF M1]!>0+X<,S)Z)UEMKR[KH@MKZ.SF,GZ1AN94DD2.99-#15CC=RT@5% 4NRZT MU&8Z"^1'3'RBZYH>V.A]^8[L'8E=DLO@VR='19C#9'$;AV]6R8W<&V-T;8W+ MCL+NK9^Z\#7Q-#78O*T5'D*20:984)'MVZLKBS6U>95,,\*RQ.C+)'+&U0LD MY?]'?\ HX_T(?+#OWXO_9?WN_O?_>?_ $';J7;/ M]^/N?[L;7_@O]Z-7G_AGCJ_LOT?=U'Z_;%FGU7*O(_,U=/[YVTW?A\?!I=7- MMX>O'B?[CZ]>A/CTZ>W4S]^?H>:^<.6/B_=-Q;1>+P\7ZC;[._U:,Z-'U?A4 MUOJ\/75=>A:R_D1_/SV%T'M;<+1=#Y?LCL]_GAV9\'NOMC[*RG=.9VWFYE M'@[,NV@#'B33;E;6EQ$C)J*PHHNEI())C(HC1(S>RK9+9E2?S#/B3%W1@OC7 MN/N;:F#^0&3J]O;;R>QH8-V9/;N"[(W%@*+<5!U37=J?W4H>N:7LJOQM:L]! MMZMR%#N'(4I$T6/TFP6P6Z;C=[C!L\AN889+A4:@0S"V+^.T"EB)_IU1FN1; MM,+;2WC,M*]$[W3V>V[5N&[P_3&YMH)B.YA$MPRI"93H4PI-(PC@>=(?';^S M!-0&KY[_ #AQ7P@V+U9EX^NZKM3L/O?N7;'0O4&R9-[;:ZNVOE.P-U8[-9FD MEWSVGO 2[>Z_VI18G;U5+/6R4];4.ZI#3TL\TBH2N.2ZO-\VOEW;8$?<[J"Z MF7Q)/#016<7C3'5I=FD(*K'%&CO(S8 56(-C%;V^S;SO]_.T>V67TX?0ADYZ7>GQ]W'M;.[>@W!0[XZ7^1-#@-L;6[6VQ#Y6HZP04-'DJ#(!*:II(II M8T8PO#M\&V6.Z17CGQKV2T^GDB:.[%PDD<:*+=3(\J7)EC^EDA,BSMKC3]2- MU".WCOI]U;:EM5>MFMTDT3B2 PGQ?$$DM%6":W$+O<12Z3'$4FU-$X?H-NR? MYN7Q@QW0F[.\.C]U[?[:?8/^\QBX,WANM\IV-#@9.L\1V?FL-51U=%MFJS$.?K*9Q)#2.G/M+MBMO M/C';1XNCQ:?A\3Z<,;CP-5/J/I@CFY\#Q/I])\;10]*]R;]SQV\NY Q1R)&] M2"0B32"*%Y=-? 2>0A(&F\-9FQ$7Z#B+^:S_ "_I.S8NGV^1>%INP'[US/QG MGQ60V7V=C<9B^]L)DY,+)UQG]UY#9--M#;F:S.5A>GPTE?7TU)GY488R6KTF MU=D!YC7;'V4&=;RVGG@IV^*ELTBSA ^DM-%X3N]N/UQ"!/X?@.DC6W96V-]S M3=4,367TYGP6\)+J"&X@F?1JI;O'/$/J/[!)6-N\BSH\:K/>'\QGX4[![WIO MC7N[OW;.&[>FW+M_9%3AY<1N^IVO@M^[MAQU1M+KS=O9]%MRIZMV7V+NRGRU M-)BMOY?-469R4FV)N[XMQ5.R_P"[ QVYUPDV_J/#-N*MZUH^Q9,$O6E=VC0X M!&K9]L0YB3/PTJM(](J D4VM6WJ"XN-L4RPQQR25 IKCA*"0%)Y M(?$2%L2LF.M;A_NK,:W_ .F6,0/GX9N-/TXGTU^G-QK3Z<3^&9]:^%KU#INV MY_,3^&F[>YZ+H' =V8ZM[(RV[MP]>[>$FT>PJ'8.[>Q-HMFTW9UULCN/([1I M.GM[]A[7DVW7KD<%B,]6Y:A:DE$U.A4CW?;(9=XM_J=NC,D9MCV)M[R9&*M>6205&/%/XU4++K)0M6YG.\;?MDEL%BO;RR MM+>3777ROOTQ:]72==R85>RE[4?(R+ NV/X1_'FE8**0DCV MEO UBVU)(ID:_4M;>"/J/J%4.7:#P/$\94$4GB-'J">&^LKI:BFT(O3N:QG0 M;( W/B_H?3A@A0S^-X?@AQ+&4,FD/XB::ZEJ ?<7\UOHK;'1?6G?'0@QOR'V M_OGY==#_ !(W'AH\YGNJMR]9[J[HWW@]G5U1OC:V[]AU6]ML[HV32YZ&OEV[ ME\3BJVJC=%:6F619?9AM^V7%YS1R/R\^E;3?&O!%*1@\MND:L) KQ!TN!(DAC M8,%H :DJ/"?S$?AL_==-\?1W50#LFNWW4]54&O:'8IL=W1) MM%>FE#"WLNVG_=X@?:_U0T4LL?X3-% 9!/+;A]) MN8H3%)XLD D2,(Q=@!7I3N0.T"0[B/#$9B$GXO ,X@, N-&KZ8SBY@,(G\/Q M?%7P]5>A/^1WRKZ#^)>TL-O3OS?HV9B=S9^/:FT\?CML;RW[O+>FZ),=7Y== MN;&Z[ZYV]NWL#>V=&*Q=35-28K&5DZ4\$DC*$4D)VNH5NH+&K-=R([A%5G/A MQZ?$E;2#HBCU+XDKZ8TU+K85'3Z6TSVUU> *MI#H#NS*BAI&T1IJ8@%Y&[8X MQ5W;"*3T U=_-)^!&.V#TUV=4?(G 2;(^0.Y][['ZDS%!M3L7*2[IWUUSCLI MDMY[$FP^,V?69W;6^<.N'J*;^#9:FH3= M;[6SU/MC?]3NS/=EQY*KQ$_66-ZFI]I2]NU/9=+DZ">";;RX+^,P20N)*9=) MMNZ@DM+S9;"0!KG<8O%MO#(E6:'27:='B+H8$56:6?5X42JQD= IIZ"19X=] MG4E8]L\)-T4G9]/B]A[)WE/N\XV?:NV:K9%9!6;NEQM3AIVK MJBCJ:%Q+,LA>&)3'83GE7ECF2X 1]R:]I$"'54M+V:TCD293IF2YCB6XC95" MZ)%"M(M)&K=S102%HF&I'MW1HGU'46!U)&05Z M*CN+^;EV37=K_(K!]#_!#LKY&=-_$KMZ?I/O?=777:NSZGY$Q;LQ9VR=RY;J M?X@4F!R_8/:&SMO0[D\AJOXGBJW(1TTK8^CJU!8(N7A^^;+ES=[RMKLN[W3P M6TP!F$>BZELS->A*?20>-$Q9B97BB(FFCBC[NE6\0OMVX7VRVK)-OEK8178PLH*GPX_&/@)*\HT]'G[#_F$?#GJ;MS;_ $5V3WA@ M-G]I[A39O^_;RV&W::3:]3V)5"@V!C.R=UT>WJK9G5.9WQD&%/AZ+&=>C3 MGI)/,+7;+;=KQ'AM9;;ZBCJ1(D%6#3RQ9DB@1E=))Y%6%)$9&D#*0 [[,_FM M_ KJ'=W=^P]]]WY"BW?\;FKSWE@L%TYWOO:KZVIL;U_1=I563SYV/UCN. 8/ M^XE"*5ZFFJ(8DMM-%=V4.Y0R#]WO<- )6[(Q,EXE@T;N^E8 MV%U(L8UE05)F!,"M(#&6QNX;R#;WA/UTL,^.QL'\1M\_-/:6PI$[#QF!W/T?LF/ M&)+O+.]A[2ZQ[)HMD[?R>1S5+!3M+05F4JMV2[_;/:5N] MJO\ ;[2\4MI\"3<;MK2!=5"))"T2Z5+(558GBU/(44&15&J0B,\]\?S0?A=TY2=84W>O=>V>L M]V]C=:[#[2K-OQX[?6\<;U_M/L"@6?![F[+W7MW9,V)ZMV+7Y%)J.BSV[AMW M'UL\)1666\2G%WMICYHWGE:RE\6\L]P-F2P6-6N"^B*#67,/U,P*LEJLSRLK M H'4AB4[5>R[AROL?-,EMHM;ZR%RBH6D8QB-'E>--"SRPPZP))A JI_H@0U4 M+SL7^81\,^INWL!T5V!WYM+;_9>XAL\P8LT>Y,G@<(_8E6*#KN#?&_<-@\CU M_P!^BF>$K0K6>-!));( M6TK)_=F.PF_J/=6V]AYN0[1["R.P-H;]WD MN"?:&P=_=P8G:-?U%U[OO=4>Y\>^-PN2'7XT=L7TBYDB\.02QP&1XV1E[^Z?]RO\ 2K%N*7^_=O[L;E_O)_ ?X!;^%_Y!]UY?^!<.GU:VE/WIS=LG M*U?#^LL]SG\7XM'[NL)K[1HQJ\;PO"U:U\/5KH]-!UN/^(XV=A37G1X?U?B_ ^OP_#[=6M47%_-9_E_2=FQ=/M\B\+3=@/WKF?C/ M/BLALOL[&XS%][83)R863KC/[KR&R:;:&W,UF.>(?4?V"2L;=Y%G1XU _Y[?SFOBM\*-J= MRTF+W!@>Y>^>F,GUMA<_TE19G4MHVX%[?<]_M]L,PX1M++X4\L2MI^J M^DXW$<+4BP)I(J@EZ^B7:]OWN]W*40M:;'>;DJ')=;>WEF@20@GZ=;V2(6]O M+* )'?\ 169AH)L-T_S!?AWL?O'#_&[>'>.VL%W+EZW:^%;;4V-W358/![HW MQ'32[*V5NWL6BV_4=;[*WUO5*R-L+@\QEJ#+YA'#4=-,IO[>VZ%MWNKRTVK] M>6&66/&/$D@C,L\<.JGCR01 R3QPF1X4J9 HZ+YKCZ/:;#=]R406\]O%-D@E M(IF,</^(M9U MT_5_<:]C'O[*XO\ CN.VA1]?GKW^^.3PE7M\'))N6FHIMK?PU&J_XC]LC2BN MU0R;XNPOM2^,FYQ7DD!! &C;R1>F;53Z7Z9@%D%UX)#/&H!,L891N979FWI= MR81';X;26:I![+X@6G@E:BY:X)(C2V\5R5<:08WTGW]M];Z][]U[KWOW7NO> M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[ MKWOW7NO_T]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0?]L; _TK]6=E]6_P!] M>P.M?])77^\M@?Z1>I]Q_P!SNT]@_P!\=N9+;O\ ?7K3=WV>1_NKV!M7^(_? M8;)?;S_8Y&"&;QOHTGW7NJ0?^&"__!U'\_[_ -.-_P#Z'/?NO=&^ZE_ECXOI MGXP?)?X\+\OOF[\EQ&SMNY6E MVSL' [6Q&4R=3DJV&BQ%-DL[+4F'(UU33TN,BH/=>ZIJA_D3?*CL\[#V#V)_ M,,_G0[6QM-N?:F6[HWAO/^:MA^V>KZR@VAE:+?W*_O=_S*[_ 'YNTO[I?WM_O;_N;_X$??\ \,H/\W]MZ_=> MZ+!M/^3%CME]^[:[RP_\T?\ G/5F(VGW!ANV,7T!NS^8#NK?O055CL%O2FW? M0]/;EVYOK9VX][;TZ?GIJ5<+6T68W#7Y7(X4O%5Y&>HDDJ6]U[I2_P TGH'M MWO27J.AA^$/Q\_F(_&C%P;R_TN_'#L;+;-V#W9C]W55)1Q[#[&Z)[/[(K\9L M;$56.B-;1Y6BJ:_"U,\,\;PUPTO&2L6D$V[73[GMQEMVM%2UGB<1RVTYE'C> M-E7>WEATC]%M<;H6,I^4.1W9EI_@ ME38:''4_PYC^2^[J,35Y:#;M53E\3+D&II)&<^OYHI7]NSS M#&=\DV_;MQCOI AFO+AKEMLN-,IB%U^[%DBCUSE'D=5F"%H(AT4V@:)N?FY M> V-[[]WK9FI81+"UO\ O,J(1(+([C<:BV$@MP>TCQG*A7TO\ R\/YIFP/ MC]_,"^.='UG4[9^&G<_PX^2G7_P<^(V=^3O6F\M\?'7>N_CF\QANM]^U]%MJ M@V+N&NW/G-WU-)A0KW9=WOAN7.$-QM M0@NE%%DL[.Y*^"3(MN1/%:I$UQ.T?^,&.-8E#^)J/^6;[;MK]R.6N8K"S&V\ ML?5W,M[#BOU$]M #Z0V?M'=6]M_]L=G=Y;EV5GJ_9^$I.Q=O[#R_979'9&#V)B*W M,TT\,U/M9J+&2Q I$# P!&G,6YVB;_S>G+4]-AO+R4*]&\2:V6=I(%EEE'U, MB"B/HFG=+>T@$0*P2I!!.)Y(8[ABP6.>81W$XT*93;0(Q(C2DK[%N-@ MFX\B+-,+([9O)O6N64SQF30D4$LELJAY#9H;DQ*LG<;F0A0P5NBF[*^"?\QC MXX8#XO\ ;6'ZUVA\I>XV_E59?^7YV[LRDW;U[T;4]4[FJ,_AMV=3Y2J?+;XW M)LS=FRNLZ:IJL#N;(8;+UN5RIH5R%!12FH%-&//<)K?F?<_?+8MON5.WXV]S<26VGQXHKN.]$UM!&LK0R(()FTDS] /D>,[)LWM%>[A;2 MQ7'+&YWT/Y0VR_Y;V_LB_9V!ZXH^K^W]D2;LDQO;F4BWK48VIW)T M]7_Z1,C]U#B%JMPQ-0PB*A<3,48YVE@YTNO=CER,M:2W$0=#,725T3]0&7)\G]6Y/:OFJ\@\7?.7I-T>>TC;,X MW"^M=SB2"9PL0\"YBFBF:71JAD62,,Z>$;!?F%\'NU:O^2%OCX ]'X>+L_MS M!_#W8G0NRL5!F\#MB#>&X]EX':>"=X,WO;+[?P.*@KSA99D>OK*9%4@,P;CV MNYSW@/AVHVV M,STY5E7RBXZ*N6KD^Q>K,MA[EF\AVN^Y4NKR:LMESYMGZA!)CY=VW=MTW.*7 MS) .YHG@K6XTVB)X 58RR>XMYYK,1BZ;P[KD7VNZ_YD_9&S]B8/[;>_?7\KGY#_'K&[IWS MM&BVSW_+\-<5C,MV5UMFEQ^6R^5V='7U^.>@IIL]14-)+7&"96:F5YD*N6K^ M3ENWY3W5K0W%YMO/^][D]LI4.]AN.V6VWQW$+L1")T)FFA1Y$97@[]&M"7]S MM%W>W&SF988;KVTBV9IF4LD%_'NM]>^'(B_J-$4:!99(E==$S:"[HT8%?K/X M2?+[Y$_,7Y^]W=VX_N[^7GL_Y.=/_"W%]9[X^,_?G3%9WMB,KTE6=H?WQVCN M7<>/Q'9VW:+-O'F*1:&=X;V-C:V'*.X;4V\N=R/.%Q MN(2$,L,MO+M=K:)4N@+('1F=&$,@NXBZJT CDF4;AN$U_N7*LZ;6!;6W+T]D M[2E6>.9]R2\!0*:*6 =$93*I@/>8Y9#%$(&3^)_RY^$GS#JOE=\9=C9[Y];< M[3^)_4_QM[HV_P!J]Y['ZZ^1M1O7HK,9JHV'W+4[\W7@MO\ 66]5W;B=SU,& MXZ=$P$VI3U6\LK>[7E#^M9$D&LS6MW="^0PNH M4+-!,'A2.73$T+QUE0QDGW;^R/YOF]^G?BEEM]T.V,MNU_D!OK<_RJZH^'N_ M=B=7]B[\>ZI,=C:W)]=9:OHY-VYG#U&V\OEZ2*1,9Z@4 MJ??2V,>\;3;3SRW5@NP30RSJS6T;[NS0E;ATC)NDL3$)XA'$[R>,4G>(I^C' MN.XN9MJYHECAAM;R3=+>2TBD'U#IMT99IH2Q7Z=[Z1UC>)Y(UA128_$5AXYI MVVS\=OE1\+=U_P J+8V^>A#G>X8?YM/\PSMO9O6FY^^-O[ZJ]^[$WUU%V1O' M;V:IN[,OD=S5.7W;4;:JI9::NW4,9DZS-4P?(_9B8U*KN5[UX]WY0M(+19KW M;?:G=+6Z2-4A:*1-VLU)MU[8"'$L3!5E51;3.A995:'I/O\ :&XVKW2W!Y1' M8;ES[R]=6\DI:0,ALU2DM TJO'-#)%(?#95D37#XL.AVV'/Y7_QT[MZ7P/RS M[1[_ -H8OJO?GR^^7G8_R7CZ3PVZ\/O6FZBVYN3;^S]I8#;.7W'MIIMK93>F M1H=GC)9N7%SU5 U?6.(IY@OD:L:VVVFDQRUP1O'X/,#'[1\L ML)>4O:WEG=O\1EVS;5L[B1OU%0O>W5PTM(=;.L:7(JJ:F8HVD&HZ4\U@)S=[ MB&JL\UJX5F*H RDL%J>@EP7\NWYCTF] M=DYBJZ=\./Q/_"A_L;YTY&?_ $@]62?;?%C/;&W+A\5VCXH][M--]UDLA#'_ M 2-6W$FO4] JAF#O)3IM$7LLFX-X9VCE+F>RN_Q>%<[A/N3V+X?Z/B M:X]2/RG\JWYJR_(CMSK'.5_?.Z_C7VO_ #%Z7YSX_?.Q^^OAEUSTOA&.]CO)8M#3S/#),BQ11[YX_W<2<]S M[6BZ.8=NL[5TC[)(O M+*SD6>2?QHU2+Z3Q[26UC=JB,2VZR^+++)Z7K'>NYH*[:>R M.TMO9_[.NQM7E(/M)%CDC^XI7*3 DG@BDW7;I=QVPW>S)'/41LB7$-P4I;7$ M3.54HC:UFC#Q.ZN-,@ 96-+6=XMNW5+'D,UEODC\'=U=<=>TG9W5.=[YW)M+ISNOK MW=_;^\.X.P\-O=NH9L/M_$;?GEVWCZ'*U.4EQ\1C>):HQTS4V!;7;>;/:[?+ MJ\_2L^:6O+@(K".WLOH9XD>8&K37C32E9A;K)&J^'H>4:W5/N[7=[RG[@;'! M:#Q[GD^ZL8BS F:_EG+".UX"&R,:HRFY,;M*SLZQ"B]%FR?\JWYJR_(CMSK# M.5_?.Z_C7VO_ #%J3YST&^=C]]?#+KGI?"T$?8&T.S,<^\L!N[XG=F_,:;N/ M8^:V^E#2T.&RQVYE\;0Q0ME,4DLB^T_(,@V2#VX7&.]CO)8M#3S/#),BQ11KN=Z[P_/4^V(NCF';K*U=(^R2+P+2R MLY%GDG\:-4B^D\>TEM8W:HC$MNLOBRRK'='\N;Y>9#XV_*S8M!TQ#+O;LW^> MQM7YE[0QXWWU5%+GOCABOD!U#O.H[)DR)3Q &IX-+;;=M,,T?=3P@D]OFHANF>[CANWN-"*@-J[;_:#JK?.0[YW M'\>-O_S']R?.[!=B[5[Y^&6R>AXJ/*]IYSMW"5E1LZN^)V^/FCD.XJ*OR8PV M6Q!S]-MS*4#R"'.4<#K30[Y)G&U6W($FY1J-PY8YK=V5#H>,1_0$BY>8.%: MU>U#63VJ2AUMH$E2 L[N*G5/P%^:_47SOVOV+\>]G]J?%;K.O^3>]>Q_D7A, M=\K]K=R? 'M_IK=V7W=E]PU_7/QVWDLO=G6?R0WU75]/55;46+P>WL755E0T M=;6(JK[]R7(NV6-C8;LS-L4&T36YM9OUI89Q$ZV:;9$:;%[D EK1N=[Y&O /\7L^9=HNIC_!;VNXVT\\ ME.+>'%&[Z5#.U-**S$ G>PW=O97.X27,FE'VR_B7!-9)[&XAB7 --4CJM3VK M6K$*"0$GS9^,??NZ-Q?RZ/D=TML+!]N;W^#'8>9W=NKH#-[PPFSJKL3 ;ZZ5 MR_5>>;9&ZMP5"[%H>R=E5>2CK,2^4J*2@F F3[R#6&8YEW,[;[@,OMZR)+!(T0=@&69GC=%D4311U&DZEKWJ?Y<'S3R.[Y_G0W5? M7E)W3)_,ZV_\\(/A%4]DX%\:.MZ;+,=8D;8W,CB[$'B:5N3-*J>&9_#\"V9 M@V0C?VA_+U^;'&]>PMWP[BH.NL]V;D\7C*JOR5'MW(YNU75G;P0*RK/(@D6 R,(EK<7,KZ!&K2=4WZ:;? MK+W%F2T,,MQR99[/:1L5,MU+;;BUZ\LS*6B3$\D5OKD[((%5R&8(%0?@'\U= MB?/9.V_B[M#M7XMX7Q?@+W1TMG=P4F1[)S6X/BSOR.3 MMC9ORAW_ (AJM-6W<1C\'1Y"IDF.6D#%B7VFE^I,(52Z)#*$5.G>V1\Q]Y3_&-OC'C]X;AZXPO;^2 MJODYM+J+?_6/4W>V=Z\R&S,SB-M3]:]F]JFBQ&U:+!;RK:>LSO\ #,EBL_4X MN)HZ"H,A,,J&UB$G, _>*.VS-M=TB%)&B$=\SP&"2X:*EPUMX*W$96"K"5XI M'CD1-(7O(@V#YCB5@T0N7(A\%IU$8HX+Q%@XJ" M^'G\M3YG=6;C_E[_ .D+I.NQ>.^/W\SWY^?(7LO(YKO#8W:]7A>H>[>N^PJ/ MJK?4^],WO:JWUV7D49;UDC:T M]M+W:)-,814W!]UMI4B1(P55)K:.25&3])(B(I&CE)BZ)=\B>]B]SE@5G.Y\ MZ;+N5OJ;47M;>RB2X9V>FF2WE!CD1J:G4FV\:+1(5-LW^7?\TNLXMH=Y8KI2 MAWAOCX^_SEOF?\RL%\?JGLWK/$57='0'?V,WCLO;FZ-H;FGW-5;"V_O[&X_= M$66Q=%N&OQ,L CFBJ333,BL4\JW4G+^W^TRS6_B2VW).X[)>J"-=E->[C)=Q MSJ3V2(JQQ)<>"SL8)W6,/(K1]&',\<>][G[O?3R*MON&^[#N5G(RG3<#:]NV M^">$@=\3/(EPL32(%\:&-FI$XE%C7\J[X_\ R2Z:W9_,4WU\D>J<#U'D_DO\ MW]P=]=?X#;6^-L[[Q=3L/<74O5N%I:ALIMVJ::'+4.8P5719!:VDH99LA333 M01O224\\JVT%KM_M[R%RTMV)=SL&W3QP%945KG=+JYC\,L.Z)HY5:&M)!$4$ MT<,NN)&=UGDW/G+=M\2V:.PEVK:H(]3*7+6EN\+APOPN.PN!JC#,5BEF5?$: ML'YX_P O'Y<_(GLOO:>/^7MT-NCY+;@WQDJ_XA_S3^B>_L3\7-W]([/*8NFV M)6]\8+%9BE[KWGOSK>C>IBDCQM/N+$[@AB$3#'Q,B FY5BN+&7ERXCNCM&\P M7R2;A.@\6UO(A>>)*8K1:JSW%H%BE@N55!(#)]0YH 8[U<6D[[C'75/=WPSZ5V%CJWK[K_K786\Y.[*?NWXJ][?(S%YO#5VQ' MS&UZGKV2OIW:5(IH,?.LE5,<;%<6<.X[+#-;&WV[:N;KO>+?722%8Y;]+^W\ M)(!'.]U"P6WDBN)$@EB@0"ZC1RG15/\ 6065M>M.+S=9.4K?:+A.ED=GFA@,, M@=B>]LK;>?:Z3E*^ AO;C>^8;B2- 0(X]PN8WM95(++J**&0!VDCT*'TD#IR MS>YV7G[:N8]M(L^A4DU52M&"U3]&?RH/ MFYMGX)_S1]F=P[4I=Z?(S>_Q>R7\OCX48@;XZ^J:K#U=?!F*W'3T[T<+5BPV%E6^[AN.^\F;+->*'YVW?F#;]XWH M*H6XM9=OMB@8'1(D<%G<7J^&S#5?2(H\74O1ELL6V[1[@E[9]'(^TV&XVVVF MA/;NS=M/$4IXUCM]61:BQUU:,K(32X?XR?/_ .+?;'=V]>E_B]UA\GD^ M7GQA^&/7'A[3[.V'@MC_ !V[2^.W6>2V#NC$=TX')Y:FS>^>G*Y:J.OISLT9 MW)29)ID,"0LE2#Z^O;:^W/F[91*B;3=<]7>]1WKJS*]G>&P21!" )A>PK9LU MF7580&0R2(R%&">S;>UERY[<7MRLB[OMG):[//:(5U>/&]S/'(LA;P&AD>Z: M&\'BAF2(>$'#:@7'Y,_RL?G)O7O;YF[1QFZ*OHGNSX==) M]2;+.Q=C=<['W3A>T:7OCXL=]?);%2;/GV.M+])M'-=UN\,TY61662^2_@D5+<1SO>HX$,T4[I;S)"H%U&CE M.C[! MWGG/FG\3.R*6#<&9[2.U<+546/?8^"JXZUZ2FFFR-&S.ONW*5S]#O%F^X 1< MO?O:YGN[.0&:U:UN)FEE&V49I[:\N-;E_$,,,,DCD/*#J*;>[2&;ET6UNS3; MQ%L,5K;7$9$5XMY#!-';_6.56"XL8)/!;522=X^WP5TA5LJ_F9_'7N;Y!R? M!NH]H#>)Z3_F*_''O?M%US^UMO+MOJO8=-O./=N[%3=&=PYRXQ\VFYM;9=*U=O$GD2/4JE4 MKJD*("PO9O\]C:OS+VACEWWU5%+G?CABOD!U#O.H[ M)DR'($]SD'W>Z]_)+$F1-ZY>VRUL36GC2VV MW;3#-&-5/""3V]R*R^&C%2Z,RNK,COEO_+Y^?T_2'\S/XH].?'?:O=&V?F!\ MS,+\QM@][UW<776V:N# 9/>/3VZ=P]5YG:N\,IA=P/V-M&NZ^FI,142O3X 8 M)E?[\5424,S')\@LG]A;+= T%MRAS+'//*#J^HM7W>ZOOJ8E6K!XX[NEZK@2 M.(BMLDYD&E=S#,LUY[E[MMP\>?F#D][".%NQ;>ZAV4[:(W)QX4YC66T,>I5N MI:W)MX@THP=Q_P JSYL;F^0/RKZ[2J[UW1\;?ES\N^M?D_+N;K/OGX9=5=6; M1H=L'J*HGI^TZ3M#XH]S_*U.S.N\IUTLFWO[FUE3A,G1T=-#--BI'J9IU')L MR;;)R+%NLKC^K>]7E]$\G?'+XU[=WT36\=OX$K22&X^GO(;R5$9#(4N3$R0Q M%6^QRW&V[Q)MZ@7&Z\JVFU31)VR*T5C^[YTEDF,L @9*SQ3VZ/-%+(6^G9T5 MRN-P_"3YZ2?S=H?YL6'^,6PZC$[:[0P?Q3IN@*G=/30[-W9\4%VG7[>S?S63 M?$N_ALJB[7H]P9>]!A9:RFSIV?328]XA42B$UY!DBV6+<(-U(A7F=;Y[PH/^ M20Z-;G;X^W4;A+L62MN/TYD77/ RB0P.5]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_ MU-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=(K2%F%"8G>*-WC)T,T:,02BD>D)FMFLY>ZT,L_=>Z][]U[KWOW7NO>_=>Z][]U[KWO MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z] L[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_]D! end XML 24 tech20200630_10k_htm.xml IDEA: XBRL DOCUMENT 0000842023 2019-07-01 2020-06-30 0000842023 2019-12-31 0000842023 2020-08-21 0000842023 2018-07-01 2019-06-30 0000842023 2017-07-01 2018-06-30 0000842023 2020-06-30 0000842023 2019-06-30 0000842023 us-gaap:CommonStockMember 2017-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0000842023 us-gaap:RetainedEarningsMember 2017-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000842023 2017-06-30 0000842023 us-gaap:RetainedEarningsMember 2017-07-01 2018-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-07-01 2018-06-30 0000842023 us-gaap:CommonStockMember 2017-07-01 2018-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2017-07-01 2018-06-30 0000842023 us-gaap:CommonStockMember 2018-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000842023 us-gaap:RetainedEarningsMember 2018-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000842023 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-06-30 0000842023 us-gaap:RetainedEarningsMember 2018-07-01 2019-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2019-06-30 0000842023 us-gaap:CommonStockMember 2018-07-01 2019-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2019-06-30 0000842023 us-gaap:CommonStockMember 2019-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000842023 us-gaap:RetainedEarningsMember 2019-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:CommonStockMember 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-06-30 0000842023 us-gaap:RetainedEarningsMember 2019-07-01 2020-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2020-06-30 0000842023 us-gaap:CommonStockMember 2019-07-01 2020-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2020-06-30 0000842023 us-gaap:CommonStockMember 2020-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000842023 us-gaap:RetainedEarningsMember 2020-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000842023 srt:MinimumMember us-gaap:EquipmentMember 2019-07-01 2020-06-30 0000842023 srt:MaximumMember us-gaap:EquipmentMember 2019-07-01 2020-06-30 0000842023 srt:MinimumMember tech:BuildingBuildingImprovementsAndLeaseholdImprovementsMember 2019-07-01 2020-06-30 0000842023 srt:MaximumMember tech:BuildingBuildingImprovementsAndLeaseholdImprovementsMember 2019-07-01 2020-06-30 0000842023 srt:MinimumMember 2019-07-01 2020-06-30 0000842023 srt:MaximumMember 2019-07-01 2020-06-30 0000842023 us-gaap:TradeNamesMember 2019-07-01 2020-06-30 0000842023 us-gaap:TradeNamesMember 2020-06-30 0000842023 2002-07-01 2020-06-30 0000842023 us-gaap:AccountingStandardsUpdate201602Member 2019-07-01 0000842023 tech:ConsumablesMember 2019-07-01 2020-06-30 0000842023 tech:ConsumablesMember 2018-07-01 2019-06-30 0000842023 tech:ConsumablesMember 2017-07-01 2018-06-30 0000842023 tech:InstrumentsMember 2019-07-01 2020-06-30 0000842023 tech:InstrumentsMember 2018-07-01 2019-06-30 0000842023 tech:InstrumentsMember 2017-07-01 2018-06-30 0000842023 us-gaap:ServiceMember 2019-07-01 2020-06-30 0000842023 us-gaap:ServiceMember 2018-07-01 2019-06-30 0000842023 us-gaap:ServiceMember 2017-07-01 2018-06-30 0000842023 tech:ProductAndServicesMember 2019-07-01 2020-06-30 0000842023 tech:ProductAndServicesMember 2018-07-01 2019-06-30 0000842023 tech:ProductAndServicesMember 2017-07-01 2018-06-30 0000842023 us-gaap:RoyaltyMember 2019-07-01 2020-06-30 0000842023 us-gaap:RoyaltyMember 2018-07-01 2019-06-30 0000842023 us-gaap:RoyaltyMember 2017-07-01 2018-06-30 0000842023 country:US 2019-07-01 2020-06-30 0000842023 country:US 2018-07-01 2019-06-30 0000842023 country:US 2017-07-01 2018-06-30 0000842023 tech:EMEAExcludingUKMember 2019-07-01 2020-06-30 0000842023 tech:EMEAExcludingUKMember 2018-07-01 2019-06-30 0000842023 tech:EMEAExcludingUKMember 2017-07-01 2018-06-30 0000842023 country:GB 2019-07-01 2020-06-30 0000842023 country:GB 2018-07-01 2019-06-30 0000842023 country:GB 2017-07-01 2018-06-30 0000842023 tech:APACExcludingGreaterChinaMember 2019-07-01 2020-06-30 0000842023 tech:APACExcludingGreaterChinaMember 2018-07-01 2019-06-30 0000842023 tech:APACExcludingGreaterChinaMember 2017-07-01 2018-06-30 0000842023 country:CN 2019-07-01 2020-06-30 0000842023 country:CN 2018-07-01 2019-06-30 0000842023 country:CN 2017-07-01 2018-06-30 0000842023 tech:RestOfWorldMember 2019-07-01 2020-06-30 0000842023 tech:RestOfWorldMember 2018-07-01 2019-06-30 0000842023 tech:RestOfWorldMember 2017-07-01 2018-06-30 0000842023 tech:ChemoCentryxIncCCXIMember 2020-06-30 0000842023 tech:ChemoCentryxIncCCXIMember 2019-06-30 0000842023 tech:ChemoCentryxIncCCXIMember 2020-06-30 0000842023 tech:ChemoCentryxIncCCXIMember 2019-06-30 0000842023 us-gaap:OtherNoncurrentAssetsMember 2020-06-30 0000842023 us-gaap:OtherNoncurrentAssetsMember 2019-06-30 0000842023 us-gaap:LandMember 2020-06-30 0000842023 us-gaap:LandMember 2019-06-30 0000842023 us-gaap:BuildingAndBuildingImprovementsMember 2020-06-30 0000842023 us-gaap:BuildingAndBuildingImprovementsMember 2019-06-30 0000842023 us-gaap:MachineryAndEquipmentMember 2020-06-30 0000842023 us-gaap:MachineryAndEquipmentMember 2019-06-30 0000842023 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2019-07-01 2020-06-30 0000842023 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2019-07-01 2020-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0000842023 srt:MinimumMember us-gaap:TradeNamesMember 2019-07-01 2020-06-30 0000842023 srt:MaximumMember us-gaap:TradeNamesMember 2019-07-01 2020-06-30 0000842023 us-gaap:TradeNamesMember 2019-06-30 0000842023 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2019-07-01 2020-06-30 0000842023 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2019-07-01 2020-06-30 0000842023 us-gaap:CustomerRelationshipsMember 2020-06-30 0000842023 us-gaap:CustomerRelationshipsMember 2019-06-30 0000842023 us-gaap:PatentsMember 2019-07-01 2020-06-30 0000842023 us-gaap:PatentsMember 2020-06-30 0000842023 us-gaap:PatentsMember 2019-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember us-gaap:CostOfSalesMember 2019-07-01 2020-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember us-gaap:CostOfSalesMember 2018-07-01 2019-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember us-gaap:CostOfSalesMember 2017-07-01 2018-06-30 0000842023 tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2020-06-30 0000842023 tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2019-06-30 0000842023 tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2018-06-30 0000842023 tech:ProteinSciencesMember 2018-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2018-06-30 0000842023 tech:ProteinSciencesMember 2018-07-01 2019-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2018-07-01 2019-06-30 0000842023 tech:ProteinSciencesMember 2019-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2019-06-30 0000842023 tech:ProteinSciencesMember 2019-07-01 2020-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2019-07-01 2020-06-30 0000842023 tech:ProteinSciencesMember 2020-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2020-06-30 0000842023 tech:QTHoldingsCorporationMember 2018-07-02 2018-07-02 0000842023 tech:QTHoldingsCorporationMember 2018-07-02 0000842023 tech:QTHoldingsCorporationMember us-gaap:DevelopedTechnologyRightsMember 2018-07-02 2018-07-02 0000842023 tech:ExosomeDiagnosticsIncMember 2018-08-01 2018-08-01 0000842023 tech:ExosomeDiagnosticsIncMember 2018-08-01 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:TradeNamesMember 2018-08-01 2018-08-01 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:DevelopedTechnologyRightsMember 2018-08-01 2018-08-01 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:CustomerRelationshipsMember 2018-08-01 2018-08-01 0000842023 tech:BMoGenMember 2019-06-04 2019-06-04 0000842023 tech:BMoGenMember 2019-06-04 0000842023 tech:BMoGenMember 2019-07-01 2020-06-30 0000842023 tech:BMoGenMember us-gaap:DevelopedTechnologyRightsMember 2019-06-04 2019-06-04 0000842023 tech:TrevigenIncMember 2017-09-05 2017-09-05 0000842023 tech:TrevigenIncMember 2017-09-05 0000842023 tech:AtlantaBiologicalsMember 2018-01-02 2018-01-02 0000842023 tech:AtlantaBiologicalsMember 2018-01-02 0000842023 tech:AtlantaBiologicalsMember us-gaap:DevelopedTechnologyRightsMember 2018-01-02 2018-01-02 0000842023 tech:AtlantaBiologicalsMember us-gaap:CustomerRelationshipsMember 2018-01-02 2018-01-02 0000842023 tech:AtlantaBiologicalsMember us-gaap:TradeNamesMember 2018-01-02 2018-01-02 0000842023 tech:EurocellDiagnosticsSASMember 2018-02-01 2019-02-01 0000842023 tech:EurocellDiagnosticsSASMember 2018-02-01 2018-02-01 0000842023 tech:EurocellDiagnosticsSASMember 2019-02-01 2019-02-01 0000842023 tech:EurocellDiagnosticsSASMember 2018-02-01 0000842023 tech:EurocellDiagnosticsSASMember us-gaap:CustomerRelationshipsMember 2018-02-01 2018-02-01 0000842023 tech:BMoGenMember 2020-06-30 0000842023 tech:ExosomeDiagnosticsIncMember 2020-06-30 0000842023 tech:QTHoldingsCorporationMember 2020-06-30 0000842023 tech:TrevigenIncMember 2020-06-30 0000842023 tech:AtlantaBiologicalsMember 2020-06-30 0000842023 tech:EurocellDiagnosticsSASMember 2020-06-30 0000842023 tech:BMoGenMember us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000842023 tech:QTHoldingsCorporationMember us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000842023 tech:TrevigenIncMember us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000842023 tech:AtlantaBiologicalsMember us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:TradeNamesMember 2020-06-30 0000842023 tech:TrevigenIncMember us-gaap:TradeNamesMember 2020-06-30 0000842023 tech:AtlantaBiologicalsMember us-gaap:TradeNamesMember 2020-06-30 0000842023 tech:BMoGenMember us-gaap:CustomerRelationshipsMember 2020-06-30 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:CustomerRelationshipsMember 2020-06-30 0000842023 tech:TrevigenIncMember us-gaap:CustomerRelationshipsMember 2020-06-30 0000842023 tech:AtlantaBiologicalsMember us-gaap:CustomerRelationshipsMember 2020-06-30 0000842023 tech:EurocellDiagnosticsSASMember us-gaap:CustomerRelationshipsMember 2020-06-30 0000842023 tech:ExosomeDiagnosticsIncMember 2019-07-01 2020-06-30 0000842023 tech:QTHoldingsCorporationMember 2019-07-01 2020-06-30 0000842023 tech:TrevigenIncMember 2019-07-01 2020-06-30 0000842023 tech:AtlantaBiologicalsMember 2019-07-01 2020-06-30 0000842023 tech:EurocellDiagnosticsSASMember 2019-07-01 2020-06-30 0000842023 us-gaap:EquitySecuritiesMember 2020-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2020-06-30 0000842023 us-gaap:CertificatesOfDepositMember 2020-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2020-06-30 0000842023 us-gaap:FairValueInputsLevel1Member 2020-06-30 0000842023 us-gaap:FairValueInputsLevel2Member 2020-06-30 0000842023 us-gaap:FairValueInputsLevel3Member 2020-06-30 0000842023 us-gaap:EquitySecuritiesMember 2019-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000842023 us-gaap:CertificatesOfDepositMember 2019-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000842023 us-gaap:FairValueInputsLevel1Member 2019-06-30 0000842023 us-gaap:FairValueInputsLevel2Member 2019-06-30 0000842023 us-gaap:FairValueInputsLevel3Member 2019-06-30 0000842023 tech:CCXIMember 2020-06-30 0000842023 tech:CCXIMember 2019-06-30 0000842023 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:CashFlowHedgingMember 2018-10-31 0000842023 srt:ScenarioForecastMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:CashFlowHedgingMember 2020-10-01 2020-10-31 0000842023 srt:ScenarioForecastMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:CashFlowHedgingMember 2021-10-01 2021-10-31 0000842023 srt:ScenarioForecastMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:CashFlowHedgingMember 2022-10-01 2022-10-31 0000842023 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2019-07-01 2020-06-30 0000842023 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:CashFlowHedgingMember 2020-06-30 0000842023 2019-07-01 0000842023 us-gaap:FairValueInputsLevel3Member tech:ContingentConsiderationMember 2019-06-30 0000842023 us-gaap:FairValueInputsLevel3Member tech:ContingentConsiderationMember 2018-06-30 0000842023 us-gaap:FairValueInputsLevel3Member tech:ContingentConsiderationMember 2019-07-01 2020-06-30 0000842023 us-gaap:FairValueInputsLevel3Member tech:ContingentConsiderationMember 2018-07-01 2019-06-30 0000842023 us-gaap:FairValueInputsLevel3Member tech:ContingentConsiderationMember 2020-06-30 0000842023 us-gaap:RevolvingCreditFacilityMember tech:CreditAgreementMember 2018-08-01 0000842023 tech:CreditAgreementMember tech:TermLoanMember 2018-08-01 0000842023 us-gaap:RevolvingCreditFacilityMember tech:CreditAgreementMember 2019-07-01 2020-06-30 0000842023 us-gaap:RevolvingCreditFacilityMember tech:CreditAgreementMember 2020-06-30 0000842023 tech:CreditAgreementMember tech:TermLoanMember 2018-08-01 2018-08-01 0000842023 us-gaap:RevolvingCreditFacilityMember tech:CreditAgreementMember 2018-08-01 2018-08-01 0000842023 tech:CreditAgreementMember 2020-06-30 0000842023 tech:CreditAgreementMember 2019-06-30 0000842023 srt:MaximumMember 2020-06-30 0000842023 2016-07-01 2017-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2017-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2017-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-07-01 2018-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2017-07-01 2018-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2017-07-01 2018-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-07-01 2019-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2018-07-01 2019-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2019-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-07-01 2020-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2020-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2020-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000842023 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2020-06-30 0000842023 srt:ScenarioForecastMember 2020-07-01 2021-06-30 0000842023 tech:EquityIncentivePlan2010Member 2010-06-30 0000842023 tech:EquityIncentivePlan2010Member 2020-06-30 0000842023 srt:MaximumMember tech:EquityIncentivePlan2010Member 2009-07-01 2010-06-30 0000842023 tech:EquityIncentivePlan2010Member 2019-06-30 0000842023 tech:NonqualifiedStockOptionsPlan1998Member 2019-06-30 0000842023 srt:MinimumMember 2018-07-01 2019-06-30 0000842023 srt:MinimumMember 2017-07-01 2018-06-30 0000842023 srt:MaximumMember 2018-07-01 2019-06-30 0000842023 srt:MaximumMember 2017-07-01 2018-06-30 0000842023 us-gaap:RestrictedStockMember 2017-06-30 0000842023 us-gaap:RestrictedStockMember 2017-07-01 2018-06-30 0000842023 us-gaap:RestrictedStockMember 2018-06-30 0000842023 us-gaap:RestrictedStockMember 2018-07-01 2019-06-30 0000842023 us-gaap:RestrictedStockMember 2019-06-30 0000842023 us-gaap:RestrictedStockMember 2019-07-01 2020-06-30 0000842023 us-gaap:RestrictedStockMember 2020-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2017-07-01 2018-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2018-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2019-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2020-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2020-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2019-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2018-06-30 0000842023 us-gaap:CostOfSalesMember 2019-07-01 2020-06-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2014-10-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2019-07-01 2020-06-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2018-07-01 2019-06-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2017-07-01 2018-06-30 0000842023 tech:USProfitSharingAndSavingsPlanMember 2019-07-01 2020-06-30 0000842023 tech:USProfitSharingAndSavingsPlanMember 2018-07-01 2019-06-30 0000842023 tech:USProfitSharingAndSavingsPlanMember 2017-07-01 2018-06-30 0000842023 tech:GBProfitSharingAndSavingsPlanMember 2018-07-01 2019-06-30 0000842023 tech:GBProfitSharingAndSavingsPlanMember 2019-07-01 2020-06-30 0000842023 tech:GBProfitSharingAndSavingsPlanMember 2017-07-01 2018-06-30 0000842023 srt:ExecutiveOfficerMember tech:PerformanceIncentiveProgramsMember 2019-07-01 2020-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockMember tech:PerformanceIncentiveProgramsMember 2019-07-01 2020-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember tech:PerformanceIncentiveProgramsMember 2019-07-01 2020-06-30 0000842023 srt:ExecutiveOfficerMember tech:PerformanceIncentiveProgramsMember 2018-07-01 2019-06-30 0000842023 srt:ExecutiveOfficerMember tech:PerformanceIncentiveProgramsMember 2017-07-01 2018-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockMember tech:PerformanceIncentiveProgramsMember 2018-07-01 2019-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockMember tech:PerformanceIncentiveProgramsMember 2017-07-01 2018-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember tech:PerformanceIncentiveProgramsMember 2018-07-01 2019-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember tech:PerformanceIncentiveProgramsMember 2017-07-01 2018-06-30 0000842023 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2020-06-30 0000842023 us-gaap:StateAndLocalJurisdictionMember 2020-06-30 0000842023 us-gaap:ForeignCountryMember 2020-06-30 0000842023 tech:OperatingLossCarryforwardsMember 2020-06-30 0000842023 tech:TaxCreditCarryforwardsMember 2020-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:ProteinSciencesMember 2019-07-01 2020-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:ProteinSciencesMember 2018-07-01 2019-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:ProteinSciencesMember 2017-07-01 2018-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:DiagnosticsAndGenomicsMember 2019-07-01 2020-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:DiagnosticsAndGenomicsMember 2018-07-01 2019-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:DiagnosticsAndGenomicsMember 2017-07-01 2018-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:ProteinSciencesMember 2019-07-01 2020-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:ProteinSciencesMember 2018-07-01 2019-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:ProteinSciencesMember 2017-07-01 2018-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:DiagnosticsAndGenomicsMember 2019-07-01 2020-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:DiagnosticsAndGenomicsMember 2018-07-01 2019-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:DiagnosticsAndGenomicsMember 2017-07-01 2018-06-30 0000842023 us-gaap:IntersegmentEliminationMember 2019-07-01 2020-06-30 0000842023 us-gaap:IntersegmentEliminationMember 2018-07-01 2019-06-30 0000842023 us-gaap:IntersegmentEliminationMember 2017-07-01 2018-06-30 0000842023 us-gaap:OperatingSegmentsMember 2019-07-01 2020-06-30 0000842023 us-gaap:OperatingSegmentsMember 2018-07-01 2019-06-30 0000842023 us-gaap:OperatingSegmentsMember 2017-07-01 2018-06-30 0000842023 us-gaap:CorporateNonSegmentMember 2019-07-01 2020-06-30 0000842023 us-gaap:CorporateNonSegmentMember 2018-07-01 2019-06-30 0000842023 us-gaap:CorporateNonSegmentMember 2017-07-01 2018-06-30 0000842023 tech:ConsumablesMember tech:ProteinSciencesMember 2019-07-01 2020-06-30 0000842023 tech:ConsumablesMember tech:ProteinSciencesMember 2018-07-01 2019-06-30 0000842023 tech:ConsumablesMember tech:ProteinSciencesMember 2017-07-01 2018-06-30 0000842023 tech:ConsumablesMember tech:DiagnosticsAndGenomicsMember 2019-07-01 2020-06-30 0000842023 tech:ConsumablesMember tech:DiagnosticsAndGenomicsMember 2018-07-01 2019-06-30 0000842023 tech:ConsumablesMember tech:DiagnosticsAndGenomicsMember 2017-07-01 2018-06-30 0000842023 tech:UnitedStatesAndCanadaMember 2020-06-30 0000842023 tech:UnitedStatesAndCanadaMember 2019-06-30 0000842023 srt:EuropeMember 2020-06-30 0000842023 srt:EuropeMember 2019-06-30 0000842023 srt:AsiaMember 2020-06-30 0000842023 srt:AsiaMember 2019-06-30 0000842023 2019-07-01 2019-09-30 0000842023 2019-10-01 2019-12-31 0000842023 2020-01-01 2020-03-31 0000842023 2020-04-01 2020-06-30 0000842023 2018-07-01 2018-09-30 0000842023 2018-10-01 2018-12-31 0000842023 2019-01-01 2019-03-31 0000842023 2019-04-01 2019-06-30 iso4217:USD shares thunderdome:item iso4217:USD shares utr:Y pure 0000842023 BIO-TECHNE Corp false --06-30 FY 2020 398000 775000 980000 0 0 5000000 5000000 0 0 0 0 0.01 0.01 100000000 100000000 38453046 38453046 37934040 37934040 0 0 0 0 3239000 0 0 P15Y 0 0 0 0 P5Y 1.28 1.28 P10Y P3Y 1400000 1400000 -2522000 0 0 0 0 10-K true 2020-06-30 false 0-17272 MN 41-1427402 614 McKinley Place N.E. Minneapolis MN 55413 612 379-8854 Common Stock, $0.01 par value TECH NASDAQ Yes No Yes Yes Large Accelerated Filer false false false 8400000000 38550371 738691000 714006000 642993000 255497000 240515000 210850000 483194000 473491000 432143000 260583000 264359000 240636000 65192000 62413000 55329000 325775000 326772000 295965000 157419000 146719000 136178000 19197000 21705000 10188000 605000 569000 409000 137650000 -13568000 -447000 119058000 -34704000 -10226000 276477000 112015000 125952000 47181000 15943000 -198000 229296000 96072000 126150000 -9963000 -4487000 -1572000 -3715000 -9537000 0 0 0 5693000 -13678000 -14024000 4121000 215618000 82048000 130271000 6.00 2.54 3.36 5.82 2.47 3.31 38201000 37781000 37476000 39401000 38892000 38055000 146625000 100886000 124268000 65147000 122534000 137466000 103152000 91050000 24341000 18058000 520920000 412607000 176829000 154039000 71465000 0 728308000 732667000 516545000 579429000 13522000 5668000 2027589000 1884410000 23090000 16210000 31087000 28638000 9093000 26389000 13049000 9084000 2376000 5764000 9535000 0 5938000 3400000 12500000 12500000 106668000 101985000 101090000 89754000 344243000 492660000 199000 9200000 67248000 0 26949000 25222000 0 0 385000 379000 420536000 316797000 1057470000 931934000 -97199000 -83521000 1381192000 1165589000 2027589000 1884410000 37356000 374000 199161000 799027000 -48935000 949627000 126150000 126150000 4121000 4121000 204000 2000 17661000 17663000 34000 -273000 -273000 47973000 47973000 27959000 27959000 14000 1506000 1506000 281000 281000 37608000 376000 246568000 876931000 -44814000 1079061000 25276000 -24682000 594000 96072000 96072000 -14024000 -14024000 95000 1000 15404000 15405000 382000 4000 36272000 36276000 29000 -2575000 -2575000 48366000 48364000 31775000 31775000 10000 1676000 1676000 505000 505000 37934000 379000 316797000 931934000 -83521000 1165589000 -879000 -879000 229296000 229296000 -13678000 -13678000 279000 3000 50109000 50112000 -2000 0 -400000 -400000 730000 7000 69461000 -1642000 67826000 56000 1000 -1000 -2229000 -2228000 48902000 48902000 31932000 31932000 14000 2312000 2312000 435000 435000 38453000 385000 420536000 1057470000 -97199000 1381192000 229296000 96072000 126150000 82737000 78171000 64463000 0 3739000 2455000 13130000 -13582000 -46716000 32367000 32280000 28240000 -905000 -2000000 20100000 -958000 0 -26600000 -0 3702000 397000 -137527000 16067000 0 225000 0 0 7170000 -0 -0 -732000 2325000 776000 -6556000 15000000 2700000 14861000 13647000 13327000 2605000 698000 -2782000 10343000 6101000 5026000 2552000 5013000 -89000 -7231000 -9520000 10204000 205217000 181619000 170367000 147120000 21579000 36390000 70187000 43475000 8571000 51744000 25411000 20934000 -0 289492000 67851000 -1906000 -0 -21574000 -0 -0 -680000 27095000 -336799000 -38712000 48902000 48364000 47973000 70983000 37950000 19170000 50112000 15405000 -0 40000000 580000000 55000000 188500000 413500000 59500000 3400000 -0 61900000 -3872000 -6297000 -3985000 -183802000 134384000 -99188000 -2771000 -308000 -2089000 45739000 -21104000 30378000 100886000 121990000 91612000 146625000 100886000 121990000 <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">1.</em></b><i><b> Description of Business and Summary of Significant Accounting Policies:</b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Description of business:</i> Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (the Company), develop, manufacture and sell life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Use of estimates:</i> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Principles of consolidation:</i> The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Translation of foreign financial statements:</i> Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Revenue recognition:</i> The Company adopted <i>ASC <em style="font: inherit;">606</em> </i>- <i>Revenue from Contracts with Customers</i> on <em style="font: inherit;"> July 1, 2018 </em>using the modified retrospective transition approach. ASC <em style="font: inherit;">606</em> provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC <em style="font: inherit;">606</em> is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to the <i>Recently Adopted Accounting Pronouncements </i>section of Note <em style="font: inherit;">1</em> for additional information regarding our adoption of ASC <em style="font: inherit;">606</em> and Note <em style="font: inherit;">2</em> for additional information regarding our revenue recognition policy under <i>ASC <em style="font: inherit;">606</em></i>.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Research and development:</i> Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Advertising costs:</i> Advertising expenses were $4.2 million, $4.1 million, and $3.8 million for fiscal <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> respectively. The Company expenses advertising expenses as incurred.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>  </i></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Income taxes:</i> The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than <em style="font: inherit;">not</em> that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than <em style="font: inherit;">fifty</em> percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">See Note <em style="font: inherit;">11</em> for additional information regarding income taxes.</p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"/> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"><i/></p><p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"><i>Comprehensive income: </i>Comprehensive income includes charges and credits to shareholders' equity that are <em style="font: inherit;">not</em> the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity.</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"><i> </i></p><p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"><i/></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Cash and cash equivalents:</i> Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of <em style="font: inherit;">three</em> months or less.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Available-for-sale investments:</i> Available-for-sale investments consist of debt instruments with original maturities of generally <em style="font: inherit;">three</em> months to <em style="font: inherit;">six</em> months and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value.  Unrealized gains and losses on available-for-sale securities are included within other income (expense) beginning in fiscal <em style="font: inherit;">2019</em> as the Company adopted ASU  <em style="font: inherit;">2018</em>-<em style="font: inherit;">02</em> on <em style="font: inherit;"> July 1, 2018, </em>as further described in the <i>Recently Adopted Accounting Pronouncements </i>section of Note <em style="font: inherit;">1.</em> Unrealized gains or losses on available-for-sale securities were recorded within comprehensive income in fiscal year <em style="font: inherit;">2018.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"/> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Trade accounts receivable: </i>Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do <em style="font: inherit;">not</em> bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&amp;A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Inventories:</i> Inventories are stated at the lower of cost (<em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory <em style="font: inherit;">not</em> meeting quality control standards and inventory subject to expiration.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been <em style="font: inherit;">no</em> material changes to the Company’s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with <i>ASC <em style="font: inherit;">330</em> - Inventory</i>.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p><p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"/> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Property and equipment:</i> Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of 5 to 40 years.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Contingent Consideration:</i> Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results <em style="font: inherit;"> may </em>differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"/> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Intangibles assets: </i>Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life. In the current year, the Company identified <em style="font: inherit;">one</em> item as described in the <i>Impairment of long-lived assets and amortizable intangibles</i> section below. </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"/> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Impairment of long-lived assets and amortizable intangibles: </i>We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Such circumstances could include, but are <em style="font: inherit;">not</em> limited to, (<em style="font: inherit;">1</em>) a significant decrease in the market value of an asset, (<em style="font: inherit;">2</em>) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (<em style="font: inherit;">3</em>) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are <em style="font: inherit;">not</em> available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results <em style="font: inherit;"> may </em>differ from assumed and estimated amounts. During fiscal year <em style="font: inherit;">2020,</em> the Company accelerated the amortization of a certain trade name based on the Company's planned integration of the products under that acquired trade name into a legacy brand. The accelerated amortization resulted in $1.3 million in additional amortization expense in fiscal <em style="font: inherit;">2020</em> and an estimated $0.6 million in fiscal <em style="font: inherit;">2021.</em> <em style="font: inherit;">No</em> other triggering events were identified and no impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years <em style="font: inherit;">2018,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2020.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Impairment of goodwill: </i>We evaluate the carrying value of goodwill during the <em style="font: inherit;">fourth</em> quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are <em style="font: inherit;">not</em> limited to, (<em style="font: inherit;">1</em>) a significant adverse change in legal factors or in business climate, (<em style="font: inherit;">2</em>) unanticipated competition, (<em style="font: inherit;">3</em>) an adverse action or assessment by a regulator, or (<em style="font: inherit;">4</em>) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">2020</em> <i>Goodwill Impairment Analyses</i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">In completing our <em style="font: inherit;">2020</em> annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU <em style="font: inherit;">2017</em>- <em style="font: inherit;">04,</em> a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit’s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value- weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">The result of our quantitative assessment, where we compared the discounted cash flows of each reporting unit to its carrying value, indicated that all of the reporting units had a substantial amount of headroom as of <em style="font: inherit;"> April 1, 2020. </em>This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did <em style="font: inherit;">not</em> identify any triggering events after our annual goodwill impairment through <em style="font: inherit;"> June 30, 2020, </em>the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">2019</em> <i>Goodwill Impairment Analyses</i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">At the beginning of the quarter ended <em style="font: inherit;"> March 31, 2019, </em>the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">Because our quantitative analysis performed as of <em style="font: inherit;"> January 1, 2019 </em>included all of our reporting units, except for Exosome a recent acquisition that was a separate reporting unit that was <em style="font: inherit;">not</em> impacted by the business process realignment, the summation of the calculated reporting units’ fair values combined with the fair value of the Exosome acquisition, was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">The quantitative assessments completed as of <em style="font: inherit;"> January 1, 2019 </em>indicated that all tested reporting units had a substantial amount of headroom. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">In conducting our annual goodwill impairment test on <em style="font: inherit;"> April 1, </em>we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than <em style="font: inherit;">not</em> that the fair value of a reporting unit is less than its carrying amount.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">Based on its annual analysis, the Company determined there was no indication of impairment of goodwill. Further, <em style="font: inherit;">no</em> triggering events or items beyond the realignment discussed above were identified in the year ended <em style="font: inherit;"> June 30, 2019 </em>that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><em style="font: inherit;">2018</em> <i>Goodwill Impairment Analyses</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">In completing our <em style="font: inherit;">2018</em> annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units, with a process consistent to that described in our <em style="font: inherit;">2020</em> Goodwill Impairment Analyses section above. The quantitative assessment completed indicated that all of the reporting units had a substantial amount of headroom. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">There has been no impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC <em style="font: inherit;">350</em> guidance for goodwill and other intangibles on <em style="font: inherit;"> July 1, 2002.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i/></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Investments in unconsolidated entities: </i>The Company periodically invests in the equity of start-up and early development stage companies. The accounting treatment of each investment (cost method or equity method) is dependent upon a number of factors, including, but <em style="font: inherit;">not</em> limited to, the Company's share in the equity of the investee and the Company's ability to exercise significant influence over the operating and financial policies of the investee.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p><p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"/> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Other Significant Accounting Policies </b></i></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"><b> </b></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-right: 20%;"><tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="width: 81%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Policy</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-bottom-width: thin; border-left-width: thin; border-bottom-style: solid; border-left-style: solid;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Note</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value measurements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-left-color: rgb(0, 0, 0); border-left-width: thin; border-left-style: solid;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">5</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Earnings per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-left-color: rgb(0, 0, 0); border-left-width: thin; border-left-style: solid;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">9</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-left-color: rgb(0, 0, 0); border-left-width: thin; border-left-style: solid;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">10</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating segments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-left-color: rgb(0, 0, 0); border-left-width: thin; border-left-style: solid;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">12</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> </div> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b/></i></p><p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Recently Adopted Accounting Pronouncements</b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt 7.2pt 0pt -2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <i><em style="font: inherit;"> February 2016, </em></i>the FASB issued ASU <i><em style="font: inherit;">2016</em></i>-<i><em style="font: inherit;">02,</em></i> Leases (Topic <i><em style="font: inherit;">842</em></i>), which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. The FASB has issued narrow codification improvements to Leases (Topic <i><em style="font: inherit;">842</em></i>) through ASU <i><em style="font: inherit;">No.</em></i> <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">10</em></i> and ASU <i><em style="font: inherit;">2019</em></i>-<i><em style="font: inherit;">01.</em></i> Additionally, the FASB issued ASU <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">11,</em></i> allowing an entity to elect a transition method where they do <i><em style="font: inherit;">not</em></i> recast prior periods presented in the financial statements in the period of adoption. The Company has elected the transition method allowed for under ASU <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">11</em></i> when adopting Leases (Topic <i><em style="font: inherit;">842</em></i>). The Company adopted the standard effective <i><em style="font: inherit;"> July 1, 2019 </em></i>and correspondingly recorded incremental operating lease liabilities of $80.6 million, a right-of-use lease asset of $79.5 million, retained earnings of $0.8 million and a deferred tax adjustment of $0.3 million. Additionally, the Company reclassified $4.0 million of deferred rent recorded within accrued expenses under ASC <i><em style="font: inherit;">840</em></i> - Leases into operating lease liabilities upon adoption of Topic <i><em style="font: inherit;">842.</em></i> In adopting ASC <i><em style="font: inherit;">842,</em></i> the Company elected the package of available practical expedients and to use hindsight in determining the lease term for all existing leases. Further, as part of our adoption of ASC <i><em style="font: inherit;">842,</em></i> the Company also made the accounting policy elections to <i><em style="font: inherit;">not</em></i> capitalize short term leases (defined as a lease with a lease term that is less than <i><em style="font: inherit;">12</em></i> months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Refer to Note <i><em style="font: inherit;">7</em></i> for additional information on leases.</p> <p style="margin: 0pt 7.2pt 0pt -2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Pronouncements Issued but </b></i><b><em style="font: inherit;">Not</em></b><i><b> Yet Adopted</b></i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic </i><em style="font: inherit;">326</em><i>), Measurement of Credit Losses on Financial Instruments</i>. The amendment in this update replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade and loan receivables and available-for-sale debt securities. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. This ASU is effective for annual periods and interim periods for those annual periods beginning after <em style="font: inherit;"> December 15, 2019, </em>which for us is <em style="font: inherit;"> July 1, 2020. </em>Entities <em style="font: inherit;"> may </em>early adopt beginning after <em style="font: inherit;"> December 15, 2018. </em>We have completed our evaluation of the impact of the adoption of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> noting the impact of adoption is <em style="font: inherit;">not</em> expected to have a material impact on our consolidated financial statements.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> <i>Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</i>. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is <em style="font: inherit;">not</em> affected by the new standard.  This ASU is effective for annual periods and interim periods for those annual periods beginning after <em style="font: inherit;"> December 15, 2019, </em>which for us is <em style="font: inherit;"> July 1, 2020 </em>and <em style="font: inherit;"> may </em>be adopted retrospectively or prospectively to eligible costs incurred on or after the date the guidance is <em style="font: inherit;">first</em> applied. We do <em style="font: inherit;">not</em> expect this standard to have a material impact on our consolidated financial statements and we will adopt the standard prospectively on <em style="font: inherit;"> July 1, 2020.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -2pt; text-align: left;">In <i><em style="font: inherit;"> March 2020, </em></i>the FASB issued ASU <i><em style="font: inherit;">No.</em></i> <i><em style="font: inherit;">2020</em></i>-<i><em style="font: inherit;">04,</em></i> <i>Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>. This ASU provides expedients and exceptions to existing guidance on contract modifications and hedge accounting that is optional to facilitate the market transition from a reference rate, including LIBOR which is being phased out in <i><em style="font: inherit;">2021,</em></i> to a new reference rate. The provisions of the ASU would impact contract modifications and other changes that occur while LIBOR is phased out. The Company is in the process of evaluating the optional relief guidance provided within this ASU and is also reviewing its debt and derivative instrument that utilizes LIBOR as the reference rate. The Company will continue to evaluate and monitor developments and our assessment of ASU <i><em style="font: inherit;">2020</em></i>-<i><em style="font: inherit;">04</em></i> during the LIBOR transition period.</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -2pt; text-align: left;"/> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Use of estimates:</i> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Principles of consolidation:</i> The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Translation of foreign financial statements:</i> Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Revenue recognition:</i> The Company adopted <i>ASC <em style="font: inherit;">606</em> </i>- <i>Revenue from Contracts with Customers</i> on <em style="font: inherit;"> July 1, 2018 </em>using the modified retrospective transition approach. ASC <em style="font: inherit;">606</em> provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC <em style="font: inherit;">606</em> is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to the <i>Recently Adopted Accounting Pronouncements </i>section of Note <em style="font: inherit;">1</em> for additional information regarding our adoption of ASC <em style="font: inherit;">606</em> and Note <em style="font: inherit;">2</em> for additional information regarding our revenue recognition policy under <i>ASC <em style="font: inherit;">606</em></i>.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Research and development:</i> Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Advertising costs:</i> Advertising expenses were $4.2 million, $4.1 million, and $3.8 million for fiscal <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> respectively. The Company expenses advertising expenses as incurred.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>  </i></p> 4200000 4100000 3800000 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Income taxes:</i> The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than <em style="font: inherit;">not</em> that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than <em style="font: inherit;">fifty</em> percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">See Note <em style="font: inherit;">11</em> for additional information regarding income taxes.</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"><i>Comprehensive income: </i>Comprehensive income includes charges and credits to shareholders' equity that are <em style="font: inherit;">not</em> the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity.</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Cash and cash equivalents:</i> Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of <em style="font: inherit;">three</em> months or less.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Available-for-sale investments:</i> Available-for-sale investments consist of debt instruments with original maturities of generally <em style="font: inherit;">three</em> months to <em style="font: inherit;">six</em> months and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value.  Unrealized gains and losses on available-for-sale securities are included within other income (expense) beginning in fiscal <em style="font: inherit;">2019</em> as the Company adopted ASU  <em style="font: inherit;">2018</em>-<em style="font: inherit;">02</em> on <em style="font: inherit;"> July 1, 2018, </em>as further described in the <i>Recently Adopted Accounting Pronouncements </i>section of Note <em style="font: inherit;">1.</em> Unrealized gains or losses on available-for-sale securities were recorded within comprehensive income in fiscal year <em style="font: inherit;">2018.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Trade accounts receivable: </i>Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do <em style="font: inherit;">not</em> bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&amp;A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Inventories:</i> Inventories are stated at the lower of cost (<em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory <em style="font: inherit;">not</em> meeting quality control standards and inventory subject to expiration.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been <em style="font: inherit;">no</em> material changes to the Company’s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with <i>ASC <em style="font: inherit;">330</em> - Inventory</i>.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Property and equipment:</i> Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of 5 to 40 years.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> P3Y P5Y P5Y P40Y <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Contingent Consideration:</i> Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results <em style="font: inherit;"> may </em>differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Intangibles assets: </i>Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life. In the current year, the Company identified <em style="font: inherit;">one</em> item as described in the <i>Impairment of long-lived assets and amortizable intangibles</i> section below. </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> P1Y P20Y <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Impairment of long-lived assets and amortizable intangibles: </i>We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Such circumstances could include, but are <em style="font: inherit;">not</em> limited to, (<em style="font: inherit;">1</em>) a significant decrease in the market value of an asset, (<em style="font: inherit;">2</em>) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (<em style="font: inherit;">3</em>) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are <em style="font: inherit;">not</em> available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results <em style="font: inherit;"> may </em>differ from assumed and estimated amounts. During fiscal year <em style="font: inherit;">2020,</em> the Company accelerated the amortization of a certain trade name based on the Company's planned integration of the products under that acquired trade name into a legacy brand. The accelerated amortization resulted in $1.3 million in additional amortization expense in fiscal <em style="font: inherit;">2020</em> and an estimated $0.6 million in fiscal <em style="font: inherit;">2021.</em> <em style="font: inherit;">No</em> other triggering events were identified and no impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years <em style="font: inherit;">2018,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2020.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Impairment of goodwill: </i>We evaluate the carrying value of goodwill during the <em style="font: inherit;">fourth</em> quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are <em style="font: inherit;">not</em> limited to, (<em style="font: inherit;">1</em>) a significant adverse change in legal factors or in business climate, (<em style="font: inherit;">2</em>) unanticipated competition, (<em style="font: inherit;">3</em>) an adverse action or assessment by a regulator, or (<em style="font: inherit;">4</em>) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">2020</em> <i>Goodwill Impairment Analyses</i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">In completing our <em style="font: inherit;">2020</em> annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU <em style="font: inherit;">2017</em>- <em style="font: inherit;">04,</em> a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit’s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value- weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">The result of our quantitative assessment, where we compared the discounted cash flows of each reporting unit to its carrying value, indicated that all of the reporting units had a substantial amount of headroom as of <em style="font: inherit;"> April 1, 2020. </em>This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did <em style="font: inherit;">not</em> identify any triggering events after our annual goodwill impairment through <em style="font: inherit;"> June 30, 2020, </em>the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">2019</em> <i>Goodwill Impairment Analyses</i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">At the beginning of the quarter ended <em style="font: inherit;"> March 31, 2019, </em>the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">Because our quantitative analysis performed as of <em style="font: inherit;"> January 1, 2019 </em>included all of our reporting units, except for Exosome a recent acquisition that was a separate reporting unit that was <em style="font: inherit;">not</em> impacted by the business process realignment, the summation of the calculated reporting units’ fair values combined with the fair value of the Exosome acquisition, was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">The quantitative assessments completed as of <em style="font: inherit;"> January 1, 2019 </em>indicated that all tested reporting units had a substantial amount of headroom. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">In conducting our annual goodwill impairment test on <em style="font: inherit;"> April 1, </em>we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than <em style="font: inherit;">not</em> that the fair value of a reporting unit is less than its carrying amount.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">Based on its annual analysis, the Company determined there was no indication of impairment of goodwill. Further, <em style="font: inherit;">no</em> triggering events or items beyond the realignment discussed above were identified in the year ended <em style="font: inherit;"> June 30, 2019 </em>that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><em style="font: inherit;">2018</em> <i>Goodwill Impairment Analyses</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">In completing our <em style="font: inherit;">2018</em> annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units, with a process consistent to that described in our <em style="font: inherit;">2020</em> Goodwill Impairment Analyses section above. The quantitative assessment completed indicated that all of the reporting units had a substantial amount of headroom. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">There has been no impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC <em style="font: inherit;">350</em> guidance for goodwill and other intangibles on <em style="font: inherit;"> July 1, 2002.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> 1300000 600000 0 1 0 0 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Investments in unconsolidated entities: </i>The Company periodically invests in the equity of start-up and early development stage companies. The accounting treatment of each investment (cost method or equity method) is dependent upon a number of factors, including, but <em style="font: inherit;">not</em> limited to, the Company's share in the equity of the investee and the Company's ability to exercise significant influence over the operating and financial policies of the investee.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Recently Adopted Accounting Pronouncements</b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt 7.2pt 0pt -2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <i><em style="font: inherit;"> February 2016, </em></i>the FASB issued ASU <i><em style="font: inherit;">2016</em></i>-<i><em style="font: inherit;">02,</em></i> Leases (Topic <i><em style="font: inherit;">842</em></i>), which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. The FASB has issued narrow codification improvements to Leases (Topic <i><em style="font: inherit;">842</em></i>) through ASU <i><em style="font: inherit;">No.</em></i> <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">10</em></i> and ASU <i><em style="font: inherit;">2019</em></i>-<i><em style="font: inherit;">01.</em></i> Additionally, the FASB issued ASU <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">11,</em></i> allowing an entity to elect a transition method where they do <i><em style="font: inherit;">not</em></i> recast prior periods presented in the financial statements in the period of adoption. The Company has elected the transition method allowed for under ASU <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">11</em></i> when adopting Leases (Topic <i><em style="font: inherit;">842</em></i>). The Company adopted the standard effective <i><em style="font: inherit;"> July 1, 2019 </em></i>and correspondingly recorded incremental operating lease liabilities of $80.6 million, a right-of-use lease asset of $79.5 million, retained earnings of $0.8 million and a deferred tax adjustment of $0.3 million. Additionally, the Company reclassified $4.0 million of deferred rent recorded within accrued expenses under ASC <i><em style="font: inherit;">840</em></i> - Leases into operating lease liabilities upon adoption of Topic <i><em style="font: inherit;">842.</em></i> In adopting ASC <i><em style="font: inherit;">842,</em></i> the Company elected the package of available practical expedients and to use hindsight in determining the lease term for all existing leases. Further, as part of our adoption of ASC <i><em style="font: inherit;">842,</em></i> the Company also made the accounting policy elections to <i><em style="font: inherit;">not</em></i> capitalize short term leases (defined as a lease with a lease term that is less than <i><em style="font: inherit;">12</em></i> months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Refer to Note <i><em style="font: inherit;">7</em></i> for additional information on leases.</p> <p style="margin: 0pt 7.2pt 0pt -2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Pronouncements Issued but </b></i><b><em style="font: inherit;">Not</em></b><i><b> Yet Adopted</b></i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic </i><em style="font: inherit;">326</em><i>), Measurement of Credit Losses on Financial Instruments</i>. The amendment in this update replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade and loan receivables and available-for-sale debt securities. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. This ASU is effective for annual periods and interim periods for those annual periods beginning after <em style="font: inherit;"> December 15, 2019, </em>which for us is <em style="font: inherit;"> July 1, 2020. </em>Entities <em style="font: inherit;"> may </em>early adopt beginning after <em style="font: inherit;"> December 15, 2018. </em>We have completed our evaluation of the impact of the adoption of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> noting the impact of adoption is <em style="font: inherit;">not</em> expected to have a material impact on our consolidated financial statements.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> <i>Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</i>. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is <em style="font: inherit;">not</em> affected by the new standard.  This ASU is effective for annual periods and interim periods for those annual periods beginning after <em style="font: inherit;"> December 15, 2019, </em>which for us is <em style="font: inherit;"> July 1, 2020 </em>and <em style="font: inherit;"> may </em>be adopted retrospectively or prospectively to eligible costs incurred on or after the date the guidance is <em style="font: inherit;">first</em> applied. We do <em style="font: inherit;">not</em> expect this standard to have a material impact on our consolidated financial statements and we will adopt the standard prospectively on <em style="font: inherit;"> July 1, 2020.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -2pt; text-align: left;">In <i><em style="font: inherit;"> March 2020, </em></i>the FASB issued ASU <i><em style="font: inherit;">No.</em></i> <i><em style="font: inherit;">2020</em></i>-<i><em style="font: inherit;">04,</em></i> <i>Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>. This ASU provides expedients and exceptions to existing guidance on contract modifications and hedge accounting that is optional to facilitate the market transition from a reference rate, including LIBOR which is being phased out in <i><em style="font: inherit;">2021,</em></i> to a new reference rate. The provisions of the ASU would impact contract modifications and other changes that occur while LIBOR is phased out. The Company is in the process of evaluating the optional relief guidance provided within this ASU and is also reviewing its debt and derivative instrument that utilizes LIBOR as the reference rate. The Company will continue to evaluate and monitor developments and our assessment of ASU <i><em style="font: inherit;">2020</em></i>-<i><em style="font: inherit;">04</em></i> during the LIBOR transition period.</p> 80600000 79500000 800000 -300000 4000000.0 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note <em style="font: inherit;">2</em></b></i><b>.</b><i><b> Revenue Recognition:</b></i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. The vast majority of service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects. Revenue for these contracts are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has <em style="font: inherit;">no</em> alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. The remaining service revenues were <em style="font: inherit;">not</em> material to the period and consist of laboratory services recognized at point in time. Given the Company does <em style="font: inherit;">not</em> have significant historical experience collecting payments from Medicare or insurance providers, the Company considered the variable consideration for such services to be constrained as it would <em style="font: inherit;">not</em> be probable that a significant amount of revenue would <em style="font: inherit;">not</em> need to be reversed in future periods for the services provided. Accordingly, the Company does <em style="font: inherit;">not</em> record revenue upon completion of the performance obligation, but rather upon cash receipt, which is subsequent to the performance obligation being satisfied. Royalty revenues are based on net sales of the Company’s licensed products by a <em style="font: inherit;">third</em> party. We recognize royalty revenues in the period the sales occur using <em style="font: inherit;">third</em> party evidence to estimate the amount to be recorded. The Company has also elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has elected the exemption to <em style="font: inherit;">not</em> disclose the unfulfilled performance obligations for contracts with an original length of <em style="font: inherit;">one</em> year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance.  The Company's unfulfilled performance obligations for contracts with an original length greater than <em style="font: inherit;">one</em> year were <em style="font: inherit;">not</em> material as of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> June 30, 2019.</em></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Contracts with customers that contain instruments <em style="font: inherit;"> may </em>include multiple performance obligations. For these contracts, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts’ inception.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Payment terms for shipments to end-users are generally net <em style="font: inherit;">30</em> days. Payment terms for distributor shipments <em style="font: inherit;"> may </em>range from <em style="font: inherit;">30</em> to <em style="font: inherit;">90</em> days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than <em style="font: inherit;">one</em> year. We elected the practical expedient allowing us to expense costs of obtaining contracts less than <em style="font: inherit;">one</em> year that would otherwise be capitalized and amortized over the contract period. Contract assets as of <em style="font: inherit;"> June 30, 2020 </em>are <em style="font: inherit;">not</em> material.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> June 30, 2019 </em>were approximately $14.2 million and $10.4 million, respectively. Contract liabilities as of <em style="font: inherit;"> June 30, 2019 </em>subsequently recognized as revenue during the year ended <em style="font: inherit;"> June 30, </em><em style="font: inherit;">2020</em> were approximately $7.6 million. Contract liabilities in excess of <em style="font: inherit;">one</em> year are included in Other long-term liabilities on the balance sheet. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any claims for credit or return of goods must be made within <em style="font: inherit;">10</em> days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have <em style="font: inherit;">not</em> been material.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We have elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following tables present our disaggregated revenue for the periods presented.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Revenue by type is as follows:</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Year ended June 30,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>2020</i></i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>2019</i></i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><i>2018</i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Consumables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">602,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">588,979</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">534,738</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">61,784</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,459</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">34,137</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total product and services revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">721,563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">694,567</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">630,659</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,439</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">12,334</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total revenues, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">738,691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">714,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">642,993</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="margin: 0pt 7.2pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Revenue by geography is as follows:</p> <p style="margin: 0pt 7.2pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i>2020</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i>2019</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i>2018</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">404,407</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">391,191</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">346,293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">EMEA, excluding U.K.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">155,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">155,821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">148,599</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.K.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,411</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,704</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">APAC, excluding Greater China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60,362</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Greater China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,792</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47,950</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Rest of world</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,430</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,307</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,055</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total external sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">738,691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">714,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">642,993</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 14200000 10400000 7600000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Year ended June 30,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>2020</i></i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>2019</i></i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><i>2018</i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Consumables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">602,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">588,979</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">534,738</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">61,784</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,459</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">34,137</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total product and services revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">721,563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">694,567</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">630,659</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,439</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">12,334</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total revenues, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">738,691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">714,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">642,993</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i>2020</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i>2019</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i>2018</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">404,407</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">391,191</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">346,293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">EMEA, excluding U.K.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">155,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">155,821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">148,599</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.K.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,411</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,704</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">APAC, excluding Greater China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60,362</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Greater China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,792</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47,950</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Rest of world</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,430</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,307</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,055</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total external sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">738,691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">714,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">642,993</td></tr> </tbody></table> 602642000 588979000 534738000 71462000 67538000 61784000 47459000 38050000 34137000 721563000 694567000 630659000 17128000 19439000 12334000 738691000 714006000 642993000 404407000 391191000 346293000 155289000 155821000 148599000 30411000 34975000 33704000 60362000 52913000 48392000 68792000 57799000 47950000 19430000 21307000 18055000 738691000 714006000 642993000 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">3.</em></b><i><b> Supplemental Balance Sheet and Cash Flow Information:</b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b> </b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Available-For-Sale Investments:</i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of the Company's available-for-sale investments as of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> June 30, 2019 </em>were $87.8 million and $38.2 million, respectively. The increase was due to year-over-year increase in the stock price of CCXI, which was $9.30 per share at <em style="font: inherit;"> June 30, 2019 </em>compared to $57.54 per share at <em style="font: inherit;"> June 30, 2020. </em>The amortized cost basis of the Company's investment in CCXI was $6.6 million and $18.8 million as of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> respectively.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Inventories:</i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Inventories consist of (in thousands):</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51,530</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Finished goods<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">56,268</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">53,376</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Inventories, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">107,798</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">94,289</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(<em style="font: inherit;">1</em>) Finished goods inventory of $4,646 and <span style="-sec-ix-hidden:c64739071">$3,239</span> is included within other long-term assets in the <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> June 30, 2019 </em>Balance Sheets, respectively, as it forecasted to be sold after the <em style="font: inherit;">12</em> months subsequent to the consolidated balance sheet date.  </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Property and Equipment:</i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Property and equipment consist of (in thousands):</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Land</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,516</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,065</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Buildings and improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">184,430</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175,019</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Machinery, equipment and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">153,704</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">124,233</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">346,650</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">306,317</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(169,821</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(152,278</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">176,829</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">154,039</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangibles assets were comprised of the following (in thousands):</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom;"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Useful Life</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>(years)</i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><em style="font: inherit;">2020</em></i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><em style="font: inherit;">2019</em></i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 55%;"> </td><td style="width: 1%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">434,653</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">435,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Trade names</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">146,713</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">147,296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">211,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">214,320</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">2,475</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">2,133</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">795,591</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">799,428</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(279,046</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(219,999</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Intangibles assets, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">516,545</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">579,429</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Changes to the carrying amount of net intangible assets consist of (in thousands):</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>2020</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>2019</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">579,429</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">446,332</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Acquisitions (Note 4)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">191,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other additions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">633</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Amortization expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(61,095</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(58,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Currency translation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(2,100</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(777</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">516,545</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">579,429</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Amortization expense related to technologies included in cost of sales was $34.5 million, $33.3 million, and $25.3 million in fiscal <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was $26.6  million, $25.4 million, and $21.6 million, in fiscal <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> respectively.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The estimated future amortization expense for intangible assets as of <em style="font: inherit;"> June 30, 2020 </em>is as follows (in thousands):</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 83%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">53,198</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,024</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">240,297</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">516,545</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Changes in goodwill by segment and in total consist of (in thousands):</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Protein</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Sciences</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Diagnostics &amp;</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Genomics</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Total</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">June 30, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">249,972</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">597,890</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Acquisitions (Note 4)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">105,362</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">136,301</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Currency translation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1,450</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(74</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1,524</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">377,407</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">355,260</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">732,667</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Acquisitions (Note 4)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(326</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(326</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Currency Translation</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(4,000</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(31</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(4,031</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">June 30, 2020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">373,081</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">355,229</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">728,310</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Other Assets:</i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Other assets consist of (in thousands):</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-term deposits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,234</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">487</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">7,288</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">5,181</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Other long-term assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">13,522</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">5,668</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of <em style="font: inherit;"> June 30, 2020, </em>the Company had $13.5 million of other assets compared to $5.7 million as of <em style="font: inherit;"> June 30, 2019.  </em>The increase in other long-term assets in fiscal <em style="font: inherit;">2020</em> is primarily attributable to deposits made on our GMP manufacturing facility. </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Supplemental Cash Flow Information:</i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Supplemental cash flow information was as follows (in thousands):</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2018</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income taxes paid</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,992</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,814</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,076</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest paid</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,497</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,844</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-cash activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Acquisition-related liabilities <sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,105</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,396</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;"> </p> </td><td> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">1</em>)</sup> Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes <em style="font: inherit;">4</em> and <em style="font: inherit;">5.</em></p> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> 87800000 38200000 9.30 57.54 6600000 18800000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51,530</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Finished goods<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">56,268</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">53,376</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Inventories, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">107,798</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">94,289</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 51530000 40913000 56268000 53376000 107798000 94289000 4646000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Land</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,516</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,065</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Buildings and improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">184,430</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175,019</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Machinery, equipment and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">153,704</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">124,233</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">346,650</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">306,317</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(169,821</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(152,278</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">176,829</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">154,039</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 8516000 7065000 184430000 175019000 153704000 124233000 346650000 306317000 169821000 152278000 176829000 154039000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom;"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Useful Life</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>(years)</i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><em style="font: inherit;">2020</em></i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><em style="font: inherit;">2019</em></i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 55%;"> </td><td style="width: 1%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">434,653</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">435,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Trade names</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">146,713</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">147,296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">211,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">214,320</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">2,475</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">2,133</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">795,591</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">799,428</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(279,046</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(219,999</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Intangibles assets, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">516,545</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">579,429</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> P9Y P15Y 434653000 435679000 P2Y P20Y 146713000 147296000 P7Y P16Y 211750000 214320000 P10Y 2475000 2133000 795591000 799428000 279046000 219999000 516545000 579429000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>2020</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>2019</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">579,429</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">446,332</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Acquisitions (Note 4)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">191,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other additions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">633</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Amortization expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(61,095</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(58,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Currency translation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(2,100</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(777</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">516,545</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">579,429</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 579429000 446332000 0 191956000 311000 633000 61095000 58715000 2100000 777000 516545000 579429000 34500000 33300000 25300000 26600000 25400000 21600000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 83%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">53,198</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,024</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">240,297</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">516,545</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 59766000 57564000 55696000 53198000 50024000 240297000 516545000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Protein</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Sciences</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Diagnostics &amp;</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Genomics</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Total</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">June 30, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">249,972</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">597,890</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Acquisitions (Note 4)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">105,362</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">136,301</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Currency translation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1,450</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(74</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1,524</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">377,407</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">355,260</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">732,667</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Acquisitions (Note 4)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(326</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(326</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Currency Translation</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(4,000</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(31</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(4,031</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">June 30, 2020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">373,081</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">355,229</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">728,310</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 347918000 249972000 597890000 30939000 105362000 136301000 -1450000 -74000 -1524000 377407000 355260000 732667000 -326000 0 -326000 -4000000 -31000 -4031000 373081000 355229000 728310000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-term deposits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,234</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">487</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">7,288</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">5,181</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Other long-term assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">13,522</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">5,668</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 6234000 487000 7288000 5181000 13522000 5668000 13500000 5700000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2018</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income taxes paid</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,992</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,814</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,076</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest paid</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,497</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,844</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-cash activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Acquisition-related liabilities <sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,105</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,396</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 41992000 36814000 35076000 18615000 21497000 9844000 -2105000 12600000 1396000 <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note <em style="font: inherit;">4</em></b></i><b>.</b><i><b> Acquisitions:</b></i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">2019</em> <i>Acquisitions</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Quad Technologies</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">On <em style="font: inherit;"> July 2, 2018, </em>the Company acquired QT Holdings Corporation (Quad) for approximately $20.5 million, net of cash acquired, plus contingent consideration of up to $51.0 million, subject to certain product development milestones and revenue thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is <span style="-sec-ix-hidden:c64739215">not</span> deductible for income tax purposes. The business became part of the Protein Sciences operating segment in the <em style="font: inherit;">first</em> quarter of fiscal year <em style="font: inherit;">2019.</em> Purchase accounting was finalized during fiscal <em style="font: inherit;">2019.</em></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible assets acquired in fiscal <em style="font: inherit;">2019</em> is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is <em style="font: inherit;">not</em> deductible for income tax purposes offset by the deferred tax asset for our calculation of acquired net operating losses (NOLs).</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Exosome Diagnostics</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">On <em style="font: inherit;"> August 1, 2018, </em>the Company acquired Exosome Diagnostics, Inc. (ExosomeDx) for approximately $251.6 million, net of cash acquired, plus contingent consideration of up to $325.0 million, subject to certain EBITA thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’ product portfolio and the expected revenue growth from increased market penetration. The goodwill is <span style="-sec-ix-hidden:c64739224">not</span> deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the <em style="font: inherit;">first</em> quarter of fiscal year <em style="font: inherit;">2019.</em> Purchase accounting was finalized during fiscal <em style="font: inherit;">2019.</em> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using either a relief-from-royalty or a multiperiod excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal <em style="font: inherit;">2019</em> are 15 years for developed technology and trade names, and 14 years for customer relationships. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is <em style="font: inherit;">not</em> deductible for income tax purposes offset by the deferred tax asset for the preliminary calculation of acquired NOLs.</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Note: As part of the ExosomeDx acquisition, a certain amount of the cash payment was held in escrow. As part of the finalization of the outstanding amounts held in escrow, the Company recognized a gain of $7.2 million related to returned proceeds and a relief of any future contingent payments as described in Note <em style="font: inherit;">5.</em> The gain was recorded within selling, general, and administrative costs in the Consolidated Statement of Comprehensive Income. </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>B-MoGen Biotechnologies</i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">On <em style="font: inherit;"> June 4, 2019, </em>the Company acquired the remaining interest in B-MoGen Biotechnologies Inc. (B-MoGen) for approximately $17.5 million, net of cash acquired, plus contingent consideration of up to $38.0 million, subject to certain product development milestones and revenue thresholds. The Company previously held an investment of $1.4 million in B-MoGen and recognized a gain of approximately $3.7 million on the transaction within other non-operating income fiscal year <em style="font: inherit;">2019</em> in the consolidated statements of earnings and comprehensive income, which represented the adjustment of our historical investment to its fair value. </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is <span style="-sec-ix-hidden:c64739240">not</span> deductible for income tax purposes. The business became part of the Protein Sciences segment in the <em style="font: inherit;">fourth</em> quarter of fiscal year <em style="font: inherit;">2019.</em> Purchase accounting remained opened as disclosed in our prior year <em style="font: inherit;">10</em>-K/A for working capital adjustments and our income tax assessment of acquired net operating losses (NOLs) with the completion of the stub period tax returns. Our purchase accounting was finalized in fiscal <em style="font: inherit;">2020</em> with an immaterial adjustment of $0.3 million to deferred tax amounts and goodwill. </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible asset acquired in fiscal <em style="font: inherit;">2019</em> is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is <em style="font: inherit;">not</em> deductible for income tax purposes offset by the deferred tax asset for the preliminary calculation of acquired NOLs.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">2018</em><i> Acquisitions</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Trevigen</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em style="font: inherit;"> September 5, 2017 </em>the Company acquired the stock of Trevigen Inc. for approximately $10.6 million, net of cash received. The Company has had a long-standing business relationship with Trevigen as a distributor of its product line. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is <span style="-sec-ix-hidden:c64739252">not</span> deductible for income tax purposes. The business became part of the Protein Sciences segment in the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2018.</em> <i><b> </b></i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Atlanta Biologicals</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em style="font: inherit;"> January 2, 2018 </em>the Company acquired the stock of Atlanta Biologicals, Inc. and its affiliated company, Scientific Ventures, Inc., for approximately $51.3 million, net of cash acquired. The transaction was financed through available cash on hand and an additional draw from the Company’s line-of-credit. Atlanta Biologicals fetal bovine serum (FBS) product line strengthens and complements our current tissue culture reagents offering and furthers our efforts to provide more complete solutions to our research customers. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is <span style="-sec-ix-hidden:c64739256">not</span> deductible for income tax purposes. The business became part of the Protein Sciences segment in the <em style="font: inherit;">third</em> quarter of fiscal <em style="font: inherit;">2018.</em> Purchase accounting was finalized during fiscal <em style="font: inherit;">2018.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Tangible assets acquired in the acquisition, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal <em style="font: inherit;">2018</em> are 13 years for developed technology, 12 years for customer relationships, and 15 years for trade names. The deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are <em style="font: inherit;">not</em> deductible for income tax purposes.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Eurocell Diagnostics</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em style="font: inherit;"> February 1, 2018, </em>the Company acquired Eurocell Diagnostics SAS, a company based in Rennes, France, for approximately $7.3 million, net of cash acquired. The Company paid $6.0 million on the acquisition date and the remaining $1.3 million was paid on <em style="font: inherit;"> February 1, 2019. </em>The Company has had a long-standing business relationship with Eurocell as a distributor of its product line. Eurocell sells directly to the laboratory markets in the French region as well as servicing the EMEA markets via a network of distributors. The transaction was financed through cash on hand.  The primary asset in this acquisition is the customer relationships; however, the acquisition resulted in some goodwill as we expect strategic benefits of revenue growth from increased market penetration. The goodwill is <span style="-sec-ix-hidden:c64739269">not</span> deductible for income tax purposes. The business became part of the Company’s Diagnostics and Genomics segment in the <em style="font: inherit;">third</em> quarter of fiscal <em style="font: inherit;">2018.</em> Purchase accounting was finalized during fiscal <em style="font: inherit;">2018.</em> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Tangible assets acquired, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to customer relationships was based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. Amortization expense related customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships acquired in fiscal <em style="font: inherit;">2018</em> is 7 years. The deferred income tax liability represents the net amount of the estimated future impact of intangible asset amortization, which is <em style="font: inherit;">not</em> deductible for income tax purposes.</p> <p style="margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">B-MoGen Biotechnologies</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Exosome Diagnostics</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Quad Technologies</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Trevigen</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">Atlanta Biologicals</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">Eurocell Diagnostics</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current assets, net of cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">504</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,611</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,722</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">512</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Equipment and other long-term assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">269</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">228</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,901</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">188</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="24" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Intangible assets:</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Developed technology</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">14,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">105,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12,256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Trade name</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">58,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">160</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">260</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,272</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">16,131</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">105,362</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">14,481</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,195</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,910</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">31,304</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">275,485</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">27,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,226</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,718</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,882</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">211</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3,716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">3,051</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">16,346</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">943</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,195</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,354</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">28,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">255,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">25,762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,644</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash paid, net of cash acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">17,448</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">251,623</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,644</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51,274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,933</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Consideration payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,396</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Contingent consideration payable</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">5,094</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">3,800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">5,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net assets acquired</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">28,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">255,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">25,762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,644</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of good sold in the Consolidated Statements of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statements of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are <em style="font: inherit;">not</em> deductible for income tax purposes, and the future tax benefit of net operating loss and tax credit carryforwards which will be deductible by the Company in future periods. </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"> </p> 20500000 51000000.0 P14Y 251600000 325000000.0 P15Y P14Y 7200000 17500000 38000000.0 1400000 3700000 300000 P14Y 10600000 51300000 P13Y P12Y P15Y 7300000 6000000.0 1300000 P7Y <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">B-MoGen Biotechnologies</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Exosome Diagnostics</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Quad Technologies</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Trevigen</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">Atlanta Biologicals</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">Eurocell Diagnostics</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current assets, net of cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">504</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,611</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,722</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">512</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Equipment and other long-term assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">269</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">228</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,901</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">188</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="24" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Intangible assets:</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Developed technology</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">14,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">105,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12,256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Trade name</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">58,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">160</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">260</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,272</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">16,131</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">105,362</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">14,481</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,195</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,910</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">31,304</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">275,485</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">27,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,226</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,718</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,882</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">211</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3,716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">3,051</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">16,346</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">943</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,195</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,354</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">28,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">255,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">25,762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,644</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash paid, net of cash acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">17,448</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">251,623</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,644</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51,274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,933</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Consideration payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,396</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Contingent consideration payable</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">5,094</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">3,800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">5,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net assets acquired</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">28,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">255,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">25,762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,644</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt;"> </p> 504000 2611000 36000 1662000 15722000 512000 269000 2212000 228000 53000 4901000 188000 14000000 105000000 12256000 5100000 23000000 58000000 160000 2300000 400000 2300000 260000 3600000 6272000 16131000 105362000 14481000 5991000 10195000 2910000 31304000 275485000 27001000 13226000 59718000 9882000 211000 3716000 296000 387000 90000 483000 3051000 16346000 943000 2195000 8354000 2070000 28042000 255423000 25762000 10644000 51274000 7329000 17448000 251623000 20462000 10644000 51274000 5933000 5500000 0 0 0 0 1396000 5094000 3800000 5300000 0 0 0 28042000 255423000 25762000 10644000 51274000 7329000 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">5.</em></b><i><b> Fair Value Measurements:</b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into <em style="font: inherit;">three</em> levels. Level <em style="font: inherit;">1</em> inputs are quoted prices in active markets for identical assets or liabilities. Level <em style="font: inherit;">2</em> inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are <em style="font: inherit;">not</em> active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level <em style="font: inherit;">3</em> inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least <em style="font: inherit;">one</em> significant model assumption or input is unobservable. Level <em style="font: inherit;">3</em> <em style="font: inherit;"> may </em>also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-right: 5%;"><tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Total carrying</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>value as of</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Fair Value Measurements Using</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Inputs Considered as</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>June 30, 2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 1</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 2</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 3</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 48%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Equity securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">87,842</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">79,846</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,996</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Certificates of deposit <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">36,426</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">36,426</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">124,268</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">116,272</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">7,996</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,137</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,137</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">    Derivative instruments - cash flow hedges</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">17,331</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">17,331</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">    Total Liabilities</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">23,468</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">17,331</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">6,137</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-right: 5%;"><tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Total carrying</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>value as of</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Fair Value Measurements Using</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Inputs Considered as</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>June 30, 2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 1</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 2</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 3</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 48%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Equity securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">38,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">38,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Certificates of deposit <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">26,928</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">26,928</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">65,147</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">65,147</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Liabilities</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Contingent consideration</td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">12,600</td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">12,600</td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Derivative instruments - cash flow hedges</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">12,458</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"></td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">12,458</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"></td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Total Liabilities</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">25,058</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">12,458</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">12,600</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;"><tbody><tr style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"><td style="width: 18pt; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">1</em>)</sup> Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> June 30, 2019 </em>was $6.6 million and $18.8 million respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $8.0 million as of <em style="font: inherit;"> June </em><em style="font: inherit;">30,</em> <em style="font: inherit;">2020.</em> The fair value of the warrant as of <em style="font: inherit;"> June 30, 2019 </em>was <em style="font: inherit;">not</em> material. </p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 18pt; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">2</em>)</sup> Included in available-for-sale investments on the balance sheet.  The certificate of deposits have contractual maturity dates within <em style="font: inherit;">one</em> year.</td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Fair value measurements of available for sale securities</i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Available for sale securities excluding warrants are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level <i><em style="font: inherit;">1</em></i> assets. The Company's warrant to purchase additional shares at a specified future price was valued using a Black-Scholes model with observable inputs in active markets and therefore was classified as a Level <i><em style="font: inherit;">2</em></i> asset. </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Fair value measurements of derivative instruments</i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">In <em style="font: inherit;"> October 2018, </em>the Company entered into forward starting swaps designated as cash flow hedges on outstanding debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt described in Note <em style="font: inherit;">6</em> to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company will exchange, at specified intervals, the difference between floating and fixed interest amounts based on an initial $380 million of notional principal amount, with the notional amount decreasing by $100 million in <em style="font: inherit;"> October, 2020, </em>$80 million in <em style="font: inherit;"> October 2021, </em>and $200 million in <em style="font: inherit;"> October 2022. </em>The change in the fair value of the designated hedged instrument is reported as a component of other comprehensive income and reclassified into interest expense over the corresponding term of the cash flow hedge. The Company reclassified $3.5 million, net of taxes, out of other comprehensive income into interest expense during the fiscal year ended <em style="font: inherit;"> June 30, </em><em style="font: inherit;">2020.</em> In <em style="font: inherit;"> June 2020, </em>the Company de-designated $80 million of the notional amount set to expire in <em style="font: inherit;"> October 2020. </em>The change in fair value of the dedesignated notional hedged amount was <em style="font: inherit;">not</em> material as of <em style="font: inherit;"> June 30, 2020. </em>The net loss associated with the dedesignated portion of the derivative instrument was <em style="font: inherit;">not</em> reclassified into earnings based on the amount of probable variable interest payments to occur within a <em style="font: inherit;">two</em> month time period of the forecasted hedged transaction. The liability related to the derivative instrument was recorded within Other long-term liabilities on the Consolidated Balance Sheet. The instrument was valued using observable market inputs in active markets and therefore classified as a Level <em style="font: inherit;">2</em> liability.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Fair value measurements of contingent consideration</i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">In connection with the ExosomeDx, Quad, and B-Mogen acquisitions the Company is required to make contingent consideration payments of up to $325.0 million, $51.0 million, and $38.0 million respectively. The contingent consideration agreement with ExosomeDx was based on achieving certain EBITA thresholds, the contingent agreement with Quad is based on meeting certain product development milestones and revenue thresholds, and the contingent agreement with B-Mogen is based on meeting certain product development milestones and revenue thresholds. The preliminary fair value of the liabilities for the contingent payments recognized upon the acquisition as part of the purchase accounting opening balance sheet totaled $14.6 million ($3.8 million for ExosomeDx, $5.3 million for Quad, and $5.5 million for B-Mogen) as discussed in Note <em style="font: inherit;">4.</em>  The preliminary fair value of the development milestone payments was estimated by discounting the probability-weighted contingent payments expected to be made to present value. Assumptions used in these calculations were probability of success, duration of the earn-out, and discount rate.   The preliminary fair value for the EBITA and revenue milestone payments was determined using a Monte Carlo simulation-based model discounted to present value.  Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate and various probability factors.</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">During the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2020,</em> the Company's obligation for potential contingent consideration payments related to the ExosomeDx acqusition were relieved as part of the Company's escrow settlement with the former shareholders of ExosomeDx. As the result of this settlement, the Company reversed an accrual for the fair value of the contingent liability at the date of settlement. The ultimate settlement of contingent consideration liabilities for the Quad and B-Mogen acquisitions could deviate from current estimates based on the actual results of the financial measures described above. This liability is considered to be a Level <em style="font: inherit;">3</em> financial liability that is re-measured each reporting period. The change in fair value of contingent consideration for these acquisitions is included in general and administrative expense.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level <em style="font: inherit;">3</em>) (in thousands):</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-right: 10%;"><tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>2020</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>2019</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 66%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value at the beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Purchase price contingent consideration (Note 4)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,358</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Gain on escrow settlement</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,200</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(905</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(2,000</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Contingent consideration payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">6,137</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">12,600</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>Fair value measurements of other financial instruments </i>– The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility  and long-term debt approximates fair value because our interest rate is variable and reflects current market rates.<i><b> </b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-right: 5%;"><tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Total carrying</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>value as of</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Fair Value Measurements Using</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Inputs Considered as</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>June 30, 2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 1</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 2</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 3</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 48%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Equity securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">87,842</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">79,846</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,996</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Certificates of deposit <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">36,426</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">36,426</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">124,268</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">116,272</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">7,996</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,137</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,137</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">    Derivative instruments - cash flow hedges</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">17,331</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">17,331</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">    Total Liabilities</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">23,468</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">17,331</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">6,137</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-right: 5%;"><tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Total carrying</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>value as of</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Fair Value Measurements Using</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Inputs Considered as</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>June 30, 2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 1</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 2</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Level 3</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 48%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Equity securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">38,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">38,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Certificates of deposit <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">26,928</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">26,928</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">65,147</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">65,147</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Liabilities</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Contingent consideration</td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">12,600</td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">12,600</td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Derivative instruments - cash flow hedges</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">12,458</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"></td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">12,458</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"></td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Total Liabilities</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">25,058</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">12,458</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">12,600</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 87842000 79846000 7996000 0 36426000 36426000 0 0 124268000 116272000 7996000 0 6137000 0 0 6137000 17331000 0 17331000 0 23468000 0 17331000 6137000 38219000 38219000 0 0 26928000 26928000 0 0 65147000 65147000 0 0 12600000 12600000 12458000 12458000 25058000 0 12458000 12600000 6600000 18800000 8000000.0 380000000 100000000 80000000 200000000 3500000 80000000 325000000.0 51000000.0 38000000.0 14600000 3800000 5300000 5500000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-right: 10%;"><tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>2020</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i>2019</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 66%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value at the beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Purchase price contingent consideration (Note 4)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,358</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Gain on escrow settlement</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,200</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(905</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(2,000</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Contingent consideration payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">6,137</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">12,600</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 12600000 0 0 14600000 4358000 -0 1200000 905000 2000000 6137000 12600000 <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">6</em></b><i><b>. Debt and Other Financing Arrangements: </b></i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b> </b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em style="font: inherit;"> August 1, 2018, </em>the Company entered into a new uncollateralized revolving line-of-credit and term loan governed by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $600.0 million, which can be increased by an additional $200.0 million subject to certain conditions, and a term loan of $250.0 million. Borrowings under the Credit Agreement <em style="font: inherit;"> may </em>be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the Eurodollar Loans term for which the interest rate is calculated as the sum of LIBOR plus an applicable margin. The applicable margin is determined for the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 15 basis points. The Company has recorded $12.5 million of our outstanding borrowings under the Credit Agreement as a current liability in our Consolidated Balance sheet, which represents our required quarterly debt payments to be made in fiscal year <em style="font: inherit;">2021.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Credit Agreement matures on <em style="font: inherit;"> August 1, 2023 </em>and contains customary restrictive and financial covenants and customary events of default. At the closing on <em style="font: inherit;"> August 1, 2018 </em>the company borrowed $250.0 million under the term loan and $330.0 million under the revolving credit facility. As of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> the outstanding balance under the Credit Agreement was $357 million and $505.2 million respectively. </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">  </p> 600000000.0 200000000.0 250000000.0 0.0015 12500000 250000000.0 330000000.0 357000000 505200000 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note <em style="font: inherit;">7.</em> Leases:</b></i> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em> and related standards (collectively ASC <em style="font: inherit;">842,</em> <i>Leases</i>), which replaced previous lease accounting guidance, on <em style="font: inherit;"> July 1, 2019. </em></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><br/> The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company’s incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During fiscal year <em style="font: inherit;">2020,</em> the Company recognized $3.4 million in variable lease expense in the Consolidated Statements of Earnings and Comprehensive Income.  During fiscal year <em style="font: inherit;">2020,</em> the Company also recognized $13.0 million relating to fixed lease expense in the Consolidated Statements of Earnings and Comprehensive Income. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The following table summarizes the balance sheet classification of the Company’s operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands):</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 37.8%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Balance Sheet Classification</i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i><i>As of: </i></i></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i><i>June 30,</i></i></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i><i>2020</i></i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating leases:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Operating lease right of use assets</p> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><em style="font: inherit;">Right of Use Asset</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">71,465</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Current operating lease liabilities</p> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><em style="font: inherit;">Operating lease liabilities current</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,535</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Noncurrent operating lease liabilities</p> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><em style="font: inherit;">Operating lease liabilities</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,248</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 27pt;">Total operating lease liabilities</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">76,783</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 18pt;">Weighted average remaining lease term (in years):</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 18pt;">Weighted average discount rate:</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended  <em style="font: inherit;"> June 30, 2020 (</em>in thousands):</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>For the year ended June 30, <i>2020</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash amounts paid on operating lease liabilities(1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,763</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Right of use assets obtained in exchange for lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,758</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">(<em style="font: inherit;">1</em>) Total cash paid for the Company's operating leases during the year ended <em style="font: inherit;"> June 30, 2020 </em>include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.  </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The following table summarizes payments by date for the Company’s operating leases, which is then reconciled to our total lease obligation (in thousands):</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2020</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Operating</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Leases</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,317</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,388</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,316</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">93,020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Less: Amounts representing interest</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,237</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total lease obligations</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,783</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Certain leases include <em style="font: inherit;">one</em> or more options to renew, with terms that extend the lease term up to <span style="-sec-ix-hidden:c64739505">five</span> years. The Company includes option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is <em style="font: inherit;">not</em> reasonably certain to exercise such options.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i><b>Disclosures related to periods prior to adoption of new lease standard:</b></i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">At <em style="font: inherit;"> June 30, 2019, </em>aggregate net minimum rental commitments under non-cancelable leases having an initial or remaining term of more than <em style="font: inherit;">one</em> year are payable as follows (in thousands):</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Operating</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Leases</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,469</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,154</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,895</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Total rent expense was approximately $12.9 million, $10.8 million, and $9.8 million for the years ended <em style="font: inherit;"> June 30, 2019, </em><em style="font: inherit;">2018,</em> and <em style="font: inherit;">2017,</em> respectively. <b> </b></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> 3400000 13000000.0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 37.8%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Balance Sheet Classification</i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i><i>As of: </i></i></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i><i>June 30,</i></i></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i><i><i>2020</i></i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating leases:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Operating lease right of use assets</p> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><em style="font: inherit;">Right of Use Asset</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">71,465</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Current operating lease liabilities</p> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><em style="font: inherit;">Operating lease liabilities current</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,535</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Noncurrent operating lease liabilities</p> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><em style="font: inherit;">Operating lease liabilities</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,248</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 27pt;">Total operating lease liabilities</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">76,783</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 18pt;">Weighted average remaining lease term (in years):</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 18pt;">Weighted average discount rate:</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> 71465000 9535000 67248000 76783000 P8Y8M19D 0.0440 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>For the year ended June 30, <i>2020</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash amounts paid on operating lease liabilities(1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,763</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Right of use assets obtained in exchange for lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,758</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 12763000 1758000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2020</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Operating</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Leases</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,317</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,388</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,316</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">93,020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Less: Amounts representing interest</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,237</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total lease obligations</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,783</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 12590000 12113000 11296000 10317000 9388000 37316000 93020000 16237000 76783000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Operating</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Leases</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,469</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,154</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,895</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 13707000 13469000 13154000 12716000 11392000 51895000 116333000 12900000 10800000 9800000 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">8.</em></b><i><b> </b></i><i><b>Supplemental Equity and </b></i><i><b>Accumulated Other Comprehensive Income (loss): </b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b> </b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Supplemental Equity </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has declared cash dividends per share of $1.28 in each of the full fiscal years ended  <em style="font: inherit;"> June 30, 2020, </em><em style="font: inherit;"> June 30, 2019, </em>and <em style="font: inherit;"> June 30, 2018. </em>During the years ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> June 30, 2019, </em>the Company repurchased 279,381 shares at an average share price of $179.37 and 95,000 shares at an average share price of $162.15, respectively. The Company's accounting policy is to record the portion of share repurchases in excess of the par value entirely in retained earnings. During fiscal year <em style="font: inherit;">2020,</em> the Company recorded ($0.4) million within the Consolidated Statements of Shareholders' Equity for the surrender and retirement of stock to exercise option due to net settlement stock options exercises. </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Accumulated Other Comprehensive Income (loss) </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Changes in accumulated other comprehensive income (loss), net of tax, at <em style="font: inherit;"> June 30 </em>consists of (in thousands):</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b> </b></i></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Unrealized</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Gains (Losses)</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>on Available-</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>for-Sale </i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Investments</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Foreign </i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Currency</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Translation </i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Adjustments</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Unrealized Gains (Losses) on Derivatives Instruments</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Total</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2017</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(67,924</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(48,935</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income (loss) before reclassifications</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,108</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Amounts reclassified from accumulated other comprehensive loss to income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(12,415</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(12,415</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24,682</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(69,496</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(44,814</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Cumulative effect adjustment for adoption for ASU 2018-02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,371</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,371</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Cumulative effect adjustment for adoption for ASU 2016-01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(27,053</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(27,053</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income (loss) before reclassifications </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(4,487</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(9,537</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(14,024</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(73,983</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(9,537</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(83,521</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Other comprehensive income (loss) before reclassifications</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(9,963</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(7,179</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(17,142</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Reclassification from loss on derivatives to interest expense, net of taxes<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">3,464</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">3,464</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Balance June 30, 2020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(83,946</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(13,253</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(97,199</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> <p style="margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">1</em>)</sup> Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made.The Company reclassified ($4,503) to interest expense and a related tax benefit tax of $1,040 during fiscal <em style="font: inherit;">2020.</em> Approximately $7,035 of the $13,253 will be reclassified in the <em style="font: inherit;">12</em> months subsequent to <em style="font: inherit;"> June 30, 2020. </em>The Company had deferred tax benefits of $4,058 and $2,921 included in the accumulated other comprehensive income loss as of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> June 30, 2019</em><i>, </i>respectively.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> 1.28 279381 179.37 95000 162.15 -400000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Unrealized</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Gains (Losses)</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>on Available-</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>for-Sale </i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Investments</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Foreign </i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Currency</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Translation </i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Adjustments</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i>Unrealized Gains (Losses) on Derivatives Instruments</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><i><i>Total</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2017</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(67,924</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(48,935</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income (loss) before reclassifications</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,108</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Amounts reclassified from accumulated other comprehensive loss to income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(12,415</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(12,415</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24,682</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(69,496</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(44,814</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Cumulative effect adjustment for adoption for ASU 2018-02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,371</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,371</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Cumulative effect adjustment for adoption for ASU 2016-01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(27,053</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(27,053</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income (loss) before reclassifications </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(4,487</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(9,537</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(14,024</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(73,983</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(9,537</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(83,521</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Other comprehensive income (loss) before reclassifications</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(9,963</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(7,179</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(17,142</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Reclassification from loss on derivatives to interest expense, net of taxes<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">3,464</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">3,464</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Balance June 30, 2020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">-</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(83,946</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(13,253</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(97,199</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> 18989000 -67924000 0 -48935000 18108000 -1572000 0 16536000 12415000 -0 -0 12415000 24682000 -69496000 0 -44814000 2371000 0 0 2371000 -27053000 0 0 -27053000 0 -4487000 -9537000 -14024000 0 -73983000 -9537000 -83521000 0 -9963000 -7179000 -17142000 -0 -0 -3464000 -3464000 0 -83946000 -13253000 -97199000 4503000 1040000 7035000 -13253000 -4058000 -2921000 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">9.</em></b><i><b> Earnings Per Share:</b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>2019</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>8</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Earnings per share – basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Income allocated to participating securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(224</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(105</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(108</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Income available to common shareholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">229,072</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">95,967</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">126,042</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average shares outstanding – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Earnings per share – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.54</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Earnings per share – diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Income allocated to participating securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(224</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(105</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(108</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Income available to common shareholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">229,072</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">95,967</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">126,042</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average shares outstanding – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Dilutive effect of stock options and restricted stock units</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,200</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,111</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">579</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average common shares outstanding – diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">39,401</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">38,892</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">38,055</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Earnings per share – diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have <em style="font: inherit;">not</em> yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.9 million, 1.3 million, and 0.9 million for the fiscal years ended <em style="font: inherit;"> June 30, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>2019</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>8</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Earnings per share – basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Income allocated to participating securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(224</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(105</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(108</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Income available to common shareholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">229,072</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">95,967</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">126,042</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average shares outstanding – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Earnings per share – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.54</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Earnings per share – diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Income allocated to participating securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(224</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(105</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(108</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Income available to common shareholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">229,072</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">95,967</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">126,042</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average shares outstanding – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Dilutive effect of stock options and restricted stock units</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,200</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,111</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">579</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average common shares outstanding – diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">39,401</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">38,892</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">38,055</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Earnings per share – diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 229296000 96072000 126150000 224000 105000 108000 229072000 95967000 126042000 38201000 37781000 37476000 6.00 2.54 3.36 229296000 96072000 126150000 224000 105000 108000 229072000 95967000 126042000 38201000 37781000 37476000 1200000 1111000 579000 39401000 38892000 38055000 5.82 2.47 3.31 900000 1300000 900000 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">10.</em></b><i><b> Share-based Compensation and Other Benefit Plans:</b></i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Equity incentive plan:</i> The Company's Second Amended and Restated <em style="font: inherit;">2010</em> Equity Incentive Plan (the Second A&amp;R <em style="font: inherit;">2010</em> Plan) provides for the granting of incentive and nonqualified stock options, restricted stock, restricted stock units, performance shares, performance units and stock appreciation rights. There are 7.5 million shares of common stock authorized for grant under the Second A&amp;R <em style="font: inherit;">2010</em> Plan. At <em style="font: inherit;"> June 30, 2020, </em>there were 1.9 million shares of common stock available for grant under the Second A&amp;R <em style="font: inherit;">2010</em> Plan. The maximum term of incentive options granted under the Second A&amp;R <em style="font: inherit;">2010</em> Plan is <span style="-sec-ix-hidden:c64739668">ten</span> years. The Second A&amp;R <em style="font: inherit;">2010</em> Plan amended and restated the Company's Amended and Restate <em style="font: inherit;">2010</em> Equity Incentive Plan (the A&amp;R <em style="font: inherit;">2010</em> Plan). The A&amp;R <em style="font: inherit;">2010</em> Plan replaced the Company's <em style="font: inherit;">1998</em> Nonqualified Stock Option Plan (the <em style="font: inherit;">1998</em> Plan). The Second A&amp;R <em style="font: inherit;">2010</em> Plan and the <em style="font: inherit;">1998</em> Plan (collectively, the Plans) are administered by the Board of Directors and its Executive Compensation Committee, which determine the persons who are to receive awards under the Plans, the number of shares subject to each award and the term and exercise price of each award. The number of shares of common stock subject to outstanding awards as of  <em style="font: inherit;"> June 30, 2020 </em>under the Second A&amp;R <em style="font: inherit;">2010</em> Plan were 3.6 million. For <em style="font: inherit;"> June 30, 2019 </em>under the Second A&amp;R <em style="font: inherit;">2010</em> Plan and the <em style="font: inherit;">1998</em> Plan were 3.6 million and 20,000, respectively.  On <em style="font: inherit;"> April 26, 2018 </em>the Executive Compensation Committee of the Board of Directors approved a modification to the Plans.   The modification implements a new retirement policy that permits retirees to continue vesting in certain time-based stock options granted during employment, resulting in accelerated stock compensation expense for those employees meeting the definition of retirement eligible.  This modification resulted in an additional $8.3 million of expense during fiscal year <em style="font: inherit;">2018</em> and affected all employees who participate in the plan.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">  </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="13" style="width: 36%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Year Ended June 30,</i></i></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>2020</i></i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>2019</i></i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>2018</i></i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 58%;"> </td><td style="width: 1%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.67%</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.74%</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.1%</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">23%</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">24%</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Risk-free interest rates</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.3%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.9%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.5%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.0%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.7%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.8%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected lives (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.0</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.1</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.7</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stock option activity under the Plans for the <em style="font: inherit;">three</em> years ended <em style="font: inherit;"> June 30, 2020, </em>consists of the following (shares in thousands): </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Number of </i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Shares (in</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>thousands)</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Weighted<br/> Average<br/> Exercise<br/> Price</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Aggregate<br/> Intrinsic<br/> Value</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>(millions)</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Weighted</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Average</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Contractual</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Life (years)</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2017</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">98.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,087</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">120.67</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(252</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86.62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(204</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">111.51</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,452</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">105.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">917</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">173.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">129.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(383</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">95.29</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,656</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121.16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">190.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95.97</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(743</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">157.45</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">3,609</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">140.28</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">446.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2018:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,151</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90.75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2019:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,467</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">98.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2020:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">112.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">236.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">  </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The weighted average fair value of options granted during fiscal <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> was $37.01, $34.66, and $22.07 respectively. The total intrinsic value of options exercised during fiscal <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> were $99.3 million, $159.0 million, and $10.6 million, respectively. The total fair value of options vested during fiscal <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> were $71.1 million, $31.7 million, and $8.8 million, respectively.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Restricted common stock activity under the Plans for the <em style="font: inherit;">three</em> years ended <em style="font: inherit;"> June 30, 2020, </em>consists of the following (units in thousands):</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Number of </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Shares (in </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>thousands)</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Weighted </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Average Grant</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Date Fair </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Value</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Weighted</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Average</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Remaining</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Contractual</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Term</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>(years)</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2017</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">105.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">125.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">104.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">117.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">177.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116.76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Unvested at June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">147.94</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">193.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">142.12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">28</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">177.20</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The total fair value of restricted shares that vested was $2.5 million for fiscal <em style="font: inherit;">2020,</em> $2.3 million for fiscal <em style="font: inherit;">2019,</em> and $1.7 million for fiscal <em style="font: inherit;">2018.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Restricted stock unit activity under the Plans for the <em style="font: inherit;">three</em> years ended <em style="font: inherit;"> June 30, 2020, </em>consists of the following (units in thousands):</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Number of </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Units</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>(in thousands)</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Weighted </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Average Grant</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Date Fair </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Value</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Weighted </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Average</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Remaining</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Contractual</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Term</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>(years)</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2017</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">111</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">106.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">129.99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95.46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(18</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">115.01</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">117.95</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">170.96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110.86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(36</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">143.72</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">139</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">134.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">192.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">111.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(3</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">155.6</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">116</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">159.25</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The total fair value of restricted stock units that vested was $5.7 million for fiscal <em style="font: inherit;">2020,</em> $3.1 million for fiscal <em style="font: inherit;">2019,</em> and $1.6 million for fiscal <em style="font: inherit;">2018.</em> The restricted stock units vest over a <span style="-sec-ix-hidden:c64739719">three</span>-year period.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stock-based compensation cost of $32.4 million, $32.3 million, and $28.2 million was included in selling, general and administrative expense in fiscal <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively. Additionally, Stock-based compensation costs of $1.6 million was included in cost of goods sold in <em style="font: inherit;">2020.</em> As of <em style="font: inherit;"> June 30, 2020, </em>there was $25.3 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal <em style="font: inherit;">2021</em> through <em style="font: inherit;">2023</em> using a 3% forfeiture rate. The weighted average period over which the compensation cost is expected to be recognized is 1.9 years.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Employee stock purchase plan: </i>In fiscal year <em style="font: inherit;">2015,</em> the Company established the Bio-Techne Corporation <em style="font: inherit;">2014</em> Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on <em style="font: inherit;"> October 30, 2014, </em>and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. The Company recorded expense of $0.4 million, $0.5 million, and $0.3 million for the ESPP in fiscal <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Profit sharing and savings plans: </i>The Company has profit sharing and savings plans for its U.S. employees, which conform to IRS provisions for <em style="font: inherit;">401</em>(k) plans. The Company makes matching contributions to the Plan. The Company has recorded an expense for contributions to the plans of $3.2 million, $2.8 million, and $2.5 million for the years ended <em style="font: inherit;"> June 30, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively. The Company operates defined contribution pension plans for its U.K. employees. The Company has recorded an expense for contributions to the plans of $1.4 million for each of the years ended <em style="font: inherit;"> June 30, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Performance incentive programs: </i>In fiscal <em style="font: inherit;">2020,</em> under certain employment agreements and a Management Incentive Plan available to executive officers and certain management personnel, the Company recorded cash bonuses of $10.5 million, granted options for 751,499 shares of common stock, issued 15,398 restricted common shares and 30,858 restricted stock units. In fiscal <em style="font: inherit;">2019</em> and fiscal <em style="font: inherit;">2018,</em> the Company recorded cash bonuses of $9.3 million and $7.2 million, granted options for 618,898 and 553,750 shares of common stock, and issued 11,279 and 14,194 restricted common stock shares and 25,903 and 35,174 restricted stock, respectively.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">  </p> 7500000 1900000 3600000 3600000 20000 8300000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="13" style="width: 36%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Year Ended June 30,</i></i></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>2020</i></i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>2019</i></i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="width: 8%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>2018</i></i></i></p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 58%;"> </td><td style="width: 1%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 4%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.67%</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.74%</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.1%</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">23%</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">24%</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Risk-free interest rates</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.3%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.9%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.5%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.0%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.7%</td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.8%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected lives (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.0</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.1</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.7</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> 0.0067 0.0074 0.011 0.22 0.24 0.20 0.21 0.013 0.019 0.025 0.030 0.017 0.028 P4Y P4Y1M6D P4Y8M12D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Number of </i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Shares (in</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>thousands)</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Weighted<br/> Average<br/> Exercise<br/> Price</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Aggregate<br/> Intrinsic<br/> Value</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>(millions)</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Weighted</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Average</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Contractual</i></i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Life (years)</i></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2017</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">98.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,087</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">120.67</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(252</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86.62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(204</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">111.51</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,452</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">105.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">917</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">173.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">129.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(383</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">95.29</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,656</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121.16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">190.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95.97</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(743</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">157.45</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">3,609</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">140.28</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">446.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2018:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,151</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90.75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2019:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,467</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">98.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2020:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">112.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">236.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 2821000 98.42 1087000 120.67 252000 86.62 204000 111.51 3452000 105.17 917000 173.89 330000 129.93 383000 95.29 3656000 121.16 752000 190.80 56000 95.97 743000 157.45 3609000 140.28 446700000 P4Y3M18D 1151000 90.75 1467000 98.70 1564000 112.60 236800000 P3Y3M18D 37.01 34.66 22.07 99300000 159000000.0 10600000 71100000 31700000 8800000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Number of </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Shares (in </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>thousands)</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Weighted </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Average Grant</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Date Fair </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Value</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Weighted</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Average</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Remaining</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Contractual</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Term</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>(years)</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2017</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">105.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">125.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">104.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">117.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">177.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116.76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Unvested at June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">147.94</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">193.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">142.12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">28</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">177.20</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Number of </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Units</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>(in thousands)</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Weighted </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Average Grant</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Date Fair </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Value</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Weighted </i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Average</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Remaining</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Contractual</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Term</i></i></p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>(years)</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2017</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">111</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">106.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">129.99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95.46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(18</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">115.01</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">117.95</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">170.96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110.86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(36</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">143.72</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">139</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">134.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">192.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">111.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(3</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">155.6</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">116</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">159.25</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 32000 105.80 20000 125.05 17000 104.66 0 0 35000 117.39 15000 177.93 20000 116.76 0 0 30000 147.94 15000 193.48 18000 142.12 0 0 28000 177.20 P6Y1M20D 2500000 2300000 1700000 111000 106.39 71000 129.99 16000 95.46 18000 115.01 148000 117.95 56000 170.96 28000 110.86 36000 143.72 139000 134.17 31000 192.08 51000 111.07 3000 155.6 116000 159.25 P5Y2M12D 5700000 3100000 1600000 32400000 32300000 28200000 1600000 25300000 0.03 P1Y10M24D 200000 400000 500000 300000 3200000 2800000 2500000 1400000 10500000 751499 15398 30858 9300000 7200000 618898 553750 11279 14194 25903 35174 <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">11.</em></b><i><b> Income Taxes:</b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Income before income taxes was comprised of the following (in thousands):</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>8</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">245,365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64,081</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81,557</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">31,112</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">47,934</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">44,395</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">276,477</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">112,015</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">125,952</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The provision for income taxes consisted of the following (in thousands):</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>8</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Taxes on income consist of:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Currently tax provision:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,976</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,090</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,416</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,018</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">544</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">8,580</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">13,329</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">11,983</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total current tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29,963</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45,714</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax provision:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,074</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,903</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(40,378</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,055</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,977</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,381</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><span style="-sec-ix-hidden:c64740058">(2,522)</span></td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(3,142</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(4,154</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">13,607</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(14,021</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(45,912</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total income tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">47,181</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">15,943</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(198</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company's effective income tax rate for fiscal <em style="font: inherit;">2020</em> was 17.1% for fiscal <em style="font: inherit;">2020</em> vs 14.2% in the prior year. The change in the effective tax rate for fiscal <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> were driven by the changes in the net discrete tax benefits $19.4 million and $12.7 million, respectively. </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company’s effective income tax rate for fiscal <em style="font: inherit;">2019</em> was 14.2% vs (0.2%) in the prior year. The change in the effective tax rate for fiscal <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> was driven by changes in net discrete tax benefits of $12.7 million and $34.4 million for fiscal year <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <div style="text-align: justify; font-size: 10pt;"> The Company's discrete tax benefits in fiscal <em style="font: inherit;">2020</em> primarily related to share-based compensation excess tax benefits of $17.7 million. </div> <div style="text-align: justify; font-size: 10pt;">   </div> <div style="text-align: justify; font-size: 10pt;"> The Company's discrete tax benefits in fiscal <em style="font: inherit;">2019</em> primarily related to share-based compensation excess tax benefits of $7.2 million,  $3.2 million related to fiscal <em style="font: inherit;">2019</em> acquisitions, and $2.0 million for tax refunds relating to certain state apportionments. The prior fiscal year was benefited from acquisition payments made to employees and <em style="font: inherit;">third</em> parties, which were deductible for tax purposes.  </div> <div style="text-align: justify; font-size: 10pt;">   </div> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="font-family: Times New Roman; font-size: 10pt;">In fiscal <em style="font: inherit;">2018,</em> the Company recognized net discrete tax benefits of $34.4 million. The primary driver in fiscal <em style="font: inherit;">2018</em> discrete tax benefits was a discrete net tax benefit of $33.0 million related to the Tax Act (as described further below). This net tax benefit consisted of $36.5 million due to the re-measurement of the Company’s deferred tax accounts to reflect the U.S. federal corporate tax rate reduction impact to our net deferred tax balances offset by expense for the federal transition tax of $3.3 million. Also impacting the Company’s fiscal <em style="font: inherit;">2018</em> effective tax rate was a $2.2 million tax benefit related to stock option exercises offset by a net discrete tax expense of $4.2 million related to the revaluation of contingent consideration, which is <em style="font: inherit;">not</em> a tax deductible expens</span>e.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em style="font: inherit;"> December 22, 2017, </em>the Tax Cuts and Jobs Act (the “Tax Act”) was enacted, which reduced the U.S. federal corporate tax rate from <em style="font: inherit;">35%</em> to <em style="font: inherit;">21%,</em> required companies to pay a <em style="font: inherit;">one</em>-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and created new taxes on certain foreign sourced earnings. The Tax Act added many new provisions including changes the deduction for executive compensation, a tax on global intangible low taxed income (“GILTI”), the base erosion anti abuse tax (“BEAT”) and a deduction for foreign derived intangible income (“FDII”).</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company continues to monitor newly enacted regulations, clarifications, and changes in guidance  the “Tax Act”, which was enacted on <em style="font: inherit;"> December 22, 2017. </em>The Company recognizes changes in legislation in the period enacted, which <em style="font: inherit;"> may </em>have a material impact on our effective tax rate in future periods.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following is a reconciliation of the federal tax calculated at the statutory rate of to the actual income taxes provided:</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="width: 33%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Year Ended June 30,</i></i></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>2020</i></p> </td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i><i>201</i><i>9</i></i></i></td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i><i>201</i><i>8</i></i></i></td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 53%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 2%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 2%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense at federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21.0</p> </td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.3</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.8</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Qualified production activity deduction</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development tax credit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.7</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.6</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Contingent consideration adjustment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.4</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax rate differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.2</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Option exercises</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5.7</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5.8</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Domestic tax legislation changes</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.7</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(26.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">State apportionment changes</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.3</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Executive compensation limitations</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.6</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.4</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1.0</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">0.2</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1.2</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Effective tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">17.1</td><td style="width: 2%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">14.2</td><td style="width: 2%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(0.2</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">  </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands):</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 20%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>9</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,769</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryovers</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax credit carryovers</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,568</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,640</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Excess tax basis in equity investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,433</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,755</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Derivative - cash flow hedge</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,058</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,921</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Lease liability</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(7,523</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(6,974</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">73,353</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">65,597</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net unrealized gain on available-for-sale investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19,102</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,542</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible asset amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(128,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(141,998</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,371</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Right of use asset</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,118</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1,180</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(440</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(174,443</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(155,351</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(101,090</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(89,754</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A deferred tax valuation allowance is required when it is more likely than <em style="font: inherit;">not</em> that all or a portion of deferred tax assets will <em style="font: inherit;">not</em> be realized. The valuation allowance as of <em style="font: inherit;"> June 30, 2020 </em>was $7.5 million compared to $7.0 million in the prior year. </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of <em style="font: inherit;"> June 30, 2020, </em>the $7.5 million valuation allowance relates to certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired Quad, Exosome, ACD, Novus, ProteinSimple and CyVek as well as immaterial amounts generated after the acquisitions. The Company believes it is more likely than <em style="font: inherit;">not</em> that these tax carryovers will <em style="font: inherit;">not</em> be realized.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">As of <em style="font: inherit;"> June 30, 2020, </em>the Company has federal operating loss carryforwards of approximately $64.2 million and state operating loss carryforwards of $130.6 million from its acquisitions of Quad, Exosome, ACD, ProteinSimple and CyVek, which are <em style="font: inherit;">not</em> limited under IRC Section <em style="font: inherit;">382.</em> As of <em style="font: inherit;"> June 30, 2020, </em>the Company has foreign net operating loss carryforwards of $13.7 million. The net operating loss carryforwards expire between fiscal <em style="font: inherit;">2021</em> and <em style="font: inherit;">2036.</em> The Company has a deferred tax asset of $20.2 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of <em style="font: inherit;"> June 30, 2020, </em>the Company has federal and state tax credit carryforwards of $5.0 million and $5.7 million, respectively. The federal tax credit carryforwards expire between <em style="font: inherit;">2028</em> and <em style="font: inherit;">2038.</em> The majority of the state credit carryforwards have <em style="font: inherit;">no</em> expiry date. The Company has a deferred tax asset of $7.5 million, net of the valuation allowance discussed above, related to the tax credit carryovers.</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">The Company has <em style="font: inherit;">not</em> recognized a deferred tax liability for unremitted foreign earnings of approximately $186 million from its foreign operations because its subsidiaries have invested or will invest the undistributed earnings indefinitely. The transition tax included as part of the Tax Act resulted in the previously untaxed foreign earnings being included in the federal and state fiscal <em style="font: inherit;">2018</em> taxable income.  The <em style="font: inherit;">one</em>-time transition tax was based on certain foreign earnings for which earnings have been previously indefinitely reinvested as well as the amount of earnings held in cash and other specified assets.   <em style="font: inherit;">No</em> additional income taxes have been provided for cumulative unremitted foreign earnings as at this time our intention with respect to unremitted foreign earnings is to continue to indefinitely reinvest outside the U.S. those earnings needed for working capital or additional foreign investment. If there are policy changes, we would record applicable taxes at that time.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation.  In addition, we anticipate that further guidance from the IRS and US Treasury related to the Tax Act could impact the amount of any related taxes.  Therefore, it is <em style="font: inherit;">not</em> practical to estimate the amount of the deferred income tax liabilities related to investments in these foreign subsidiaries.</p> <p style="margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>2020</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>9</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>8</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,947</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions due to acquisitions</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">900</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions for tax positions of current year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">306</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,185</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Closure of tax years</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1,041</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Tax reform</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">165</td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Ending balances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">4,297</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">5,032</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">1,947</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company does <em style="font: inherit;">not</em> believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next <em style="font: inherit;">twelve</em> months. The Company files income tax returns in the U.S. federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company's federal returns are subject to tax assessment for <em style="font: inherit;">2017</em> and subsequent years. State and foreign income tax returns are generally subject to examination for a period of <em style="font: inherit;">three</em> to <em style="font: inherit;">five</em> years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to <em style="font: inherit;">one</em> year after formal notification to the states.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>8</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">245,365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64,081</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81,557</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">31,112</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">47,934</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">44,395</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">276,477</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">112,015</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">125,952</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2019</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>8</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Taxes on income consist of:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Currently tax provision:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,976</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,090</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,416</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,018</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">544</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">8,580</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">13,329</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">11,983</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total current tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29,963</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45,714</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax provision:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,074</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,903</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(40,378</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,055</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,977</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,381</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><span style="-sec-ix-hidden:c64740058">(2,522)</span></td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(3,142</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(4,154</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">13,607</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(14,021</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(45,912</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total income tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">47,181</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">15,943</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(198</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> 245365000 64081000 81557000 31112000 47934000 44395000 276477000 112015000 125952000 18976000 16090000 28416000 6018000 544000 5315000 8580000 13329000 11983000 33574000 29963000 45714000 14074000 -6903000 -40378000 2055000 -3977000 -1381000 -3142000 -4154000 13607000 -14021000 -45912000 47181000 15943000 -198000 0.171 0.142 19400000 12700000 0.142 -0.002 12700000 34400000 17700000 7200000 -3200000 2000000.0 34400000 33000000.0 36500000 3300000 2200000 4200000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="width: 33%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><i>Year Ended June 30,</i></i></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>2020</i></p> </td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i><i>201</i><i>9</i></i></i></td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i><i>201</i><i>8</i></i></i></td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 53%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 2%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 2%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense at federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21.0</p> </td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.3</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.8</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Qualified production activity deduction</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development tax credit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.7</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.6</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Contingent consideration adjustment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.4</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax rate differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.2</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Option exercises</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5.7</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5.8</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Domestic tax legislation changes</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.7</td><td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(26.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">State apportionment changes</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.3</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Executive compensation limitations</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.6</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.4</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1.0</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">0.2</td><td style="width: 2%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1.2</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Effective tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">17.1</td><td style="width: 2%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">14.2</td><td style="width: 2%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(0.2</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p> </td></tr> </tbody></table> 0.210 0.210 0.281 0.023 0.008 0.025 -0 -0 0.024 0.007 0.016 0.014 -0.002 -0.004 0.033 -0.002 0.002 -0.035 -0.057 -0.058 -0.018 0 0.017 -0.262 0 -0.023 0 0.016 0.004 0 -0.010 0.002 0.012 0.171 0.142 -0.002 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 20%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>June 30</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>9</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,769</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryovers</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax credit carryovers</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,568</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,640</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Excess tax basis in equity investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,433</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,755</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Derivative - cash flow hedge</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,058</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,921</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Lease liability</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(7,523</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(6,974</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">73,353</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">65,597</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net unrealized gain on available-for-sale investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19,102</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,542</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible asset amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(128,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(141,998</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,371</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Right of use asset</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,118</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1,180</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(440</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(174,443</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(155,351</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(101,090</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(89,754</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> </tbody></table> 7769000 7743000 25707000 33294000 9568000 9640000 2423000 3433000 10755000 10333000 4058000 2921000 16256000 0 4340000 5207000 7523000 6974000 73353000 65597000 19102000 4542000 128279000 141998000 10764000 8371000 15118000 -0 1180000 440000 174443000 155351000 101090000 89754000 7500000 7000000.0 7500000 64200000 130600000 13700000 20200000 5000000.0 5700000 7500000 186000000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>2020</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>9</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>8</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,947</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions due to acquisitions</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">900</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions for tax positions of current year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">306</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,185</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Closure of tax years</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1,041</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Tax reform</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">165</td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Ending balances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">4,297</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">5,032</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">1,947</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 5032000 1947000 1747000 0 900000 0 306000 2185000 35000 1041000 -0 -0 0 0 165000 4297000 5032000 1947000 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">12.</em></b><i><b> Segment Information:</b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company's Protein Sciences segment is comprised of the Reagent Sol<span style="background-color:null;">utions division and Analytical Solution division. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields. No customer in the Protein Sciences segment accounted for more than <em style="font: inherit;">10%</em> of the segment’s net sales for the years ended <em style="font: inherit;"> June 30, 2020</em></span>, <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018.</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">  </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company's Diagnostics and Genomics is comprised of the Diagnostics Reagents division and the Genomics division. The Diagnostics Reagents division develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits. The Genomics division consists of Genomics and Exosome products and sells a portfolio of clinical molecular diagnostic oncology assays, as well as tissue-based in-situ hybridization assays for research in clinical use. No customer in the Diagnostics and Genomics segment accounted for more than <em style="font: inherit;">10%</em> of the segment’s net sales for the fiscal years ended <em style="font: inherit;"> June 30, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018.</em> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There are <em style="font: inherit;">no</em> concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term.</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Following is financial information relating to the operating segments (in thousands):</p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>9</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>8</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Protein Sciences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">555,352</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">543,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">482,378</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">184,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">171,674</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">161,151</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intersegment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1,210</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(827</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(536</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Consolidated net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">738,691</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">714,006</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">642,993</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating Income:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Protein Sciences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">234,929</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">240,919</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">209,880</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">14,965</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">10,079</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">35,496</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Segment operating income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">249,894</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">250,998</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">245,376</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Costs recognized upon sale of acquired inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,739</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,455</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amortization of acquired intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(60,865</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(58,550</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(46,983</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 9pt;">Gain on escrow settlement</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,169</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Acquisition related expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(416</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,429</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restructuring costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(34,262</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(33,057</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(28,240</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Corporate general, selling and administrative expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(4,015</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(6,651</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(6,715</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Consolidated operating income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">157,419</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">146,719</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">136,178</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by operating segment has <em style="font: inherit;">not</em> been provided and is <em style="font: inherit;">not</em> available, since the Company does <em style="font: inherit;">not</em> produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each operating segment’s operating results, it is <em style="font: inherit;">not</em> discretely identifiable.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note <em style="font: inherit;">2.</em> The Company has disclosed dis-aggregated product and service revenue by consumables, instruments, and services in Note <em style="font: inherit;">2.</em> The Company considers total instrument and total service revenue to represent similar groups of products in the fiscal years presented. The Company considered our consumables sold in the Protein Sciences and Diagnostics and Genomics segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands) :</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>9</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>2018</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consumables revenue - Protein Sciences</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">431,052</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">430,655</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">384,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Consumables revenue - Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">171,590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">158,324</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">150,388</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total consumable revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">602,642</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">588,979</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">534,738</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following is financial information relating to geographic areas (in thousands):</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 68%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><em style="font: inherit;">2020</em></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>9</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States and Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">162,039</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">138,016</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,439</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asia</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,670</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,584</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total long-lived assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">176,829</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">154,039</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States and Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">499,875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">556,951</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,349</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,637</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asia</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">4,321</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">5,841</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">516,545</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">579,429</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.</p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> 2 0 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>9</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>8</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Protein Sciences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">555,352</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">543,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">482,378</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">184,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">171,674</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">161,151</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intersegment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1,210</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(827</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(536</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Consolidated net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">738,691</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">714,006</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">642,993</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating Income:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Protein Sciences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">234,929</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">240,919</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">209,880</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">14,965</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">10,079</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">35,496</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Segment operating income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">249,894</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">250,998</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">245,376</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Costs recognized upon sale of acquired inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,739</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,455</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amortization of acquired intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(60,865</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(58,550</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(46,983</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 9pt;">Gain on escrow settlement</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,169</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Acquisition related expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(416</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,429</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restructuring costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(34,262</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(33,057</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(28,240</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Corporate general, selling and administrative expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(4,015</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(6,651</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(6,715</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Consolidated operating income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">157,419</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">146,719</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">136,178</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>2020</i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>9</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>2018</i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consumables revenue - Protein Sciences</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">431,052</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">430,655</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">384,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Consumables revenue - Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">171,590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">158,324</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">150,388</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total consumable revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">602,642</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">588,979</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">534,738</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i>Year ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 68%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><i><em style="font: inherit;">2020</em></i></i></p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><i><i>201</i><i>9</i></i></td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States and Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">162,039</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">138,016</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,439</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asia</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,670</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,584</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total long-lived assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">176,829</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">154,039</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States and Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">499,875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">556,951</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,349</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,637</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asia</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">4,321</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">5,841</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">516,545</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">579,429</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 555352000 543159000 482378000 184549000 171674000 161151000 -1210000 -827000 -536000 738691000 714006000 642993000 234929000 240919000 209880000 14965000 10079000 35496000 249894000 250998000 245376000 -0 3739000 2455000 60865000 58550000 46983000 7169000 0 0 416000 2282000 24429000 87000 -0 376000 34262000 33057000 28240000 4015000 6651000 6715000 157419000 146719000 136178000 431052000 430655000 384350000 171590000 158324000 150388000 602642000 588979000 534738000 162039000 138016000 13120000 14439000 1670000 1584000 176829000 154039000 499875000 556951000 12349000 16637000 4321000 5841000 516545000 579429000 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">13.</em></b><i><b> Quarterly Financial Data (unaudited):</b></i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b> </b></i></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(in thousands, except per share data)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">First</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Second</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Third</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Fourth</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Year</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">183,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">184,934</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">194,680</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175,834</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">738,691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64,829</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63,531</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64,617</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62,520</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">255,497</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net earnings<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,398</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119,623</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,432</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">58,847</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td>(1) - Amounts do not total due to rounding</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Earnings per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.95</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.54</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,303</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,304</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,550</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,435</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,401</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b> </b></i></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(in thousands, except per share data)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">First</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Second</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Third</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Fourth</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Year</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">162,970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">174,510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">184,861</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">191,664</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">714,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,367</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">61,492</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60,251</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63,405</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">240,515</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,403</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,556</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,654</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,459</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Earnings per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.54</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,697</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,772</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,881</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,813</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,861</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,892</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(in thousands, except per share data)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">First</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Second</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Third</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Fourth</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Year</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">183,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">184,934</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">194,680</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175,834</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">738,691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64,829</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63,531</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64,617</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62,520</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">255,497</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net earnings<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,398</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119,623</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,432</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">58,847</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td>(1) - Amounts do not total due to rounding</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Earnings per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.95</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.54</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,303</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,304</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,550</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,435</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,401</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr style="vertical-align: bottom;"><td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(in thousands, except per share data)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">First</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Second</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Third</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Fourth</p> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quarter</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Year</p> </td><td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">162,970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">174,510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">184,861</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">191,664</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">714,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,367</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">61,492</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60,251</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63,405</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">240,515</td><td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net earnings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,403</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,556</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,654</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,459</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Earnings per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.54</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,697</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,772</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,881</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,813</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,861</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,892</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 183243000 184934000 194680000 175834000 738691000 64829000 63531000 64617000 62520000 255497000 14398000 119623000 36432000 58847000 229296000 0.38 3.13 0.95 1.54 6.00 0.37 3.02 0.92 1.48 5.82 38032000 38167000 38303000 38304000 38201000 39253000 39550000 39435000 39700000 39401000 162970000 174510000 184861000 191664000 714006000 55367000 61492000 60251000 63405000 240515000 17403000 17556000 44654000 16459000 96072000 0.46 0.46 1.18 0.43 2.54 0.45 0.45 1.15 0.42 2.47 37697000 37766000 37772000 37881000 37781000 38813000 38748000 38861000 39135000 38892000 <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Note </b></i><b><em style="font: inherit;">14.</em></b><i><b> Subsequent Events:</b></i></p> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i> </i></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">None</em></p> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made.The Company reclassified ($4,503) to interest expense and a related tax benefit tax of $1,040 during fiscal 2020. Approximately $7,035 of the $13,253 will be reclassified in the 12 months subsequent to June 30, 2020. The Company had deferred tax benefits of $4,058 and $2,921 included in the accumulated other comprehensive income loss as of June 30, 2020 and June 30, 2019, respectively. Total cash paid for the Company's operating leases during the year ended June 30, 2020 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity. Consists of holdback payments due at future dates and liabilities for contingent consideration. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5. Included in available-for-sale investments on the condensed consolidated balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) was $7.6 million and $18.8 million as of March 31, 2020 and June 30, 2019, respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $5.6 million as of March 31, 2020. The fair value of the warrant as of June 30, 2019 was not material. Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year. Finished goods inventory of $4,646 and $3,239 is included within other long-term assets in the June 30, 2020 and June 30, 2019 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date. Amounts do not total due to rounding XML 25 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document And Entity Information - USD ($)
 12 Months Ended
Jun. 30, 2020
Aug. 21, 2020
Dec. 31, 2019
Document Information [Line Items]      
Entity Central Index Key 0000842023    
Entity Registrant Name BIO-TECHNE Corp    
Amendment Flag false    
Current Fiscal Year End Date --06-30    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2020    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Jun. 30, 2020    
Document Transition Report false    
Entity File Number 0-17272    
Entity Incorporation, State or Country Code MN    
Entity Tax Identification Number 41-1427402    
Entity Address, Address Line One 614 McKinley Place N.E.    
Entity Address, City or Town Minneapolis    
Entity Address, State or Province MN    
Entity Address, Postal Zip Code 55413    
City Area Code 612    
Local Phone Number 379-8854    
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol TECH    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 8,400,000,000
Entity Common Stock, Shares Outstanding   38,550,371  

XML 26 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Earnings and Comprehensive Income - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Net sales $ 738,691 $ 714,006 $ 642,993
Cost of sales 255,497 240,515 210,850
Gross margin 483,194 473,491 432,143
Operating expenses:      
Selling, general and administrative 260,583 264,359 240,636
Research and development 65,192 62,413 55,329
Total operating expenses 325,775 326,772 295,965
Operating income 157,419 146,719 136,178
Other income (expense):      
Interest expense (19,197) (21,705) (10,188)
Interest income 605 569 409
Other non-operating income (expense), net 137,650 (13,568) (447)
Total other income (expense), net 119,058 (34,704) (10,226)
Income before income taxes 276,477 112,015 125,952
Income taxes (benefit) 47,181 15,943 (198)
Net earnings 229,296 [1] 96,072 126,150
Other comprehensive income (loss):      
Foreign currency translation adjustments (9,963) (4,487) (1,572)
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8. (3,715) (9,537) 0
Unrealized gains (losses) on available-for-sale investments, net of tax of $398 in FY18 0 0 5,693
Other comprehensive income (loss) (13,678) (14,024) 4,121
Comprehensive income $ 215,618 $ 82,048 $ 130,271
Earnings per share:      
Basic (in dollars per share) $ 6.00 $ 2.54 $ 3.36
Diluted (in dollars per share) $ 5.82 $ 2.47 $ 3.31
Weighted average common shares outstanding:      
Basic (in shares) 38,201 37,781 37,476
Diluted (in shares) 39,401 38,892 38,055
[1] Amounts do not total due to rounding
XML 27 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Earnings and Comprehensive Income (Parentheticals)
$ in Thousands
 12 Months Ended
Jun. 30, 2018
USD ($)
Unrealized gains (losses) on available-for-sale investments, tax $ 398
XML 28 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2020
Jun. 30, 2019
Current assets:    
Cash and cash equivalents $ 146,625 $ 100,886
Short-term available-for-sale investments 124,268 65,147
Accounts receivable, less allowance for doubtful accounts of $775 and $980, respectively 122,534 137,466
Inventories 103,152 91,050
Other current assets 24,341 18,058
Total current assets 520,920 412,607
Property and equipment, net 176,829 154,039
Right of use asset 71,465 0
Goodwill 728,308 732,667
Intangible assets, net 516,545 579,429
Other assets 13,522 5,668
Total assets 2,027,589 1,884,410
Current liabilities:    
Trade accounts payable 23,090 16,210
Salaries, wages and related accruals 31,087 28,638
Accrued expenses 9,093 26,389
Contract liabilities 13,049 9,084
Income taxes payable 2,376 5,764
Operating lease liabilities - current 9,535 0
Contingent consideration payable 5,938 3,400
Current portion of long-term debt obligations 12,500 12,500
Total current liabilities 106,668 101,985
Deferred income taxes 101,090 89,754
Long-term debt obligations 344,243 492,660
Long-term contingent consideration payable 199 9,200
Operating lease liabilities 67,248 0
Other long-term liabilities 26,949 25,222
Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 38,453,046 and 37,934,040 shares, respectively 385 379
Additional paid-in capital 420,536 316,797
Retained earnings 1,057,470 931,934
Accumulated other comprehensive loss (97,199) (83,521)
Total shareholders' equity 1,381,192 1,165,589
Total liabilities and shareholders’ equity $ 2,027,589 $ 1,884,410
XML 29 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Thousands
Jun. 30, 2020
Jun. 30, 2019
Accounts receivable, allowance for doubtful accounts $ 775 $ 980
Undesignated capital stock, no par (in dollars per share) $ 0 $ 0
Undesignated capital stock, shares authorized (in shares) 5,000,000 5,000,000
Undesignated capital stock, shares issued (in shares) 0 0
Undesignated capital stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 38,453,046 37,934,040
Common stock, shares outstanding (in shares) 38,453,046 37,934,040
XML 30 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Cumulative Effect, Period of Adoption, Adjustment [Member]
Common Stock [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Additional Paid-in Capital [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Retained Earnings [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
AOCI Attributable to Parent [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balances (in shares) at Jun. 30, 2017           37,356,000        
Balance at Jun. 30, 2017           $ 374 $ 199,161 $ 799,027 $ (48,935) $ 949,627
Net earnings               126,150   126,150
Other comprehensive income (loss)                 4,121 $ 4,121
Common stock issued for exercise of options (in shares)           204,000       204,000
Common stock issued for exercise of options           $ 2 17,661     $ 17,663
Common stock issued for restricted stock awards (in shares)           34,000        
Common stock issued for restricted stock awards               (273)   (273)
Cash dividends               (47,973)   (47,973)
Stock-based compensation expense             27,959     27,959
Common stock issued to employee stock purchase plan (in shares)           14,000        
Common stock issued to employee stock purchase plan             1,506     1,506
Employee stock purchase plan expense             281     281
Balances (in shares) at Jun. 30, 2018           37,608,000        
Balance at Jun. 30, 2018     $ 25,276 $ (24,682) $ 594 $ 376 246,568 876,931 (44,814) 1,079,061
Net earnings               96,072   96,072
Other comprehensive income (loss)                 (14,024) $ (14,024)
Common stock issued for exercise of options (in shares)           382,000       383,000
Common stock issued for exercise of options           $ 4 36,272     $ 36,276
Common stock issued for restricted stock awards (in shares)           29,000        
Common stock issued for restricted stock awards               (2,575)   (2,575)
Cash dividends               (48,366)   (48,364)
Stock-based compensation expense             31,775     31,775
Common stock issued to employee stock purchase plan (in shares)           10,000        
Common stock issued to employee stock purchase plan             1,676     1,676
Employee stock purchase plan expense             505     $ 505
Share repurchases (in shares)           (95,000)       (95,000)
Share repurchases           $ (1)   (15,404)   $ (15,405)
Balances (in shares) at Jun. 30, 2019           37,934,000       37,934,040
Balance at Jun. 30, 2019 $ (879) $ (879) $ 379 316,797 931,934 (83,521) $ 1,165,589
Net earnings               229,296   229,296 [1]
Other comprehensive income (loss)                 (13,678) $ (13,678)
Common stock issued for exercise of options (in shares)           730,000       743,000
Common stock issued for exercise of options           $ 7 69,461 (1,642)   $ 67,826
Common stock issued for restricted stock awards (in shares)           56,000        
Common stock issued for restricted stock awards           $ 1 (1) (2,229)   (2,228)
Cash dividends               (48,902)   (48,902)
Stock-based compensation expense             31,932     31,932
Common stock issued to employee stock purchase plan (in shares)           14,000        
Common stock issued to employee stock purchase plan             2,312     2,312
Employee stock purchase plan expense             435     $ 435
Share repurchases (in shares)           (279,000)       (279,381)
Share repurchases           $ (3) (50,109) $ (50,112)
Surrender and retirement of stock to exercise option (in shares)           (2,000)        
Surrender and retirement of stock to exercise option           $ 0 (400) $ (400)
Balances (in shares) at Jun. 30, 2020           38,453,000       38,453,046
Balance at Jun. 30, 2020           $ 385 $ 420,536 $ 1,057,470 $ (97,199) $ 1,381,192
[1] Amounts do not total due to rounding
XML 31 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Cash flows from operating activities:      
Net earnings $ 229,296 [1] $ 96,072 $ 126,150
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Depreciation and amortization 82,737 78,171 64,463
Costs recognized on sale of acquired inventory 0 3,739 2,455
Deferred income taxes 13,130 (13,582) (46,716)
Stock-based compensation expense 32,367 32,280 28,240
Fair value adjustment to contingent consideration payable (905) (2,000) 20,100
Contingent consideration payments (958) 0 (26,600)
(Gain) Loss on investment, net 0 (3,702) (397)
Fair value adjustment on available for sale investments (137,527) 16,067 0
Leases, net 225 0 0
Gain on escrow settlement (7,170) 0 0
Other operating activity (732) 2,325 776
Change in operating assets and liabilities, net of acquisitions:      
Trade accounts and other receivables 6,556 (15,000) (2,700)
Inventories (14,861) (13,647) (13,327)
Prepaid expenses (2,605) (698) 2,782
Trade accounts payable and accrued expenses 10,343 6,101 5,026
Salaries, wages and related accruals 2,552 5,013 (89)
Income taxes payable (7,231) (9,520) 10,204
Net cash provided by operating activities 205,217 181,619 170,367
Cash flows from investing activities:      
Proceeds from sale and maturities of available-for-sale investments 147,120 21,579 36,390
Purchase of available-for-sale investments (70,187) (43,475) (8,571)
Additions to property and equipment (51,744) (25,411) (20,934)
Acquisitions, net of cash acquired 0 (289,492) (67,851)
Investment in unconsolidated entity 1,906 0 21,574
Other investing activities 0 0 680
Net cash provided by (used in) investing activities 27,095 (336,799) (38,712)
Cash flows from financing activities:      
Cash dividends (48,902) (48,364) (47,973)
Proceeds from stock option exercises 70,983 37,950 19,170
Re-purchases of common stock (50,112) (15,405) 0
Borrowings under line-of-credit agreement 40,000 580,000 55,000
Payments on line-of-credit (188,500) (413,500) (59,500)
Contingent consideration payments (3,400) 0 (61,900)
Other financing activities (3,872) (6,297) (3,985)
Net cash provided by (used in) financing activities (183,802) 134,384 (99,188)
Effect of exchange rate changes on cash and cash equivalents (2,771) (308) (2,089)
Net change in cash and cash equivalents 45,739 (21,104) 30,378
Cash and cash equivalents at beginning of year 100,886 121,990 91,612
Cash and cash equivalents at end of year $ 146,625 $ 100,886 $ 121,990
[1] Amounts do not total due to rounding
XML 32 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Description of Business and Summary of Significant Accounting Policies
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Business Description and Accounting Policies [Text Block]

Note 1. Description of Business and Summary of Significant Accounting Policies:

 

Description of business: Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (the Company), develop, manufacture and sell life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

 

Use of estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.

 

Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.

 

Translation of foreign financial statements: Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.

 

Revenue recognition: The Company adopted ASC 606 - Revenue from Contracts with Customers on July 1, 2018 using the modified retrospective transition approach. ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to the Recently Adopted Accounting Pronouncements section of Note 1 for additional information regarding our adoption of ASC 606 and Note 2 for additional information regarding our revenue recognition policy under ASC 606.

 

Research and development: Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.

 

Advertising costs: Advertising expenses were $4.2 million, $4.1 million, and $3.8 million for fiscal 2020, 2019, and 2018 respectively. The Company expenses advertising expenses as incurred.

  

Income taxes: The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense.

 

See Note 11 for additional information regarding income taxes.

 

Comprehensive income: Comprehensive income includes charges and credits to shareholders' equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity.

 

Cash and cash equivalents: Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of three months or less.

 

Available-for-sale investments: Available-for-sale investments consist of debt instruments with original maturities of generally three months to six months and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value.  Unrealized gains and losses on available-for-sale securities are included within other income (expense) beginning in fiscal 2019 as the Company adopted ASU  2018-02 on July 1, 2018, as further described in the Recently Adopted Accounting Pronouncements section of Note 1. Unrealized gains or losses on available-for-sale securities were recorded within comprehensive income in fiscal year 2018.

 

Trade accounts receivable: Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer.

 

Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration.

 

For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Company’s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with ASC 330 - Inventory.

 

Property and equipment: Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of 5 to 40 years.

 

Contingent Consideration: Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income

 

Intangibles assets: Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life. In the current year, the Company identified one item as described in the Impairment of long-lived assets and amortizable intangibles section below. 

 

Impairment of long-lived assets and amortizable intangibles: We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.

 

The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During fiscal year 2020, the Company accelerated the amortization of a certain trade name based on the Company's planned integration of the products under that acquired trade name into a legacy brand. The accelerated amortization resulted in $1.3 million in additional amortization expense in fiscal 2020 and an estimated $0.6 million in fiscal 2021. No other triggering events were identified and no impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years 2018, 2019, and 2020.

 

Impairment of goodwill: We evaluate the carrying value of goodwill during the fourth quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.

 

To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business.

 

2020 Goodwill Impairment Analyses

 

In completing our 2020 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU 2017- 04, a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit’s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value- weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

 

The result of our quantitative assessment, where we compared the discounted cash flows of each reporting unit to its carrying value, indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2020. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2020, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. 

 

2019 Goodwill Impairment Analyses

 

At the beginning of the quarter ended March 31, 2019, the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment.

 

Because our quantitative analysis performed as of January 1, 2019 included all of our reporting units, except for Exosome a recent acquisition that was a separate reporting unit that was not impacted by the business process realignment, the summation of the calculated reporting units’ fair values combined with the fair value of the Exosome acquisition, was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.

 

The quantitative assessments completed as of January 1, 2019 indicated that all tested reporting units had a substantial amount of headroom. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

In conducting our annual goodwill impairment test on April 1, we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than not that the fair value of a reporting unit is less than its carrying amount.

 

Based on its annual analysis, the Company determined there was no indication of impairment of goodwill. Further, no triggering events or items beyond the realignment discussed above were identified in the year ended June 30, 2019 that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.

 

2018 Goodwill Impairment Analyses

 

In completing our 2018 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units, with a process consistent to that described in our 2020 Goodwill Impairment Analyses section above. The quantitative assessment completed indicated that all of the reporting units had a substantial amount of headroom. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

There has been no impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC 350 guidance for goodwill and other intangibles on July 1, 2002.

 

Investments in unconsolidated entities: The Company periodically invests in the equity of start-up and early development stage companies. The accounting treatment of each investment (cost method or equity method) is dependent upon a number of factors, including, but not limited to, the Company's share in the equity of the investee and the Company's ability to exercise significant influence over the operating and financial policies of the investee.

 

Other Significant Accounting Policies

 

The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:

 

Policy

 

Note

 

Fair value measurements

  5 

Earnings per share

  9 

Share-based compensation

  10 

Operating segments

  12 

 

 

Recently Adopted Accounting Pronouncements

 

In  February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. The FASB has issued narrow codification improvements to Leases (Topic 842) through ASU No. 2018-10 and ASU 2019-01. Additionally, the FASB issued ASU 2018-11, allowing an entity to elect a transition method where they do not recast prior periods presented in the financial statements in the period of adoption. The Company has elected the transition method allowed for under ASU 2018-11 when adopting Leases (Topic 842). The Company adopted the standard effective  July 1, 2019 and correspondingly recorded incremental operating lease liabilities of $80.6 million, a right-of-use lease asset of $79.5 million, retained earnings of $0.8 million and a deferred tax adjustment of $0.3 million. Additionally, the Company reclassified $4.0 million of deferred rent recorded within accrued expenses under ASC 840 - Leases into operating lease liabilities upon adoption of Topic 842. In adopting ASC 842, the Company elected the package of available practical expedients and to use hindsight in determining the lease term for all existing leases. Further, as part of our adoption of ASC 842, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Refer to Note 7 for additional information on leases.

 

Pronouncements Issued but Not Yet Adopted

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The amendment in this update replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade and loan receivables and available-for-sale debt securities. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. This ASU is effective for annual periods and interim periods for those annual periods beginning after December 15, 2019, which for us is July 1, 2020. Entities may early adopt beginning after December 15, 2018. We have completed our evaluation of the impact of the adoption of ASU 2016-13, noting the impact of adoption is not expected to have a material impact on our consolidated financial statements.

 

In August 2018, the FASB issued ASU No. 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is not affected by the new standard.  This ASU is effective for annual periods and interim periods for those annual periods beginning after December 15, 2019, which for us is July 1, 2020 and may be adopted retrospectively or prospectively to eligible costs incurred on or after the date the guidance is first applied. We do not expect this standard to have a material impact on our consolidated financial statements and we will adopt the standard prospectively on July 1, 2020.

 

In  March 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides expedients and exceptions to existing guidance on contract modifications and hedge accounting that is optional to facilitate the market transition from a reference rate, including LIBOR which is being phased out in 2021, to a new reference rate. The provisions of the ASU would impact contract modifications and other changes that occur while LIBOR is phased out. The Company is in the process of evaluating the optional relief guidance provided within this ASU and is also reviewing its debt and derivative instrument that utilizes LIBOR as the reference rate. The Company will continue to evaluate and monitor developments and our assessment of ASU 2020-04 during the LIBOR transition period.

.

 
XML 33 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Revenue Recognition
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

Note 2. Revenue Recognition:

 

Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. The vast majority of service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects. Revenue for these contracts are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. The remaining service revenues were not material to the period and consist of laboratory services recognized at point in time. Given the Company does not have significant historical experience collecting payments from Medicare or insurance providers, the Company considered the variable consideration for such services to be constrained as it would not be probable that a significant amount of revenue would not need to be reversed in future periods for the services provided. Accordingly, the Company does not record revenue upon completion of the performance obligation, but rather upon cash receipt, which is subsequent to the performance obligation being satisfied. Royalty revenues are based on net sales of the Company’s licensed products by a third party. We recognize royalty revenues in the period the sales occur using third party evidence to estimate the amount to be recorded. The Company has also elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date. 

 

The Company has elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance.  The Company's unfulfilled performance obligations for contracts with an original length greater than one year were not material as of June 30, 2020 and June 30, 2019.

 

Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts’ inception.

 

Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.

 

Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense costs of obtaining contracts less than one year that would otherwise be capitalized and amortized over the contract period. Contract assets as of June 30, 2020 are not material.

 

Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of June 30, 2020 and June 30, 2019 were approximately $14.2 million and $10.4 million, respectively. Contract liabilities as of June 30, 2019 subsequently recognized as revenue during the year ended June 30, 2020 were approximately $7.6 million. Contract liabilities in excess of one year are included in Other long-term liabilities on the balance sheet. 

 

Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material.

 

Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We have elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized.

 

The following tables present our disaggregated revenue for the periods presented.

 

Revenue by type is as follows:

 

  

Year ended June 30,

     
  

2020

  

2019

  2018 

Consumables

 $602,642  $588,979  $534,738 

Instruments

  71,462   67,538   61,784 

Services

  47,459   38,050   34,137 

Total product and services revenue, net

  721,563  $694,567   630,659 

Royalty revenues

  17,128   19,439   12,334 

Total revenues, net

 $738,691  $714,006  $642,993 

 

Revenue by geography is as follows:

 

  

Year Ended June 30,

 
  

2020

  

2019

  

2018

 

Net sales:

            

United States

 $404,407  $391,191  $346,293 

EMEA, excluding U.K.

  155,289   155,821   148,599 

U.K.

  30,411   34,975   33,704 

APAC, excluding Greater China

  60,362   52,913   48,392 

Greater China

  68,792   57,799   47,950 

Rest of world

  19,430   21,307   18,055 

Total external sales

 $738,691  $714,006  $642,993

 
XML 34 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

Note 3. Supplemental Balance Sheet and Cash Flow Information:

 

Available-For-Sale Investments:

 

The fair value of the Company's available-for-sale investments as of June 30, 2020 and June 30, 2019 were $87.8 million and $38.2 million, respectively. The increase was due to year-over-year increase in the stock price of CCXI, which was $9.30 per share at June 30, 2019 compared to $57.54 per share at June 30, 2020. The amortized cost basis of the Company's investment in CCXI was $6.6 million and $18.8 million as of June 30, 2020 and 2019 respectively.

 

Inventories:

 

Inventories consist of (in thousands):

 

  

June 30,

 
  

2020

  

2019

 
         

Raw materials

 $51,530  $40,913 

Finished goods(1)

  56,268   53,376 

Inventories, net

 $107,798  $94,289 

 

(1) Finished goods inventory of $4,646 and $3,239 is included within other long-term assets in the June 30, 2020 and June 30, 2019 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.  

 

Property and Equipment:

 

Property and equipment consist of (in thousands):

 

  

June 30,

 
  

2020

  

2019

 

Cost:

        

Land

 $8,516  $7,065 

Buildings and improvements

  184,430   175,019 

Machinery, equipment and other

  153,704   124,233 

Property and equipment

  346,650   306,317 

Accumulated depreciation and amortization

  (169,821

)

  (152,278

)

Property and equipment, net

 $176,829  $154,039 

 

Intangibles assets were comprised of the following (in thousands):

 

       

June 30,

 
  

Useful Life

(years)

  

2020

  

2019

 
              

Developed technology

 9-15  $434,653  $435,679 

Trade names

 2-20   146,713   147,296 

Customer relationships

 7-16   211,750   214,320 

Patents

  10    2,475   2,133 

Intangible assets

       795,591   799,428 

Accumulated amortization

       (279,046

)

  (219,999

)

Intangibles assets, net

      $516,545  $579,429 

 

Changes to the carrying amount of net intangible assets consist of (in thousands):

 

  

June 30,

 
  

2020

  

2019

 
         

Beginning balance

 $579,429  $446,332 

Acquisitions (Note 4)

  -   191,956 

Other additions

  311   633 

Amortization expense

  (61,095)  (58,715

)

Currency translation

  (2,100)  (777

)

Ending balance

 $516,545  $579,429 

 

Amortization expense related to technologies included in cost of sales was $34.5 million, $33.3 million, and $25.3 million in fiscal 2020, 2019, and 2018, respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was $26.6  million, $25.4 million, and $21.6 million, in fiscal 2020, 2019, and 2018 respectively.

 

The estimated future amortization expense for intangible assets as of June 30, 2020 is as follows (in thousands):

 

2021

 $59,766 

2020

  57,564 

2023

  55,696 

2024

  53,198 

2025

  50,024 

Thereafter

  240,297 

Total

 $516,545 

 

Changes in goodwill by segment and in total consist of (in thousands):

 

  

Protein

Sciences

  

Diagnostics &

Genomics

  

Total

 

June 30, 2018

 $347,918  $249,972  $597,890 

Acquisitions (Note 4)

  30,939   105,362   136,301 

Currency translation

  (1,450)  (74)  (1,524

)

June 30, 2019

 $377,407  $355,260  $732,667 
Acquisitions (Note 4)  (326)  -   (326)
Currency Translation  (4,000)  (31)  (4,031)
June 30, 2020 $373,081  $355,229  $728,310 

 

Other Assets:

 

Other assets consist of (in thousands):

 

  

June 30,

 
  

2020

  

2019

 
         

Long-term deposits

 $6,234  $487 

Other

  7,288   5,181 

Other long-term assets

 $13,522  $5,668 

 

As of June 30, 2020, the Company had $13.5 million of other assets compared to $5.7 million as of June 30, 2019.  The increase in other long-term assets in fiscal 2020 is primarily attributable to deposits made on our GMP manufacturing facility. 

 

Supplemental Cash Flow Information:

 

Supplemental cash flow information was as follows (in thousands):

 

  

Year Ended June 30,

 
  

2020

  

2019

  

2018

 

Income taxes paid

 $41,992  $36,814  $35,076 

Interest paid

  18,615   21,497   9,844 

Non-cash activities:

            

Acquisition-related liabilities (1)

  (2,105)  12,600   1,396 

 

 

(1) Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.

 
XML 35 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Acquisitions
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Business Combination Disclosure [Text Block]

Note 4. Acquisitions:

 

We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.

 

2019 Acquisitions

 

Quad Technologies

 

On July 2, 2018, the Company acquired QT Holdings Corporation (Quad) for approximately $20.5 million, net of cash acquired, plus contingent consideration of up to $51.0 million, subject to certain product development milestones and revenue thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences operating segment in the first quarter of fiscal year 2019. Purchase accounting was finalized during fiscal 2019.

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible assets acquired in fiscal 2019 is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for our calculation of acquired net operating losses (NOLs).

 

Exosome Diagnostics

 

On August 1, 2018, the Company acquired Exosome Diagnostics, Inc. (ExosomeDx) for approximately $251.6 million, net of cash acquired, plus contingent consideration of up to $325.0 million, subject to certain EBITA thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’ product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the first quarter of fiscal year 2019. Purchase accounting was finalized during fiscal 2019. 

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using either a relief-from-royalty or a multiperiod excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2019 are 15 years for developed technology and trade names, and 14 years for customer relationships. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the preliminary calculation of acquired NOLs.

 

Note: As part of the ExosomeDx acquisition, a certain amount of the cash payment was held in escrow. As part of the finalization of the outstanding amounts held in escrow, the Company recognized a gain of $7.2 million related to returned proceeds and a relief of any future contingent payments as described in Note 5. The gain was recorded within selling, general, and administrative costs in the Consolidated Statement of Comprehensive Income. 

 

B-MoGen Biotechnologies

 

On June 4, 2019, the Company acquired the remaining interest in B-MoGen Biotechnologies Inc. (B-MoGen) for approximately $17.5 million, net of cash acquired, plus contingent consideration of up to $38.0 million, subject to certain product development milestones and revenue thresholds. The Company previously held an investment of $1.4 million in B-MoGen and recognized a gain of approximately $3.7 million on the transaction within other non-operating income fiscal year 2019 in the consolidated statements of earnings and comprehensive income, which represented the adjustment of our historical investment to its fair value. 

 

The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences segment in the fourth quarter of fiscal year 2019. Purchase accounting remained opened as disclosed in our prior year 10-K/A for working capital adjustments and our income tax assessment of acquired net operating losses (NOLs) with the completion of the stub period tax returns. Our purchase accounting was finalized in fiscal 2020 with an immaterial adjustment of $0.3 million to deferred tax amounts and goodwill. 

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible asset acquired in fiscal 2019 is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the preliminary calculation of acquired NOLs.

 

2018 Acquisitions

 

Trevigen

 

On September 5, 2017 the Company acquired the stock of Trevigen Inc. for approximately $10.6 million, net of cash received. The Company has had a long-standing business relationship with Trevigen as a distributor of its product line. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences segment in the first quarter of fiscal 2018.  

 

Atlanta Biologicals

 

On January 2, 2018 the Company acquired the stock of Atlanta Biologicals, Inc. and its affiliated company, Scientific Ventures, Inc., for approximately $51.3 million, net of cash acquired. The transaction was financed through available cash on hand and an additional draw from the Company’s line-of-credit. Atlanta Biologicals fetal bovine serum (FBS) product line strengthens and complements our current tissue culture reagents offering and furthers our efforts to provide more complete solutions to our research customers. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences segment in the third quarter of fiscal 2018. Purchase accounting was finalized during fiscal 2018.

 

Tangible assets acquired in the acquisition, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2018 are 13 years for developed technology, 12 years for customer relationships, and 15 years for trade names. The deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not deductible for income tax purposes.

 

Eurocell Diagnostics

 

On February 1, 2018, the Company acquired Eurocell Diagnostics SAS, a company based in Rennes, France, for approximately $7.3 million, net of cash acquired. The Company paid $6.0 million on the acquisition date and the remaining $1.3 million was paid on February 1, 2019. The Company has had a long-standing business relationship with Eurocell as a distributor of its product line. Eurocell sells directly to the laboratory markets in the French region as well as servicing the EMEA markets via a network of distributors. The transaction was financed through cash on hand.  The primary asset in this acquisition is the customer relationships; however, the acquisition resulted in some goodwill as we expect strategic benefits of revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Company’s Diagnostics and Genomics segment in the third quarter of fiscal 2018. Purchase accounting was finalized during fiscal 2018. 

 

Tangible assets acquired, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to customer relationships was based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. Amortization expense related customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships acquired in fiscal 2018 is 7 years. The deferred income tax liability represents the net amount of the estimated future impact of intangible asset amortization, which is not deductible for income tax purposes.

 

  B-MoGen Biotechnologies  Exosome Diagnostics  Quad Technologies  

Trevigen

  Atlanta Biologicals  Eurocell Diagnostics 

Current assets, net of cash

 $504  $2,611  $36  $1,662  $15,722  $512 

Equipment and other long-term assets

  269   2,212   228   53   4,901   188 

Intangible assets:

 
Developed technology  14,000   105,000   12,256   5,100   23,000   - 
Trade name  -   58,000   -   160   2,300   - 

Customer relationships

  400   2,300   -   260   3,600   6,272 

Goodwill

  16,131   105,362   14,481   5,991   10,195   2,910 

Total assets acquired

  31,304   275,485   27,001   13,226   59,718   9,882 
                         

Liabilities

  211   3,716   296   387   90   483 

Deferred income taxes, net

  3,051   16,346   943   2,195   8,354   2,070 

Net assets acquired

 $28,042  $255,423  $25,762  $10,644  $51,274  $7,329 
                         

Cash paid, net of cash acquired

  17,448   251,623   20,462  $10,644  $51,274  $5,933 

Consideration payable

  5,500   -   -   -   -   1,396 
Contingent consideration payable  5,094   3,800   5,300   -   -   - 
Net assets acquired $28,042  $255,423  $25,762  $10,644  $51,274  $7,329 

 

 

Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of good sold in the Consolidated Statements of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statements of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not deductible for income tax purposes, and the future tax benefit of net operating loss and tax credit carryforwards which will be deductible by the Company in future periods. 

 
XML 36 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Fair Value Measurements
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]

Note 5. Fair Value Measurements:

 

The Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt.

 

Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.

 

The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.

 

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):

 

  

Total carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30, 2020

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $87,842  $79,846  $7,996  $- 

Certificates of deposit (2)

  36,426   36,426   -   - 

Total Assets

 $124,268  $116,272  $7,996  $- 
                 

Liabilities

                

Contingent consideration

 $6,137  $-  $-  $6,137 
    Derivative instruments - cash flow hedges  17,331   -   17,331   - 
    Total Liabilities $23,468  $-  $17,331  $6,137 

 

  

Total carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30, 2019

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $38,219  $38,219  $-  $- 

Certificates of deposit (2)

  26,928   26,928   -   - 

Total Assets

 $65,147  $65,147  $-  $- 
                 
Liabilities                
Contingent consideration  12,600         12,600 
Derivative instruments - cash flow hedges  12,458      12,458    
Total Liabilities $25,058  $-  $12,458  $12,600 

 

 

(1) Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at June 30, 2020 and June 30, 2019 was $6.6 million and $18.8 million respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $8.0 million as of June 30, 2020. The fair value of the warrant as of  June 30, 2019 was not material. 

 (2) Included in available-for-sale investments on the balance sheet.  The certificate of deposits have contractual maturity dates within one year.

 

Fair value measurements of available for sale securities

 

Available for sale securities excluding warrants are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 assets. The Company's warrant to purchase additional shares at a specified future price was valued using a Black-Scholes model with observable inputs in active markets and therefore was classified as a Level 2 asset. 

 

Fair value measurements of derivative instruments

 

In October 2018, the Company entered into forward starting swaps designated as cash flow hedges on outstanding debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt described in Note 6 to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company will exchange, at specified intervals, the difference between floating and fixed interest amounts based on an initial $380 million of notional principal amount, with the notional amount decreasing by $100 million in  October, 2020, $80 million in October 2021, and $200 million in October 2022. The change in the fair value of the designated hedged instrument is reported as a component of other comprehensive income and reclassified into interest expense over the corresponding term of the cash flow hedge. The Company reclassified $3.5 million, net of taxes, out of other comprehensive income into interest expense during the fiscal year ended June 30, 2020. In June 2020, the Company de-designated $80 million of the notional amount set to expire in  October 2020. The change in fair value of the dedesignated notional hedged amount was not material as of June 30, 2020. The net loss associated with the dedesignated portion of the derivative instrument was not reclassified into earnings based on the amount of probable variable interest payments to occur within a two month time period of the forecasted hedged transaction. The liability related to the derivative instrument was recorded within Other long-term liabilities on the Consolidated Balance Sheet. The instrument was valued using observable market inputs in active markets and therefore classified as a Level 2 liability.

 

Fair value measurements of contingent consideration

 

In connection with the ExosomeDx, Quad, and B-Mogen acquisitions the Company is required to make contingent consideration payments of up to $325.0 million, $51.0 million, and $38.0 million respectively. The contingent consideration agreement with ExosomeDx was based on achieving certain EBITA thresholds, the contingent agreement with Quad is based on meeting certain product development milestones and revenue thresholds, and the contingent agreement with B-Mogen is based on meeting certain product development milestones and revenue thresholds. The preliminary fair value of the liabilities for the contingent payments recognized upon the acquisition as part of the purchase accounting opening balance sheet totaled $14.6 million ($3.8 million for ExosomeDx, $5.3 million for Quad, and $5.5 million for B-Mogen) as discussed in Note 4.  The preliminary fair value of the development milestone payments was estimated by discounting the probability-weighted contingent payments expected to be made to present value. Assumptions used in these calculations were probability of success, duration of the earn-out, and discount rate.   The preliminary fair value for the EBITA and revenue milestone payments was determined using a Monte Carlo simulation-based model discounted to present value.  Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate and various probability factors.

 

During the fourth quarter of fiscal 2020, the Company's obligation for potential contingent consideration payments related to the ExosomeDx acqusition were relieved as part of the Company's escrow settlement with the former shareholders of ExosomeDx. As the result of this settlement, the Company reversed an accrual for the fair value of the contingent liability at the date of settlement. The ultimate settlement of contingent consideration liabilities for the Quad and B-Mogen acquisitions could deviate from current estimates based on the actual results of the financial measures described above. This liability is considered to be a Level 3 financial liability that is re-measured each reporting period. The change in fair value of contingent consideration for these acquisitions is included in general and administrative expense.

 

The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

 

  

June 30,

 
  

2020

  

2019

 
         

Fair value at the beginning of period

 $12,600  $- 

Purchase price contingent consideration (Note 4)

  -   14,600 

Payments

  (4,358

)

  -

 

Gain on escrow settlement  (1,200)   

Change in fair value of contingent consideration

  (905)  (2,000)

Contingent consideration payable

 $6,137  $12,600 

 

Fair value measurements of other financial instruments – The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.

 

Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items.

 

Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility  and long-term debt approximates fair value because our interest rate is variable and reflects current market rates. 

 
XML 37 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Debt and Other Financing Arrangements
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Debt Disclosure [Text Block]

Note 6. Debt and Other Financing Arrangements: 

 

On August 1, 2018, the Company entered into a new uncollateralized revolving line-of-credit and term loan governed by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $600.0 million, which can be increased by an additional $200.0 million subject to certain conditions, and a term loan of $250.0 million. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the Eurodollar Loans term for which the interest rate is calculated as the sum of LIBOR plus an applicable margin. The applicable margin is determined for the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 15 basis points. The Company has recorded $12.5 million of our outstanding borrowings under the Credit Agreement as a current liability in our Consolidated Balance sheet, which represents our required quarterly debt payments to be made in fiscal year 2021.

 

The Credit Agreement matures on August 1, 2023 and contains customary restrictive and financial covenants and customary events of default. At the closing on August 1, 2018 the company borrowed $250.0 million under the term loan and $330.0 million under the revolving credit facility. As of June 30, 2020 and 2019, the outstanding balance under the Credit Agreement was $357 million and $505.2 million respectively. 

  
XML 38 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Leases
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

Note 7. Leases: 

 

As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU No. 2016-02 and related standards (collectively ASC 842, Leases), which replaced previous lease accounting guidance, on July 1, 2019. 


The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company’s incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During fiscal year 2020, the Company recognized $3.4 million in variable lease expense in the Consolidated Statements of Earnings and Comprehensive Income.  During fiscal year 2020, the Company also recognized $13.0 million relating to fixed lease expense in the Consolidated Statements of Earnings and Comprehensive Income. 

 

The following table summarizes the balance sheet classification of the Company’s operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands):

 

 

Balance Sheet Classification

 

As of:

June 30,

2020

 

Operating leases:

     

Operating lease right of use assets

Right of Use Asset

 $71,465 
      

Current operating lease liabilities

Operating lease liabilities current

 $9,535 

Noncurrent operating lease liabilities

Operating lease liabilities

  67,248 
Total operating lease liabilities  $76,783 
 

 

    
Weighted average remaining lease term (in years):   8.72 
 

 

    
Weighted average discount rate:   4.40%

 

The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended  June 30, 2020 (in thousands):

 

  

For the year ended June 30, 2020

 

Cash amounts paid on operating lease liabilities(1)

 $12,763 
     

Right of use assets obtained in exchange for lease liabilities

  1,758 

 

(1) Total cash paid for the Company's operating leases during the year ended June 30, 2020 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.  

 

The following table summarizes payments by date for the Company’s operating leases, which is then reconciled to our total lease obligation (in thousands):

 

  

June 30, 2020

Operating

Leases

 

2021

 $12,590 

2022

  12,113 

2023

  11,296 

2024

  10,317 

2025

  9,388 

Thereafter

  37,316 

Total

 $93,020 
Less: Amounts representing interest  16,237 
Total lease obligations  76,783 

 

Certain leases include one or more options to renew, with terms that extend the lease term up to five years. The Company includes option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is not reasonably certain to exercise such options.

 

Disclosures related to periods prior to adoption of new lease standard:

 

At June 30, 2019, aggregate net minimum rental commitments under non-cancelable leases having an initial or remaining term of more than one year are payable as follows (in thousands):

 

  

Operating

Leases

 

2020

 $13,707 

2021

  13,469 

2022

  13,154 

2023

  12,716 

2024

  11,392 

Thereafter

  51,895 

Total

 $116,333 

 

Total rent expense was approximately $12.9 million, $10.8 million, and $9.8 million for the years ended June 30, 2019, 2018, and 2017, respectively.  

 
XML 39 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Comprehensive Income (Loss) Note [Text Block]

Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (loss): 

 

Supplemental Equity

 

The Company has declared cash dividends per share of $1.28 in each of the full fiscal years ended   June 30, 2020, June 30, 2019, and June 30, 2018. During the years ended June 30, 2020 and June 30, 2019, the Company repurchased 279,381 shares at an average share price of $179.37 and 95,000 shares at an average share price of $162.15, respectively. The Company's accounting policy is to record the portion of share repurchases in excess of the par value entirely in retained earnings. During fiscal year 2020, the Company recorded ($0.4) million within the Consolidated Statements of Shareholders' Equity for the surrender and retirement of stock to exercise option due to net settlement stock options exercises. 

 

Accumulated Other Comprehensive Income (loss) 

 

Changes in accumulated other comprehensive income (loss), net of tax, at June 30 consists of (in thousands):

 

   

Unrealized

Gains (Losses)

on Available-

for-Sale

Investments

  

Foreign

Currency

Translation

Adjustments

  

Unrealized Gains (Losses) on Derivatives Instruments

  

Total

 
 

Balance June 30, 2017

 $18,989  $(67,924

)

 $-  $(48,935

)

 

Other comprehensive income (loss) before reclassifications

  18,108   (1,572

)

  -   16,536 
 

Amounts reclassified from accumulated other comprehensive loss to income

  (12,415

)

  -   -   (12,415

)

 

Balance June 30, 2018

 $24,682  $(69,496

)

 $-  $(44,814

)

 Cumulative effect adjustment for adoption for ASU 2018-02  2,371   -   -   2,371 
 Cumulative effect adjustment for adoption for ASU 2016-01  (27,053)  -   -   (27,053)
 

Other comprehensive income (loss) before reclassifications 

  -   (4,487)  (9,537)  (14,024)
 

Balance June 30, 2019

 $-  $(73,983

)

 $(9,537) $(83,521

)

 Other comprehensive income (loss) before reclassifications  -   (9,963)  (7,179)  (17,142)
 Reclassification from loss on derivatives to interest expense, net of taxes(1)  -   -   3,464   3,464 
 Balance June 30, 2020 $-  $(83,946) $(13,253) $(97,199)

 

(1) Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made.The Company reclassified ($4,503) to interest expense and a related tax benefit tax of $1,040 during fiscal 2020. Approximately $7,035 of the $13,253 will be reclassified in the 12 months subsequent to June 30, 2020. The Company had deferred tax benefits of $4,058 and $2,921 included in the accumulated other comprehensive income loss as of June 30, 2020 and June 30, 2019, respectively.

 
XML 40 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Earnings Per Share
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Earnings Per Share [Text Block]

Note 9. Earnings Per Share:

 

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

 

  

Year Ended June 30,

 
  

2020

  2019  2018 

Earnings per share – basic:

            

Net income

 $229,296  $96,072  $126,150 

Income allocated to participating securities

  (224

)

  (105

)

  (108

)

Income available to common shareholders

 $229,072  $95,967  $126,042 

Weighted-average shares outstanding – basic

  38,201   37,781   37,476 

Earnings per share – basic

 $6.00  $2.54  $3.36 
             

Earnings per share – diluted:

            

Net income

 $229,296  $96,072  $126,150 

Income allocated to participating securities

  (224

)

  (105

)

  (108

)

Income available to common shareholders

 $229,072  $95,967  $126,042 

Weighted-average shares outstanding – basic

  38,201   37,781   37,476 

Dilutive effect of stock options and restricted stock units

  1,200   1,111   579 

Weighted-average common shares outstanding – diluted

  39,401   38,892   38,055 

Earnings per share – diluted

 $5.82  $2.47  $3.31 

 

Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period.

 

The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.9 million, 1.3 million, and 0.9 million for the fiscal years ended June 30, 2020, 2019 and 2018, respectively.

 
XML 41 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Share-based Compensation and Other Benefit Plans
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

Note 10. Share-based Compensation and Other Benefit Plans:

 

The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. 

 

Equity incentive plan: The Company's Second Amended and Restated 2010 Equity Incentive Plan (the Second A&R 2010 Plan) provides for the granting of incentive and nonqualified stock options, restricted stock, restricted stock units, performance shares, performance units and stock appreciation rights. There are 7.5 million shares of common stock authorized for grant under the Second A&R 2010 Plan. At June 30, 2020, there were 1.9 million shares of common stock available for grant under the Second A&R 2010 Plan. The maximum term of incentive options granted under the Second A&R 2010 Plan is ten years. The Second A&R 2010 Plan amended and restated the Company's Amended and Restate 2010 Equity Incentive Plan (the A&R 2010 Plan). The A&R 2010 Plan replaced the Company's 1998 Nonqualified Stock Option Plan (the 1998 Plan). The Second A&R 2010 Plan and the 1998 Plan (collectively, the Plans) are administered by the Board of Directors and its Executive Compensation Committee, which determine the persons who are to receive awards under the Plans, the number of shares subject to each award and the term and exercise price of each award. The number of shares of common stock subject to outstanding awards as of  June 30, 2020 under the Second A&R 2010 Plan were 3.6 million. For June 30, 2019 under the Second A&R 2010 Plan and the 1998 Plan were 3.6 million and 20,000, respectively.  On April 26, 2018 the Executive Compensation Committee of the Board of Directors approved a modification to the Plans.   The modification implements a new retirement policy that permits retirees to continue vesting in certain time-based stock options granted during employment, resulting in accelerated stock compensation expense for those employees meeting the definition of retirement eligible.  This modification resulted in an additional $8.3 million of expense during fiscal year 2018 and affected all employees who participate in the plan.

  

The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:

 

  

Year Ended June 30,

 
  

2020

  

2019

  

2018

 
                

Dividend yield

  0.67%    0.74%    1.1%  

Expected volatility

 22%-24%  20%-23%  21%-24% 
Risk-free interest rates 1.3%-1.9%  2.5%-3.0%  1.7%-2.8% 

Expected lives (years)

  4.0    4.1    4.7  

 

The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted.

 

Stock option activity under the Plans for the three years ended June 30, 2020, consists of the following (shares in thousands): 

 

  

Number of

Shares (in

thousands)

  

Weighted
Average
Exercise
Price

  

Aggregate
Intrinsic
Value

(millions)

  

Weighted

Average

Contractual

Life (years)

 
                 

Outstanding at June 30, 2017

  2,821  $98.42         

Granted

  1,087   120.67         

Forfeited

  (252

)

  86.62         

Exercised

  (204

)

  111.51         

Outstanding at June 30, 2018

  3,452  $105.17         

Granted

  917   173.89         

Forfeited

  (330

)

  129.93         

Exercised

  (383

)

  95.29         

Outstanding at June 30, 2019

  3,656  $121.16         

Granted

  752   190.80         

Forfeited

  (56

)

  95.97         

Exercised

  (743

)

  157.45         

Outstanding at June 30, 2020

  3,609  $140.28  $446.7   4.3 
                 

Exercisable at June 30, 2018:

  1,151   90.75         

Exercisable at June 30, 2019:

  1,467   98.70         

Exercisable at June 30, 2020:

  1,564   112.60  $236.8   3.3 

  

The weighted average fair value of options granted during fiscal 2020, 2019, and 2018 was $37.01, $34.66, and $22.07 respectively. The total intrinsic value of options exercised during fiscal 2020, 2019, and 2018 were $99.3 million, $159.0 million, and $10.6 million, respectively. The total fair value of options vested during fiscal 2020, 2019, and 2018 were $71.1 million, $31.7 million, and $8.8 million, respectively.

 

Restricted common stock activity under the Plans for the three years ended June 30, 2020, consists of the following (units in thousands):

 

  

Number of

Shares (in

thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Unvested at June 30, 2017

  32  $105.80     

Granted

  20   125.05     

Vested

  (17

)

  104.66     

Forfeited

  -   -     

Unvested at June 30, 2018

  35  $117.39     

Granted

  15   177.93     

Vested

  (20

)

  116.76     

Forfeited

  -   -     

Unvested at June 30, 2019

  30  $147.94     

Granted

  15   193.48     

Vested

  (18

)

  142.12     

Forfeited

  -   -     

Unvested at June 30, 2020

  28  $177.20   6.14 

 

The total fair value of restricted shares that vested was $2.5 million for fiscal 2020, $2.3 million for fiscal 2019, and $1.7 million for fiscal 2018.

 

Restricted stock unit activity under the Plans for the three years ended June 30, 2020, consists of the following (units in thousands):

 

  

Number of

Units

(in thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Outstanding at June 30, 2017

  111  $106.39     

Granted

  71   129.99     

Vested

  (16

)

  95.46     

Forfeited

  (18

)

  115.01     

Outstanding at June 30, 2018

  148  $117.95     

Granted

  56   170.96     

Vested

  (28

)

  110.86     

Forfeited

  (36

)

  143.72     

Outstanding at June 30, 2019

  139  $134.17     

Granted

  31   192.08     

Vested

  (51

)

  111.07     

Forfeited

  (3

)

  155.6     

Outstanding at June 30, 2020

  116  $159.25   5.20 

 

The total fair value of restricted stock units that vested was $5.7 million for fiscal 2020, $3.1 million for fiscal 2019, and $1.6 million for fiscal 2018. The restricted stock units vest over a three-year period.

 

Stock-based compensation cost of $32.4 million, $32.3 million, and $28.2 million was included in selling, general and administrative expense in fiscal 2020, 2019 and 2018, respectively. Additionally, Stock-based compensation costs of $1.6 million was included in cost of goods sold in 2020. As of June 30, 2020, there was $25.3 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal 2021 through 2023 using a 3% forfeiture rate. The weighted average period over which the compensation cost is expected to be recognized is 1.9 years.

 

Employee stock purchase plan: In fiscal year 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. The Company recorded expense of $0.4 million, $0.5 million, and $0.3 million for the ESPP in fiscal 2020, 2019, and 2018, respectively.

 

Profit sharing and savings plans: The Company has profit sharing and savings plans for its U.S. employees, which conform to IRS provisions for 401(k) plans. The Company makes matching contributions to the Plan. The Company has recorded an expense for contributions to the plans of $3.2 million, $2.8 million, and $2.5 million for the years ended June 30, 2020, 2019, and 2018, respectively. The Company operates defined contribution pension plans for its U.K. employees. The Company has recorded an expense for contributions to the plans of $1.4 million for each of the years ended June 30, 2020, 2019, and 2018.

 

Performance incentive programs: In fiscal 2020, under certain employment agreements and a Management Incentive Plan available to executive officers and certain management personnel, the Company recorded cash bonuses of $10.5 million, granted options for 751,499 shares of common stock, issued 15,398 restricted common shares and 30,858 restricted stock units. In fiscal 2019 and fiscal 2018, the Company recorded cash bonuses of $9.3 million and $7.2 million, granted options for 618,898 and 553,750 shares of common stock, and issued 11,279 and 14,194 restricted common stock shares and 25,903 and 35,174 restricted stock, respectively.

  
XML 42 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Income Taxes
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

Note 11. Income Taxes:

 

Income before income taxes was comprised of the following (in thousands):

 

  

Year Ended June 30,

 
  

2020

  

2019

  2018 

Domestic

 $245,365  $64,081  $81,557 

Foreign

  31,112   47,934   44,395 

Income before income taxes

 $276,477  $112,015  $125,952 

 

The provision for income taxes consisted of the following (in thousands):

 

  

Year Ended June 30,

 
  

2020

  

2019

  2018 

Taxes on income consist of:

            

Currently tax provision:

            

Federal

 $18,976  $16,090  $28,416 

State

  6,018   544   5,315 

Foreign

  8,580   13,329   11,983 

Total current tax provision

  33,574   29,963   45,714 

Deferred tax provision:

            

Federal

  14,074   (6,903

)

  (40,378

)

State

  2,055

 

  (3,977

)

  (1,381

)

Foreign

  (2,522)   (3,142

)

  (4,154

)

Total deferred tax provision

  13,607   (14,021

)

  (45,912

)

Total income tax provision

 $47,181  $15,943

 

 $(198)

 

The Company's effective income tax rate for fiscal 2020 was 17.1% for fiscal 2020 vs 14.2% in the prior year. The change in the effective tax rate for fiscal 2020 and 2019 were driven by the changes in the net discrete tax benefits $19.4 million and $12.7 million, respectively. 

 

The Company’s effective income tax rate for fiscal 2019 was 14.2% vs (0.2%) in the prior year. The change in the effective tax rate for fiscal 2019 and 2018 was driven by changes in net discrete tax benefits of $12.7 million and $34.4 million for fiscal year 2019 and 2018, respectively.

 

The Company's discrete tax benefits in fiscal 2020 primarily related to share-based compensation excess tax benefits of $17.7 million.
 
The Company's discrete tax benefits in fiscal 2019 primarily related to share-based compensation excess tax benefits of $7.2 million,  $3.2 million related to fiscal 2019 acquisitions, and $2.0 million for tax refunds relating to certain state apportionments. The prior fiscal year was benefited from acquisition payments made to employees and third parties, which were deductible for tax purposes. 
 

In fiscal 2018, the Company recognized net discrete tax benefits of $34.4 million. The primary driver in fiscal 2018 discrete tax benefits was a discrete net tax benefit of $33.0 million related to the Tax Act (as described further below). This net tax benefit consisted of $36.5 million due to the re-measurement of the Company’s deferred tax accounts to reflect the U.S. federal corporate tax rate reduction impact to our net deferred tax balances offset by expense for the federal transition tax of $3.3 million. Also impacting the Company’s fiscal 2018 effective tax rate was a $2.2 million tax benefit related to stock option exercises offset by a net discrete tax expense of $4.2 million related to the revaluation of contingent consideration, which is not a tax deductible expense.

 

On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted, which reduced the U.S. federal corporate tax rate from 35% to 21%, required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and created new taxes on certain foreign sourced earnings. The Tax Act added many new provisions including changes the deduction for executive compensation, a tax on global intangible low taxed income (“GILTI”), the base erosion anti abuse tax (“BEAT”) and a deduction for foreign derived intangible income (“FDII”).

 

The Company continues to monitor newly enacted regulations, clarifications, and changes in guidance  the “Tax Act”, which was enacted on  December 22, 2017. The Company recognizes changes in legislation in the period enacted, which may have a material impact on our effective tax rate in future periods.

 

The following is a reconciliation of the federal tax calculated at the statutory rate of to the actual income taxes provided:

 

  

Year Ended June 30,

 
  

2020

  2019  2018 
             

Income tax expense at federal statutory rate

  

21.0

%

  21.0

%

  28.1

%

State income taxes, net of federal benefit

  2.3

%

  0.8

%

  2.5

%

Qualified production activity deduction

  -

%

  -

%

  (2.4

)%

Research and development tax credit

  (0.7

)%

  (1.6

)%

  (1.4

)%

Contingent consideration adjustment

  (0.2)%  (0.4

)%

  3.3

%

Foreign tax rate differences

  (0.2)%  0.2

%

  (3.5

)%

Option exercises

  (5.7)%  (5.8

)%

  (1.8

)%

Domestic tax legislation changes  -   1.7

%

  (26.2

)%

State apportionment changes  -   (2.3)%  - 
Executive compensation limitations  1.6%  0.4%  - 

Other, net

  (1.0

)%

  0.2

%

  1.2

%

Effective tax rate

  17.1

%

  14.2

%

  (0.2

)%

  

Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands):

 

  

June 30

 
  

2020

  2019 
         

Inventory

 $7,769  $7,743 

Net operating loss carryovers

  25,707   33,294 

Tax credit carryovers

  9,568   9,640 

Excess tax basis in equity investments

  2,423   3,433 

Deferred compensation

  10,755   10,333 
Derivative - cash flow hedge  4,058   2,921 
Lease liability  16,256   - 

Other

  4,340   5,207 

Valuation allowance

  (7,523

)

  (6,974

)

Deferred tax assets

  73,353   65,597 
         

Net unrealized gain on available-for-sale investments

  (19,102)  (4,542

)

Intangible asset amortization

  (128,279)  (141,998

)

Depreciation

  (10,764)  (8,371

)

Right of use asset  (15,118)  - 

Other

  (1,180)  (440

)

Deferred tax liabilities

  (174,443

)

  (155,351

)

Net deferred tax liabilities

 $(101,090) $(89,754

)

 

A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. The valuation allowance as of June 30, 2020 was $7.5 million compared to $7.0 million in the prior year. 

 

As of June 30, 2020, the $7.5 million valuation allowance relates to certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired Quad, Exosome, ACD, Novus, ProteinSimple and CyVek as well as immaterial amounts generated after the acquisitions. The Company believes it is more likely than not that these tax carryovers will not be realized.

 

As of June 30, 2020, the Company has federal operating loss carryforwards of approximately $64.2 million and state operating loss carryforwards of $130.6 million from its acquisitions of Quad, Exosome, ACD, ProteinSimple and CyVek, which are not limited under IRC Section 382. As of June 30, 2020, the Company has foreign net operating loss carryforwards of $13.7 million. The net operating loss carryforwards expire between fiscal 2021 and 2036. The Company has a deferred tax asset of $20.2 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of June 30, 2020, the Company has federal and state tax credit carryforwards of $5.0 million and $5.7 million, respectively. The federal tax credit carryforwards expire between 2028 and 2038. The majority of the state credit carryforwards have no expiry date. The Company has a deferred tax asset of $7.5 million, net of the valuation allowance discussed above, related to the tax credit carryovers.

 

The Company has not recognized a deferred tax liability for unremitted foreign earnings of approximately $186 million from its foreign operations because its subsidiaries have invested or will invest the undistributed earnings indefinitely. The transition tax included as part of the Tax Act resulted in the previously untaxed foreign earnings being included in the federal and state fiscal 2018 taxable income.  The one-time transition tax was based on certain foreign earnings for which earnings have been previously indefinitely reinvested as well as the amount of earnings held in cash and other specified assets.   No additional income taxes have been provided for cumulative unremitted foreign earnings as at this time our intention with respect to unremitted foreign earnings is to continue to indefinitely reinvest outside the U.S. those earnings needed for working capital or additional foreign investment. If there are policy changes, we would record applicable taxes at that time.

 

We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation.  In addition, we anticipate that further guidance from the IRS and US Treasury related to the Tax Act could impact the amount of any related taxes.  Therefore, it is not practical to estimate the amount of the deferred income tax liabilities related to investments in these foreign subsidiaries.

 

The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):

 

  

Year Ended June 30,

 
  

2020

  2019  2018 

Beginning balance

 $5,032  $1,947  $1,747 

Additions due to acquisitions

  -   900   - 

Additions for tax positions of current year

  306   2,185   35 

Closure of tax years

  (1,041)  -   -

 

Tax reform

  -   -   165 

Ending balances

 $4,297  $5,032  $1,947 

 

The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelve months. The Company files income tax returns in the U.S. federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company's federal returns are subject to tax assessment for 2017 and subsequent years. State and foreign income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.

 
XML 43 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Note 12 - Segment Information
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 12. Segment Information:

 

The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics.

 

The Company's Protein Sciences segment is comprised of the Reagent Solutions division and Analytical Solution division. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields. No customer in the Protein Sciences segment accounted for more than 10% of the segment’s net sales for the years ended June 30, 2020, 2019, and 2018.

  

The Company's Diagnostics and Genomics is comprised of the Diagnostics Reagents division and the Genomics division. The Diagnostics Reagents division develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits. The Genomics division consists of Genomics and Exosome products and sells a portfolio of clinical molecular diagnostic oncology assays, as well as tissue-based in-situ hybridization assays for research in clinical use. No customer in the Diagnostics and Genomics segment accounted for more than 10% of the segment’s net sales for the fiscal years ended June 30, 2020, 2019, and 2018. 

 

There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term.

 

Following is financial information relating to the operating segments (in thousands):

 

  

Year Ended June 30,

 
  

2020

  2019  2018 

Net sales:

            

Protein Sciences

 $555,352  $543,159  $482,378 

Diagnostics and Genomics

  184,549   171,674   161,151 

Intersegment

  (1,210

)

  (827

)

  (536

)

Consolidated net sales

 $738,691  $714,006  $642,993 
             

Operating Income:

            

Protein Sciences

 $234,929  $240,919  $209,880 

Diagnostics and Genomics

  14,965   10,079   35,496 

Segment operating income

  249,894   250,998   245,376 

Costs recognized upon sale of acquired inventory

  -

 

  (3,739

)

  (2,455

)

Amortization of acquired intangible assets

  (60,865

)

  (58,550

)

  (46,983

)

Gain on escrow settlement  7,169   -   - 

Acquisition related expenses

  (416

)

  (2,282

)

  (24,429

)

Restructuring costs

  (87

)

  -

 

  (376)

Stock-based compensation

  

(34,262

)

  (33,057

)

  (28,240

)

Corporate general, selling and administrative expenses

  (4,015

)

  (6,651

)

  (6,715

)

Consolidated operating income

 $157,419  $146,719  $136,178 

 

The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by operating segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each operating segment’s operating results, it is not discretely identifiable.

 

The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note 2. The Company has disclosed dis-aggregated product and service revenue by consumables, instruments, and services in Note 2. The Company considers total instrument and total service revenue to represent similar groups of products in the fiscal years presented. The Company considered our consumables sold in the Protein Sciences and Diagnostics and Genomics segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands) :

 

  

Year Ended June 30,

 
  

2020

  2019  

2018

 
Consumables revenue - Protein Sciences $

431,052

  $430,655  $384,350 

Consumables revenue - Diagnostics and Genomics

  171,590   158,324   150,388 

Total consumable revenue

 $602,642  $588,979  $534,738 

 

The following is financial information relating to geographic areas (in thousands):

 

  

Year ended June 30,

 

Long-lived assets:

 

2020

  2019 

United States and Canada

 $162,039  $138,016 

Europe

  13,120   14,439 

Asia

  1,670   1,584 

Total long-lived assets

 $176,829  $154,039 

Intangible assets:

        

United States and Canada

 $499,875  $556,951 

Europe

  12,349   16,637 

Asia

  4,321   5,841 

Total intangible assets

 $516,545  $579,429 

 

Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

 
XML 44 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Note 13 - Quarterly Financial Data (Unaudited)
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Quarterly Financial Information [Text Block]

Note 13. Quarterly Financial Data (unaudited):

 

(in thousands, except per share data)

                    

2020

 

First

Quarter

  

Second

Quarter

  

Third

Quarter

  

Fourth

Quarter

  

Year

 

Net sales

 $183,243  $184,934  $194,680  $175,834  $738,691 

Cost of sales

 $64,829  $63,531  $64,617  $62,520  $255,497 

Net earnings1

 $14,398  $119,623  $36,432  $58,847  $229,296 
                     
(1) - Amounts do not total due to rounding                    
                     

Earnings per common share:

                    

Basic

 $0.38  $3.13  $0.95  $1.54  $6.00 

Diluted

 $0.37  $3.02  $0.92  $1.48  $5.82 
                     

Weighted average common shares outstanding:

                    

Basic

  38,032   38,167   38,303   38,304   38,201 

Diluted

  39,253   39,550   39,435   39,700   39,401 

 

(in thousands, except per share data)

                    

2019

 

First

Quarter

  

Second

Quarter

  

Third

Quarter

  

Fourth

Quarter

  

Year

 

Net sales

 $162,970  $174,510  $184,861  $191,664  $714,006 

Cost of sales

 $55,367  $61,492  $60,251  $63,405  $240,515 

Net earnings

 $17,403  $17,556  $44,654  $16,459  $96,072 
                     

Earnings per common share:

                    

Basic

 $0.46  $0.46  $1.18  $0.43  $2.54 

Diluted

 $0.45  $0.45  $1.15  $0.42  $2.47 
                     

Weighted average common shares outstanding:

                    

Basic

  37,697   37,766   37,772   37,881   37,781 

Diluted

  38,813   38,748   38,861   39,135   38,892 

 

 
XML 45 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Note 14 - Subsequent Events
 12 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Subsequent Events [Text Block]

Note 14. Subsequent Events:

 

None

 
XML 46 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies (Policies)
 12 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Use of Estimates, Policy [Policy Text Block]

Use of estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.

 
Consolidation, Policy [Policy Text Block]

Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.

 
Foreign Currency Transactions and Translations Policy [Policy Text Block]

Translation of foreign financial statements: Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.

 
Revenue [Policy Text Block]

Revenue recognition: The Company adopted ASC 606 - Revenue from Contracts with Customers on July 1, 2018 using the modified retrospective transition approach. ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to the Recently Adopted Accounting Pronouncements section of Note 1 for additional information regarding our adoption of ASC 606 and Note 2 for additional information regarding our revenue recognition policy under ASC 606.

 
Research and Development Expense, Policy [Policy Text Block]

Research and development: Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.

 
Advertising Cost [Policy Text Block]

Advertising costs: Advertising expenses were $4.2 million, $4.1 million, and $3.8 million for fiscal 2020, 2019, and 2018 respectively. The Company expenses advertising expenses as incurred.

  
Income Tax, Policy [Policy Text Block]

Income taxes: The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense.

 

See Note 11 for additional information regarding income taxes.
Comprehensive Income, Policy [Policy Text Block]

Comprehensive income: Comprehensive income includes charges and credits to shareholders' equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity.

 
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and cash equivalents: Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of three months or less.

 
Marketable Securities, Policy [Policy Text Block]

Available-for-sale investments: Available-for-sale investments consist of debt instruments with original maturities of generally three months to six months and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value.  Unrealized gains and losses on available-for-sale securities are included within other income (expense) beginning in fiscal 2019 as the Company adopted ASU  2018-02 on July 1, 2018, as further described in the Recently Adopted Accounting Pronouncements section of Note 1. Unrealized gains or losses on available-for-sale securities were recorded within comprehensive income in fiscal year 2018.

 
Accounts Receivable [Policy Text Block]

Trade accounts receivable: Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer.

 
Inventory, Policy [Policy Text Block]

Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration.

 

For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Company’s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with ASC 330 - Inventory.

 
Property, Plant and Equipment, Policy [Policy Text Block]

Property and equipment: Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of 5 to 40 years.

 
Contingent Consideration, Policy [Policy Text Block]

Contingent Consideration: Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income

 
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangibles assets: Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life. In the current year, the Company identified one item as described in the Impairment of long-lived assets and amortizable intangibles section below. 

 
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

Impairment of long-lived assets and amortizable intangibles: We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.

 

The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During fiscal year 2020, the Company accelerated the amortization of a certain trade name based on the Company's planned integration of the products under that acquired trade name into a legacy brand. The accelerated amortization resulted in $1.3 million in additional amortization expense in fiscal 2020 and an estimated $0.6 million in fiscal 2021. No other triggering events were identified and no impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years 2018, 2019, and 2020.

 

Impairment of goodwill: We evaluate the carrying value of goodwill during the fourth quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.

 

To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business.

 

2020 Goodwill Impairment Analyses

 

In completing our 2020 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU 2017- 04, a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit’s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value- weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

 

The result of our quantitative assessment, where we compared the discounted cash flows of each reporting unit to its carrying value, indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2020. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2020, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. 

 

2019 Goodwill Impairment Analyses

 

At the beginning of the quarter ended March 31, 2019, the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment.

 

Because our quantitative analysis performed as of January 1, 2019 included all of our reporting units, except for Exosome a recent acquisition that was a separate reporting unit that was not impacted by the business process realignment, the summation of the calculated reporting units’ fair values combined with the fair value of the Exosome acquisition, was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.

 

The quantitative assessments completed as of January 1, 2019 indicated that all tested reporting units had a substantial amount of headroom. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

In conducting our annual goodwill impairment test on April 1, we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than not that the fair value of a reporting unit is less than its carrying amount.

 

Based on its annual analysis, the Company determined there was no indication of impairment of goodwill. Further, no triggering events or items beyond the realignment discussed above were identified in the year ended June 30, 2019 that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.

 

2018 Goodwill Impairment Analyses

 

In completing our 2018 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units, with a process consistent to that described in our 2020 Goodwill Impairment Analyses section above. The quantitative assessment completed indicated that all of the reporting units had a substantial amount of headroom. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

There has been no impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC 350 guidance for goodwill and other intangibles on July 1, 2002.

 
Equity Method Investments [Policy Text Block]

Investments in unconsolidated entities: The Company periodically invests in the equity of start-up and early development stage companies. The accounting treatment of each investment (cost method or equity method) is dependent upon a number of factors, including, but not limited to, the Company's share in the equity of the investee and the Company's ability to exercise significant influence over the operating and financial policies of the investee.

 
New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Pronouncements

 

In  February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. The FASB has issued narrow codification improvements to Leases (Topic 842) through ASU No. 2018-10 and ASU 2019-01. Additionally, the FASB issued ASU 2018-11, allowing an entity to elect a transition method where they do not recast prior periods presented in the financial statements in the period of adoption. The Company has elected the transition method allowed for under ASU 2018-11 when adopting Leases (Topic 842). The Company adopted the standard effective  July 1, 2019 and correspondingly recorded incremental operating lease liabilities of $80.6 million, a right-of-use lease asset of $79.5 million, retained earnings of $0.8 million and a deferred tax adjustment of $0.3 million. Additionally, the Company reclassified $4.0 million of deferred rent recorded within accrued expenses under ASC 840 - Leases into operating lease liabilities upon adoption of Topic 842. In adopting ASC 842, the Company elected the package of available practical expedients and to use hindsight in determining the lease term for all existing leases. Further, as part of our adoption of ASC 842, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Refer to Note 7 for additional information on leases.

 

Pronouncements Issued but Not Yet Adopted

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The amendment in this update replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade and loan receivables and available-for-sale debt securities. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. This ASU is effective for annual periods and interim periods for those annual periods beginning after December 15, 2019, which for us is July 1, 2020. Entities may early adopt beginning after December 15, 2018. We have completed our evaluation of the impact of the adoption of ASU 2016-13, noting the impact of adoption is not expected to have a material impact on our consolidated financial statements.

 

In August 2018, the FASB issued ASU No. 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is not affected by the new standard.  This ASU is effective for annual periods and interim periods for those annual periods beginning after December 15, 2019, which for us is July 1, 2020 and may be adopted retrospectively or prospectively to eligible costs incurred on or after the date the guidance is first applied. We do not expect this standard to have a material impact on our consolidated financial statements and we will adopt the standard prospectively on July 1, 2020.

 

In  March 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides expedients and exceptions to existing guidance on contract modifications and hedge accounting that is optional to facilitate the market transition from a reference rate, including LIBOR which is being phased out in 2021, to a new reference rate. The provisions of the ASU would impact contract modifications and other changes that occur while LIBOR is phased out. The Company is in the process of evaluating the optional relief guidance provided within this ASU and is also reviewing its debt and derivative instrument that utilizes LIBOR as the reference rate. The Company will continue to evaluate and monitor developments and our assessment of ASU 2020-04 during the LIBOR transition period.
XML 47 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Revenue Recognition (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Disaggregation of Revenue [Table Text Block]
  

Year ended June 30,

     
  

2020

  

2019

  2018 

Consumables

 $602,642  $588,979  $534,738 

Instruments

  71,462   67,538   61,784 

Services

  47,459   38,050   34,137 

Total product and services revenue, net

  721,563  $694,567   630,659 

Royalty revenues

  17,128   19,439   12,334 

Total revenues, net

 $738,691  $714,006  $642,993 
  

Year Ended June 30,

 
  

2020

  

2019

  

2018

 

Net sales:

            

United States

 $404,407  $391,191  $346,293 

EMEA, excluding U.K.

  155,289   155,821   148,599 

U.K.

  30,411   34,975   33,704 

APAC, excluding Greater China

  60,362   52,913   48,392 

Greater China

  68,792   57,799   47,950 

Rest of world

  19,430   21,307   18,055 

Total external sales

 $738,691  $714,006  $642,993
XML 48 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
  

June 30,

 
  

2020

  

2019

 
         

Raw materials

 $51,530  $40,913 

Finished goods(1)

  56,268   53,376 

Inventories, net

 $107,798  $94,289 
Property, Plant and Equipment [Table Text Block]
  

June 30,

 
  

2020

  

2019

 

Cost:

        

Land

 $8,516  $7,065 

Buildings and improvements

  184,430   175,019 

Machinery, equipment and other

  153,704   124,233 

Property and equipment

  346,650   306,317 

Accumulated depreciation and amortization

  (169,821

)

  (152,278

)

Property and equipment, net

 $176,829  $154,039 
Schedule of Intangible Assets and Goodwill [Table Text Block]
       

June 30,

 
  

Useful Life

(years)

  

2020

  

2019

 
              

Developed technology

 9-15  $434,653  $435,679 

Trade names

 2-20   146,713   147,296 

Customer relationships

 7-16   211,750   214,320 

Patents

  10    2,475   2,133 

Intangible assets

       795,591   799,428 

Accumulated amortization

       (279,046

)

  (219,999

)

Intangibles assets, net

      $516,545  $579,429 
Schedule of Finite-Lived Intangible Assets [Table Text Block]
  

June 30,

 
  

2020

  

2019

 
         

Beginning balance

 $579,429  $446,332 

Acquisitions (Note 4)

  -   191,956 

Other additions

  311   633 

Amortization expense

  (61,095)  (58,715

)

Currency translation

  (2,100)  (777

)

Ending balance

 $516,545  $579,429 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

2021

 $59,766 

2020

  57,564 

2023

  55,696 

2024

  53,198 

2025

  50,024 

Thereafter

  240,297 

Total

 $516,545 
Schedule of Goodwill [Table Text Block]
  

Protein

Sciences

  

Diagnostics &

Genomics

  

Total

 

June 30, 2018

 $347,918  $249,972  $597,890 

Acquisitions (Note 4)

  30,939   105,362   136,301 

Currency translation

  (1,450)  (74)  (1,524

)

June 30, 2019

 $377,407  $355,260  $732,667 
Acquisitions (Note 4)  (326)  -   (326)
Currency Translation  (4,000)  (31)  (4,031)
June 30, 2020 $373,081  $355,229  $728,310 
Schedule of Other Assets, Noncurrent [Table Text Block]
  

June 30,

 
  

2020

  

2019

 
         

Long-term deposits

 $6,234  $487 

Other

  7,288   5,181 

Other long-term assets

 $13,522  $5,668 
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]
  

Year Ended June 30,

 
  

2020

  

2019

  

2018

 

Income taxes paid

 $41,992  $36,814  $35,076 

Interest paid

  18,615   21,497   9,844 

Non-cash activities:

            

Acquisition-related liabilities (1)

  (2,105)  12,600   1,396 
XML 49 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Acquisitions (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
  B-MoGen Biotechnologies  Exosome Diagnostics  Quad Technologies  

Trevigen

  Atlanta Biologicals  Eurocell Diagnostics 

Current assets, net of cash

 $504  $2,611  $36  $1,662  $15,722  $512 

Equipment and other long-term assets

  269   2,212   228   53   4,901   188 

Intangible assets:

 
Developed technology  14,000   105,000   12,256   5,100   23,000   - 
Trade name  -   58,000   -   160   2,300   - 

Customer relationships

  400   2,300   -   260   3,600   6,272 

Goodwill

  16,131   105,362   14,481   5,991   10,195   2,910 

Total assets acquired

  31,304   275,485   27,001   13,226   59,718   9,882 
                         

Liabilities

  211   3,716   296   387   90   483 

Deferred income taxes, net

  3,051   16,346   943   2,195   8,354   2,070 

Net assets acquired

 $28,042  $255,423  $25,762  $10,644  $51,274  $7,329 
                         

Cash paid, net of cash acquired

  17,448   251,623   20,462  $10,644  $51,274  $5,933 

Consideration payable

  5,500   -   -   -   -   1,396 
Contingent consideration payable  5,094   3,800   5,300   -   -   - 
Net assets acquired $28,042  $255,423  $25,762  $10,644  $51,274  $7,329 

 
XML 50 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Fair Value Measurements (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
  

Total carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30, 2020

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $87,842  $79,846  $7,996  $- 

Certificates of deposit (2)

  36,426   36,426   -   - 

Total Assets

 $124,268  $116,272  $7,996  $- 
                 

Liabilities

                

Contingent consideration

 $6,137  $-  $-  $6,137 
    Derivative instruments - cash flow hedges  17,331   -   17,331   - 
    Total Liabilities $23,468  $-  $17,331  $6,137 
  

Total carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30, 2019

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $38,219  $38,219  $-  $- 

Certificates of deposit (2)

  26,928   26,928   -   - 

Total Assets

 $65,147  $65,147  $-  $- 
                 
Liabilities                
Contingent consideration  12,600         12,600 
Derivative instruments - cash flow hedges  12,458      12,458    
Total Liabilities $25,058  $-  $12,458  $12,600 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
  

June 30,

 
  

2020

  

2019

 
         

Fair value at the beginning of period

 $12,600  $- 

Purchase price contingent consideration (Note 4)

  -   14,600 

Payments

  (4,358

)

  -

 

Gain on escrow settlement  (1,200)   

Change in fair value of contingent consideration

  (905)  (2,000)

Contingent consideration payable

 $6,137  $12,600 
XML 51 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Leases (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Lessee, Operating Lease, Asset and Liabilities [Table Text Block]
 

Balance Sheet Classification

 

As of:

June 30,

2020

 

Operating leases:

     

Operating lease right of use assets

Right of Use Asset

 $71,465 
      

Current operating lease liabilities

Operating lease liabilities current

 $9,535 

Noncurrent operating lease liabilities

Operating lease liabilities

  67,248 
Total operating lease liabilities  $76,783 
 

 

    
Weighted average remaining lease term (in years):   8.72 
 

 

    
Weighted average discount rate:   4.40%
Lessee, Operating Lease, Cash Flow Information [Table Text Block]
  

For the year ended June 30, 2020

 

Cash amounts paid on operating lease liabilities(1)

 $12,763 
     

Right of use assets obtained in exchange for lease liabilities

  1,758 
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
  

June 30, 2020

Operating

Leases

 

2021

 $12,590 

2022

  12,113 

2023

  11,296 

2024

  10,317 

2025

  9,388 

Thereafter

  37,316 

Total

 $93,020 
Less: Amounts representing interest  16,237 
Total lease obligations  76,783 
Lessee, Operating Lease, Disclosure [Table Text Block]
  

Operating

Leases

 

2020

 $13,707 

2021

  13,469 

2022

  13,154 

2023

  12,716 

2024

  11,392 

Thereafter

  51,895 

Total

 $116,333 
XML 52 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
   

Unrealized

Gains (Losses)

on Available-

for-Sale

Investments

  

Foreign

Currency

Translation

Adjustments

  

Unrealized Gains (Losses) on Derivatives Instruments

  

Total

 
 

Balance June 30, 2017

 $18,989  $(67,924

)

 $-  $(48,935

)

 

Other comprehensive income (loss) before reclassifications

  18,108   (1,572

)

  -   16,536 
 

Amounts reclassified from accumulated other comprehensive loss to income

  (12,415

)

  -   -   (12,415

)

 

Balance June 30, 2018

 $24,682  $(69,496

)

 $-  $(44,814

)

 Cumulative effect adjustment for adoption for ASU 2018-02  2,371   -   -   2,371 
 Cumulative effect adjustment for adoption for ASU 2016-01  (27,053)  -   -   (27,053)
 

Other comprehensive income (loss) before reclassifications 

  -   (4,487)  (9,537)  (14,024)
 

Balance June 30, 2019

 $-  $(73,983

)

 $(9,537) $(83,521

)

 Other comprehensive income (loss) before reclassifications  -   (9,963)  (7,179)  (17,142)
 Reclassification from loss on derivatives to interest expense, net of taxes(1)  -   -   3,464   3,464 
 Balance June 30, 2020 $-  $(83,946) $(13,253) $(97,199)
XML 53 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Earnings Per Share (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Year Ended June 30,

 
  

2020

  2019  2018 

Earnings per share – basic:

            

Net income

 $229,296  $96,072  $126,150 

Income allocated to participating securities

  (224

)

  (105

)

  (108

)

Income available to common shareholders

 $229,072  $95,967  $126,042 

Weighted-average shares outstanding – basic

  38,201   37,781   37,476 

Earnings per share – basic

 $6.00  $2.54  $3.36 
             

Earnings per share – diluted:

            

Net income

 $229,296  $96,072  $126,150 

Income allocated to participating securities

  (224

)

  (105

)

  (108

)

Income available to common shareholders

 $229,072  $95,967  $126,042 

Weighted-average shares outstanding – basic

  38,201   37,781   37,476 

Dilutive effect of stock options and restricted stock units

  1,200   1,111   579 

Weighted-average common shares outstanding – diluted

  39,401   38,892   38,055 

Earnings per share – diluted

 $5.82  $2.47  $3.31 
XML 54 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Share-based Compensation and Other Benefit Plans (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
  

Year Ended June 30,

 
  

2020

  

2019

  

2018

 
                

Dividend yield

  0.67%    0.74%    1.1%  

Expected volatility

 22%-24%  20%-23%  21%-24% 
Risk-free interest rates 1.3%-1.9%  2.5%-3.0%  1.7%-2.8% 

Expected lives (years)

  4.0    4.1    4.7  
Share-based Payment Arrangement, Option, Activity [Table Text Block]
  

Number of

Shares (in

thousands)

  

Weighted
Average
Exercise
Price

  

Aggregate
Intrinsic
Value

(millions)

  

Weighted

Average

Contractual

Life (years)

 
                 

Outstanding at June 30, 2017

  2,821  $98.42         

Granted

  1,087   120.67         

Forfeited

  (252

)

  86.62         

Exercised

  (204

)

  111.51         

Outstanding at June 30, 2018

  3,452  $105.17         

Granted

  917   173.89         

Forfeited

  (330

)

  129.93         

Exercised

  (383

)

  95.29         

Outstanding at June 30, 2019

  3,656  $121.16         

Granted

  752   190.80         

Forfeited

  (56

)

  95.97         

Exercised

  (743

)

  157.45         

Outstanding at June 30, 2020

  3,609  $140.28  $446.7   4.3 
                 

Exercisable at June 30, 2018:

  1,151   90.75         

Exercisable at June 30, 2019:

  1,467   98.70         

Exercisable at June 30, 2020:

  1,564   112.60  $236.8   3.3 
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
  

Number of

Shares (in

thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Unvested at June 30, 2017

  32  $105.80     

Granted

  20   125.05     

Vested

  (17

)

  104.66     

Forfeited

  -   -     

Unvested at June 30, 2018

  35  $117.39     

Granted

  15   177.93     

Vested

  (20

)

  116.76     

Forfeited

  -   -     

Unvested at June 30, 2019

  30  $147.94     

Granted

  15   193.48     

Vested

  (18

)

  142.12     

Forfeited

  -   -     

Unvested at June 30, 2020

  28  $177.20   6.14 
  

Number of

Units

(in thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Outstanding at June 30, 2017

  111  $106.39     

Granted

  71   129.99     

Vested

  (16

)

  95.46     

Forfeited

  (18

)

  115.01     

Outstanding at June 30, 2018

  148  $117.95     

Granted

  56   170.96     

Vested

  (28

)

  110.86     

Forfeited

  (36

)

  143.72     

Outstanding at June 30, 2019

  139  $134.17     

Granted

  31   192.08     

Vested

  (51

)

  111.07     

Forfeited

  (3

)

  155.6     

Outstanding at June 30, 2020

  116  $159.25   5.20 
XML 55 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Income Taxes (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

Year Ended June 30,

 
  

2020

  

2019

  2018 

Domestic

 $245,365  $64,081  $81,557 

Foreign

  31,112   47,934   44,395 

Income before income taxes

 $276,477  $112,015  $125,952 
  

Year Ended June 30,

 
  

2020

  

2019

  2018 

Taxes on income consist of:

            

Currently tax provision:

            

Federal

 $18,976  $16,090  $28,416 

State

  6,018   544   5,315 

Foreign

  8,580   13,329   11,983 

Total current tax provision

  33,574   29,963   45,714 

Deferred tax provision:

            

Federal

  14,074   (6,903

)

  (40,378

)

State

  2,055

 

  (3,977

)

  (1,381

)

Foreign

  (2,522)   (3,142

)

  (4,154

)

Total deferred tax provision

  13,607   (14,021

)

  (45,912

)

Total income tax provision

 $47,181  $15,943

 

 $(198)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

Year Ended June 30,

 
  

2020

  2019  2018 
             

Income tax expense at federal statutory rate

  

21.0

%

  21.0

%

  28.1

%

State income taxes, net of federal benefit

  2.3

%

  0.8

%

  2.5

%

Qualified production activity deduction

  -

%

  -

%

  (2.4

)%

Research and development tax credit

  (0.7

)%

  (1.6

)%

  (1.4

)%

Contingent consideration adjustment

  (0.2)%  (0.4

)%

  3.3

%

Foreign tax rate differences

  (0.2)%  0.2

%

  (3.5

)%

Option exercises

  (5.7)%  (5.8

)%

  (1.8

)%

Domestic tax legislation changes  -   1.7

%

  (26.2

)%

State apportionment changes  -   (2.3)%  - 
Executive compensation limitations  1.6%  0.4%  - 

Other, net

  (1.0

)%

  0.2

%

  1.2

%

Effective tax rate

  17.1

%

  14.2

%

  (0.2

)%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

June 30

 
  

2020

  2019 
         

Inventory

 $7,769  $7,743 

Net operating loss carryovers

  25,707   33,294 

Tax credit carryovers

  9,568   9,640 

Excess tax basis in equity investments

  2,423   3,433 

Deferred compensation

  10,755   10,333 
Derivative - cash flow hedge  4,058   2,921 
Lease liability  16,256   - 

Other

  4,340   5,207 

Valuation allowance

  (7,523

)

  (6,974

)

Deferred tax assets

  73,353   65,597 
         

Net unrealized gain on available-for-sale investments

  (19,102)  (4,542

)

Intangible asset amortization

  (128,279)  (141,998

)

Depreciation

  (10,764)  (8,371

)

Right of use asset  (15,118)  - 

Other

  (1,180)  (440

)

Deferred tax liabilities

  (174,443

)

  (155,351

)

Net deferred tax liabilities

 $(101,090) $(89,754

)
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
  

Year Ended June 30,

 
  

2020

  2019  2018 

Beginning balance

 $5,032  $1,947  $1,747 

Additions due to acquisitions

  -   900   - 

Additions for tax positions of current year

  306   2,185   35 

Closure of tax years

  (1,041)  -   -

 

Tax reform

  -   -   165 

Ending balances

 $4,297  $5,032  $1,947 
XML 56 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Note 12 - Segment Information (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
  

Year Ended June 30,

 
  

2020

  2019  2018 

Net sales:

            

Protein Sciences

 $555,352  $543,159  $482,378 

Diagnostics and Genomics

  184,549   171,674   161,151 

Intersegment

  (1,210

)

  (827

)

  (536

)

Consolidated net sales

 $738,691  $714,006  $642,993 
             

Operating Income:

            

Protein Sciences

 $234,929  $240,919  $209,880 

Diagnostics and Genomics

  14,965   10,079   35,496 

Segment operating income

  249,894   250,998   245,376 

Costs recognized upon sale of acquired inventory

  -

 

  (3,739

)

  (2,455

)

Amortization of acquired intangible assets

  (60,865

)

  (58,550

)

  (46,983

)

Gain on escrow settlement  7,169   -   - 

Acquisition related expenses

  (416

)

  (2,282

)

  (24,429

)

Restructuring costs

  (87

)

  -

 

  (376)

Stock-based compensation

  

(34,262

)

  (33,057

)

  (28,240

)

Corporate general, selling and administrative expenses

  (4,015

)

  (6,651

)

  (6,715

)

Consolidated operating income

 $157,419  $146,719  $136,178 
  

Year Ended June 30,

 
  

2020

  2019  

2018

 
Consumables revenue - Protein Sciences $

431,052

  $430,655  $384,350 

Consumables revenue - Diagnostics and Genomics

  171,590   158,324   150,388 

Total consumable revenue

 $602,642  $588,979  $534,738 
  

Year ended June 30,

 

Long-lived assets:

 

2020

  2019 

United States and Canada

 $162,039  $138,016 

Europe

  13,120   14,439 

Asia

  1,670   1,584 

Total long-lived assets

 $176,829  $154,039 

Intangible assets:

        

United States and Canada

 $499,875  $556,951 

Europe

  12,349   16,637 

Asia

  4,321   5,841 

Total intangible assets

 $516,545  $579,429 
XML 57 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Note 13 - Quarterly Financial Data (Unaudited) (Tables)
 12 Months Ended
Jun. 30, 2020
Notes Tables  
Quarterly Financial Information [Table Text Block]

(in thousands, except per share data)

                    

2020

 

First

Quarter

  

Second

Quarter

  

Third

Quarter

  

Fourth

Quarter

  

Year

 

Net sales

 $183,243  $184,934  $194,680  $175,834  $738,691 

Cost of sales

 $64,829  $63,531  $64,617  $62,520  $255,497 

Net earnings1

 $14,398  $119,623  $36,432  $58,847  $229,296 
                     
(1) - Amounts do not total due to rounding                    
                     

Earnings per common share:

                    

Basic

 $0.38  $3.13  $0.95  $1.54  $6.00 

Diluted

 $0.37  $3.02  $0.92  $1.48  $5.82 
                     

Weighted average common shares outstanding:

                    

Basic

  38,032   38,167   38,303   38,304   38,201 

Diluted

  39,253   39,550   39,435   39,700   39,401 

(in thousands, except per share data)

                    

2019

 

First

Quarter

  

Second

Quarter

  

Third

Quarter

  

Fourth

Quarter

  

Year

 

Net sales

 $162,970  $174,510  $184,861  $191,664  $714,006 

Cost of sales

 $55,367  $61,492  $60,251  $63,405  $240,515 

Net earnings

 $17,403  $17,556  $44,654  $16,459  $96,072 
                     

Earnings per common share:

                    

Basic

 $0.46  $0.46  $1.18  $0.43  $2.54 

Diluted

 $0.45  $0.45  $1.15  $0.42  $2.47 
                     

Weighted average common shares outstanding:

                    

Basic

  37,697   37,766   37,772   37,881   37,781 

Diluted

  38,813   38,748   38,861   39,135   38,892 
XML 58 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual)
$ in Thousands
 12 Months Ended 216 Months Ended
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2020
USD ($)
Jul. 01, 2019
USD ($)
Advertising Expense $ 4,200 $ 4,100 $ 3,800    
Amortization of Intangible Assets, Total 61,095 58,715      
Impairment of Long-Lived Assets Held-for-use $ 0 0 0    
Number of Reporting Units 1        
Goodwill, Impairment Loss $ 0 0 $ 0 $ 0  
Operating Lease, Liability, Total 76,783     76,783  
Operating Lease, Right-of-Use Asset 71,465 0   71,465  
Retained Earnings (Accumulated Deficit), Ending Balance 1,057,470 931,934   1,057,470  
Deferred Tax Liabilities, Net, Noncurrent 101,090 $ 89,754   101,090  
Accounting Standards Update 2016-02 [Member]          
Operating Lease, Liability, Total         $ 80,600
Operating Lease, Right-of-Use Asset         79,500
Retained Earnings (Accumulated Deficit), Ending Balance         800
Deferred Tax Liabilities, Net, Noncurrent         (300)
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification         $ 4,000
Trade Names [Member]          
Amortization of Intangible Assets, Total 1,300        
Finite-Lived Intangible Asset, Expected Amortization, Year One $ 600     $ 600  
Minimum [Member]          
Finite-Lived Intangible Asset, Useful Life (Year) 1 year        
Minimum [Member] | Trade Names [Member]          
Finite-Lived Intangible Asset, Useful Life (Year) 2 years        
Maximum [Member]          
Finite-Lived Intangible Asset, Useful Life (Year) 20 years        
Maximum [Member] | Trade Names [Member]          
Finite-Lived Intangible Asset, Useful Life (Year) 20 years        
Equipment [Member] | Minimum [Member]          
Property, Plant and Equipment, Useful Life (Year) 3 years        
Equipment [Member] | Maximum [Member]          
Property, Plant and Equipment, Useful Life (Year) 5 years        
Building, Building Improvements and Leasehold Improvements [Member] | Minimum [Member]          
Property, Plant and Equipment, Useful Life (Year) 5 years        
Building, Building Improvements and Leasehold Improvements [Member] | Maximum [Member]          
Property, Plant and Equipment, Useful Life (Year) 40 years        
XML 59 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Revenue Recognition (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Contract with Customer, Liability, Total $ 14.2 $ 10.4
Contract with Customer, Liability, Revenue Recognized $ 7.6  
XML 60 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Revenues, net $ 738,691 $ 714,006 $ 642,993
UNITED STATES      
Revenues, net 404,407 391,191 346,293
EMEA, excluding U.K. [Member]      
Revenues, net 155,289 155,821 148,599
UNITED KINGDOM      
Revenues, net 30,411 34,975 33,704
APAC, excluding Greater China [Member]      
Revenues, net 60,362 52,913 48,392
CHINA      
Revenues, net 68,792 57,799 47,950
Rest of World [Member]      
Revenues, net 19,430 21,307 18,055
Consumables [Member]      
Revenues, net 602,642 588,979 534,738
Instruments [Member]      
Revenues, net 71,462 67,538 61,784
Service [Member]      
Revenues, net 47,459 38,050 34,137
Product and Services [Member]      
Revenues, net 721,563 694,567 630,659
Royalty [Member]      
Revenues, net $ 17,128 $ 19,439 $ 12,334
XML 61 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Available-for-sale Securities, Total $ 87,800 $ 38,200  
Amortization of Intangible Assets, Total 61,095 58,715  
Other Assets, Noncurrent, Total 13,522 5,668  
Developed Technology Rights [Member] | Cost of Sales [Member]      
Amortization of Intangible Assets, Total 34,500 33,300 $ 25,300
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] | Selling, General and Administrative Expenses [Member]      
Amortization of Intangible Assets, Total 26,600 25,400 $ 21,600
Other Noncurrent Assets [Member]      
Inventory, Finished Goods, Net of Reserves, Non-current 4,646 3,239  
ChemoCentryx, Inc (CCXI) [Member]      
Available-for-sale Equity Securities, Amortized Cost Basis, Total $ 6,600 $ 18,800  
ChemoCentryx, Inc (CCXI) [Member]      
Share Price (in dollars per share) $ 9.30 $ 57.54  
XML 62 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Jun. 30, 2019
Raw materials $ 51,530 $ 40,913
Finished goods(1) [1] 56,268 53,376
Inventories, net $ 107,798 $ 94,289
[1] Finished goods inventory of $4,646 and $3,239 is included within other long-term assets in the June 30, 2020 and June 30, 2019 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.
XML 63 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Jun. 30, 2019
Property and equipment, cost $ 346,650 $ 306,317
Accumulated depreciation and amortization (169,821) (152,278)
Property and equipment, net 176,829 154,039
Land [Member]    
Property and equipment, cost 8,516 7,065
Building and Building Improvements [Member]    
Property and equipment, cost 184,430 175,019
Machinery and Equipment [Member]    
Property and equipment, cost $ 153,704 $ 124,233
XML 64 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Intangible assets $ 795,591 $ 799,428  
Accumulated amortization (279,046) (219,999)  
Intangibles assets, net $ 516,545 579,429 $ 446,332
Minimum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 1 year    
Maximum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 20 years    
Developed Technology Rights [Member]      
Intangible assets $ 434,653 435,679  
Developed Technology Rights [Member] | Minimum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 9 years    
Developed Technology Rights [Member] | Maximum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 15 years    
Trade Names [Member]      
Intangible assets $ 146,713 147,296  
Trade Names [Member] | Minimum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 2 years    
Trade Names [Member] | Maximum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 20 years    
Customer Relationships [Member]      
Intangible assets $ 211,750 214,320  
Customer Relationships [Member] | Minimum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 7 years    
Customer Relationships [Member] | Maximum [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 16 years    
Patents [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 10 years    
Intangible assets $ 2,475 $ 2,133  
XML 65 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Beginning balance $ 579,429 $ 446,332
Acquisitions (Note 4) 0 191,956
Other additions 311 633
Amortization expense (61,095) (58,715)
Currency translation (2,100) (777)
Ending balance $ 516,545 $ 579,429
XML 66 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)
$ in Thousands
Jun. 30, 2020
USD ($)
2021 $ 59,766
2020 57,564
2023 55,696
2024 53,198
2025 50,024
Thereafter 240,297
Total $ 516,545
XML 67 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Balance $ 732,667 $ 597,890
Acquisitions (Note 4)   136,301
Currency translation (4,031) (1,524)
Acquisitions (Note 4) (326)  
Balance 728,308 732,667
Protein Sciences [Member]    
Balance 377,407 347,918
Acquisitions (Note 4)   30,939
Currency translation (4,000) (1,450)
Acquisitions (Note 4) (326)  
Balance 373,081 377,407
Diagnostics and Genomics [Member]    
Balance 355,260 249,972
Acquisitions (Note 4)   105,362
Currency translation (31) (74)
Acquisitions (Note 4) 0  
Balance $ 355,229 $ 355,260
XML 68 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Jun. 30, 2019
Long-term deposits $ 6,234 $ 487
Other 7,288 5,181
Other long-term assets $ 13,522 $ 5,668
XML 69 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Income taxes paid $ 41,992 $ 36,814 $ 35,076
Interest paid 18,615 21,497 9,844
Acquisition-related liabilities (1) [1] $ (2,105) $ 12,600 $ 1,396
[1] Consists of holdback payments due at future dates and liabilities for contingent consideration. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.
XML 70 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Acquisitions (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 04, 2019
Feb. 01, 2019
Aug. 01, 2018
Jul. 02, 2018
Feb. 01, 2018
Jan. 02, 2018
Sep. 05, 2017
Jun. 30, 2020
Jun. 30, 2019
Feb. 01, 2019
Jun. 30, 2018
Payments to Acquire Businesses, Net of Cash Acquired, Total               $ (0) $ 289,492   $ 67,851
Gain (Loss) on Escrow Settlement               7,170 $ (0)   $ (0)
QT Holdings Corporation [Member]                      
Payments to Acquire Businesses, Net of Cash Acquired, Total       $ 20,500       20,462      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       51,000       51,000      
Business Acquisition, Goodwill, Expected Tax Deductible Amount       $ 0              
QT Holdings Corporation [Member] | Developed Technology Rights [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)       14 years              
Exosome Diagnostics, Inc [Member]                      
Payments to Acquire Businesses, Net of Cash Acquired, Total     $ 251,600         251,623      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     325,000         325,000      
Business Acquisition, Goodwill, Expected Tax Deductible Amount     0                
Gain (Loss) on Escrow Settlement     $ 7,200                
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)     15 years                
Exosome Diagnostics, Inc [Member] | Trade Names [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)     15 years                
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)     14 years                
B-MoGen [Member]                      
Payments to Acquire Businesses, Net of Cash Acquired, Total $ 17,500             17,448      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 38,000             38,000      
Business Acquisition, Goodwill, Expected Tax Deductible Amount 0                    
Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value 1,400                    
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain $ 3,700                    
Goodwill, Purchase Accounting Adjustments               300      
B-MoGen [Member] | Developed Technology Rights [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year) 14 years                    
Trevigen Inc. [Member]                      
Payments to Acquire Businesses, Net of Cash Acquired, Total             $ 10,600 10,644      
Business Acquisition, Goodwill, Expected Tax Deductible Amount             $ 0        
Atlanta Biologicals [Member]                      
Payments to Acquire Businesses, Net of Cash Acquired, Total           $ 51,300   51,274      
Business Acquisition, Goodwill, Expected Tax Deductible Amount           $ 0          
Atlanta Biologicals [Member] | Developed Technology Rights [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)           13 years          
Atlanta Biologicals [Member] | Trade Names [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)           15 years          
Atlanta Biologicals [Member] | Customer Relationships [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)           12 years          
Eurocell Diagnostics, SAS [Member]                      
Payments to Acquire Businesses, Net of Cash Acquired, Total   $ 1,300     $ 6,000     $ 5,933   $ 7,300  
Business Acquisition, Goodwill, Expected Tax Deductible Amount         $ 0            
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)         7 years            
XML 71 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 04, 2019
Feb. 01, 2019
Aug. 01, 2018
Jul. 02, 2018
Feb. 01, 2018
Jan. 02, 2018
Sep. 05, 2017
Jun. 30, 2020
Jun. 30, 2019
Feb. 01, 2019
Jun. 30, 2018
Goodwill               $ 728,308 $ 732,667   $ 597,890
Payments to Acquire Businesses, Net of Cash Acquired, Total               (0) 289,492   $ 67,851
Contingent consideration payable               199 $ 9,200    
B-MoGen [Member]                      
Current assets, net of cash               504      
Equipment and other long-term assets               269      
Goodwill               16,131      
Total assets acquired               31,304      
Liabilities               211      
Deferred income taxes, net               3,051      
Net assets acquired               28,042      
Payments to Acquire Businesses, Net of Cash Acquired, Total $ 17,500             17,448      
Consideration payable               5,500      
Contingent consideration payable               5,094      
Net assets acquired               28,042      
B-MoGen [Member] | Developed Technology Rights [Member]                      
Intangible assets               14,000      
B-MoGen [Member] | Customer Relationships [Member]                      
Intangible assets               400      
Exosome Diagnostics, Inc [Member]                      
Current assets, net of cash               2,611      
Equipment and other long-term assets               2,212      
Goodwill               105,362      
Total assets acquired               275,485      
Liabilities               3,716      
Deferred income taxes, net               16,346      
Net assets acquired               255,423      
Payments to Acquire Businesses, Net of Cash Acquired, Total     $ 251,600         251,623      
Consideration payable               0      
Contingent consideration payable               3,800      
Net assets acquired               255,423      
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]                      
Intangible assets               105,000      
Exosome Diagnostics, Inc [Member] | Trade Names [Member]                      
Intangible assets               58,000      
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member]                      
Intangible assets               2,300      
QT Holdings Corporation [Member]                      
Current assets, net of cash               36      
Equipment and other long-term assets               228      
Goodwill               14,481      
Total assets acquired               27,001      
Liabilities               296      
Deferred income taxes, net               943      
Net assets acquired               25,762      
Payments to Acquire Businesses, Net of Cash Acquired, Total       $ 20,500       20,462      
Consideration payable               0      
Contingent consideration payable               5,300      
Net assets acquired               25,762      
QT Holdings Corporation [Member] | Developed Technology Rights [Member]                      
Intangible assets               12,256      
Trevigen Inc. [Member]                      
Current assets, net of cash               1,662      
Equipment and other long-term assets               53      
Goodwill               5,991      
Total assets acquired               13,226      
Liabilities               387      
Deferred income taxes, net               2,195      
Net assets acquired               10,644      
Payments to Acquire Businesses, Net of Cash Acquired, Total             $ 10,600 10,644      
Consideration payable               0      
Contingent consideration payable               0      
Net assets acquired               10,644      
Trevigen Inc. [Member] | Developed Technology Rights [Member]                      
Intangible assets               5,100      
Trevigen Inc. [Member] | Trade Names [Member]                      
Intangible assets               160      
Trevigen Inc. [Member] | Customer Relationships [Member]                      
Intangible assets               260      
Atlanta Biologicals [Member]                      
Current assets, net of cash               15,722      
Equipment and other long-term assets               4,901      
Goodwill               10,195      
Total assets acquired               59,718      
Liabilities               90      
Deferred income taxes, net               8,354      
Net assets acquired               51,274      
Payments to Acquire Businesses, Net of Cash Acquired, Total           $ 51,300   51,274      
Consideration payable               0      
Contingent consideration payable               0      
Net assets acquired               51,274      
Atlanta Biologicals [Member] | Developed Technology Rights [Member]                      
Intangible assets               23,000      
Atlanta Biologicals [Member] | Trade Names [Member]                      
Intangible assets               2,300      
Atlanta Biologicals [Member] | Customer Relationships [Member]                      
Intangible assets               3,600      
Eurocell Diagnostics, SAS [Member]                      
Current assets, net of cash               512      
Equipment and other long-term assets               188      
Goodwill               2,910      
Total assets acquired               9,882      
Liabilities               483      
Deferred income taxes, net               2,070      
Net assets acquired               7,329      
Payments to Acquire Businesses, Net of Cash Acquired, Total   $ 1,300     $ 6,000     5,933   $ 7,300  
Consideration payable               1,396      
Contingent consideration payable               0      
Net assets acquired               7,329      
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member]                      
Intangible assets               $ 6,272      
XML 72 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Fair Value Measurements (Details Textual) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Oct. 31, 2022
Oct. 31, 2021
Oct. 31, 2020
Jun. 30, 2020
Jul. 01, 2019
Jun. 30, 2019
Jun. 04, 2019
Oct. 31, 2018
Aug. 01, 2018
Jul. 02, 2018
Business Combination, Liabilities Arising from Contingencies, Amount Recognized         $ 14.6          
Exosome Diagnostics, Inc [Member]                    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       $ 325.0         $ 325.0  
Business Combination, Liabilities Arising from Contingencies, Amount Recognized                 $ 3.8  
QT Holdings Corporation [Member]                    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       51.0           $ 51.0
Business Combination, Liabilities Arising from Contingencies, Amount Recognized                   $ 5.3
B-MoGen [Member]                    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       38.0     $ 38.0      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized             $ 5.5      
Embedded Derivative Financial Instruments [Member]                    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax       3.5            
Embedded Derivative Financial Instruments [Member] | Cash Flow Hedging [Member]                    
Derivative, Notional Amount               $ 380.0    
Embedded Derivative Financial Instruments [Member] | Cash Flow Hedging [Member] | Other Noncurrent Liabilities [Member]                    
Derivative Notional Amount, Dedesignated       80.0            
Embedded Derivative Financial Instruments [Member] | Cash Flow Hedging [Member] | Forecast [Member]                    
Derivative Notional Amount, Decrease in Period $ 200.0 $ 80.0 $ 100.0              
CCXI [Member]                    
Investments, Total       6.6   $ 18.8        
Investments, Fair Value Disclosure, Total       $ 8.0            
XML 73 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Jun. 30, 2019
Total Assets $ 124,268 $ 65,147
Contingent consideration 6,137 12,600
Derivative instruments - cash flow hedges 17,331 12,458
Total Liabilities 23,468 25,058
Fair Value, Inputs, Level 1 [Member]    
Total Assets 116,272 65,147
Contingent consideration 0
Derivative instruments - cash flow hedges 0
Total Liabilities 0 0
Fair Value, Inputs, Level 2 [Member]    
Total Assets 7,996 0
Contingent consideration 0
Derivative instruments - cash flow hedges 17,331 12,458
Total Liabilities 17,331 12,458
Fair Value, Inputs, Level 3 [Member]    
Total Assets 0 0
Contingent consideration 6,137 12,600
Derivative instruments - cash flow hedges 0
Total Liabilities 6,137 12,600
Equity Securities [Member]    
Investments, Fair Value Disclosure [1] 87,842 38,219
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [1] 79,846 38,219
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [1] 7,996 0
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [1] 0 0
Certificates of Deposit [Member]    
Investments, Fair Value Disclosure [2] 36,426 26,928
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [2] 36,426 26,928
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [2] 0 0
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [2] $ 0 $ 0
[1] Included in available-for-sale investments on the condensed consolidated balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) was $7.6 million and $18.8 million as of March 31, 2020 and June 30, 2019, respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $5.6 million as of March 31, 2020. The fair value of the warrant as of June 30, 2019 was not material.
[2] Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year.
XML 74 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) - Contingent Consideration [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Fair value at the beginning of period $ 12,600 $ 0
Purchase price contingent consideration (Note 4) 0 14,600
Payments (4,358) 0
Gain on escrow settlement (1,200)
Change in fair value of contingent consideration (905) (2,000)
Contingent consideration payable $ 6,137 $ 12,600
XML 75 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Debt and Other Financing Arrangements (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Aug. 01, 2018
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Proceeds from Long-term Lines of Credit   $ 40.0 $ 580.0 $ 55.0
Credit Agreement [Member]        
Long-term Debt, Total   $ 357.0 $ 505.2  
Credit Agreement [Member] | Term Loan [Member]        
Debt Instrument, Face Amount $ 250.0      
Proceeds from Issuance of Long-term Debt, Total 250.0      
Revolving Credit Facility [Member] | Credit Agreement [Member]        
Line of Credit Facility, Maximum Borrowing Capacity 600.0      
Line of Credit Facility, Additional Borrowing Capacity 200.0      
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage   0.15%    
Line of Credit, Current   $ 12.5    
Proceeds from Long-term Lines of Credit $ 330.0      
XML 76 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Leases (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2017
Variable Lease, Cost $ 3.4      
Fixed Lease, Cost $ 13.0      
Operating Lease, Expense   $ 12.9 $ 10.8 $ 9.8
Maximum [Member]        
Lessee, Operating Lease, Renewal Term (Year) 5 years      
XML 77 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Leases - Balance Sheet Classification (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Jun. 30, 2019
Operating Lease, Right-of-Use Asset $ 71,465 $ 0
Current operating lease liabilities 9,535 0
Noncurrent operating lease liabilities 67,248 $ 0
Total operating lease liabilities $ 76,783  
Weighted average remaining lease term (in years): (Year) 8 years 8 months 19 days  
Weighted average discount rate: 4.40%  
XML 78 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Leases - Cash Paid (Details)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
USD ($)
Cash amounts paid on operating lease liabilities(1) $ 12,763 [1]
Right of use assets obtained in exchange for lease liabilities $ 1,758
[1] Total cash paid for the Company's operating leases during the year ended June 30, 2020 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.
XML 79 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details)
$ in Thousands
Jun. 30, 2020
USD ($)
2021 $ 12,590
2022 12,113
2023 11,296
2024 10,317
2025 9,388
Thereafter 37,316
Total 93,020
Less: Amounts representing interest 16,237
Total lease obligations $ 76,783
XML 80 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Leases - Aggregate Net Minimum Rental Commitments (Details)
$ in Thousands
Jun. 30, 2019
USD ($)
2020 $ 13,707
2021 13,469
2022 13,154
2023 12,716
2024 11,392
Thereafter 51,895
Total $ 116,333
XML 81 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2017
Common Stock, Dividends, Per Share, Declared (in dollars per share)   $ 1.28 $ 1.28 $ 1.28  
Stock Repurchased During Period, Shares (in shares)   279,381 95,000    
Stock Repurchased During Period, Average Share Price (in dollars per share)   $ 179.37 $ 162.15    
Surrender and Retirement of Stock to Exercise Options, Value   $ (400)      
Interest Expense, Total   19,197 $ 21,705 $ 10,188  
Stockholders' Equity Attributable to Parent, Ending Balance   1,381,192 1,165,589 1,079,061 $ 949,627
Deferred Income Tax Expense (Benefit), Total   13,607 (14,021) (45,912)  
Forecast [Member]          
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent $ 7,035        
AOCI Attributable to Parent [Member]          
Surrender and Retirement of Stock to Exercise Options, Value        
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent   (3,464) [1]   12,415  
Stockholders' Equity Attributable to Parent, Ending Balance   (97,199) (83,521) (44,814) (48,935)
Deferred Income Tax Expense (Benefit), Total   (4,058) (2,921)    
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]          
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent   (3,464) [1]   (0)  
Stockholders' Equity Attributable to Parent, Ending Balance   (13,253) $ (9,537) $ 0 $ 0
Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]          
Interest Expense, Total   4,503      
Reclassification from AOCI, Current Period, Tax, Total   $ 1,040      
[1] Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made.The Company reclassified ($4,503) to interest expense and a related tax benefit tax of $1,040 during fiscal 2020. Approximately $7,035 of the $13,253 will be reclassified in the 12 months subsequent to June 30, 2020. The Company had deferred tax benefits of $4,058 and $2,921 included in the accumulated other comprehensive income loss as of June 30, 2020 and June 30, 2019, respectively.
XML 82 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Balance $ 1,165,589 $ 1,079,061 $ 949,627
Balance 1,381,192 1,165,589 1,079,061
Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance (879) 594  
Balance   (879) 594
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]      
Balance 0 24,682 18,989
Other comprehensive income (loss) before reclassifications 0 0 18,108
Amounts reclassified from accumulated other comprehensive loss to income 0 [1]   (12,415)
Balance 0 0 24,682
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance   2,371  
Balance     2,371
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance   (27,053)  
Balance     (27,053)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]      
Balance (73,983) (69,496) (67,924)
Other comprehensive income (loss) before reclassifications (9,963) (4,487) (1,572)
Amounts reclassified from accumulated other comprehensive loss to income 0 [1]   0
Balance (83,946) (73,983) (69,496)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance   0  
Balance     0
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance   0  
Balance     0
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]      
Balance (9,537) 0 0
Other comprehensive income (loss) before reclassifications (7,179) (9,537) 0
Amounts reclassified from accumulated other comprehensive loss to income 3,464 [1]   0
Balance (13,253) (9,537) 0
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance   0  
Balance     0
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance   0  
Balance     0
AOCI Attributable to Parent [Member]      
Balance (83,521) (44,814) (48,935)
Other comprehensive income (loss) before reclassifications (17,142) (14,024) 16,536
Amounts reclassified from accumulated other comprehensive loss to income 3,464 [1]   (12,415)
Balance (97,199) (83,521) (44,814)
AOCI Attributable to Parent [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance (24,682)  
Balance   (24,682)
AOCI Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance   2,371  
Balance     2,371
AOCI Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance   $ (27,053)  
Balance     $ (27,053)
[1] Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made.The Company reclassified ($4,503) to interest expense and a related tax benefit tax of $1,040 during fiscal 2020. Approximately $7,035 of the $13,253 will be reclassified in the 12 months subsequent to June 30, 2020. The Company had deferred tax benefits of $4,058 and $2,921 included in the accumulated other comprehensive income loss as of June 30, 2020 and June 30, 2019, respectively.
XML 83 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Earnings Per Share (Details Textual) - shares
shares in Millions
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 0.9 1.3 0.9
XML 84 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Net earnings $ 58,847 [1] $ 36,432 [1] $ 119,623 [1] $ 14,398 [1] $ 16,459 $ 44,654 $ 17,556 $ 17,403 $ 229,296 [1] $ 96,072 $ 126,150
Income allocated to participating securities                 (224) (105) (108)
Income available to common shareholders                 $ 229,072 $ 95,967 $ 126,042
Basic (in shares) 38,304 38,303 38,167 38,032 37,881 37,772 37,766 37,697 38,201 37,781 37,476
Basic (in dollars per share) $ 1.54 $ 0.95 $ 3.13 $ 0.38 $ 0.43 $ 1.18 $ 0.46 $ 0.46 $ 6.00 $ 2.54 $ 3.36
Net income $ 58,847 [1] $ 36,432 [1] $ 119,623 [1] $ 14,398 [1] $ 16,459 $ 44,654 $ 17,556 $ 17,403 $ 229,296 [1] $ 96,072 $ 126,150
Income allocated to participating securities                 (224) (105) (108)
Income available to common shareholders                 $ 229,072 $ 95,967 $ 126,042
Dilutive effect of stock options and restricted stock units (in shares)                 1,200 1,111 579
Diluted (in shares) 39,700 39,435 39,550 39,253 39,135 38,861 38,748 38,813 39,401 38,892 38,055
Diluted (in dollars per share) $ 1.48 $ 0.92 $ 3.02 $ 0.37 $ 0.42 $ 1.15 $ 0.45 $ 0.45 $ 5.82 $ 2.47 $ 3.31
[1] Amounts do not total due to rounding
XML 85 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2010
Jun. 30, 2017
Oct. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) 3,609,000 3,656,000 3,452,000   2,821,000  
Share-based Payment Arrangement, Accelerated Cost     $ 8.3      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) $ 37.01 $ 34.66 $ 22.07      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value $ 99.3 $ 159.0 $ 10.6      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 71.1 31.7 8.8      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total $ 25.3          
Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate 3.00%          
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) 1 year 10 months 24 days          
US Profit Sharing and Savings Plan [Member]            
Defined Contribution Plan, Cost $ 3.2 2.8 2.5      
GB Profit Sharing and Savings Plan [Member]            
Defined Contribution Plan, Cost 1.4 1.4 1.4      
Selling, General and Administrative Expenses [Member]            
Share-based Payment Arrangement, Expense 32.4 32.3 28.2      
Cost of Sales [Member]            
Share-based Payment Arrangement, Expense 1.6          
Restricted Stock [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value 2.5 2.3 1.7      
Restricted Stock Units (RSUs) [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value $ 5.7 $ 3.1 $ 1.6      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)     3 years      
Equity Incentive Plan 2010 [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)       7,500,000    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) 1,900,000          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) 3,600,000 3,600,000        
Equity Incentive Plan 2010 [Member] | Maximum [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)       10 years    
Nonqualified Stock Options Plan 1998 [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)   20,000        
Employee Stock Purchase Plan 2014 [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)           200,000
Share-based Payment Arrangement, Expense $ 0.4 $ 0.5 $ 0.3      
Performance Incentive Programs [Member] | Executive Officer [Member]            
Salary and Wage, Officer, Excluding Cost of Good and Service Sold $ 10.5 $ 9.3 $ 7.2      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) 751,499 618,898 553,750      
Performance Incentive Programs [Member] | Restricted Stock [Member] | Executive Officer [Member]            
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) 15,398 11,279 14,194      
Performance Incentive Programs [Member] | Restricted Stock Units (RSUs) [Member] | Executive Officer [Member]            
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) 30,858 25,903 35,174      
XML 86 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Dividend yield 0.67% 0.74% 1.10%
Expected lives (years) (Year) 4 years 4 years 1 month 6 days 4 years 8 months 12 days
Minimum [Member]      
Expected volatility 22.00% 20.00% 21.00%
Risk-free interest rates 1.30% 2.50% 1.70%
Maximum [Member]      
Expected volatility 24.00%    
Risk-free interest rates 1.90% 3.00% 2.80%
XML 87 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Outstanding, shares (in shares) 3,656 3,452 2,821
Outstanding, weighted average exercise price (in dollars per share) $ 121.16 $ 105.17 $ 98.42
Granted, shares (in shares) 752 917 1,087
Granted, weighted average exercise price (in dollars per share) $ 190.80 $ 173.89 $ 120.67
Forfeited, shares (in shares) (56) (330) (252)
Forfeited, weighted average exercise price (in dollars per share) $ 95.97 $ 129.93 $ 86.62
Exercised, shares (in shares) (743) (383) (204)
Exercised, weighted average exercise price (in dollars per share) $ 157.45 $ 95.29 $ 111.51
Outstanding, shares (in shares) 3,609 3,656 3,452
Outstanding, weighted average exercise price (in dollars per share) $ 140.28 $ 121.16 $ 105.17
Outstanding, aggregate intrinsic value $ 446.7    
Outstanding, weighted average contractual life (Year) 4 years 3 months 18 days    
Exercisable, shares (in shares) 1,564 1,467 1,151
Exercisable, weighted average exercise price (in dollars per share) $ 112.60 $ 98.70 $ 90.75
Exercisable, aggregate intrinsic value $ 236.8    
Exercisable, weighted average contractual life (Year) 3 years 3 months 18 days    
XML 88 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) - $ / shares
shares in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Restricted Stock [Member]      
Balance, shares (in shares) 30 35 32
Balance, weighted average exercise price (in dollars per share) $ 147.94 $ 117.39 $ 105.80
Granted, shares (in shares) 15 15 20
Granted, weighted average exercise price (in dollars per share) $ 193.48 $ 177.93 $ 125.05
Vested, shares (in shares) (18) (20) (17)
Vested, weighted average exercise price (in dollars per share) $ 142.12 $ 116.76 $ 104.66
Forfeited, shares (in shares) 0 0 0
Forfeited, weighted average exercise price (in dollars per share) $ 0 $ 0 $ 0
Balance, shares (in shares) 28 30 35
Balance, weighted average exercise price (in dollars per share) $ 177.20 $ 147.94 $ 117.39
Balance, weighted average contractual life (Year) 6 years 1 month 20 days    
Forfeited, shares (in shares) 0 0 0
Forfeited, shares (in shares) 0 0 0
Restricted Stock Units (RSUs) [Member]      
Balance, shares (in shares) 139 148 111
Balance, weighted average exercise price (in dollars per share) $ 134.17 $ 117.95 $ 106.39
Granted, shares (in shares) 31 56 71
Granted, weighted average exercise price (in dollars per share) $ 192.08 $ 170.96 $ 129.99
Vested, shares (in shares) (51) (28) (16)
Vested, weighted average exercise price (in dollars per share) $ 111.07 $ 110.86 $ 95.46
Forfeited, shares (in shares) 3 36 18
Forfeited, weighted average exercise price (in dollars per share) $ 155.6 $ 143.72 $ 115.01
Balance, shares (in shares) 116 139 148
Balance, weighted average exercise price (in dollars per share) $ 159.25 $ 134.17 $ 117.95
Balance, weighted average contractual life (Year) 5 years 2 months 12 days    
Forfeited, shares (in shares) (3) (36) (18)
Forfeited, shares (in shares) (3) (36) (18)
XML 89 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Effective Income Tax Rate Reconciliation, Percent, Total 17.10% 14.20% (0.20%)
Income Tax Expense (Benefit), Discrete Tax Items $ 19,400 $ 12,700 $ 34,400
Excess Tax Benefit from Share-based Compensation, Operating Activities 17,700 7,200  
Income Tax Expense (Benefit), Discrete Tax Items, Acquisitions   (3,200)  
Income Tax Expense (Benefit) Discrete Tax Items State Apportionments   2,000  
Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount     33,000
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability     36,500
Income Tax Expense (Benefit), Federal Translation Tax     3,300
Income Tax Expense (Benefit), Stock Options Exercises     2,200
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Revaluation of Contingent Consideration     $ 4,200
Deferred Tax Assets, Valuation Allowance, Total 7,523 6,974  
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 7,500    
Deferred Tax Assets, Net of Valuation Allowance, Total 73,353 $ 65,597  
Undistributed Earnings of Foreign Subsidiaries 186,000    
Operating Loss Carryforwards [Member]      
Deferred Tax Assets, Net of Valuation Allowance, Total 20,200    
Tax Credit Carryforwards [Member]      
Deferred Tax Assets, Net of Valuation Allowance, Total 7,500    
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]      
Operating Loss Carryforwards, Total 64,200    
Tax Credit Carryforward, Amount 5,000    
State and Local Jurisdiction [Member]      
Operating Loss Carryforwards, Total 130,600    
Tax Credit Carryforward, Amount 5,700    
Foreign Tax Authority [Member]      
Operating Loss Carryforwards, Total $ 13,700    
XML 90 R66.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Domestic $ 245,365 $ 64,081 $ 81,557
Foreign 31,112 47,934 44,395
Income before income taxes 276,477 112,015 125,952
Federal 18,976 16,090 28,416
State 6,018 544 5,315
Foreign 8,580 13,329 11,983
Total current tax provision 33,574 29,963 45,714
Federal 14,074 (6,903) (40,378)
State 2,055 (3,977) (1,381)
Foreign (2,522) (3,142) (4,154)
Total deferred tax provision 13,607 (14,021) (45,912)
Total income tax provision $ 47,181 $ 15,943 $ (198)
XML 91 R67.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Income tax expense at federal statutory rate 21.00% 21.00% 28.10%
State income taxes, net of federal benefit 2.30% 0.80% 2.50%
Qualified production activity deduction 0.00% 0.00% (2.40%)
Research and development tax credit (0.70%) (1.60%) (1.40%)
Contingent consideration adjustment (0.20%) (0.40%) 3.30%
Foreign tax rate differences (0.20%) 0.20% (3.50%)
Option exercises (5.70%) (5.80%) (1.80%)
Domestic tax legislation changes 0.00% 1.70% (26.20%)
State apportionment changes 0.00% (2.30%) 0.00%
Executive compensation limitations 1.60% 0.40% 0.00%
Other, net (1.00%) 0.20% 1.20%
Effective tax rate 17.10% 14.20% (0.20%)
XML 92 R68.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Jun. 30, 2019
Inventory $ 7,769 $ 7,743
Net operating loss carryovers 25,707 33,294
Tax credit carryovers 9,568 9,640
Excess tax basis in equity investments 2,423 3,433
Deferred compensation 10,755 10,333
Derivative - cash flow hedge 4,058 2,921
Lease liability 16,256 0
Other 4,340 5,207
Valuation allowance (7,523) (6,974)
Deferred tax assets 73,353 65,597
Net unrealized gain on available-for-sale investments (19,102) (4,542)
Intangible asset amortization (128,279) (141,998)
Depreciation (10,764) (8,371)
Right of use asset 15,118 (0)
Other 1,180 440
Deferred tax liabilities (174,443) (155,351)
Net deferred tax liabilities $ (101,090) $ (89,754)
XML 93 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Balance $ 5,032 $ 1,947 $ 1,747
Additions due to acquisitions 0 900 0
Additions for tax positions of current year 306 2,185 35
Closure of tax years (1,041) 0 0
Tax reform 0 0 165
Ending balances $ 4,297 $ 5,032 $ 1,947
XML 94 R70.htm IDEA: XBRL DOCUMENT v3.20.2
Note 12 - Segment Information (Details Textual)
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Number of Reportable Segments 2    
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Protein Sciences [Member]      
Number of Major Customers 0 0 0
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Diagnostics and Genomics [Member]      
Number of Major Customers 0 0 0
XML 95 R71.htm IDEA: XBRL DOCUMENT v3.20.2
Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Revenues, net $ 738,691 $ 714,006 $ 642,993
Operating income 157,419 146,719 136,178
Costs recognized upon sale of acquired inventory 0 (3,739) (2,455)
Gain on escrow settlement 7,170 (0) (0)
Corporate general, selling and administrative expenses (260,583) (264,359) (240,636)
Total long-lived assets 176,829 154,039  
Total intangible assets 516,545 579,429 446,332
United States and Canada [Member]      
Total long-lived assets 162,039 138,016  
Total intangible assets 499,875 556,951  
Europe [Member]      
Total long-lived assets 13,120 14,439  
Total intangible assets 12,349 16,637  
Asia [Member]      
Total long-lived assets 1,670 1,584  
Total intangible assets 4,321 5,841  
Consumables [Member]      
Revenues, net 602,642 588,979 534,738
Protein Sciences [Member] | Consumables [Member]      
Revenues, net 431,052 430,655 384,350
Diagnostics and Genomics [Member] | Consumables [Member]      
Revenues, net 171,590 158,324 150,388
Operating Segments [Member]      
Operating income 249,894 250,998 245,376
Costs recognized upon sale of acquired inventory 0 (3,739) (2,455)
Amortization of acquired intangible assets (60,865) (58,550) (46,983)
Gain on escrow settlement 7,169 0 0
Acquisition related expenses (416) (2,282) (24,429)
Restructuring costs (87) 0 (376)
Stock-based compensation (34,262) (33,057) (28,240)
Operating Segments [Member] | Protein Sciences [Member]      
Revenues, net 555,352 543,159 482,378
Operating income 234,929 240,919 209,880
Operating Segments [Member] | Diagnostics and Genomics [Member]      
Revenues, net 184,549 171,674 161,151
Operating income 14,965 10,079 35,496
Intersegment Eliminations [Member]      
Revenues, net (1,210) (827) (536)
Corporate, Non-Segment [Member]      
Corporate general, selling and administrative expenses $ (4,015) $ (6,651) $ (6,715)
XML 96 R72.htm IDEA: XBRL DOCUMENT v3.20.2
Note 13 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Net sales $ 175,834 $ 194,680 $ 184,934 $ 183,243 $ 191,664 $ 184,861 $ 174,510 $ 162,970 $ 738,691 $ 714,006  
Cost of sales 62,520 64,617 63,531 64,829 63,405 60,251 61,492 55,367 255,497 240,515 $ 210,850
Net earnings1 $ 58,847 [1] $ 36,432 [1] $ 119,623 [1] $ 14,398 [1] $ 16,459 $ 44,654 $ 17,556 $ 17,403 $ 229,296 [1] $ 96,072 $ 126,150
Basic (in dollars per share) $ 1.54 $ 0.95 $ 3.13 $ 0.38 $ 0.43 $ 1.18 $ 0.46 $ 0.46 $ 6.00 $ 2.54 $ 3.36
Diluted (in dollars per share) $ 1.48 $ 0.92 $ 3.02 $ 0.37 $ 0.42 $ 1.15 $ 0.45 $ 0.45 $ 5.82 $ 2.47 $ 3.31
Basic (in shares) 38,304 38,303 38,167 38,032 37,881 37,772 37,766 37,697 38,201 37,781 37,476
Diluted (in shares) 39,700 39,435 39,550 39,253 39,135 38,861 38,748 38,813 39,401 38,892 38,055
[1] Amounts do not total due to rounding
EXCEL 97 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( )>$&E$'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "7A!I1YTOIL^X K @ $0 &1O8U!R;W!S+V-O&ULS9)- M:L,P$$:O4K2W1[;!%.%XT])5 H4&6KH3TB01M7Z0IMBY?64W<2CM 0K::.;3 MFS>@3@6A?,3GZ -&,ICN)CNX)%38L!-1$ !)G=#*5.:$R\V#CU92OL8C!*D^ MY!&AYKP%BR2U) DSL @KD?6=5D)%E.3C!:_5B@^?<5A@6@$.:-%1@JJL@/7S MQ'">A@YN@!E&&&WZ+J!>B4OU3^S2 79)3LFLJ7$M:/+A[[/K#[^;L/7:',P_ M-KX*]AW\^A?]%U!+ P04 " "7A!I1F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M )>$&E$O_%;NI 4 )\7 8 >&PO=V]R:W-H965T&UL MI9A=<]HX%(:ON[]"P_2BG0E@R^8C'<(,@63+MDG9D+;3W=D+Q1;@B2VQDAR2 M?[_'PM@T:XZ]LUPD^..\>GR._!ZAT4ZJ1[WAW)#G)!;ZHK4Q9ONAV]7!AB=, M=^26"[BRDBIA!@[5NJNWBK/0!B5QESI.OYNP2+3&(WMNH<8CF9HX$GRAB$Z3 MA*F72Q[+W47+;1U.W$7KCC+5OS)3=?MPL%1]U")8P2+G0D!5%\==&: MN!]F7B\+L'=\B_A.'WTGV:,\2/F8'3Y UG 0,;: M_B6[_;V^WR)!JHU,\F @2"*Q_\^>\T0ZI$;P\P'L=T#L1 MX.D+:I>1&"K/1 MH!OR\&>!+G 6L/0 >TE1Q=]2T2&>/DG7'4+=D^$S/'S& QC= MAKOGR--X1>H]J^?5I?XXWW]^AKO(W/!$_X6,X1=C^'8,_\08>46G,(QB,8P4 M\F?RB;]451-7L79'U4<0(5"6U5KF.VKB+"XU5S!YO6-5*'AO#+FS=UE2M=V?4:5@Z,24?6 ME9&DX6)U=N"61NXVN*K$J3'QMCN@ XH!E1;N-O+PN0C >:6R M[>N,+ U4DD@%?IQ"SX'6(\/JRN+J-[<89.GF+F['.>0]>R;S$(H:K:)@WVB1 M'.*2OMMV?3KP'32-I<^[N#7GA),P5%SKL\,78M_E3E2BXG(WD1"<;64<:0RO; 4N[M^O M\8KIN%#R*1)!=3IQ370JTK(C4-S17Z,MI#;@QW]$VY/O2(UBK^>[V&J,EDV" MXMYNJSB!WXVG47"!OHN]#;3L#10W],_2+BHV4F N5R/B#<[;PV'/QXC*=D!Q M![^/##BN7!&7OGMX3Y8\2!5DJQ(+5YK*) 'C61H9/)Z1MT['<F*JX9H_..9;M.P"M%$7 M^"9CZ)I,[?N\JES UBC=2@RH]'G:R.G(%!K/6JI*HZC1^PXTZ9UPF+([)9:KALJZL9HU.W<+6*RW?P]TZ)[I*N%IG$^Q7 M4# ;:$3)EHGJ].&"M6A'&S2X8Q^2M0'+0('^WX\ KS1XK]&/@$7Z$$RY7[A]Q><->S_$&[BNJ[M&.9C8Q[,ZP)D'VHV*_N5F<+7:?)W;/M5O>OM^Z MOF'9O-(DYBL(=3H#@%#[W>#]@9%;NS_Z((V1B?VZX2SD*KL!KJ^D-(>#;(!B M3W[\#U!+ P04 " "7A!I1P_98N-@& Y&P & 'AL+W=OS_2A%N5:U*75-&O5P,;FB9W/.6H,.\7NIGLS!;])2N=?Z:WOQMKB81.V, M5*46MAU"PM=6W:BJ:D>">?S3#SK9/[,U//S]//I/'7D@I";RG[43[^HGE#D^R5./C29DL3%6KWMCF,&ZK'??\EOOB ,# MGHX8L-Z .0:4CQCPWH"[!F+$0/0&XD<-XMZ@HS[;<>\<=RNMO#QO]!-I6C2, MUO[HO-]9@[_*N@V4.]O OR78V5LO]%J1*?E\=TN.WAP3LY*-,J2LR:>5WABP,"?DS8OK M\YF%^;9/G2WZN5WOYL9&YD89>:=KNS)D7A>J>#G #(CNV;)GMMS[:'A!$8%9!D7L+F/BP1+,_Y'O:"@-@3$$$"-]K8-M)&2>S,DX/' MLC@6>>J00& BBFGLD$!@-,KB""<1[TG$01(_-]H8V)+-LJPQ#K'W5)%QF@N' M P)+N7#7:X[ .*-B9"&2/8>DL^,C''Y[5(VTL-F)^@829)0Y"\1GNA\U#7KF M#M(_C'E"EJJ&\:LND<@"LEAI;/N\K<(1!,I^TA<717@Q@9')O IS%:>ILM5L,EJ2I0WKNPU@>YTF,\Z'1(&I1 MD-$0SV6G5*CV1-[#:9P*Z@30+8832>KBYAB.)S3-1L@<*#0-;TZ[4DU/A!SU MBW,UE:!<-OG-4<=Q3QB4YI3+PMC.$;3R$W#Z'B@B&..&N20 MAO5P3R:PZ-S?9NX$;Q%0G'C+[8-$-+(1Z2"(-*R(N[6N=3W53@@/*W]":H4F M&NH+'.5I24(.T;W"IHX]Y$!TT2DWM[R M<91"&>GM+03'XCQF([0&*:=A+7][0(086G@B,QKEP M!0^!0?(92Q6#?-.P?K>EL^K[&Y2$+[2,Y2QWZN*;5Q[S)_T+ZS*0T?,D\M01 M@5&6T+&"E0YZ3_,?4)3%BY;N>2=64,T&Q84-*LS"*@R=//3I-;2Q3:/JQ7<" M15]M*KD[(2C^ANZV:S:Q!6"^FD[S/'&+0 PF1.9LGSD& [$?V15LD&9&@PP_ MUXV25?DO],Y+6=9FYSYEC@DP+%13;KLJ%YP+!>]FUUE/R4*:%7FHX&$K52R5 MZ9)>VP?![B)RK3)ZU_OCI#[>![IWA MEQ:N^+T.F2,0T/^1%HL-Y0D+ER>O[CJ4D5]F@%8GJ:M[*$Y$S-4]!"7%?M(.FA2T]C;]U]%#\= MZX+94!:P<%EP6U:;]N3P?S!*O8G$IYG;#2,H=BJ\;.6C@-38X@_% #UW_8K5U;.D:^CL++%=_U-LH)K6I(&_VDC" FEV<*R_5LVR M>Y]B(!IAM-WYY/[N_IW-5?>FPKE_3<_F%+O/SFXP_!5O7_Z@%IP]OQ::#5/: MO51ZUQV!&E*I!YA>=)I"UFIV[VEV%U8_=B\B[K6U>MW]7"D)95(+@/\?-)0Y M_47[@/W;LLO_ %!+ P04 " "7A!I1'>CBG#(" !4! & 'AL+W=O MT1<,W&[):>#9MD[JM15%'D%9IGF4?4BVD2O /(!D$?=?:"H\E9X41:6]F"#-[.%34PUHEF< M-.%15M[RK62<+Q=D'"E9"X\UK#PO7''O@#9P)ZR1IG$@3 T+TOSH;7B-'<*] MJ4@CG"Z%9>\6O:R$/'RO]+T M$2]CQ#!+NW+ZZ:I(=\QL !@ !X;"]W;W)K>.&D_0R(D<4(2*@#Z MZ*_O@J1%F0!AMQ\2B](">!?'/KO@Q;U4W_1."(,>ZJK1EXN=,?LWRZ5>[T3- M];GR5XT36JJR7%.%G6O&P65Q?==S?JZD*VIBH;<:.0 M;NN:J\?WHI+WEPNR>/KB<[G=&?O%\NIBS[?B5IBO^QL%3\M#+T59BT:7LD%* M;"X7[\B;:Y;:!IW%GZ6XUT>?D75E)>4W^_"QN%Q@JTA48FUL%QS^W(EK456V M)]#Q]]#IXC"F;7C\^:GWGSOGP9D5U^):5G^5A=E=+K(%*L2&MY7Y+.]_%8-# ML>UO+2O=_8_N!UN\0.M6&UD/C4%!73;]7_XP3,11 Q+--*!# _K:!FQHP#I' M>V6=6Q^XX5<72MXC9:VA-_NAFYNN-7A3-G89;XV"7TMH9ZZN9:-E51;H;-"7G6PU;PI]L30PLFV_7 ^CO.]'H3.C M_-8VYXCA4T0QQ9[FUZ]N3O+GS9?@[\%I>G":=OVQ.:=;I41C$-<:_'P3Z)$= M>F1=C]%TJ>>4]UTG MQY)H1)-LHMPU2V(2I7[A\4%X'!3^;KV6+>B"X+$6,+V@^Q150FO$*PA&W<8% M/U AVY79M!5$B*&!W*"3-(V[]3G),]A'2NB]Z )(]>CS,_;X26,63?STF+$4 MEM+O:')P- DZ^A'6H#%2E<*[!HD[*&8DIA-MKEE.<(S]TM*#M#0H[9/9"05A MZ?CX^#2FSN T8A&92'2M2(;CS"\Q.TC,@A*_2,.K5TC,G,%CBG.*)QI=LXC0 M!,_LY?P@,@^*O%' 864>NRUIH\7>'KE3U CCTYJ[$Y4F&HE:+?D:]!,#.\"G$M6E4\YC-;$IRQ# 2%/B+E,5]655>6<25 M13.&IS'+9\=HDLRL-!E90^@+Q]GP9EM"N!IVX^PR#QT]VY,DB2-G"CUV:1[1 MN84>(4;"%.N/]_R9&9H_#W@QG88>CUF<)#/GFHS@(F%R]2<[H,[%#J0;:9Q- MSXG'D&19%)&YC3@BBL2O2BRJDJ_*JC00PD/9!1F10,),^*)X(4:B[?FCY9]W M%MS 3QG.IW'-8T82.CL#(R!(F!"WD$):Z@"=!?@E*BZ]!+DJY97_L5S M8< (SM*I; ]9LH3-[:T1&B1,C7=6&D@4#U ?:3]XB M/58SQXH>%2QAB-C5!\$VMJRA8BN+S@,H@T-S[,%$SJ;<\UBQ",\)'E%"7RB( MADBXAVK#ZH3LH9+-MB\\"K&"?&)5E=O.">\^IA[6T!A/X]B+9L_UC["AKX'- MVHWG7JT>H. D<>HBKQW)LWA&[<@=&JZ-/HB- *4%U&_C^?,J]90LF+AX\-AE M>1K/';V18S3,L=__VQYP(<6B"$J)J5K7+LHA=YO;!2/-:)AFH]SU_SF G@(G MGP9BCQ%4(7/*1Z#1,- ",\%Y"A2@U7$"]&F1L!!E["61U#:=F\ N<0G>\:@4Z.<<$\=Z7 M9WZ2WLMGG@Y.VMSRR$O$LM,H9JGQJ^?._#/##,G'LYCU$Z MD]^QHPO$,##?%45I PHL^IZ7Q5G9/&T"KU 7>Q'%,9MF4!X[1I(TGZEJVGN88Y(SF;X0T;PO#1LZ[8O/V1_ M>27K/9Q@^R+B#L*BU'[E+O_.\M2-WCZ[#$IB,B-\!"5[H>#K\@_MB39>N9YJ MCF6$Y-/2W&=(DCB>JT_8B$H61F4O^#B5MF?PV('OO\LH2=^&W$B=*V]_!>\Q M]%?PRZ,W(_:UU!]<;R M!O#[1DKS]&#?OQS>MUW]"U!+ P04 " "7A!I1,F" ;0 # Y"@ & M 'AL+W=O+$^=KS4,,^)Q[SX&+8;3AXD5F&"OP MFE,FQTZF5''GNC+)<(YDCQ>8Z3=++G*D=%>L7%D(C%)+RJGK0]AWRRI09<">C JWP'*OG8B9TSVVB MI"3'3!+.@,#+L7/OW4T]: @6\9/@C=QJ V-EP?F+Z7Q-QPXTBC#%B3(AD'ZL M\113:B)I';_KH$Z3TQ"WV^_1/UOSVLP"23SE]!=)539V!@Y(\1*55#WQS1=< M&XI,O(13:?_!IL+&T %)*17/:[)6D!-6/=%K/1%;!"\\0/!K@G\N(:@)@35: M*;.V'I%"DY'@&R ,6DJT M#U5:_T#:;R7K@0#> A_ZL(,^/9ON#=MT5T] ,PM^,PN^C1<>B'>?)+QDVK+ M"29KM*#X%B"J:]S.A]XM(.7E0BU+J@NOPG:9KK)$-HO90.M)'$=, 8Z4:[=1?I>IOJ8N@ M_>VX.(UK>8D:+]%'O1 IR],^HCU]NPZ.(5K:^XWV_D>UZY- *KWG"5N=,M _ M:> 8HF4@;@S$1PU,>9[KLZ&6;.I^C6B)+ZC^*GZ\+:D'O1W=)T MZ8-&^N " MZ1=7_6!O*CT(.^O^'&3+P;!Q,+S!B$,#VCW MX+]S$%ZN_H)JK\.?X:$+V6W"W3K7S:7J.Q(KPB2@>*FIL!?K+X"H[BE51_'" M'O4+KO3%P38S?;?#P@#T^R7GZKUC;@_-;7'R%U!+ P04 " "7A!I1YZ.' MLM(( "$, & 'AL+W=O\:QG7A)6T_\X%F,.GLOI:+QAKP/<\*^JCR:)IE@>S63U?L#RNWY=+5O G]V65 MQPW_6CW,ZF7%XJ1SRK,9\KQ@EL=I,3D^['Z[J8X/RU63I06[J4"]RO.X^O&! M9>73T01.GG_XDCXLFO:'V?'A,GY@MZSY8WE3\6^S32M)FK.B3LL"5.S^:'(" M#S[[7NO06?R9LJ=ZZS-HAW)7EE_;+Y?)T<1K$;&,S9NVB9C_>62G+,O:ECB. M;WVCDTV?K>/VY^?6/W:#YX.YBVMV6F9_I4FS.)I$$Y"P^WB5-5_*IPO6#\AO MVYN76=W]"Y[6MB&>@/FJ;LJ\=^8(\K18_XV_]Q.QY1!Y%@?4.Z!='7#O@'=U M(+T#V=7![QU\Q<&G%H>@=P@4!X0L#F'O$"H..+ X1+U#I/806AQH[T#5'FP. MT'M>.4]Q@=:UWBRVNMIVE^?EAMUZS]:!U47E6=S$QX=5^02JUIZWUW[H0KOS MY\&8%NTNO&TJ_C3E?LWQ:5G4998F<<,2<-OP/WR+-34H[\'M(J[8HLP25M4_ M@_-OJ[3Y :;@C]LS\.:GM^ GD!;@]T6YJN,BJ0]G#4?3MCF;]SU_6/>,;#VO M\E46MWL0G-_?\TWY#MRP*BV3MN^3I%RVN_0=__0OGX<6%/C[%Y;?L>J?TS+/ M^0:^;+KE MZW<>5T5:/-0N%.>O-BF_G5Z"DZ:ITKM5$]]E##0EGYYJV\: Y^-KX3'T]6F@ MKQWCZL+=S+CHN'0WNM<:7PT '+=2U^Y6?R_Y"&6W&4]&FXR$-AD)=>T02SL? MXBPNYJP&;_C$U6T.JM^"N %7J^(]P-X[@#P8FA9WW6S0-=N*C\=C'&(_\#SO M^-IF2D80VV* - MG&C[Y%-WR2>MZQ7?ZUQD _:=5?.T9FV^6V<[:6>8@C#0QH \LKT-UJ,8-)/& M$6[&$;[4.$S80VUJD;)]0CU8PD#=/==Z.ZT5-H\MVHPM&C4VOA \FL.SS3S<8Z4MB-.U:JN&:HA K$SQ@)&&'GE"CGAM]7"] DCZF M"3.+RLN^ :EC$E(-W["=#'%+,$,GQ$X>3-O*+^F2"\\L<5=0LN_M9V84#%#? M:R'UJ8IYR$R&+!@5NBG5%!.<\EF^S,H?C/4/EJMJON## DO.=T.Q"W6VA?;@ MA8)KH9ML1T U3CC6X?E>H,[W@)4\!D&*T,V*YZYY=46)SH,H4A/;@)$,65 E M='/E+J(K,L:!3I@X#+S('@J"$*&;$2VZRP3CK&]*X@T?A#$59[O( &EB6!'T2*VC/816% L;+\5P:[*2$1)&J8Z';0"ZD7 MV$)%\#MT$_R0YH,Z0=/ "Y$*<,A,ABI3J@SH53WDZ0]JL1GK\R'8R M:D':9F?9N$AP/7)S_1@UB'0*QS#49W7(3(8LN!ZYN?X5 MU"#250#T["$L) #:OR@>H0:1@0P#E:JOAZSD,0B^1&Z^'*L&D4Z0OJ?%B%[G M;AO)D 6'(C>'=B?_/$\\8QU.80;^I+[..<-V,F+!G\C-GQIB(TIJ8&]%AR%# M70M]XJE*P-@6M[/,/1;LB=WLN8L2I\:C1P,IAA0;#GZLEL1V4BJH$;NIT:+9 M38 _N)MJKY\/ZF4\9T<3+N5J5CVRR3$P7?.\5$-G?4/2HD:A4J6?OU1W'W?J M[I/!"JM&%UC7$)@G+ZJ<%E\:['B-P==>/576[:81]K634 ,X" /?CRQG%EBH M%^Q6+T-E!M8U!T(4436K[VCW>0#.WU"Y$I&'M767X)8TH\H3;% O$ =AI([5 MJ2Z6)+DP8F&\1SB;I>9C/;'A2B# ]@V!UXJ;1L<40T5F<:'?NQ@B!K9&(=4I MSF*(;XET>E\ZGO04[+GU4MU>&T: M'>_0&L)"/Q"W?KA=517/P%S%Q47"Y[A)J^Z=N58WK*.ZW90;,=$IB<&0,4@! M9$\9@N.)F^/'8#7BTZ\Z/#523!<3:LA?NO'NOKQ7+]70M6%H$FYYYH5L(6[9 MLD,9CSSC5.OR 4?$QX;T8;,D%FU(A-8@;JUA+N,M@/4[$1SY:G3H1@1Y/@[4 M^-#MH.>')/34/&&XB:$AI*H:,S7($RRDMCS0BAWY=2.A)7RWEM!JQ/4YQX#7 M25ZNVC=NDQ(49<,W9/NB8++J7LJK^*.$5\"FTG.V]=)OSJJ'[E7VFNLNWMKZ MY;;-K^O7Y:_AP>?N/6/E]Q-"#SX3:GC"H3^_83\37:S?S_\EKAY27NYE[)YW MY[T/^117ZU?>UU^:$&E%U/5MC*PD +HH 8 >&PO=V]R:W-H965T&ULG5K;0AE0>8 MA"QF*$)+4K[LUP< 95$"&I!F7FR2.@!X&NCN@R8N7V3[K5L)T:/7==UT5Y-5 MWV\N9K.N6(DU[S[)C6C4+TO9KGFO;MNG6;=I!2]-HW4](U&4S-:\:B;7E^;9 M?7M]*;=]737BOD7==KWF[=NMJ.7+U01/WA]\K9Y6O7XPN[[<\"?Q(/H_-O>M MNIOM>RFKM6BZ2C:H%UZN=XU5F^PKIKA/W_=&>*@ M 4T]#1JP70-V;H-XU\!0GPW'FO.?7EZU\0:U& MJ][TA;&^::WL535ZH3STK?JU4NWZZSO9=+*N2MZ+$CWTZI]:!7V'Y!+=\6Z% M/JN5U*$I^N-ACC[\]!']A*H&_;Z2VXXW97:+\YMG M 39T/Q_4]$=]\Z&-OC1&7[9RC51$:'E?-4^#2U5]);J+P#AL/PXSXS#/./]0 M,4CPME$]@[,XM(Y-:QULGJ\)R4F>7,Z>#V!WX4'^@_\+38C;=YY$*3GN>N&B M,$EP'.UA1[SC/>\X:-^;\G_*J88UWDL5Z@K9%%4M4'-@$/V+OB_T9&Q:^5RI MI8H>W[Y[-I+]6R5!0\V%BO)%Q8?8V92(KV7;5W^9!]#T#-TE!\;)2$K38Q/. M752:X11;AG91"6,)A>V<[AFE049WLE,6UN9]:JJ_E/44L8XK.ZO PHL_MU6K MGE7-LYH(V;Y!%%/GM2*+GHN@*"L3W+J_] M6OF[=F!]IRX[Y=GMP'?#W_AC#?+=C75D^CR*+;X02NDUFS 4[DC\C$^2.3X MA,?YB9EX!S+# +,XLYFY*(<5T!%)$B\M,M(B05H?_J;4[D?TJ^PZ'4-TR!@F M\V<=HD%.Y&3D "!3FD:VQX&P//50&E,\IC^P-G7D?^95K1>GAC1%;IM)_J^-@(9)!*[\M+Y<)%(;?-;F!IK*QDCZB> MM2/#3NMF\B2.$]N\D"R(@7P"X$CJ#;RC+L!A8?!E)\XJ#PDW<4\QRQ)LTX!P M-&%.Y %QE'BB+1F5 DK@?M6;'A5ONL9D R!4G?B9'@(EN16MEP *)(>J+EC M'F-^)^'\;JVVG5P9=@M%T6[%"8IN@L819=2FZ,(2'-E;!@ 51\3CU63,]22< MZQ]XS5OCLR_\20P>U8K:U"8,1U[#W-P\3>+8CE< *HXPM:D!.3_+/%VY)CEF/Q)N%1@EV(&*7;^YI^,N9F$<_-]*PLARMTX M1O?II;_F_;8UPYC\]2X.ITH<3L\1A\1-O9BEV%XF3<*G@?ML6*R41?Y"DN\&?IA'.G.4$X!AEJ:U7(%P6'Q1-CEF.8H&$Q<)- M60[:0V]"E=\H;^G?S#0+I4LV/E%)@.P>XY0QFQZD F*&G<@-X:*<^F+"*!=( M6"[<',BKO>8R0>*]W /2<[.^LSH!84"RG.7V;@T")FD6>Z:.C@J"AA7$E_T* MU()SVQ2'-7/UU*.BJ:L##[OA(LJX8WQ?FIB8ZIGH93O1FIK+11/=][J)M_IRS+[6+*',:I MG8!M- B7YJFG($W'?$[#FWDKR^JZIQ(MNUJG:(O*HYRINQM7BR*SE3, HVD> M.P[@PG!^6"4X9C=J"!K6$%_%=+-+I$8N*+VYUC5W31-D!>SQE1S&SK0!.!PS M>V^T ' ^3J,RH&%E<"M;U<9\D=DVI8I5&C"5RVFATDG5(_[4"F\YAKJ)G$7. M]GD.P.+,Q2T@W-%N_)CCJ MH6!?<[ZJSNLQT3 \D!14%LBQV:4%?"S!U@ L( M&.>QE]@H"&A8$/Q0/9H".9PRE]U)V;" >E*;!Q\O-JH!%E8#0]:$(B[X'14H M&:@48'L9!$M(;A=)P-[RS/,YBXU*@(65P(G\>399X", SFCFY ( B"FCF9T+ MH [S7"UX#^%1,+"P8%@LEZ(P$E6\%D,M4:U.@89KXXR#=E7ZW%QHD?ZLMB.> M=VV$(P.4X\2E -HH9%A8S0:9"5Z(#'(>NCXY6L"1Q/KI ., 6"PAW;(MC MDEK3'#\9%0$+*P+X1,GMB58WZZ%F6DK42/T5N.79P MKFHMVB=SH*U#I@(['#G9/]T?FKLQ1\6LY[?X8H&AY^3B#L+?L.1BH>P$M&#I M^[F\V?A*PZF^WWBK5GB':K%4KQ=]2M6,M,-!N>&FEQMS$NQ1]KUJ&Y*8MQ-:DBV9.W7YU21W6IY;&\&R8/EOI#%4Z?N M?;&U[M&OE KBJ2R,O^RL0EB?]_L^6ZE2^IY=*X,W"^M*&7#KEGV_=DKFO*DL M^J/!X+1?2FTZ5Q?\[,Y=7=@J%-JH.R=\59;2[:Y58;>7G6&G?G"OEZM #_I7 M%VNY5#,5?EG?.=SU&RFY+I7QVAKAU.*R,QF>7Q_3>E[P=ZVVOG4M2).YM8]T M M5I>=LX[(U4)61;BWV[^JI,\)RC[32Z,7.I,FB$F6VA^E@!<1P"C5P ,1^*S-6'EQ4>3J_Q00!_:-"J-:I6N1V]*_%29GA@/ MNF(T& W>D#=N*!JSO/$;%'D1K+C11II,RT+,@@P*KAG\&_*/&_G'+/_X%?D- MU6T3$.TO\"O^^:">@K@N;/;XKY?(?O,HBO!SOY:9NNP@A+UR&]5)+M#[/WG M^7,Y\R3G7/SB%3U0/FB$$RV]9-1Y2*LP746,2"*:,.H=:I7TF4K)C ' MA,*N:25PY1OE@O8D)+.>\).O\M'O$X!;DP&6"/*)B#(V0/%%V(F94B):; A5 M2IAQ12ERHX3F'7'M5/IX;D87ZFNE-[*(3(65@XC)1NI"S@MU!%Z//%YB_P:F M*=NKO'YB3!'28'3 4?>[R.GQGAY9-5=(QKS0D[T4L %(!'X+$"98QYZTT,Z' M]$LOD8=%!N90:\3:@01M?!=J!CVW.79TH\JH6W#/ K@H7^=(EZ9:P.*5PPWV MY16LWX6*BAF49I>>P@T+Z9:*$GV &)_<%? T4NQ^,_9*@_3L', *8H\T ((3@5#VQH!1L51 MG&&W%EOU6Q]?\LD:=\VYD7?$K8?;.X0JH;6.#LF*BE2!]I[,#$X0&U H[S9\ M(M,\HAW)=T;"D,FJ064K8PN[Y"TRWR )*/\:KH0DX>-\BK-SO=%YA>WUZX*B MDN%+L59.VYPL&X3VG(P D?!PGK 5%LUUH1&#(! -D+<&CK$_E0.(?'?7HH7% MI>,8K%.P"J)UKI2!4W.V&(\'%"] .&D++E2RA53MMJ2<$P)4@X^8W8KY0[A M$J19ZCDYH/1>4>A:H\0M"-&.)) U"VN61P5R1)X6\2&RM$A"OU'L ?I>SO^P M-X*B4*6_(9+AF*_(2 H9J&JR.G]4"A]R*>*WE(^*%E4E%Q*<.D=+*185 M17',:@LTE'!6.!@'1:$77%[H.DJ?*W*T=*[*F7Y_*#6=BD2W+VK_KO(E0V)% M$65P& !#F^=9O3I5CP;T@\3VQ:9\6*?OT:#WC,6EM3D%(7(:' GNM.?G6#Q8 M'"6+W6^J61=#JA'1%5M$/2H5@:85ZB BY#:'!%:N M)O_9DA25Y$(F(H'GUU2BIJSA428FO<#W3H-&)5':L(B@D.M*%N@5@W:XT M%F3)9RF*2[B2L!!*!L-BWV0S@T?(/W$+5(WR%,N>M_L0-FXL73$4 2#7Z#<4 M5N\[ VWBN )]>YP=D@;D>.9;M$+"!>1RZ=22'(4(I?T<28=<"?T-*QS-7I? MY.J$GZ$(26HRD%/0[62PPJ\J99A4FIS:T,Q"&CXW!Q4.X\G/F7&\-J%8JAT.[DX\-W8G#HWT!)1:.DTVG]"N.KLV@&)9\_@4<7L:VAT*78Q!"A MFB$B1O;;[$VB/>9JJ8UA B,L<.3@!K HIAOQF1O"\;#.%=>H')57+[!9AR&, M2;[(Z9=D?D+MITX\B6C2ZRNV\+5-7Q7 9C=4GVJSPZ4HD33YI96ET;4'*J<- M8W3\=5WM-5<'WESC/VRSM(OILZ>N*',J1P=VK9/ MW9Y^MW-C#WMX795]4Y1?1H H1\\1[%M<4_\<.? M_G@V&@U^NIG,KOER^-./L?:?#%I=]6#4XQ8X]>$4U^BAF[D(O*G4K\5V^6?. MIK\SDK%_+-!BVBT]#JEJUSF?\@D(8-50B?*:KUIBY5[LNA8;(Q#4Y3SQ MS8$.>&."-_703&R]-+)U6[T@K:$-PE3E7+GS/S#R79QS;F")&/VB1--5U2WV MB?@H'44:QXCP*T+R7LSH_U%L0,GBR*31L88#\?,W94H,1]\SQ<"+;M3<>R;@V']((5+NN'5K7GJ/1X,Z&&/?KKQA]N$ MD7CW#1#T,$ Z1TL$DL0_T.W4Z(&1@Z.%;SCNMKSTUOC@JBCG2$R1G9%N_V8I M98@?'NP:U6L\.A4_=L7G/=_DZ(=+0>G+,C^ 3S*C&)[4:6ZO)N57:J*>+SKK M[:'&.5!,JB5U/+&UVM.*]?7,_F??MA6U3+<4X@0CVGQ*PS6-TC19L'=*,2UL ME7-&JGC;Q#FTKU')!_+H6XJ)F7(;G:GF:P&#^AW-6+']M'JH-!2*R3\6E*@/ M]E!EO9$9=3-- J1X^+A8J"RV+/=-?-Y37<=M;$Y:_-\WQ8]:TFXM6O3$2Q^H M^JWOA:!QR5]%J5* R?CIL'G:?'B=Q.^-^^7QJRUT0L'#W*P6V#KHO3OI"!>_ MA,:;8-?\]7%N VS&EU1]E:,%>+^P"/)T0P_52J(U[HR_F:T#:&YFDQ\L56U]&/;*(,O M:^MJ&=!UFXEOG)(E3ZJK23*=SB>UU&9T>\WO'MWMM6U#I8UZ=,*W=2W=_EY5 M=G]V09Z,;F];N1&/:OPJ7ETZ$T.**6NE?':&N'4^F9T%U_=9S2> M!_Q+JYT_:0MBLK+V,W5^*F]&4S)(5:H(A"#Q>%$/JJH("&;\M\<<'9:DB:?M M ?T'Y@XN*^G5@ZU^U678WHR6(U&JM6RK\&1W/ZJ>SXSP"EMY_A6[;FR6CT31 M^F#K?C(LJ+7IGO*UU^%DPG+ZE0E)/R%AN[N%V,J_RR!OKYW="4>C@48-ILJS M89PVY)3GX/!58UZX_<4&)1+Q3CRI%V5:A6=A-T:39->3@!5HW*3HT>X[M.0K M:'$B/E@3MEZ\-Z4JSP$F,.U@7S+8=Y^\B?AS:\8BG48BF2;3-_#2 ]^4\=(W M^'H1K/A!&VD*+2OQ'&10B+/@W\#/#O@9XV=?P1]D7#M;BP=HX1!W\&G8B@?V MIG+BWQ_5:Q#WE2T^_^>2QF^N0%EZY1M9J)L1TM K]Z)&@QO'E]QX178@Z>2J M G77#?"BP$OM@[!KX;795.I=ZY5HG"W;(G@A32FD4QC/0'\H=(.0HK':!*&- M",A-L;85TAK31=@J ;+&K\$0F 5Q1S@3?%MLC\#0GL86O1J1V&TUOF^444Y6 MU5[8HFB=%VV#I/5;W9!KQN(GXX-KV4U'#F'?Z((GG;"IK-DH]ZY"ML-F[Q4M MNI4A@K6.U_;MR@=I GF_EK];I\.>#950*/H_:.,I,=/ 9(A7ZTHZXE4<=1Z+ MCUCH1<*DLQ7@+EVHBUY 4"C*&K&3#D*&?:/#,[?B[[^+V'.=NBA/+RB[K" YX'>40G^,D5X.>/VPT)?<[0L8,F7I MA4(4*W?F/?)%H:!TMRKS5SQB!7^N-1"' .BI>Q(,)5,:95M/[NX06U!WU9Y" MB7T& &KW#&#*%A88BW_A3W]AJUW9_Y+L#[9NI-GS%*[_JN0UU*NJ&]X,0@=D MC>(_:J/2J$.E.>W%^?B0R;Y+Y2-]"BR6#_L?PN(8H[7Y9^F#N6MJ&3CR<5!5UWX=%!_A>6T:PZYHQ$"DOVS J$:Q%J#]R67,>2J]@*I MQ:*;@^_._4:>/%"MM(0 F*V.F@V*$"_U6A <++Z@9-2%+9.SGL3V"%MBS[5] M"(%![:YBE@J)JOOR"<.D,U"@1X>Y%W)[?-E>R7:]$91?[V$D"7.'#"@JJ?O0 M*YR"D)1N3H76&8+?6%LB5$$%BB/@H$\?"G$GY4?YRD6JZK/HC#JI54F6! [L M"WQ71)F_4[4.?01LJ)(8"GWX4;:0U/4\'85*'X<,WZLU%G<<4)Y=UJ$<5QZ2 MJ>&"8:@\F++BSFE@:S/ \3Y3=;6)S<;7RP %2NU0"-<];^#0:])LV,C&XE>% M22A]IR6F(4?2GL3Q7VI.?ZH1DC9*!#1G/B43Y?AS1N!G>7;T^4;,ITDTSQ*T9LMEE"]R:J59M$B79P>, M11QE\T3,%]$,7^9QM%AFXGG8P+)%E,URD2ZCZ6PJ,#U.%^*CI<@>DH#T.VQX MAPBDPKY(XF@V3\F8/$-K(>8P>PZ\)[N7%2K#H1;%BRA.EB+.HRS-19Q$:9KU MZPQC.LQO! A$\SRF5IQ%N) 1?I9$>9Z>BKA1=N-DL]U?5/+]FTK^HOKI %B:)U\.648+O)PM\,C)A3E\]Z2ZG,;-L2H[H4$YCE*0BN$9.3*QK2=L,74:JL* /=;>WP]G#7O>NN>,?AW47Y@W0; MG#2P%:XQ=3I>S$;=-CIT@FWXPK>R 36"FUOX PR;I#G#F6>>F2$O5Z;[81=*.7IIZM9>C1;. M+2\F$ULM5"/MV"Q5BW]FIFNDP[2;3^RR4W(:A)IZ(J(HFS12MZ/KR[!VWUU? MFM[5NE7W'=F^:63W>JMJL[H:\=%FX;N>+YQ?F%Q?+N5 MU9VJ:Z\(9ORZUCG:'ND%]\<;[9^#[_#E25IU9^I_Z:E;7(V*$4W53/:U^VY6 M?U-K?U*OKS*U#=^T&O9F8D15;YUIUL*PH-'M\"M?UCCL"131$0&Q%A#![N&@ M8.4GZ>3U96=6U/G=T.8'P=4@#>-TZX/RX#K\JR'GKG\V3E%,Y_30+Y>U MQ. MUG0K:]E6BAX"+V0[I3MI%_09(:0O[4 %8'HY<3#!*YI4Z^-NA^/$D>.XH&^F M=0M+/[53-3U4,('M6P?$QH%;\:'&O_?MF.*(D8A$](&^> M('/3%'P!BR1GZ MK%M@H('&@Y,N(&,_T)]L]2=!?W)$_P'^$R^L$M9J:L14M6J[EF-UJ$>_Z%(7]#-L]2U?*K5.;+A_$'6"O\_*^L" M,!?TN% TD[JC9UGWBLR,'%;N3+.4[>N?+6R^O=_(DK1=!,-4VF/LS M7AZ?B6C\&\&PPUO7.M-I!>OV)E09E!3K_'FGNH69IK=PW)Y=O*?FNUPAWYSJ MP 1+)Y1REL81!DG$2AY[FFBDWY3FQDPMG?(S2C,FLH+2F,5YMG\THQ8@GQ"/ MHQYU[#:'ZZ==>+SU^%X?K:K/^.WV] M,Q:JOGH5)U2PE&?XS5F4I73;ZWJJV[D-!^AFV9GG(2>(%PE+ G/4^:U?)/5 M GSL7MF>(5[*@!$=<>"21PF<@>]Q?,SR.,E8ED:P,&,QS^FFJOJFKQ&)*:HN M6(W4'.HZQ&1C.J?_-RR<\JQDA>!TAF$JF,@+#-\_9AN1/(-(Z4=IPJ+8T\?) M=JY!6$].J^#H2G4*B,)W;6'%FN(S4R-9 ,UQA'^Q:M;7]%7/%)V^*MG9LSW4 M/ZEG],8E-#I5+5I3F_DKE2C)//4TBQ/@$(=1RK*\I,=.3A6ULH%E MN@AP.L M'&3D29FRM.3X+5DBBH.8'(9 Y"6+DLR'0/"2E66)X5M(-_"#:2Q-O+MI M[E6#B@ML'0JQ![F27??J,<8Q?1OX["7U&Q-_'^%OU5RWK=?[M*Z#.PL .%"- M8P$W01>K XYT&LIHJ120L$S8_N^JY3;?5*KI.MK3<8,AY%?E^>Y_A!P_R-H6] >_? 0 %/+K/C MER^#NJWJ'CT8 Z V0.;+,GB.8GP2)^,4%XZZABZ&:3R.=]-0(42Z6_)*9FA? MZ"@>W:%>A>^"O5D)O0*57S?!L%GOT/(.";0Q'KWBG2"_URSPQ3T4)^,+,47TQ3BF-F%^"1;C2SE#F2:"PBS*G1^/[XP[F#2/A MJ2_U*SA.3Z]DU7Q;X#SA@M0'+$0=<@IK#Y5&R*'ODY;S%OCKRM*?9+/\"_U5 MM:;QT\&$_1[@>T:,)"_#2"1(K5P$MW-6E-$1JD*X1$GC4N('Z$= M9TDZT"X)%92EP@\..Q&LR'.61+D? 5N1^9:8QX)E67[$BM-8^()POAELCW_< M/Q[5=V!]' JX+\;\\'@1A>-C%A5\@K,8 ,H0)$*)UO M*W#\V;X7VUVSZ\4K_)#BW#4JUF$(W&>3JB M;GCY#1-GEN&U]60<6G 8+O!85IW?@/]G!NFPGO@#ML_OZ_\#4$L#!!0 ( M )>$&E$X_^P_BP@ $<@ 9 >&PO=V]R:W-H965TD_P3RFV=N>=D29+K=]1X_OR;!230*(2A2,.'#\WXDI4%3&" M&+]V/$?#E#1P][WG_LKK#EV6W(HK7?TB2[UN'7LLM+%NW\?LN^SW"DT3VS#"W$V0NQ986[$J/?= M\9[O3M@O@C7"2%W*@E?5'2MTW50"I,M>Q.)>1)ADPQWCE5PK0,]MF&[-/:5U M!C9:W^W/P3@4XD6A6^5$R9 :& U8@Q?U#X2L%FZC2Z97/36((K;=R&*#B 8= M=(D8KS7&:@PVX 2] 6IK!7.!HX&$W%5LDKRI:S 'M[$][9&_U* 6Z'72OZ7 MJ!Q;<6G8#:]:B&-I^H>"E=#*L_/ST%=(@D#VQ,AXIC,.6H)#V$&$P3*84ZJB M:H%VO'BK%1BA*TF\2UBN!Q(FE([T9B+FZ1S:TW'4G1&NAT MC!!+%OL._D?+2W8MBHW2E5Z3K?^NV \MT)121";SB"D-.TMCG1]^W#VON5K+ M924&WSUT66_(K=@5?]]G4)%(,:F!MC MFM84&U"RQL@"4E0(..\/1'XI;K (-=3H-;MC6UA"6"=K3W5X$@!<%-P2 7XV ML-P*BUE0#@M=:(0(X*P&C.11B$#8NR"P"&X4X;H/" B#V"S:BC0D57>57_6V MZW4I@VH'Q?>D3!(>_?2U-LY'@8]E8MVYG%906@H#5@A!---:ZQ)1KBO?2^17 MNR >,B31ONR5(+6O]@#]O0=T$+,3(23 S@R4(=Q3*DCE'H*F!PED6B&% LL> MH@2YE[?:4O"\D'RMH(4L/#8OVC462Y;\?Z$3>=#P4C#%:Y\H(6ZH"02EC"HD MJ8ULK(?Q1X"7&@' 0OH\S(F_%*LC2E)'1M_QRMTQ;7J ?\WX+HF^_#BD7^RB M_%Z$JO?F^_H-FNT)_D%)_!.&K,?-!X8FU2,G[ *.Y<;UJVX7KR]N=]M<'5&/U564'F);6 MX'TV46>WNN'J;J]V8&N2"8R^F1VG*+CA#;_[&!QKA&N-PGMC="%$&6S;AXM' M-UBN6D=%'RH"*GE(ETXGO_*6)(5=3 MVR(\O=L(W%M(N).H;%?''*IYC/"E(\E G[K23A8(+256,A0J:UBGK^0Z^_SY M3_,TF7UK2>.R+: *T+("X'17005$>@0;Q+!"D!,;Q*>O<%!G8+M($8=MWSM$ M,] K7*BPCO<5033XQ(UJ"J-#SDYBOP7XZG+W;U=9W"?G/ZJ+CZXNGLU@5#OL M%\+70+1$ %,8OA4-Y%TBAT]\%,[VJXPYDI.K..:C&*;H!>\0OURUW RULQ^& MC8XINV'A^0C@.X(^B&74-\);[KT8>%[A<7IY\F #_IXO0L@K\RM'JP M/B'S#P7!%!T.J/X ;4.P1\ V;Q#F>:31-$OQF M4SR2:#I-Z7<2S5)ZF20I>PF%&F\TCQ:_KZRT6A\Y8>K>T^ET 58IR--TSB89 MZMQ%G+!D/H13',0K%2?@%N\D4:W2"1IKYOB,8H4]T:$SF M76\R!4F4^?>KPW[)XWN2%.19-,7[-$IG*?NN+UR3:91DB1>Z_#+/0RB[)T MP:["9DZ6^P@:N":S*,_GX /X@&,:1_D3_&#)+/,A*BK"[L_M=ZC>E MU1$=8]-- E\;T1UN?]ZR[BLJZMZCIK.?HJBCZ0[Z[O.4>^^K8W#"HSPV1,W= MP_.,^ZUV=_@BZX87WOR\_ _4#+/WFT7O&MAJ_^ZH;;K"R_+J/LR""#<8KU$+ M^BLCPO;62.>PK+8-,=H-554>V'?N."UB2TU7;:ON+HRN_0.]R27X3+X7OR<,7^FINUQ*:V$BL,C8]GDQ$SX=HZ-)QN M_%4QI ,J_.M& $N&"/!]I5%_= V:8/C?@?/_ 5!+ P04 " "7A!I14I\? M\G ( 4%P &0 'AL+W=O49"FQ M,P>Z*!I3Y'O?Y-5.Z0>S$<*RQRS-S75O8VWQ:C0R\49DW Q5(7*#[*N,Q[-U=N[U[?7*G2IC(7]YJ9,LNXWM^*5.VN>V&O MWO@DUQM+&Z.;JX*OQ6=AOQ;W&E^CADHB,Y$;J7*FQ>JZ]SI\=3LE> ?PFQ0[ MTUHSTF2IU -]O$^N>V,22*0BMD2!XVIO:3VOU35/K,B%ZL4N/^LET%.^ZQN#16914R M),AD[G_Y8V6'/X(050B1D]LS%D3D[Y;#5. M)?#LS<_*"C9CY^P=EYK]QM-2L(^"FU(+F-Z:JY$%%X(=Q17%6T\Q.D$QC-A' ME=N-86_S1"1= B.(U\@8U3+>1B]2_%>9#]ED'+!H'(U?H#=I=)XX>I,7=#;, M*O9.YCR/)4_99\OM,84[]*<-_:FC/SU!_[@I&<^3SO?[O"BM"=@G$9=:RWSM M('Y6N6XV_O-%/%IVFZKXX;_'//&B')3/KTS!8W'=0\(:H;>B5SE\>,K?K]B7 MC6!W*BMXOO_[WQ91>/&38:O&4#(W5I<.%.LX+1/!8FXV3G:W$-]*N>4I002, M;[E,^3(5#/6#&6P#:RN,S:KS.%8ET8+. FB ;&T6?.]W8@04[$%6P]+(1&CN MDEHM4[EV2Q##+DA0EK?%#)QHJI+0VD,VR6,(RR@/L^( M/Y;A6<&E.[":YV8E-.,LE7PI4VGW$(9@ ME89\Z=Z#<%^3EL+NA,B1T/H!A JNK8PE3 _E(8M:.7&R5M DB-,A? 2AC85B M7$/JU"@&F\)6$I4 J&PC82$=;_;.[M)%&BL-I(1D1T.-;.N$X[9>P1RDOAY=UM8)\F MC(;LE^@2065"==/7=Q<-[!4U3?$Z8:A\#:'+)9[J)CI54&(HE M1TS(&4:5.A9FR+X>T;8EEM,5W89:$0,.L2ZSPH4MXTOT2B?0"E&A](_2HBR@ M!T$L$1K \@W<=<(F*:6'B*6.RXQ\[[2A"A CSM9*R^]5GJU:-<"Q]+ZOF4IX M?R?MIB)( GK$0R BNIX(AH& 1$O%5J3$P5G+&XM"4:YSN9(QITQ4E8&:I&WE MA!>XRTBK!X1-HG8YJ#IL+00+6<1R9=D$+A;XF_&]PUVI%+(XBY)94'BTVJ+( M=*R&Z/624D;]KC&<%A0"E:#(4MN6G]S #H4>EH'8 V<^51I0,VHO4)&)(HRTK)!=,8F M\V :S>N?<_SSRE7L^BR,ID$T7] JG ?11=0A_:%EVKM3S:#/YD$XN7 (_K__ M?G.T+P# ]:L57,\V(EF#='@13"8A3IJ%E[+-OL^B23!UDA*+"K+F]7]S67CY M5UTV6001L%N+\]]U5S0/+J-%_7/$7?-9$$XOVHOS/^ZH, KFXW']\R?<$P73 MV:+^.>J:63">-:[Q[HW7(&?'(P--R MR.L73\4CS5,4##O$CQ\"3E>0TH7-MQ+S7-*T#"U1P=W X6X[U;[Q4P#U++B[ M4[.( 4HKFI/"*DYQA)CPT5?'6_22PL>'+H0S^P7=;(E1".9;!&Q>?WOS!JWC M*.Q\1<.CGGB&A0-RRA-8VK([];+0)^=)B(V-O+HR4D=SC>?MHS(J$V\> _9K MR1,_4MZ>?U1K&DYB)!X2QW5S>YB>J1'Y><( K&GL +)@<[4Z MCY$BDC(D]FGS_ FDK:8YJF=)#P> ISN:)F,@I;9<2V=M7QO=C=8P2CM7._T4 M0L#0_]A+VJCU4ID)O7;OL2! FOA'RV:W>?)][5\Z#^#^O?@CUTA%@TO9"JCC MX<6LQ[1_@_4?5A7NW7.IK%696VX$1W03 ,Y7"AE8?1"#YB'\YG]02P,$% M @ EX0:4?POC@)0 @ '04 !D !X;"]W;W)K&ULC53;;MLP#/T50L]=[#CI94$2()<5VX"N1=-M#\,>%)NQA5 M9,=+AB38BRU2/$>'I*CQ5IMG6R 2O)92V0DKB*I1%-FTP)+;GJY0N9V--B4G M9YH\LI5!G@50*:,DCJ^BD@O%IN/@>S#3L:Y)"H4/!FQ=EMR\S5'J[83UV<[Q M*/*"O".:CBN>XPKI>_5@G!5U+)DH45FA%1C<3-BL/YH/?7P(^"%P:_?6X#-9 M:_WLC2_9A,5>$$I,R3-P]WO!!4KIB9R,/RTGZX[TP/WUCOTVY.YR67.+"RU_ MBHR*";MAD.&&UY(>]?8SMOE<>KY42QN^L&UBA]<,TMJ2+ENP4U *U?SY:UN' M/F14=KRSQO^Y 1_/X$[ MK:BP\$EEF!T21$YLISC9*9XG9QF_UJH'@_@"DCB)S_ -N@H, M_@3 4LD-ZE MS"6LB-.QA _XAQW_,/ /3_"'PBZ%3:6VM4'X]82O!'.IT^??Q^IYELW/Z,A6 M/,4)\Z^,%'"MBM'=E2S1Y&$P+J:X5-;>W\W:S M/VNN_-_PYN&XXR87RH+$C8/&O>M+!J89QL8@784!6&MRXQ26A7N_T/@ M[_1 MKGZMX0_H7L3I.U!+ P04 " "7A!I1N T6XBD% "F# &0 'AL+W=O M^-#\B%Y1Y]MM?EJ-X@. M;@M5VO/>QKEJ-AC8;(.%L'U=84D[*VT*X6AJU@-;&12Y%RK4( [#\: 0LNQ= MG/FU#^;B3-=.R1(_&+!U40BSNT2EM^>]J+=?^"C7&\<+@XNS2JSQ&MWGZH.A MV:!#R66!I96Z!(.K\]X\FET.^;P_\*?$K3T8 WNRU/HK3W[/SWLA&X0*,\<( M@GYN<(%*,1"9\:W%['4J6?!PO$>_\KZ3+TMA<:'5%YF[S7EOTH,<5Z)6[J/> M_H:M/R/&R[2R_@O;YFQ"A[/:.EVTPF1!(^T04O@9WB+Y9L\&CD!Y M:Y"U )<-0/P,0!3#.UVZC85?RQSS^P #LJ8S*=Z;=!D?17Q3EWU(P@#B, Z/ MX"6=BXG'2XZX:,%IN)*E*#,I%%P[X9!2R]DC^,,.?^CQA\_@OT5K$0/XHT(C MG"S7+9?PUR>\=7"I=/;U[Z>(/0K+U3BSE$_(?#1MM+H2ANM.QOJ4P) M:R6Y)WQ9ZY4_TQKSTP^3.$I_(0*Z8#2,D!^%KBG@+&"X5'E06R2O+=(RN^F/ M@I)BV7'#V%M?VN2AN"'0-=)EQ-==!PX.3=$0]>3Q7-J,=0-9Q,Z:%UD,I]ZR MQK#6I%WGA3 (LB0@75LZ85_-X+*EZ=K3M+A/TYP=GU$<2NQJZR!C&Y6SARM/ M,O5QO_:9UN;>QA-(HV X'L&B-H82Y*$SAYP^TG&XE[7R)S -1LF(\JG,_B?D M. WBX00^:4>%?PR$G!@'Z22!+R^)-YP2_3L4AJF?]-/XL=B]N,]@V!^&\.-+ M$CX3=@.5D+E/EGW(99FIFJ[8)NX(!=E2&W^-<32.N<8Y]%0H]=*18PTDWF8; M4:Z;!"WI.3T&N$]B)@"0+_X'J74*5]\[LF O]\YY;[F/[8^"=#0A(Z,'-GTG.)78^5<#ECO(_TLQ!["EBW4#T@>8VYF,,ELJ M,I8>)ET3BL_/QE*]5'+=U.WI@R)_KH#;>Y96HX:DT33D6 MORQ)#*V#:!S$2=I*/G3'[DML@89CM;_JVM2F!"!*J4N#4CMX3>6C-*S5/4A4Q=$J1AVA!) MX^%XVM*8!-%HV-)(.1CM:8R"9!H?*@LETU'$7$2-)DK1S?Y7A+?749..6 M7EQ154;?2NHOD9[(DRCN3ZG/4XH<"F@:]B=W4R[CD^G=RKTRM(^+C'VE[\1_ MTP">:G8&![UC@6;M.V2ZB#G&31O9K79-^+SI/>^.-QW\.V'6DF*L<$6B83\= M]9I;9S]QNO*=Z%([ZFO]<$-_)-#P =I?:6IOV@DKZ/Z:7/P+4$L#!!0 ( M )>$&E$SEX=4/ 0 '(* 9 >&PO=V]R:W-H965T>^!F#/@78&> &[!@=N"#=M7F!E2Y_T25I9TYV0CZI U/!4\5K-G$+KS=5PJ-("*Z8&8H,U MO2I&&'DI45UJH4-4C,9\["OUI&1M\J M_%[B3AV=P3!Y$.+1")^SF>.9@)!CJ@T"H[\M7B/G!HC"^+;'=#J7QO#X?$#_ M9+D3EP>F\%KP/\I,%S,G=B##G#5#*_L*NU9TD#J2-TJ+: M&U,$55FW_^QIGXO^/<#^")J72CX6&>8 MG0(,B4S'*#@P6@87$7]IZ@&$G@N!%W@7\,(N0Z'%"R]D2($6\*FL69V6E)Z5 MIG285*D+^%&''UG\Z!7\"^D$6YT_[_!)PY*+]/&O'/1N8GRZBS,78'6B-7/4#!%-R7E3!)>RE0!6;DM,ZPS!1L"5P6] M 9'#.W\0Q%#6@"PMS /R#7G#.>2E2@G\&9E4@*95@ J-7:'=8]%/3D5B>J+\ MO6X+\)](PW7!ZC4U1FDFRXNAL(;IB6%Y;.A"3:/64&-/+C!]B 7N:QJJO/R' M0'ZB8:K:'D!R1<-KL64E9P\<^T"#N+]BW,2S1:5M&P)-*)H_-5PW4F*=4OHE MJQ6%9";?(ON[.2A>]/(!9;EE9DPJ0E=:-JW1G3"%73)._8\GR9O ._!C-XD3 M.O3&$S<)(GA/Y[Z1(WH3CDC^^J.LP ,2+Z0Q3UVB5)F7J8U=&73?BZ'GNZ-) M0%!]\,?N*!S#HA*-">[%A#CE4E0_K(?Q:"[T(0(_<"-_9+'[1](YOC'1"B)W M' >6;^)&R?B(;^3&ON%_W?HWSC#/Z0,$K*N!*2")8F-K8X3%ZMYB][T C>< M^#:0]O2_D,9]SX=>,'&]47B@U4EOJ 7!1&X43PBEEU 1[,&/7,\6_5R^DD-J M)B$U26A3U9G2,0[=4>"_.:K$3<8&O#=Q_4EBHZ)39/KE]CO]MD5L"Y"0'76\ M[0B--"0UX!-M/0J/+RMI]/PVF:$;C:/][QG6-&#VK(E>$K4-TO-#-Q@=,D#1 M)39.\*W! .A#> )Q<62!"^>^/,.C/:!"N;;;CJ*LTD5I5X+N:;=0+=H]XD6] MW<:^,+DVXX%C3J;>8#)R0+8;3BMHL;%;Q8/0M*/88T%+(4JC0.]S0=^8O6 < M=&OF_%]02P,$% @ EX0:4>EXC<7!! B@P !D !X;"]W;W)K&ULY5=;;]LV%/XK!]HPI( J2_(]LPW4O6 =T")HVA7# ML =:.K*(2*1&4G'\[W=(RK+3)$[VO!=+(L_Y^'WG0M*+G50WND0T<%=70B^# MTICF&?S!<:=/WL$JV4AY8S\^YLL@MH2PPLQ8!$:/6WR+566! MB,8_'6;0+VD=3]\/Z!^<=M*R81K?RNH[STVY#&8!Y%BPMC)?Y.XW[/2,+5XF M*^U^8>=MAVD 6:N-K#MG8E!SX9_LKHO#B<,L?L(A[1Q2Q]LOY%B^8X:M%DKN M0%EK0K,O3JKS)G)^9$EQL-5RA@NN2*5P,#"U@ MS099![;V8.D38$D*GZ0PI8;W(L?\/L" F/7TT@.]=7H6\?=61#",0TCC-#Z# M-^SE#AW>\(Q<#4;"!RZ8R#BKX-HP@U1F1I_!'_7X(X<_>@+_813AKZ]X9V!= MR>SF[\=">A;0]N2E;EB&RX":3J.ZQ:!+6O1(SB[A:XE0R(J:C6; L$V%MGEL M%Y!PFLQ8E;459=B8 MDWE6RY8"^.H2_B1OGWV@W&&?._I)YO8'9D?:1X!??IJE2?*K9W,)GVDWXB*3 M-<+/D*;S,)U/Z&T^">-I2B]).@F3<0P?O0TCN1FSW"FS#5.&9[PAA10 C5FK MN.&4]8LT'<$KN$CBL7_,Z'% N&6\AC<5P&DYG[C&:3IZ-"ZTX MB>+8="#B($&V](7\*S--R M>0#2S#/T9!UX^PV>Q)URQWYXPM&%7>Q\A MF]C_Q/KJ!0@%@:BN$&B CG8HE*P?VK^PCB(J'&@U.B*&;DVZ5?O.H$;:4EV+ M]?FZ%X\?J[^UF>0^DV?V:A]UM[]'\(UV8O7TXJ$/D)(98JZ]5+Q#E7&B3,%@ MHM/H#?TVWR6&KH7:GR*9U"8$;LWW(1T^"HK6M$3%'E<\LZJ8(5E0DB(0TKA# M*G^N.SNI;"/)R!]D=/!4;4ZQH"3V=G;!78PFMIR"7F%!KG$T'0>@_,W7?QC9N-OF1AJZN[K7DOXL MH+(&-%]("F+W81?H_WZL_@502P,$% @ EX0:457]I'NA!P [1, !D M !X;"]W;W)K&ULO5AK;^.X%?TKA)%!9P&'UM.V M@B1 ,H]MB^Y.D,S,HBCZ@9%H6X@D>DDJ3OKK>RXIRW(\\:8H6@21)>KRW->Y MEZ3.-TH_F)64ECW556,N1BMKUV>3B7Y6BSEG;3?UC<:3Y,>I2AKV9A2-4S+Q<7H*CR[3DC>"7POY<8,[AEYC^8@5+FJC+NRC9=-LQ'+6V-5W4V&!779^%_Q MU,5A,&$>O#(AZB9$SFZOR%GY45AQ>:[5AFF2!AK=.%?=;!A7-I24.ZOQML0\ M>_FKLI*% 3ME=RNAY2EY6+ /JD;6C?"!:PKVQ:ZD9M>RD8O2LIM*-.9\8J&? M4"9YI^O:ZXI>T15&[!?5V)5AGYI"%OL $QC>6Q]MK;^.CB+^M6TXBX,QBX(H M.((7]]&('5Y\)!J&6<4^EXUH\E)4[,X**\%":X[@)SU^XO"35_"',;X1SP3+ MKK06S=*I8/_X*I\LNZY4_O#/'\7W*#K5[YE9BUQ>C%"@1NI'.=HFF/_'^3UC M7U>2YTS9(S5K0LC*PWS5D WR2Y$J=FCJ%I)$W:SA74/!>)/+Y8(D^7[ICOK2F>+ M6C;EOP#:FK)9,L&@3U!%GE*46"WM2D'CH_3V/4IC26XM=8EQ"@%@&NE]Q3O4 M.\#@SD*6MD4T$4"+M#"U=IKED]1Y:1 'FFO<*VX!W* &V8#T:NU+BL63=V+N;]\WV#[&C$-A+Q MV(6T2_I>5KNDT?AU)?*'T[M\I2J"=]BG,"0G@5H5DAJD]>%G-98. M #RJ"NFL*$51] ZM,H)(%+B[&'?A=NRV- ^G"XTJ*1$*I-8R+:BCA#PFF9!G M$.8CF^4^& MK4JP$H%##Q--T^(G%V:UF^]O"G;_["9B27X _??J< >6J[J&!L=S[NR06W,] MN*N]0:#>9)Q9] MXW<0QB;&M/H9SJ$[$0W!T%;[2MQ+GV.<0)WIV@G# [*L)^(1V\S.N+W^X78C MI.IEN6P[*/H&7'A1\[^V]3VDH<%U<["DI/"JUJ +@2R_N4T(#+E:+K5A>R$97.> M1.SGKNS#<3"?L3"B,F*??=_$\/LHC=A/;#[ETP@4]TV3AH,$PV$8\C0\IF[. MXG$"B!.L82F']JV^#/?A+.;S;*@MC@."C3*>Q4-U\3S&>);R*#NF+8.V:3HE M;1%ZP+37-H,)81;P>3#4!DD'FLV&NF8)Z0K3&4_2(\K0BZ LR$A9$O!HCILD MF:+,$][;+NXK>1"2,P0[1-A@SRP])IF19()\(%6SX(AD%)!D.DV0D8A/ Y@2 MQ5..X,,4*JK-ECJBH\[^HOUR#2A01G!X41HJ\WZ]ROJEY(\&;E%\: N$-6P] M__.RZ;QS:62CCWDZ;"2OE*;V%;2MX:V&K(X+*-X2VIP M:DLS<"*,4AZD[+N?]1Z"X%*0\.ETP+Q3_+V&C*2EA!S.>)SMRC-%M)8YU5 M%O',<-OGY!(H'6X&V'8"598UG4]QXM7:,B'+//T:AOL?O];CGT#R/^3 M8D>;-3JLH]ET2(99Z%MDMDM9U\F2(1>Z1(8@Y!_TZ#"9=Y3+TEX+NF,X"W@V MW5'.XZ&-[JF)IXXO,9]%QYMS&+MN&2?#A2"&,UG$@QW_T!K]TA+LK42^*Z=\ M>KPIHR1(29KQ*&4I\?$M5.SI\P,^INCI;^*C)Y;;)W0'M?S@M .])W'$DRWB MV#W&NTP-ET:4[& M!Y$9LQNMZ&!*%>^21F._^A#P&3P"::6>ND^--&^N6VL_QK3C_;?LJ[\)YR=N/\0]HO02YR7 M6247F$IK_ B;6O=QR3]8M78?=.Z5M:IVMRLIT*M( .\7"F?^[H$4]%_X+O\- M4$L#!!0 ( )>$&E%C41IGU@@ -P3 9 >&PO=V]R:W-H965T1;I'&R.YU. M'R 2DM!0A!8 +3N_OM\!+Y)2V[,[TP=1!'DN'\X=/-]I\\VNI73L85/5]F*T M=FY[-IW:8BTWPD[T5M9XL]1F(QR69C6U6R-%Z9DVU30*P]ET(U0]NCSWSSZ9 MRW/=N$K5\I-AMMELA'F\EI7>78SXJ'_P6:W6CAY,+\^W8B7OI/NZ_62PF@Y2 M2K61M56Z9D8N+T97_.PZ(7I/\(N2.WMPSV@G"ZV_T>*VO!B%!$A6LG D0>#O M7M[(JB)!@/%;)W,TJ"3&P_M>^GN_=^QE(:R\T=6OJG3KBU$^8J5&[UCAJ@AC6[\5CTWP*F:G'+G#-XJ\+G+#]I)QCD[9;=UH3>2?1$/ MTIY/'603Q;3HY%RW+?FGK" MXC!@41B%+\B+AYW&7E[\PDXM$DX@P9U^0GPSR$R\_>4;^ MWG[LK;)%I6UC)/O7%_G@V'6EBV__?LJJ+\JDC#RS6U'(BQ%2SDIS+T>]RR9' M'COK5PN)3)5,M2M'[]A.6(;EUB@K2Z:7S*TE6^H*&:GJ%1NK&D]T8T5=VI,S M]D\I3.M&!B?(P0FX\#E=6,[>0KIUJF"O6)2D03Q+<3=+@C#GN,EYD*890]X@ M*VH6\X C0)(LF,<)2Y(@GJPL_836,,HJ=Z)-5[3&?LO2RE08 !=![, MLQG=S()P'M+6\B#ALS;V&![RG*5)PF!#[+*W6!ZD>9!#.^>#"#'49!&T0E1\"3R @*>)KAIH99/ZJ==S<(, MXJ ^XIX-CN71P+=WYP'7*PH?[J.+@SR)<3/F7^!OP_$_/E/><2S-[];6!LM_I+O[X*?CI&5(#?2M4(6 MLI9+Y2P$=W)^(BA_F*57[=;*E#_=U@>@\F E+-:._:Q1DP4Z5@Y[KN4.\2YKM%-XULA54PGJKS9@126, M6JJB7R/+6+$6]4IZR*M&E2B\TBSP_:([X)&2OA[]\PO'79N(A MA@ NH/(SB.G"@D63& SA)"?N28KK/X ?#@%$X"Z;@SE(N4>D9__H%+3T&T<3 M9.]K]AFM1A@X@CQ8RGN,;MM-7W00CR6TC<-)1K1C/IEU_Y[WQ@?-BJA]J22, MK=[R/QAGO!CP1IXG;'EBC[PO*T.*E0K9AV)7P/ ]"_V!,<;^L/JX]:+E@S0% M>AO(T@Y5"C.TJ/S_T*Y(>"57RK91.\3G*>/@)!/,6D6MX<5VJPT1>MQ[XC$9 M^X2L]NY!%HVO$-1AX>)6;J4VRK6)P,A"A#SQ9OZ(V#*M$\?DZF%3W%_?#15G ML ,"GD*!)^W>.TL<5O>V0SF?N[75%1*-(OQ:5#[A[F@\?+$S8@S"1C&5'QO] MAW[9!?IAG-_6][ ,Q? KE@79;-[^HSQ_H"C=>N]# <8A !#&/.I[:2Q#+\_0 M!-"WHGGBAZ8NK@YHYD$ZRW&=)2',#$"V+8,"NZ""(G]K*(X5(+2!!;%!$L4L M#I(XWAOHR#$\##)T-?S%GL:H>^'-?0K5=LV6L A;RW(E&?I3BNH9S-&E_BXQ M^L.K8H'J J5HYU$ZZ]T)TA@@TR#"GGX15=.%/)G7>V"J$HL*GF*%G1J126/+("> M&/"PZ\:I;\NWM4/<*K"TBIC84%!_;T&..2:2*)O[#I]@U/ ]]:W$P%FHG@1& MFQ'J<8X)@7JV/[U1'#6VESI&7^:EHH"C6=)D"3> M0#S%*)22#C) ^1P+=?^0^YGJA!;Y''XEB%?'//=/> /A8RAXB&:WEICM'#W; MT"!:J6^2!CJDNN^9]#LN\%>6]GWT+!A(GWT9Y]'DQ^<1S3]1&,^>>D-].\XG M8#YJRFOT1I+GFSIU[ ^:_2J'7DW-2]2B>OR.5M88MJKT CV"CL:4AH78*AJQ MNNVW(4-5GLK!%@<+2.DZY:&Q80T'&4U5HMM0-VJ\?55;1FI=GWZ=W$UPLE^@ MX"M, =*/+LZH18,"YA.KZZJ><"MHANW;/>1530G3:QI<"MW4#O5DI]QZK:O2 MER?*$:#<(VSU^1J-E][!="!"ET$1P0*R$9>@+=36$]$.EHWQ<3E,(DNC-Q[5 M[><[K^#K'?N"C,/1#4U9MG-"![P;50@?S*#@C:(=()!-0$QN)_\,7%25)^0Z MXT\X01=DY+O?/;DLT*GJFH@(G*R],19=5:?DJXEO5?L"<30B_I&CSC"N7 _J M>AVO4-/".**A&S.W/X^AN&?LJC,SW-S%7(& LMVS4S8/0USW5#0M^WE>]S1 MWQ]E'@E;',Y0:GF>8AYE-]WIF

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end XML 98 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 99 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 100 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 347 486 1 true 85 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.bio-techne.com/20200630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Statements of Earnings and Comprehensive Income Sheet http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income Consolidated Statements of Earnings and Comprehensive Income Statements 2 false false R3.htm 002 - Statement - Consolidated Statements of Earnings and Comprehensive Income (Parentheticals) Sheet http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income-parentheticals Consolidated Statements of Earnings and Comprehensive Income (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Balance Sheets Sheet http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 4 false false R5.htm 004 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows Sheet http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies Sheet http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies Note 1 - Description of Business and Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Revenue Recognition Sheet http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition Note 2 - Revenue Recognition Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information Note 3 - Supplemental Balance Sheet and Cash Flow Information Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Acquisitions Sheet http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions Note 4 - Acquisitions Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Fair Value Measurements Sheet http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements Note 5 - Fair Value Measurements Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Debt and Other Financing Arrangements Sheet http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements Note 6 - Debt and Other Financing Arrangements Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Leases Sheet http://www.bio-techne.com/20200630/role/statement-note-7-leases Note 7 - Leases Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) Sheet http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Earnings Per Share Sheet http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share Note 9 - Earnings Per Share Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans Sheet http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans- Note 10 - Share-based Compensation and Other Benefit Plans Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Income Taxes Sheet http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes Note 11 - Income Taxes Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Segment Information Sheet http://www.bio-techne.com/20200630/role/statement-note-12-segment-information Note 12 - Segment Information Notes 19 false false R20.htm 019 - Disclosure - Note 13 - Quarterly Financial Data (Unaudited) Sheet http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited Note 13 - Quarterly Financial Data (Unaudited) Notes 20 false false R21.htm 020 - Disclosure - Note 14 - Subsequent Events Sheet http://www.bio-techne.com/20200630/role/statement-note-14-subsequent-events Note 14 - Subsequent Events Notes 21 false false R22.htm 021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies 22 false false R23.htm 022 - Disclosure - Note 2 - Revenue Recognition (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-tables Note 2 - Revenue Recognition (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition 23 false false R24.htm 023 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information 24 false false R25.htm 024 - Disclosure - Note 4 - Acquisitions (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-tables Note 4 - Acquisitions (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions 25 false false R26.htm 025 - Disclosure - Note 5 - Fair Value Measurements (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-tables Note 5 - Fair Value Measurements (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements 26 false false R27.htm 026 - Disclosure - Note 7 - Leases (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables Note 7 - Leases (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-7-leases 27 false false R28.htm 027 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss 28 false false R29.htm 028 - Disclosure - Note 9 - Earnings Per Share (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-tables Note 9 - Earnings Per Share (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share 29 false false R30.htm 029 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables Note 10 - Share-based Compensation and Other Benefit Plans (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans- 30 false false R31.htm 030 - Disclosure - Note 11 - Income Taxes (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables Note 11 - Income Taxes (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes 31 false false R32.htm 031 - Disclosure - Note 12 - Segment Information (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-tables Note 12 - Segment Information (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-12-segment-information 32 false false R33.htm 032 - Disclosure - Note 13 - Quarterly Financial Data (Unaudited) (Tables) Sheet http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-tables Note 13 - Quarterly Financial Data (Unaudited) (Tables) Tables http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited 33 false false R34.htm 033 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) Details 34 false false R35.htm 034 - Disclosure - Note 2 - Revenue Recognition (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-details-textual Note 2 - Revenue Recognition (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-tables 35 false false R36.htm 035 - Disclosure - Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) Details 36 false false R37.htm 036 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables 37 false false R38.htm 037 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) Details http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables 38 false false R39.htm 038 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) Details 39 false false R40.htm 039 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) Details 40 false false R41.htm 040 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) Details 41 false false R42.htm 041 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) Details 42 false false R43.htm 042 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) Details 43 false false R44.htm 043 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details) Details http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables 44 false false R45.htm 044 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) Details 45 false false R46.htm 045 - Disclosure - Note 4 - Acquisitions (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual Note 4 - Acquisitions (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-tables 46 false false R47.htm 046 - Disclosure - Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) Details 47 false false R48.htm 047 - Disclosure - Note 5 - Fair Value Measurements (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual Note 5 - Fair Value Measurements (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-tables 48 false false R49.htm 048 - Disclosure - Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Details 49 false false R50.htm 049 - Disclosure - Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) Details 50 false false R51.htm 050 - Disclosure - Note 6 - Debt and Other Financing Arrangements (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual Note 6 - Debt and Other Financing Arrangements (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements 51 false false R52.htm 051 - Disclosure - Note 7 - Leases (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual Note 7 - Leases (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables 52 false false R53.htm 052 - Disclosure - Note 7 - Leases - Balance Sheet Classification (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details Note 7 - Leases - Balance Sheet Classification (Details) Details 53 false false R54.htm 053 - Disclosure - Note 7 - Leases - Cash Paid (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-7-leases-cash-paid-details Note 7 - Leases - Cash Paid (Details) Details 54 false false R55.htm 054 - Disclosure - Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details) Details 55 false false R56.htm 055 - Disclosure - Note 7 - Leases - Aggregate Net Minimum Rental Commitments (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details Note 7 - Leases - Aggregate Net Minimum Rental Commitments (Details) Details 56 false false R57.htm 056 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables 57 false false R58.htm 057 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) Details http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables 58 false false R59.htm 058 - Disclosure - Note 9 - Earnings Per Share (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-details-textual Note 9 - Earnings Per Share (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-tables 59 false false R60.htm 059 - Disclosure - Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) Details 60 false false R61.htm 060 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables 61 false false R62.htm 061 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details) Details 62 false false R63.htm 062 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) Details 63 false false R64.htm 063 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) Details 64 false false R65.htm 064 - Disclosure - Note 11 - Income Taxes (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual Note 11 - Income Taxes (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables 65 false false R66.htm 065 - Disclosure - Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) Details 66 false false R67.htm 066 - Disclosure - Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details) Details 67 false false R68.htm 067 - Disclosure - Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) Details 68 false false R69.htm 068 - Disclosure - Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Details 69 false false R70.htm 069 - Disclosure - Note 12 - Segment Information (Details Textual) Sheet http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual Note 12 - Segment Information (Details Textual) Details http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-tables 70 false false R71.htm 070 - Disclosure - Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) Details 71 false false R72.htm 071 - Disclosure - Note 13 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) Sheet http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details Note 13 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) Details http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-tables 72 false false All Reports Book All Reports tech20200630_10k.htm ex_187163.htm ex_187164.htm ex_187165.htm ex_187166.htm ex_187167.htm ex_187168.htm ex_200241.htm ex_200242.htm ex_200243.htm ex_200244.htm ex_200245.htm ex_200246.htm ex_200247.htm ex_200248.htm ex_200249.htm ex_201045.htm tech-20200630.xsd tech-20200630_cal.xml tech-20200630_def.xml tech-20200630_lab.xml tech-20200630_pre.xml graph02.jpg http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true JSON 103 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tech20200630_10k.htm": { "axisCustom": 0, "axisStandard": 34, "contextCount": 347, "dts": { "calculationLink": { "local": [ "tech-20200630_cal.xml" ] }, "definitionLink": { "local": [ "tech-20200630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tech20200630_10k.htm" ] }, "labelLink": { "local": [ "tech-20200630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "tech-20200630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "tech-20200630.xsd" ], "remote": [ "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 641, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 30, "http://www.bio-techne.com/20200630": 13, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 49 }, "keyCustom": 47, "keyStandard": 439, "memberCustom": 30, "memberStandard": 54, "nsprefix": "tech", "nsuri": "http://www.bio-techne.com/20200630", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 4 - Acquisitions", "role": "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "shortName": "Note 4 - Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 5 - Fair Value Measurements", "role": "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "shortName": "Note 5 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 6 - Debt and Other Financing Arrangements", "role": "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "shortName": "Note 6 - Debt and Other Financing Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 7 - Leases", "role": "http://www.bio-techne.com/20200630/role/statement-note-7-leases", "shortName": "Note 7 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)", "role": "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "shortName": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 9 - Earnings Per Share", "role": "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share", "shortName": "Note 9 - Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans", "role": "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 11 - Income Taxes", "role": "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "shortName": "Note 11 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 12 - Segment Information", "role": "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "shortName": "Note 12 - Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Statements of Earnings and Comprehensive Income", "role": "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "shortName": "Consolidated Statements of Earnings and Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 13 - Quarterly Financial Data (Unaudited)", "role": "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited", "shortName": "Note 13 - Quarterly Financial Data (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 14 - Subsequent Events", "role": "http://www.bio-techne.com/20200630/role/statement-note-14-subsequent-events", "shortName": "Note 14 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 2 - Revenue Recognition (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-tables", "shortName": "Note 2 - Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 4 - Acquisitions (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-tables", "shortName": "Note 4 - Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 5 - Fair Value Measurements (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-tables", "shortName": "Note 5 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 7 - Leases (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables", "shortName": "Note 7 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "shortName": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 9 - Earnings Per Share (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-tables", "shortName": "Note 9 - Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Statements of Earnings and Comprehensive Income (Parentheticals)", "role": "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income-parentheticals", "shortName": "Consolidated Statements of Earnings and Comprehensive Income (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 11 - Income Taxes (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables", "shortName": "Note 11 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 12 - Segment Information (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-tables", "shortName": "Note 12 - Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 13 - Quarterly Financial Data (Unaudited) (Tables)", "role": "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-tables", "shortName": "Note 13 - Quarterly Financial Data (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 2 - Revenue Recognition (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-details-textual", "shortName": "Note 2 - Revenue Recognition (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 2 - Revenue Recognition - Disaggregation of Revenue (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "shortName": "Note 2 - Revenue Recognition - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30_StatementGeographicalAxis-US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Balance Sheets", "role": "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2018-07-01_2019-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepositsAssetsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepositsAssetsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxesPaidNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxesPaidNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 4 - Acquisitions (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "shortName": "Note 4 - Acquisitions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2018-07-02_2018-07-02_BusinessAcquisitionAxis-QTHoldingsCorporationMember_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "shortName": "Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30_BusinessAcquisitionAxis-BMoGenMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-07-01", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 5 - Fair Value Measurements (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual", "shortName": "Note 5 - Fair Value Measurements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-07-01", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "shortName": "Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentConsiderationMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "shortName": "Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2018-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentConsiderationMember", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 6 - Debt and Other Financing Arrangements (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual", "shortName": "Note 6 - Debt and Other Financing Arrangements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30_DebtInstrumentAxis-CreditAgreementMember", "decimals": "-6", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 7 - Leases (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual", "shortName": "Note 7 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 7 - Leases - Balance Sheet Classification (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details", "shortName": "Note 7 - Leases - Balance Sheet Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tech:LesseeOperatingLeaseCashFlowInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 7 - Leases - Cash Paid (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-7-leases-cash-paid-details", "shortName": "Note 7 - Leases - Cash Paid (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tech:LesseeOperatingLeaseCashFlowInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "shortName": "Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 7 - Leases - Aggregate Net Minimum Rental Commitments (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details", "shortName": "Note 7 - Leases - Aggregate Net Minimum Rental Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual", "shortName": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "shortName": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2017-06-30_StatementEquityComponentsAxis-AccumulatedNetUnrealizedInvestmentGainLossMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 9 - Earnings Per Share (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-details-textual", "shortName": "Note 9 - Earnings Per Share (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2017-06-30_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Shareholders' Equity", "role": "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2017-06-30_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "shortName": "Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2017-07-01_2018-06-30", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2017-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-06-30_AwardTypeAxis-RestrictedStockMember", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2017-06-30_AwardTypeAxis-RestrictedStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note 11 - Income Taxes (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual", "shortName": "Note 11 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-5", "lang": null, "name": "tech:IncomeTaxExpenseBenefitDiscreteTaxItems", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note 11 - Income Taxes - Components of Provision for Income Taxes (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "shortName": "Note 11 - Income Taxes - Components of Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "shortName": "Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsInventory", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "shortName": "Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsInventory", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2019-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "shortName": "Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2017-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note 12 - Segment Information (Details Textual)", "role": "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual", "shortName": "Note 12 - Segment Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "shortName": "Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note 13 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)", "role": "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "shortName": "Note 13 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies", "role": "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "shortName": "Note 1 - Description of Business and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 2 - Revenue Recognition", "role": "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition", "shortName": "Note 2 - Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 85, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "country_GB": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED KINGDOM" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r675" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r674" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r676" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income-parentheticals", "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-tables", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-tables", "http://www.bio-techne.com/20200630/role/statement-note-14-subsequent-events", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-tables", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-tables", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-tables", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-7-leases", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-cash-paid-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-tables", "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r676" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r676" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r677" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r676" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r676" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r676" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r676" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income-parentheticals", "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-tables", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-tables", "http://www.bio-techne.com/20200630/role/statement-note-14-subsequent-events", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-tables", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-tables", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-tables", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-7-leases", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-cash-paid-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-tables", "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r672" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r673" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia [Member]" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r184", "r197", "r198", "r199", "r200", "r202", "r204", "r208" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r184", "r197", "r198", "r199", "r200", "r202", "r204", "r208" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r130", "r137", "r235", "r416", "r417", "r418", "r459", "r460" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r130", "r137", "r235", "r416", "r417", "r418", "r459", "r460" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r130", "r137", "r235", "r416", "r417", "r418", "r459", "r460" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "label": "Executive Officer [Member]" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r371", "r377", "r574", "r575", "r576", "r577", "r578", "r579", "r581", "r626", "r629" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r371", "r377", "r574", "r575", "r576", "r577", "r578", "r579", "r581", "r626", "r629" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r211", "r295", "r299", "r582", "r625", "r627" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r211", "r295", "r299", "r582", "r625", "r627" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r326", "r371", "r377", "r574", "r575", "r576", "r577", "r578", "r579", "r581", "r626", "r629" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r326", "r371", "r377", "r574", "r575", "r576", "r577", "r578", "r579", "r581", "r626", "r629" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r212", "r213", "r295", "r300", "r628", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670" ], "lang": { "en-US": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r212", "r213", "r295", "r300", "r628", "r659", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r277", "r372", "r569" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r217", "r567" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_APACExcludingGreaterChinaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the APAC, excluding Greater China.", "label": "APAC, excluding Greater China [Member]" } } }, "localname": "APACExcludingGreaterChinaMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_AcquisitionRelatedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Non-cash change in the liability related to acquisition.", "label": "Acquisition-related liabilities (1)" } } }, "localname": "AcquisitionRelatedLiabilities", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details" ], "xbrltype": "monetaryItemType" }, "tech_AmortizationOfAcquiredIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of amortization of acquired intangible assets.", "label": "tech_AmortizationOfAcquiredIntangibleAssets", "negatedLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfAcquiredIntangibleAssets", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "tech_AtlantaBiologicalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining Atlanta Biologicals.", "label": "Atlanta Biologicals [Member]" } } }, "localname": "AtlantaBiologicalsMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "tech_BMoGenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to B-MoGen Biotechnologies.", "label": "B-MoGen [Member]" } } }, "localname": "BMoGenMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "tech_BuildingBuildingImprovementsAndLeaseholdImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to building, building improvements and leasehold improvements.", "label": "Building, Building Improvements and Leasehold Improvements [Member]" } } }, "localname": "BuildingBuildingImprovementsAndLeaseholdImprovementsMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets acquired, including goodwill, at the acquisition date.", "label": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "terseLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of equipment and other long-term assets acquired at the acquisition date.", "label": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets", "terseLabel": "Equipment and other long-term assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities excluding deferred income taxes assumed at the acquisition date.", "label": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal", "terseLabel": "Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "tech_BusinessCombinationStepAcquisitionEquityInterestInAcquireeBeforeRemeasurementToFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages, before remeasurement to fair value.", "label": "tech_BusinessCombinationStepAcquisitionEquityInterestInAcquireeBeforeRemeasurementToFairValue", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeBeforeRemeasurementToFairValue", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_CCXIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related to the CCXI investment.", "label": "CCXI [Member]" } } }, "localname": "CCXIMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "tech_ChemoCentryxIncCCXIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer primarily focused on orphan and rare diseases.", "label": "ChemoCentryx, Inc (CCXI) [Member]" } } }, "localname": "ChemoCentryxIncCCXIMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "tech_ConsumablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to consumables products.", "label": "Consumables [Member]" } } }, "localname": "ConsumablesMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Liabilities that are contingent on agreed-upon conditions that arise from business combinations.", "label": "Contingent Consideration [Member]" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "domainItemType" }, "tech_ContingentConsiderationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for contingent consideration.", "label": "Contingent Consideration, Policy [Policy Text Block]" } } }, "localname": "ContingentConsiderationPolicyPolicyTextBlock", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "tech_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to credit agreement.", "label": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "tech_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from lease liabilities.", "label": "tech_DeferredTaxAssetsLeaseLiabilities", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "tech_DerivativeNotionalAmountDecreaseInPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of decrease during the period in the notional amount of the derivative.", "label": "tech_DerivativeNotionalAmountDecreaseInPeriod", "terseLabel": "Derivative Notional Amount, Decrease in Period" } } }, "localname": "DerivativeNotionalAmountDecreaseInPeriod", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_DerivativeNotionalAmountDedesignated": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of dedesignated derivative notional amount.", "label": "tech_DerivativeNotionalAmountDedesignated", "terseLabel": "Derivative Notional Amount, Dedesignated" } } }, "localname": "DerivativeNotionalAmountDedesignated", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_DiagnosticsAndGenomicsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consist of the ACD operating segment and the Diagnostics operating segment.", "label": "Diagnostics and Genomics [Member]" } } }, "localname": "DiagnosticsAndGenomicsMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "domainItemType" }, "tech_EMEAExcludingUKMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regions of Europe, Middle East and Africa, excluding the United Kingdom.", "label": "EMEA, excluding U.K. [Member]" } } }, "localname": "EMEAExcludingUKMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to contingent consideration adjustments.", "label": "tech_EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment", "terseLabel": "Contingent consideration adjustment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "tech_EffectiveIncomeTaxRateReconciliationGILTIAndFDIIPercent": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Global Intangible Low-Taxed Income (GILTI) and Foreign-Derived Intangible Income (FDII).", "label": "tech_EffectiveIncomeTaxRateReconciliationGILTIAndFDIIPercent", "terseLabel": "State apportionment changes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGILTIAndFDIIPercent", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "tech_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfContingentConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expense related to the revaluation of contingent consideration.", "label": "tech_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfContingentConsideration", "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Revaluation of Contingent Consideration" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfContingentConsideration", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_EffectiveIncomeTaxRateReconciliationOptionExercises": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to option exercises.", "label": "tech_EffectiveIncomeTaxRateReconciliationOptionExercises", "terseLabel": "Option exercises" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOptionExercises", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "tech_EmployeeStockPurchasePlan2014Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the 2014 Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan 2014 [Member]" } } }, "localname": "EmployeeStockPurchasePlan2014Member", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_EquityIncentivePlan2010Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the 2010 Equity Incentive Plan.", "label": "Equity Incentive Plan 2010 [Member]" } } }, "localname": "EquityIncentivePlan2010Member", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_EurocellDiagnosticsSASMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining Eurocell Diagnostics, SAS", "label": "Eurocell Diagnostics, SAS [Member]" } } }, "localname": "EurocellDiagnosticsSASMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "tech_ExosomeDiagnosticsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information about Exosome Diagnostics, Inc.", "label": "Exosome Diagnostics, Inc [Member]" } } }, "localname": "ExosomeDiagnosticsIncMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "tech_FairValueAdjustmentOnAvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of fair value adjustment made on available for sale securities during the period.", "label": "Fair value adjustment on available for sale investments" } } }, "localname": "FairValueAdjustmentOnAvailableForSaleSecurities", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "tech_FairValueAdjustmentToContingentConsiderationPayable": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "label": "Fair value adjustment to contingent consideration payable" } } }, "localname": "FairValueAdjustmentToContingentConsiderationPayable", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "tech_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainOnEscrowSettelement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of gain on escrow settlement of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "tech_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainOnEscrowSettelement", "negatedLabel": "Gain on escrow settlement" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainOnEscrowSettelement", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "tech_FairValueWriteUpOfAcquiredInventory": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting.", "label": "Costs recognized on sale of acquired inventory", "negatedLabel": "Costs recognized upon sale of acquired inventory" } } }, "localname": "FairValueWriteUpOfAcquiredInventory", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "tech_FinitelivedIntangibleAssetsOtherAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other additions lacking physical substance with a definite life.", "label": "tech_FinitelivedIntangibleAssetsOtherAdditions", "terseLabel": "Other additions" } } }, "localname": "FinitelivedIntangibleAssetsOtherAdditions", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "tech_FixedLeaseCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of fixed lease cost.", "label": "tech_FixedLeaseCost", "terseLabel": "Fixed Lease, Cost" } } }, "localname": "FixedLeaseCost", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_GBProfitSharingAndSavingsPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the GB Profit Sharing and Savings Plan", "label": "GB Profit Sharing and Savings Plan [Member]" } } }, "localname": "GBProfitSharingAndSavingsPlanMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_GainLossOnEscrowSettlement": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of gain (loss) during the period on escrow settlement.", "label": "Gain on escrow settlement", "negatedLabel": "Gain on escrow settlement", "terseLabel": "Gain (Loss) on Escrow Settlement" } } }, "localname": "GainLossOnEscrowSettlement", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustements": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from new acquisitions and adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "tech_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustements", "verboseLabel": "Acquisitions (Note 4)" } } }, "localname": "GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustements", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "tech_IncomeTaxExpenseBenefitDiscreteTaxItems": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the income tax expense (benefit) related to discrete tax items.", "label": "tech_IncomeTaxExpenseBenefitDiscreteTaxItems", "terseLabel": "Income Tax Expense (Benefit), Discrete Tax Items" } } }, "localname": "IncomeTaxExpenseBenefitDiscreteTaxItems", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_IncomeTaxExpenseBenefitDiscreteTaxItemsAcquisitions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents income tax expense (benefit) for discrete tax items relating to acquisitions.", "label": "tech_IncomeTaxExpenseBenefitDiscreteTaxItemsAcquisitions", "terseLabel": "Income Tax Expense (Benefit), Discrete Tax Items, Acquisitions" } } }, "localname": "IncomeTaxExpenseBenefitDiscreteTaxItemsAcquisitions", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_IncomeTaxExpenseBenefitDiscreteTaxItemsStateApportionments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents income tax expense (benefit) for discrete tax items relating to certain state appointments.", "label": "tech_IncomeTaxExpenseBenefitDiscreteTaxItemsStateApportionments", "terseLabel": "Income Tax Expense (Benefit) Discrete Tax Items State Apportionments" } } }, "localname": "IncomeTaxExpenseBenefitDiscreteTaxItemsStateApportionments", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_IncomeTaxExpenseBenefitFederalTranslationTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the income tax expense (benefit) related to federal translation tax.", "label": "tech_IncomeTaxExpenseBenefitFederalTranslationTax", "terseLabel": "Income Tax Expense (Benefit), Federal Translation Tax" } } }, "localname": "IncomeTaxExpenseBenefitFederalTranslationTax", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_IncomeTaxExpenseBenefitStockOptionsExercises": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the income tax expense (benefit) related to stock options exercises.", "label": "tech_IncomeTaxExpenseBenefitStockOptionsExercises", "terseLabel": "Income Tax Expense (Benefit), Stock Options Exercises" } } }, "localname": "IncomeTaxExpenseBenefitStockOptionsExercises", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_InstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to instruments which typically consist of longer-lived assets.", "label": "Instruments [Member]" } } }, "localname": "InstrumentsMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_InventoryFinishedGoodsNetOfReservesCurrentAndNonCurrent": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details": { "order": 0.0, "parentTag": "tech_InventoryNetCurrentAndNonCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. Includes both current and non-current amounts.", "label": "Finished goods(1)" } } }, "localname": "InventoryFinishedGoodsNetOfReservesCurrentAndNonCurrent", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details" ], "xbrltype": "monetaryItemType" }, "tech_InventoryFinishedGoodsNetOfReservesNonCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non-current amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "tech_InventoryFinishedGoodsNetOfReservesNonCurrent", "terseLabel": "Inventory, Finished Goods, Net of Reserves, Non-current" } } }, "localname": "InventoryFinishedGoodsNetOfReservesNonCurrent", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_InventoryNetCurrentAndNonCurrent": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of inventory, net of reserves, including both current and non-current portions.", "label": "tech_InventoryNetCurrentAndNonCurrent", "totalLabel": "Inventories, net" } } }, "localname": "InventoryNetCurrentAndNonCurrent", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details" ], "xbrltype": "monetaryItemType" }, "tech_InvestmentInUnconsolidatedEntity": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of investment in unconsolidated entity.", "label": "tech_InvestmentInUnconsolidatedEntity", "negatedLabel": "Investment in unconsolidated entity" } } }, "localname": "InvestmentInUnconsolidatedEntity", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "tech_LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The tabular disclosure for asset and liabilities of operating leases of the lessee.", "label": "Lessee, Operating Lease, Asset and Liabilities [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables" ], "xbrltype": "textBlockItemType" }, "tech_LesseeOperatingLeaseCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The tabular disclosure of cash flow information of operating leases of the lessee.", "label": "Lessee, Operating Lease, Cash Flow Information [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseCashFlowInformationTableTextBlock", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables" ], "xbrltype": "textBlockItemType" }, "tech_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The element representing the additional borrowing capacity under a line of credit.", "label": "tech_LineOfCreditFacilityAdditionalBorrowingCapacity", "terseLabel": "Line of Credit Facility, Additional Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_NoncashPortionOfLeaseExpense": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of noncash portion of lease expense during the period.", "label": "Leases, net" } } }, "localname": "NoncashPortionOfLeaseExpense", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "tech_NonqualifiedStockOptionsPlan1998Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the 1998 Nonqualified Stock Options Plan.", "label": "Nonqualified Stock Options Plan 1998 [Member]" } } }, "localname": "NonqualifiedStockOptionsPlan1998Member", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "tech_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "tech_OperatingLossCarryforwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information for deferred tax assets related to operating loss carryforwards.", "label": "Operating Loss Carryforwards [Member]" } } }, "localname": "OperatingLossCarryforwardsMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "tech_PerformanceIncentiveProgramsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the Performance Incentive Programs.", "label": "Performance Incentive Programs [Member]" } } }, "localname": "PerformanceIncentiveProgramsMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_ProductAndServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the product and services provided by the company.", "label": "Product and Services [Member]" } } }, "localname": "ProductAndServicesMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_ProteinSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consist of the remaining portion of the Biotechnology segment and the Protein Platforms operating segment.", "label": "Protein Sciences [Member]" } } }, "localname": "ProteinSciencesMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "domainItemType" }, "tech_QTHoldingsCorporationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information about QT Holdings Corporation.", "label": "QT Holdings Corporation [Member]" } } }, "localname": "QTHoldingsCorporationMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "tech_RestOfWorldMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rest of the geographical locations in the world.", "label": "Rest of World [Member]" } } }, "localname": "RestOfWorldMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the forfeiture rate used under share-based compensation arrangement by share-based payment award.", "label": "tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "percentItemType" }, "tech_StockRepurchasedDuringPeriodAverageSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "tech_StockRepurchasedDuringPeriodAverageSharePrice", "terseLabel": "Stock Repurchased During Period, Average Share Price (in dollars per share)" } } }, "localname": "StockRepurchasedDuringPeriodAverageSharePrice", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "perShareItemType" }, "tech_SurrenderAndRetirementOfStockToExerciseOptionsShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the shares of stock surrendered and retired to exercise options during the period.", "label": "Surrender and retirement of stock to exercise option (in shares)" } } }, "localname": "SurrenderAndRetirementOfStockToExerciseOptionsShares", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "sharesItemType" }, "tech_SurrenderAndRetirementOfStockToExerciseOptionsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the value of stocks surrendered and retired to exercise options.", "label": "Surrender and retirement of stock to exercise option", "terseLabel": "Surrender and Retirement of Stock to Exercise Options, Value" } } }, "localname": "SurrenderAndRetirementOfStockToExerciseOptionsValue", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_TaxCreditCarryforwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information for deferred assets related to tax credit carryforwards.", "label": "Tax Credit Carryforwards [Member]" } } }, "localname": "TaxCreditCarryforwardsMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "tech_TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information about term loan.", "label": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "tech_TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to trade names, customer relationships, non-compete agreements and patents.", "label": "Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member]" } } }, "localname": "TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "tech_TrevigenIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to Trevigen Inc.", "label": "Trevigen Inc. [Member]" } } }, "localname": "TrevigenIncMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "tech_USProfitSharingAndSavingsPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the US Profit Sharing and Savings Plan.", "label": "US Profit Sharing and Savings Plan [Member]" } } }, "localname": "USProfitSharingAndSavingsPlanMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_UndesignatedCapitalStockNoParValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the no par value for undesignated capital stock.", "label": "Undesignated capital stock, no par (in dollars per share)" } } }, "localname": "UndesignatedCapitalStockNoParValue", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "tech_UndesignatedCapitalStockSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the shares authorized for undesignated capital stock.", "label": "Undesignated capital stock, shares authorized (in shares)" } } }, "localname": "UndesignatedCapitalStockSharesAuthorized", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "tech_UndesignatedCapitalStockSharesIssued": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the shares issued for undesignated capital stock.", "label": "Undesignated capital stock, shares issued (in shares)" } } }, "localname": "UndesignatedCapitalStockSharesIssued", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "tech_UndesignatedCapitalStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the shares outstanding for undesignated capital stock.", "label": "Undesignated capital stock, shares outstanding (in shares)" } } }, "localname": "UndesignatedCapitalStockSharesOutstanding", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "tech_UndesignatedCapitalStockValue": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the value of undesignated capital stock as of the balance sheet date.", "label": "Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding" } } }, "localname": "UndesignatedCapitalStockValue", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "tech_UnitedStatesAndCanadaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical location of the United States and Canada.", "label": "United States and Canada [Member]" } } }, "localname": "UnitedStatesAndCanadaMember", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "tech_UnrecognizedTaxBenefitsDecreaseResultingFromClosureOfTaxYears": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from closure of tax years.", "label": "tech_UnrecognizedTaxBenefitsDecreaseResultingFromClosureOfTaxYears", "negatedLabel": "Closure of tax years" } } }, "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromClosureOfTaxYears", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "tech_UnrecognizedTaxBenefitsIncreaseResultingFromTaxReform": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax reform.", "label": "Tax reform" } } }, "localname": "UnrecognizedTaxBenefitsIncreaseResultingFromTaxReform", "nsuri": "http://www.bio-techne.com/20200630", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "tech_statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)" } } }, "localname": "statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)" } } }, "localname": "statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 10 - Share-based Compensation and Other Benefit Plans" } } }, "localname": "statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 11 - Income Taxes - Components of Provision for Income Taxes (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-11-income-taxes-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 11 - Income Taxes" } } }, "localname": "statement-statement-note-11-income-taxes-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)" } } }, "localname": "statement-statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-12-segment-information-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 12 - Segment Information" } } }, "localname": "statement-statement-note-12-segment-information-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 13 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)" } } }, "localname": "statement-statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-13-quarterly-financial-data-unaudited-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 13 - Quarterly Financial Data (Unaudited)" } } }, "localname": "statement-statement-note-13-quarterly-financial-data-unaudited-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-2-revenue-recognition-disaggregation-of-revenue-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 2 - Revenue Recognition - Disaggregation of Revenue (Details)" } } }, "localname": "statement-statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-2-revenue-recognition-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 2 - Revenue Recognition" } } }, "localname": "statement-statement-note-2-revenue-recognition-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)" } } }, "localname": "statement-statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-4-acquisitions-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 4 - Acquisitions" } } }, "localname": "statement-statement-note-4-acquisitions-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)" } } }, "localname": "statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)" } } }, "localname": "statement-statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-5-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 5 - Fair Value Measurements" } } }, "localname": "statement-statement-note-5-fair-value-measurements-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-7-leases-aggregate-net-minimum-rental-commitments-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 7 - Leases - Aggregate Net Minimum Rental Commitments (Details)" } } }, "localname": "statement-statement-note-7-leases-aggregate-net-minimum-rental-commitments-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-7-leases-balance-sheet-classification-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 7 - Leases - Balance Sheet Classification (Details)" } } }, "localname": "statement-statement-note-7-leases-balance-sheet-classification-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-7-leases-cash-paid-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 7 - Leases - Cash Paid (Details)" } } }, "localname": "statement-statement-note-7-leases-cash-paid-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details)" } } }, "localname": "statement-statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-7-leases-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 7 - Leases" } } }, "localname": "statement-statement-note-7-leases-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)" } } }, "localname": "statement-statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "statement-statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)" } } }, "localname": "statement-statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-9-earnings-per-share-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 9 - Earnings Per Share" } } }, "localname": "statement-statement-note-9-earnings-per-share-tables", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "tech_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.bio-techne.com/20200630", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r532" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r553" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201802Member": { "auth_ref": [ "r73" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2018-02 Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.", "label": "Accounting Standards Update 2018-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201802Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Trade accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r20", "r218", "r219" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, less allowance for doubtful accounts of $775 and $980, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r14", "r592", "r611" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r36", "r267" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r54", "r55", "r56", "r61", "r64" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r61", "r520" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.", "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r58", "r60", "r61", "r613", "r637", "r641" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r57", "r61", "r64", "r127", "r128", "r129", "r506", "r632", "r633" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r53", "r61", "r64", "r506", "r535", "r536", "r537", "r538", "r540" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r21" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r127", "r128", "r129", "r416", "r417", "r418" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r131", "r132", "r133", "r134", "r232", "r233", "r234", "r235", "r236", "r237", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r457", "r458", "r459", "r460", "r584", "r585", "r586", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" ], "lang": { "en-US": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.", "label": "Employee stock purchase plan expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r378", "r380", "r422", "r423" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r380", "r408", "r421" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "negatedLabel": "Stock-based compensation", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r27", "r224", "r238" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r111", "r254", "r262" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "us-gaap_AmortizationOfIntangibleAssets", "negatedTerseLabel": "Amortization expense", "terseLabel": "Amortization of Intangible Assets, Total" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r120", "r192", "r199", "r206", "r231", "r502", "r507", "r531", "r590", "r610" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r49", "r120", "r231", "r502", "r507", "r531" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r521" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleEquitySecuritiesAmortizedCostBasis": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments for other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "us-gaap_AvailableForSaleEquitySecuritiesAmortizedCostBasis", "terseLabel": "Available-for-sale Equity Securities, Amortized Cost Basis, Total" } } }, "localname": "AvailableForSaleEquitySecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "us-gaap_AvailableForSaleSecurities", "terseLabel": "Available-for-sale Securities, Total" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Short-term available-for-sale investments" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r381", "r410" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r513", "r517" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r367", "r373" ], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r367", "r373", "r478", "r479" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r497" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "terseLabel": "Business Acquisition, Goodwill, Expected Tax Deductible Amount" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "us-gaap_BusinessCombinationAcquisitionRelatedCosts", "negatedLabel": "Acquisition related expenses" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "auth_ref": [ "r476", "r493" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.", "label": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "terseLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r487", "r489", "r490", "r494" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "terseLabel": "Consideration payable" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r110", "r498" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Contingent consideration payments" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r496" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r488", "r491", "r495" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r488", "r492" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Contingent consideration payable" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r488", "r492" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Long-term contingent consideration payable", "terseLabel": "Contingent consideration payable" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r499" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": { "auth_ref": [ "r482" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity.", "label": "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "terseLabel": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized" } } }, "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "auth_ref": [ "r481" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "terseLabel": "Current assets, net of cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r481" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "terseLabel": "Deferred income taxes, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r480", "r481" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r481" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "terseLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r477" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r126", "r178" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r32", "r113" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r8", "r114", "r117" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r107", "r113", "r116" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of year", "periodStartLabel": "Cash and cash equivalents at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r107", "r533" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r511" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r605" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "us-gaap_CommonStockDividendsPerShareDeclared", "terseLabel": "Common Stock, Dividends, Per Share, Declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r127", "r128" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r282" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)", "periodEndLabel": "Balances (in shares)", "periodStartLabel": "Balances (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 38,453,046 and 37,934,040 shares, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r67", "r69", "r70", "r78", "r600", "r620" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r77", "r90", "r599", "r619" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r173", "r174", "r215", "r529", "r530" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r173", "r174", "r215", "r529", "r530", "r643" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r173", "r174", "r215", "r529", "r530", "r643" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r173", "r174", "r215", "r529", "r530" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r117", "r504" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r284", "r285", "r296" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability, Total" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r284", "r285", "r296" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r197", "r198", "r199", "r200", "r202", "r208", "r210" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r84", "r582" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales", "verboseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r121", "r452", "r463" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r124", "r452" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentForeignTaxExpenseBenefit", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r452", "r463", "r465" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current tax provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r121", "r452", "r463" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r172", "r215" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r485" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r14", "r15", "r591", "r594", "r608" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r543", "r545" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r453", "r463" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r453", "r463" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r111", "r121", "r453", "r463", "r464", "r465" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "terseLabel": "Deferred Income Tax Expense (Benefit), Total", "totalLabel": "Total deferred tax provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r16", "r17", "r444", "r593", "r607" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred income taxes", "terseLabel": "Deferred Tax Liabilities, Net, Noncurrent" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r112" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "verboseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCredit": { "auth_ref": [ "r549" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.", "label": "us-gaap_DeferredRentCredit", "terseLabel": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification" } } }, "localname": "DeferredRentCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r453", "r463" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsDerivativeInstruments": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.", "label": "Derivative - cash flow hedge" } } }, "localname": "DeferredTaxAssetsDerivativeInstruments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsEquityMethodInvestments": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.", "label": "Excess tax basis in equity investments" } } }, "localname": "DeferredTaxAssetsEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "us-gaap_DeferredTaxAssetsInventory", "terseLabel": "Inventory" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r446" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance, Total", "totalLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryovers" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r449", "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Tax credit carryovers" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r445" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedTerseLabel": "Valuation allowance", "terseLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r434", "r446" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "negatedLabel": "Intangible asset amortization" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements", "verboseLabel": "Right of use asset" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "us-gaap_DeferredTaxLiabilitiesOther", "verboseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains in other comprehensive income.", "label": "us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome", "negatedLabel": "Net unrealized gain on available-for-sale investments" } } }, "localname": "DeferredTaxLiabilitiesOtherComprehensiveIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r450", "r451" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedTerseLabel": "Depreciation" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details": { "order": 0.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Long-term deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r111", "r187" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r50", "r51", "r515", "r580" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "us-gaap_DerivativeFairValueOfDerivativeLiability", "terseLabel": "Derivative instruments - cash flow hedges" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r514", "r516", "r518", "r519" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r512", "r514", "r518" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r509", "r510" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "us-gaap_DerivativeNotionalAmount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r486" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited", "http://www.bio-techne.com/20200630/role/statement-note-14-subsequent-events", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-7-leases", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "us-gaap_DividendsCommonStockCash", "negatedLabel": "Cash dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r79", "r135", "r136", "r137", "r138", "r139", "r143", "r146", "r153", "r156", "r157", "r161", "r162", "r601", "r621" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r79", "r135", "r136", "r137", "r138", "r139", "r146", "r153", "r156", "r157", "r161", "r162", "r601", "r621" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r158", "r159", "r160", "r163" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r533" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r436" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r436", "r467" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Income tax expense at federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r436", "r467" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "terseLabel": "Domestic tax legislation changes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities": { "auth_ref": [ "r436", "r467" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for qualified production activity.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities", "negatedTerseLabel": "Qualified production activity deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r436", "r467" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "terseLabel": "Foreign tax rate differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r436", "r467" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "terseLabel": "Executive compensation limitations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r436", "r467" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments", "terseLabel": "Other, net" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r436", "r467" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "terseLabel": "State income taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r436", "r467" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "negatedTerseLabel": "Research and development tax credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount": { "auth_ref": [ "r436" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative instrument embedded in host contract.", "label": "Embedded Derivative Financial Instruments [Member]" } } }, "localname": "EmbeddedDerivativeFinancialInstrumentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Salaries, wages and related accruals" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r409" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r409" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Shareholders' equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r127", "r128", "r129", "r132", "r140", "r142", "r167", "r235", "r282", "r283", "r416", "r417", "r418", "r459", "r460", "r534", "r535", "r536", "r537", "r538", "r540", "r632", "r633", "r634" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r33", "r106", "r117", "r230", "r531" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r9", "r13", "r229", "r609", "r656", "r657", "r658" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": { "auth_ref": [ "r424" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "terseLabel": "Excess Tax Benefit from Share-based Compensation, Operating Activities" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r523" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r521", "r527" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r363", "r522", "r571", "r572", "r573" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r526", "r527" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r327", "r328", "r333", "r363", "r522", "r571" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r327", "r328", "r333", "r363", "r522", "r572" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r363", "r522", "r573" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r523" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r523", "r527" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r528" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r524" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedLabel": "Change in fair value of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r525" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Purchase price contingent consideration (Note 4)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r525" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "negatedLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r523" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Contingent consideration payable", "periodStartLabel": "Fair value at the beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r363", "r571", "r572", "r573" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r261" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "verboseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "verboseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive", "verboseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "verboseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo", "verboseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r255", "r257", "r261", "r264", "r583", "r587" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "negatedTerseLabel": "Currency translation" } } }, "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r261", "r587" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsGross", "terseLabel": "Intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r255", "r260" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r261", "r583" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "us-gaap_FinitelivedIntangibleAssetsAcquired1", "terseLabel": "Acquisitions (Note 4)" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r117", "r541" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainOnSaleOfInvestments": { "auth_ref": [ "r81", "r82", "r111", "r596", "r622" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.", "label": "us-gaap_GainOnSaleOfInvestments", "negatedLabel": "(Gain) Loss on investment, net" } } }, "localname": "GainOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r243", "r245", "r589" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "us-gaap_GoodwillAcquiredDuringPeriod", "terseLabel": "Acquisitions (Note 4)" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r117", "r258" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r248" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillForeignCurrencyTranslationGainLoss", "terseLabel": "Currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r111", "r244", "r247", "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillImpairmentLoss", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r249", "r474" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillPurchaseAccountingAdjustments", "terseLabel": "Goodwill, Purchase Accounting Adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r83", "r120", "r192", "r198", "r202", "r205", "r208", "r231", "r531" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r512" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r111", "r265", "r269" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "terseLabel": "Impairment of Long-Lived Assets Held-for-use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r123", "r466" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r75", "r192", "r198", "r202", "r205", "r208", "r588", "r597", "r603", "r623" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r123", "r466" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r438" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r438" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r437", "r442", "r448", "r461", "r468", "r470", "r471", "r473" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r141", "r142", "r190", "r435", "r462", "r469", "r624" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income taxes (benefit)", "totalLabel": "Total income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": { "auth_ref": [ "r454" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.", "label": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability", "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r71", "r117", "r431", "r432", "r442", "r443", "r447", "r455", "r660" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r115" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables", "negatedLabel": "Trade accounts and other receivables" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Trade accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities", "verboseLabel": "Salaries, wages and related accruals" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Change in operating assets and liabilities, net of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r147", "r148", "r149", "r157" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Dilutive effect of stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r253", "r259" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Intangibles assets, net", "verboseLabel": "Total intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r74", "r186", "r542", "r544", "r602" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense", "terseLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r105", "r108", "r115" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r184", "r197", "r198", "r199", "r200", "r202", "r204", "r208" ], "lang": { "en-US": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r46" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r7", "r47", "r117", "r164", "r239", "r240", "r242" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r28", "r241" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details": { "order": 1.0, "parentTag": "tech_InventoryNetCurrentAndNonCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r86", "r88" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Investments": { "auth_ref": [ "r617" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "us-gaap_Investments", "terseLabel": "Investments, Total" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r521" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "us-gaap_InvestmentsFairValueDisclosure", "terseLabel": "Investments, Fair Value Disclosure, Total", "verboseLabel": "Investments, Fair Value Disclosure" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r564" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r564" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r564" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r564" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "verboseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r564" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r564" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r564" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r564" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r564" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Less: Amounts representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r558" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r566" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r120", "r231", "r531", "r595", "r615" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42", "r120", "r231", "r503", "r507", "r508", "r531" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r521" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "us-gaap_LiabilitiesFairValueDisclosure", "totalLabel": "Total Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r12", "r591" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "us-gaap_LinesOfCreditCurrent", "terseLabel": "Line of Credit, Current" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r15", "r280", "r594", "r612" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebt", "terseLabel": "Long-term Debt, Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r15" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term debt obligations" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Current portion of long-term debt obligations" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r43", "r279" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r604" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r107" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r107" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r107", "r109", "r112" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r65", "r68", "r76", "r112", "r120", "r131", "r135", "r136", "r137", "r138", "r141", "r142", "r150", "r192", "r198", "r202", "r205", "r208", "r231", "r531", "r598", "r618" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net earnings", "terseLabel": "Net income", "totalLabel": "Net earnings", "verboseLabel": "Net earnings1" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r135", "r136", "r137", "r138", "r143", "r144", "r152", "r157", "r192", "r198", "r202", "r205", "r208" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "totalLabel": "Income available to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r145", "r152", "r157" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "totalLabel": "Income available to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "us-gaap_NoncurrentAssets", "terseLabel": "Total long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "us-gaap_NumberOfReportingUnits", "terseLabel": "Number of Reporting Units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r61", "r72" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "us-gaap_OfficersCompensation", "terseLabel": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r192", "r198", "r202", "r205", "r208" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating income", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r556" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r555" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "us-gaap_OperatingLeaseLiability", "terseLabel": "Operating Lease, Liability, Total", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total lease obligations" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r555" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities - current", "terseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r555" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities", "terseLabel": "Noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r557", "r560" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash amounts paid on operating lease liabilities(1)" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-cash-paid-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r554" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r563", "r565" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted average discount rate:" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r562", "r565" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term (in years): (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r548", "r551" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r548", "r551" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r548", "r551" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r548", "r551" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r548", "r551" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r548", "r551" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details": { "order": 0.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r548", "r551" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r278", "r546", "r547", "r550", "r552" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.", "label": "Lessee, Operating Lease, Disclosure [Table Text Block]" } } }, "localname": "OperatingLeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r449" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r197", "r198", "r199", "r200", "r202", "r208" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "us-gaap_OtherAssetsMiscellaneousNoncurrent", "terseLabel": "Other" } } }, "localname": "OtherAssetsMiscellaneousNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets", "terseLabel": "Other Assets, Noncurrent, Total", "totalLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r500", "r501", "r505" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r58" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8." } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r58", "r62" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r66", "r69", "r500", "r501", "r505" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r54", "r58" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized gains (losses) on available-for-sale investments, net of tax of $398 in FY18" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r55", "r59" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized gains (losses) on available-for-sale investments, tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other non-operating income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other operating activity" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r486" ], "lang": { "en-US": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r103" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities", "negatedLabel": "Contingent consideration payments" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r93", "r97", "r125" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities", "negatedLabel": "Other investing activities" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r101" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Re-purchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r101" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "us-gaap_PaymentsOfDividendsCommonStock", "negatedLabel": "Cash dividends" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecurities": { "auth_ref": [ "r94", "r228" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.", "label": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities", "negatedLabel": "Purchase of available-for-sale investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r95" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired", "negatedLabel": "Acquisitions, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r96" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r381", "r410" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r99" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "us-gaap_ProceedsFromIssuanceOfLongTermDebt", "terseLabel": "Proceeds from Issuance of Long-term Debt, Total" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r99" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Borrowings under line-of-credit agreement", "terseLabel": "Proceeds from Long-term Lines of Credit" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r91", "r92", "r228" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from sale and maturities of available-for-sale investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r100", "r104", "r125" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Other financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r98", "r411" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r36", "r268" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r35", "r266" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r268", "r616" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r34", "r117", "r268", "r661", "r662" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10", "r268" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r266" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r61", "r72" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "negatedLabel": "Amounts reclassified from accumulated other comprehensive loss to income", "terseLabel": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r59", "r63" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "us-gaap_ReclassificationFromAociCurrentPeriodTax", "terseLabel": "Reclassification from AOCI, Current Period, Tax, Total" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r102", "r122" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "us-gaap_RepaymentsOfLinesOfCredit", "negatedLabel": "Payments on line-of-credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r428" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r117", "r428" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r111", "r272", "r274", "r275" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "us-gaap_RestructuringCharges", "negatedLabel": "Restructuring costs" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r283", "r419", "r614", "r636", "r641" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings", "terseLabel": "Retained Earnings (Accumulated Deficit), Ending Balance" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r127", "r128", "r129", "r132", "r140", "r142", "r235", "r416", "r417", "r418", "r459", "r460", "r632", "r634" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r373", "r374", "r375", "r376" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r373", "r374", "r375", "r376" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r183", "r184", "r197", "r203", "r204", "r211", "r212", "r215", "r294", "r295", "r582" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Net sales", "verboseLabel": "Revenues, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r183", "r184", "r197", "r203", "r204", "r211", "r212", "r215", "r294", "r295", "r582" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r298", "r301" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r118", "r119" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r561", "r565" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right of use assets obtained in exchange for lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-cash-paid-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueSegmentMember": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Revenue from specified business segment, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Segment Benchmark [Member]" } } }, "localname": "SalesRevenueSegmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r61", "r539", "r540" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r455" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r521", "r522" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r255", "r260" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r250", "r252" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r7", "r29", "r30", "r31" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of noncurrent assets.", "label": "Schedule of Other Assets, Noncurrent [Table Text Block]" } } }, "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r483" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r192", "r195", "r201", "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r387", "r398", "r401" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r441", "r456" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r179", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r206", "r208", "r215", "r625" ], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r179", "r181", "r182", "r192", "r196", "r202", "r206", "r207", "r208", "r209", "r211", "r214", "r215", "r216" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative", "negatedLabel": "Corporate general, selling and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "terseLabel": "Share-based Payment Arrangement, Accelerated Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited, shares (in shares)", "negatedTerseLabel": "Forfeited, shares (in shares)", "terseLabel": "Forfeited, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r397" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "terseLabel": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Granted, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Balance, shares (in shares)", "periodStartLabel": "Balance, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Balance, weighted average exercise price (in dollars per share)", "periodStartLabel": "Balance, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "terseLabel": "Balance, weighted average contractual life (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedTerseLabel": "Vested, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Vested, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r406" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r405" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r407" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rates" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "terseLabel": "Exercisable, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r410" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r389", "r410" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, shares (in shares)", "periodStartLabel": "Outstanding, shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r388" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r379", "r385" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r404", "r420" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected lives (years) (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r410" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r386" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r179", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r206", "r208", "r215", "r250", "r271", "r273", "r276", "r625" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r45", "r127", "r128", "r129", "r132", "r140", "r142", "r167", "r235", "r282", "r283", "r416", "r417", "r418", "r459", "r460", "r534", "r535", "r536", "r537", "r538", "r540", "r632", "r633", "r634" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income-parentheticals", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-tables", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-tables", "http://www.bio-techne.com/20200630/role/statement-note-14-subsequent-events", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-tables", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-tables", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-tables", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-7-leases", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-cash-paid-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-tables", "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r127", "r128", "r129", "r167", "r582" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income-parentheticals", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-tables", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-tables", "http://www.bio-techne.com/20200630/role/statement-note-14-subsequent-events", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-tables", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-other-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-tables", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-tables", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20200630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-7-leases", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-aggregate-net-minimum-rental-commitments-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-balance-sheet-classification-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-cash-paid-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-tables", "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r18", "r19", "r282", "r283" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Common stock issued to employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r282", "r283" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)", "verboseLabel": "Common stock issued for restricted stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r282", "r283", "r392" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Common stock issued for exercise of options (in shares)", "negatedLabel": "Exercised, shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r18", "r19", "r282", "r283" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Common stock issued to employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r18", "r19", "r282", "r283" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Common stock issued for restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r45", "r282", "r283" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Common stock issued for exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r18", "r19", "r282", "r283" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "us-gaap_StockRepurchasedDuringPeriodShares", "negatedLabel": "Share repurchases (in shares)", "terseLabel": "Stock Repurchased During Period, Shares (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r18", "r19", "r282", "r283" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "us-gaap_StockRepurchasedDuringPeriodValue", "negatedLabel": "Share repurchases" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r24", "r25", "r120", "r226", "r231", "r531" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r568", "r570" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-14-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-tables", "http://www.bio-techne.com/20200630/role/statement-note-12-segment-information-tables", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-tables", "http://www.bio-techne.com/20200630/role/statement-note-2-revenue-recognition-tables", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-tables", "http://www.bio-techne.com/20200630/role/statement-note-5-fair-value-measurements-tables", "http://www.bio-techne.com/20200630/role/statement-note-7-leases-tables", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r449" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r220", "r221", "r222", "r223", "r225", "r227" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r484" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r131", "r132", "r133", "r134", "r232", "r233", "r234", "r235", "r236", "r237", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r457", "r458", "r459", "r460", "r584", "r585", "r586", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" ], "lang": { "en-US": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20200630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20200630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "auth_ref": [ "r151", "r154", "r155" ], "calculation": { "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "negatedLabel": "Income allocated to participating securities", "negatedTerseLabel": "Income allocated to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r429", "r472", "r606", "r642" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.", "label": "us-gaap_UndistributedEarningsOfForeignSubsidiaries", "terseLabel": "Undistributed Earnings of Foreign Subsidiaries" } } }, "localname": "UndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r430", "r439" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "Ending balances", "periodStartLabel": "Balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Additions due to acquisitions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r440" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Additions for tax positions of current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r168", "r169", "r170", "r171", "r175", "r176", "r177" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.", "label": "Valuation Allowance by Deferred Tax Asset [Axis]" } } }, "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r559", "r565" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "us-gaap_VariableLeaseCost", "terseLabel": "Variable Lease, Cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-note-7-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r145", "r157" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r143", "r157" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20200630/role/statement-note-13-quarterly-financial-data-unaudited-quarterly-financial-information-details", "http://www.bio-techne.com/20200630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bio-techne.com/20200630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "65", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2793-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "66", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2814-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11374-113907" }, "r425": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121573983&loc=d3e28200-109314" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r473": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r499": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r52": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r528": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL75039408-165497" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r541": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 1,3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e39896-112707" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r566": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r570": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r672": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r673": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r674": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r675": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r676": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r677": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657190&loc=SL116659633-172590" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" } }, "version": "2.1" } ZIP 104 0001437749-20-018754-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-20-018754-xbrl.zip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ô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